

DESCRIPTION

TECHNICAL FIELD OF THE INVENTION

[0001]


5 The present invention relates to a novel heterocyclic compound and use thereof.

BACKGROUND OF THE INVENTION

[0002]

As a compound having a broad treatment spectrum for
10 central neurological diseases such as schizophrenia and the like, for example, a compound represented by the following formula (1) (hereinafter compound (1)) has been reported (patent document 1).

[0003]



15

[0004]

wherein each symbol is as defined in patent document 1.

The above-mentioned compound (1) is an antipsychotic agent having a broader treatment spectrum as compared to
20 conventional typical antipsychotic agents and atypical antipsychotic agents, causing less side effects, and superior in tolerability and safety. However, this compound is associated with problems in that its application to oil injections is limited and the like, since it is poorly soluble
25 in oil such as sesame oil and benzyl benzoate. Oil injections are useful as compared to aqueous suspensions from the aspects of imparted blood concentration sustainability (control of diffusion in administration site by oily base), shortened liquid preparation time when in use (unnecessitated mixing and
30 shaking), secured sterilization by filtration (oily base filtration), avoidance of physical stimulation at administration site (oily base stability), improved accuracy

of filling into injection container (container filled with oily base) and the like.

Document List

patent document

5 [0005]

patent document 1: WO2006/112464

SUMMARY OF THE INVENTION

Problems to be Solved by the Invention

[0006]

10 The problem of the present invention is to provide a superior, novel heterocyclic compound with improved solubility in oil such as sesame oil and benzyl benzoate and use thereof. Means of Solving the Problems

[0007]

15 The present inventors have conducted various studies in an attempt to solve the aforementioned problems and found that the liposolubility of compound (1) can be markedly improved by introducing a substituent into a particular position on ring Q. The present invention has been completed based on such finding.


20 [0008]

The present invention preferably provides a heterocyclic compound or a salt thereof shown in the following Items 1 - 4, a pharmaceutical composition shown in the Item 5, a prophylactic and/or therapeutic agent shown in the Items 6 and 25 7, use shown in the Item 8, a prophylactic and/or treatment method shown in the Items 9 and 10, and a production method shown in the Item 11.

[0009]

Item 1. A heterocyclic compound represented by the formula (I)

30 [0010]




[0011]

wherein

A is a lower alkylene group;


[0012]



5 [0013]

in the monocyclic heterocycle containing Q is

[0014]




[0015]

10 wherein

R^{2'} is the following group

[0016]



[0017]

15 wherein

Y^{1'} is a lower alkylene group,

R^{3'} is

(1) an alkyl group,

(2) a cycloalkyl group optionally substituted by a lower alkyl

20 group,

(3) a phenyl group,

(4) a phenyl lower alkyl group

(5) a lower alkoxy group,

(6) a cycloalkyloxy group,

25 (7) an amino group optionally having 1 or 2 substituents

selected from the group consisting of an alkyl group and a phenyl lower alkyl group, or

(8) a piperidyl group optionally having a piperidyl group;


[0018]

-----J

[0019]

at the 3-position and the 4-position of the bicyclic heterocycle skeleton containing Z and W is -CH=CH- or


5 [0020]



[0021]

wherein R⁶ and R⁷ are the same or different and each is a hydrogen or a lower alkyl group;


10 [0022]



[0023]

is

[0024]



15

[0025]

wherein

R¹ is

a lower alkoxy lower alkoxy group,


20 a phosphonooxy lower alkoxy group,

a phenyl lower alkoxy lower alkoxy group,

a phosphonooxy group optionally having 1 or 2 lower alkyl groups,

the following group

25 [0026]




[0027]

wherein


R⁸ is

- (1) an alkyl group,
 (2) a hydroxy-substituted lower alkyl group,
 (3) a cycloalkyl group,
 (4) a phenyl group,
 5 (5) a phenyl lower alkyl group,
 (6) an alkenyl group,
 (7) a lower alkoxy group,
 (8) a cycloalkyloxy group,
 (9) a lower alkoxy lower alkoxy group,
 10 (10) an amino group optionally having 1 or 2 substituents
 selected from the group consisting of an alkyl group and a
 hydroxy-substituted lower alkyl group,
 (11) a piperidyl group optionally having a piperidyl group,
 (12) a piperazinyl group optionally having a lower alkyl group,
 15 or
 (13) the following group
 [0028]



[0029]

- 20 wherein Aa is an alkylene group, and other symbols are as
 defined above, or
 the following group
 [0030]




25 [0031]

wherein

R⁹ is

- (1) an alkyl group,
 (2) a hydroxy-substituted lower alkyl group,

- (3) a cycloalkyl group,
 (4) a phenyl group,
 (5) a phenyl lower alkyl group,
 (6) an alkenyl group,
 5 (7) a lower alkoxy group,
 (8) a cycloalkyloxy group,
 (9) a lower alkoxy lower alkoxy group,
 (10) a phenyloxy group,
 (11) an amino group optionally having 1 or 2 substituents
 10 selected from the group consisting of an alkyl group and a
 hydroxy-substituted lower alkyl group,
 (12) a piperidyl group optionally having a piperidyl group,
 (13) a piperazinyl group optionally having a lower alkyl group,
 or
 15 (14) the following group
 [0032]







[0033]

wherein Ab is an alkylene group, and other symbols are as
 20 defined above;

R² is a hydrogen or
 the following group

[0034]





[0035]

wherein

 Y^1 is a lower alkylene group optionally substituted by

- 5 (1) a lower alkoxycarbonyl group or
(2) a lower alkyl group,

 Y^2 is a lower alkylene group, Y^3 is a single bond or a lower alkylene group optionally substituted by a lower alkyl group,10 R^3 is

- (1) an alkyl group,
(2) a halogen-substituted lower alkyl group,
(3) an alkenyl group,
(4) an amino lower alkyl group,
15 (5) a cycloalkyl group,
(6) a phenyl group,
(7) a phenyl lower alkyl group,
(8) a piperidyl group optionally having 1 or 2 substituents selected from the group consisting of a lower alkyl group and
20 a piperidyl group,
(9) a halogen-substituted piperidyl group,
(10) a morpholinyl group,
(11) a pyrrolidinyl group,
(12) a tetrahydropyranyl group,
25 (13) a furyl group,
(14) a thienyl group,
(15) a pyridyl group,
(16) a pyrimidinyl group,
(17) a pyridazinyl group,
30 (18) a benzofuryl group,
(19) a quinolyl group,
(20) a lower alkoxycarbonyl lower alkyl group,
(21) a lower alkoxy lower alkoxy lower alkyl group,

(22) a lower alkoxy lower alkoxy lower alkoxy lower alkyl group,


(23) an amino group optionally having 1 or 2 substituents selected from the group consisting of an alkyl group, a cycloalkyl group, a cycloalkyl lower alkyl group, a lower alkenyl group, a halogen-substituted lower alkyl group, a lower alkoxy group, a lower alkoxy lower alkyl group, a lower alkoxy carbonyl lower alkyl group, a phenyl lower alkyl group, a phenyl lower alkoxy group, a furyl lower alkyl group, a pyridyl lower alkyl group, a hydroxy-substituted lower alkyl group,

(24) an amino lower alkyl group optionally having a lower alkyl carbonyl group,

(25) a piperazinyl group optionally having a lower alkyl group, or

(26) the following group

[0036]



[0037]

wherein Ac is an alkylene group, and other symbols are as defined above,

R⁴ is

- (1) an alkyl group,
- (2) a phenyl group,
- (3) a phenyl lower alkyl group,
- (4) a halogen-substituted lower alkyl group, or
- (5) a cycloalkyl group,

R⁵ is


- (1) a hydrogen,
- (2) a lower alkyl group,
- (3) a halogen-substituted lower alkyl group,
- (4) a phenyl lower alkyl group,
- 5 (5) a phenyl lower alkoxy lower alkyl group,
- (6) a tri-lower alkylsilyl group,
- (7) a tetrahydropyranyl group, or
- (8) a phosphono group,

R¹⁰ is

- 10 (1) an alkyl group,
- (2) an alkenyl group,
- (3) a phenyl group,
- (4) a phenyl lower alkyl group,
- (5) a hydroxy-substituted lower alkyl group,
- 15 (6) a cycloalkyl group,
- (7) an amino lower alkyl group optionally having 1 or 2
substituents selected from the group consisting of an amino
lower alkylcarbonyl group and a lower alkylcarbonyl group,
- (8) a pyrrolidinyl group optionally having an amino lower
20 alkylcarbonyl group,
- (9) an alkoxy group,
- (10) a lower alkoxy lower alkoxy lower alkyl group,
- (11) a lower alkoxy lower alkoxy lower alkoxy lower alkyl
group,
- 25 (12) a phenyl lower alkoxy group,
- (13) an amino group optionally having 1 or 2 substituents
selected from the group consisting of an alkyl group, a
hydroxy-substituted lower alkyl group and a phenyl lower alkyl
group,
- 30 (14) a morpholino group,
- (15) a piperazinyl group optionally having a lower alkyl group,
- (16) a piperidyl group optionally having a piperidyl group, or
- (17) a cycloalkyloxy group;

provided when


35 [0038]



[0039]

is

[0040]



5


[0041]

then

R^2 is not a hydrogen,
or a salt thereof.

10 Item 2. The heterocyclic compound according to Item 1, which
is represented by the formula (II)

[0042]




[0043]

15 wherein each symbol is as defined in Item 1, or a salt thereof.

Item 3. The heterocyclic compound according to Item 1, which
is represented by the formula (III)


[0044]



20 [0045]

wherein


[0046]



[0047]

is

[0048]




5 [0049]

wherein

R^{1a} is the following group

[0050]




10 [0051]

wherein

R^{8a} is

- (1) an alkyl group,
- (2) a cycloalkyl group,
- 15 (3) a lower alkoxy group,
- (4) a cycloalkyloxy group,
- (5) a lower alkoxy lower alkoxy group,
- (6) an amino group optionally having 1 or 2 substituents selected from the group consisting of an alkyl group and a
- 20 hydroxy-substituted lower alkyl group, or
- (7) the following group


[0052]



[0053]

- 25 wherein Aa' is an alkylene group, and other symbol is as defined in Item 1, or
- the following group

[0054]




[0055]

wherein

5 R^{9a} is

- (1) an alkyl group,
 - (2) a hydroxy-substituted lower alkyl group,
 - (3) a cycloalkyl group,
 - (4) a lower alkoxy group,
 - 10 (5) a cycloalkyloxy group,
 - (6) a lower alkoxy lower alkoxy group,
 - (7) a phenyloxy group,
 - (8) an amino group optionally having 1 or 2 substituents selected from the group consisting of an alkyl group,
 - 15 (9) a piperidyl group optionally having a piperidyl group,
 - (10) a piperazinyl group optionally having a lower alkyl group,
- or
- (11) the following group

[0056]



20


[0057]


wherein Ab' is an alkylene group, and other symbol is as defined in Item 1;

 R^{2a} is

25 the following group

[0058]





[0059]

wherein

 Y^{1a} is a lower alkylene group,5 Y^{2a} is a lower alkylene group, R^{3a} is

(1) an alkyl group,

(2) a cycloalkyl group,

(3) a piperidyl group optionally having 1 or 2 substituents

10 selected from the group consisting of a lower alkyl group,

(4) a tetrahydropyranyl group,

(5) a lower alkoxycarbonyl lower alkyl group,


(6) a lower alkoxy lower alkoxy lower alkyl group

(7) an amino lower alkyl group optionally having a lower

15 alkylcarbonyl group, or

(8) the following group

[0060]



[0061]

20 wherein Ac' is an alkylene group, Y^{1a} is a lower alkylene group
and other symbols are as defined in Item 1,

 R^{4a} is

(1) an alkyl group, or

(2) a cycloalkyl group; and


25 A is a lower alkylene group,

or a salt thereof.

Item 4. The heterocyclic compound according to Item 2, wherein R^1 is

the following group

[0062]



[0063]


wherein

$R^{8a'}$ is

- (1) an alkyl group,
- 10 (2) a cycloalkyl group,
- (3) a lower alkoxy group,
- (4) a cycloalkyloxy group,
- (5) a lower alkoxy lower alkoxy group, or
- (6) an amino group optionally having 1 or 2 substituents
- 15 selected from the group consisting of an alkyl group and a hydroxy-substituted lower alkyl group, or

the following group

[0064]



20 [0065]

wherein

$R^{9a'}$ is



- (1) an alkyl group,
 - (2) a hydroxy-substituted lower alkyl group,
 - 25 (3) a cycloalkyl group,
 - (4) a lower alkoxy group,
 - (5) a cycloalkyloxy group,
 - (6) a lower alkoxy lower alkoxy group,
 - (7) a phenyloxy group,
 - 30 (8) an amino group optionally having 1 or 2 substituents
- selected from the group consisting of an alkyl group,

(9) a piperidyl group optionally having a piperidyl group, or
(10) a piperazinyl group optionally having a lower alkyl group;

R² is

5. the following group

[0066]



[0067]

10 wherein

Y^{1a} is a lower alkylene group,

Y^{2a} is a lower alkylene group,

R^{3a'} is

(1) an alkyl group,

15 (2) a cycloalkyl group

(3) a piperidyl group optionally having 1 or 2 substituents selected from the group consisting of a lower alkyl group,

(4) a tetrahydropyranyl group,

(5) a lower alkoxycarbonyl lower alkyl group,

20 (6) a lower alkoxy lower alkoxy lower alkyl group

(7) an amino lower alkyl group optionally having a lower alkylcarbonyl group,

R^{4a} is

(1) an alkyl group, or

25 (2) a cycloalkyl group;

or a salt thereof.

Item 5. A pharmaceutical composition comprising the heterocyclic compound according to Item 1 or a pharmaceutically acceptable salt thereof, and a

30 pharmaceutically acceptable diluent and/or a carrier.

Item 6. A prophylactic and/or therapeutic agent for a central

neurological disease, comprising the heterocyclic compound according to Item 1 or a pharmaceutically acceptable salt thereof as an active ingredient.

Item 7. The agent according to Item 6, wherein the central
5 neurological disease is selected from the group consisting of schizophrenia, treatment-resistant, refractory or chronic schizophrenia, emotional disturbance, psychotic disorder, mood disorder, bipolar disorder, mania, depression, endogenous depression, major depression, melancholic and treatment-
10 resistant depression, dysthymic disorder, cyclothymic disorder, anxiety disorder, somatoform disorder, factitious disorder, dissociative disorder, sexual disorder, eating disorder, sleep disorder, adjustment disorder, substance-related disorder, anhedonia, delirium, Alzheimer's disease, Parkinson disease,
15 cognitive impairment, cognitive impairment associated with neurodegenerative diseases, cognitive impairment caused by neurodegenerative diseases, cognitive impairment in schizophrenia, cognitive impairment caused by treatment-resistant, refractory or chronic schizophrenia, vomiting,
20 motion sickness, obesity, migraine, pain, mental retardation, autistic disorder, Tourette's disorder, tic disorder, attention deficit hyperactivity disorder, conduct disorder and Down's syndrome.

Item 8. Use of the heterocyclic compound according to Item 1
25 or a pharmaceutically acceptable salt thereof as a medicament.


Item 9. A method of preventing and/or treating a central neurological disease, comprising administering the heterocyclic compound according to Item 1 or a pharmaceutically acceptable salt thereof to a human or an
30 animal.

Item 10. The method according to Item 9, wherein the central neurological disease is selected from the group consisting of schizophrenia, treatment-resistant, refractory or chronic schizophrenia, emotional disturbance, psychotic disorder, mood
35 disorder, bipolar disorder, mania, depression, endogenous

depression, major depression, melancholic and treatment-resistant depression, dysthymic disorder, cyclothymic disorder, anxiety disorder, somatoform disorder, factitious disorder, dissociative disorder, sexual disorder, eating disorder, sleep
 5 disorder, adjustment disorder, substance-related disorder, anhedonia, delirium, Alzheimer's disease, Parkinson disease, cognitive impairment, cognitive impairment associated with neurodegenerative diseases, cognitive impairment caused by neurodegenerative diseases, cognitive impairment in
 10 schizophrenia, cognitive impairment caused by treatment-resistant, refractory or chronic schizophrenia, vomiting, motion sickness, obesity, migraine, pain, mental retardation, autistic disorder, Tourette's disorder, tic disorder, attention deficit hyperactivity disorder, conduct disorder and
 15 Down's syndrome.

Item 11. A method of producing a heterocyclic compound represented by the formula (I)


[0068]



20 [0069]

wherein each symbol is as defined in Item 1, or a salt thereof, comprising reacting a compound represented by the formula

[0070]




25

[0071]

wherein X_1 is a halogen atom or a group that causes a substitution reaction similar to that by a halogen atom, and other symbols are as defined in Item 1, or a salt thereof,
 30 with a compound represented by

[0072]



[0073]

wherein Q is as defined in Item 1, or a salt thereof.

5 [0074]

Brief description of drawings

Fig.1 is a graph showing the transition of blood concentration of test preparations 1, 2 and 3 after administration.

10 [0075]

Description of Embodiments

Each group shown in the aforementioned formula (I) is specifically as follows.

Lower means, unless otherwise specified, a group having 1 to 6 (preferably 1 - 4) carbon atoms.

[0076]

As the halogen atom, a fluorine atom, a chlorine atom, a bromine atom and an iodine atom can be mentioned.

[0077]

As the alkyl group, a straight chain or branched chain alkyl group having a carbon number of 1 - 30 (preferably 1 - 20) can be mentioned. More specific examples thereof include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, isopentyl, 1-ethylpropyl, neopentyl, n-hexyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, isohexyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 3,3-dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 2,3-dimethylbutyl, 2-ethylbutyl, n-heptyl, 1-methylhexyl, 2-methylhexyl, 3-methylhexyl, 4-methylhexyl, 5-methylhexyl, 1-propylbutyl, 1,1-dimethylpentyl, 4,4-dimethylpentyl, 1-pentylhexyl, n-octyl, 1-methylheptyl, 2-methylheptyl, 3-methylheptyl, 4-methylheptyl,

5-methylheptyl, 6-methylheptyl, 1,1-dimethylheptyl, 1-propylpentyl, 2-ethylhexyl, 5,5-dimethylhexyl, n-nonyl, 3-methyloctyl, 4-methyloctyl, 5-methyloctyl, 6-methyloctyl, 1-propylhexyl, 2-ethylheptyl, 6,6-dimethylheptyl, n-decyl, 1-methylnonyl, 3-methylnonyl, 8-methylnonyl, 3-ethyloctyl, 3,7-dimethyloctyl, 7,7-dimethyloctyl, n-undecyl, 1,1-dimethylundecyl, 4,8-dimethylnonyl, dodecyl, tridecyl, tetradecyl, pentadecyl, 3,7,11-trimethyldodecyl, hexadecyl, 4,8,12-trimethyltridecyl, 1-methylpentadecyl, 14-methylpentadecyl, 13,13-dimethyltetradecyl, heptadecyl, 15-methylhexadecyl, octadecyl, 1-methylheptadecyl, nonadecyl, icosyl, 3,7,11,15-tetramethylhexadecyl, henicosyl, docosyl, tricosyl, tetracosyl, pentacosyl, hexacosyl, heptacosyl, octacosyl, nonacosyl, triacontyl group and the like.

15 [0078]

As the lower alkyl group, a linear or branched chain alkyl group having a carbon number of 1 - 6 can be mentioned. More specific examples thereof include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1-methylbutyl, 2-methylbutyl, isopentyl, 1-ethylpropyl, neopentyl, n-hexyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, isohexyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 3,3-dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 2,3-dimethylbutyl, 2-ethylbutyl, 1,2,2-trimethylpropyl, 3,3-dimethylbutyl group and the like.

[0079]

As the alkenyl group, a straight chain or branched chain alkenyl group having 1 - 10 double bonds and a carbon number of 2 - 30 can be mentioned, including both a trans form and a cis form. More specific examples thereof include ethenyl(vinyl), 1-propenyl, 2-propenyl, 1-methyl-1-propenyl, 2-methyl-1-propenyl, 2-methyl-2-propenyl, 2-propenyl, 2-butenyl, 1-butenyl, 3-butenyl, 2-pentenyl, 1-pentenyl, 3-pentenyl, 4-pentenyl, 1,3-butadienyl, 1,3-pentadienyl, 2-pentene-4-ynyl, 2-hexenyl, 1-hexenyl, 5-hexenyl, 3-hexenyl, 4-

hexenyl, 3,3-dimethyl-1-propenyl, 2-ethyl-1-propenyl, 1,3,5-hexatrienyl, 1,3-hexadienyl, 1,4-hexadienyl, heptenyl, octenyl, nonenyl, decenyl, undecenyl, dodecenyl, tridecenyl, tetradecenyl, pentadecenyl, hexadecenyl, heptadecenyl, octadecenyl, nonadecenyl, icocenyl group and the like.

[0080]

As the lower alkenyl group, a straight chain or branched chain alkenyl group having 1 - 3 double bonds and a carbon number of 2 - 6 can be mentioned, including both a trans form and a cis form. More specific examples thereof include vinyl, 1-propenyl, 2-propenyl, 1-methyl-1-propenyl, 2-methyl-1-propenyl, 2-methyl-2-propenyl, 2-propenyl, 2-butenyl, 1-butenyl, 3-butenyl, 2-pentenyl, 1-pentenyl, 3-pentenyl, 4-pentenyl, 1,3-butadienyl, 1,3-pentadienyl, 2-pentene-4-ynyl, 2-hexenyl, 1-hexenyl, 5-hexenyl, 3-hexenyl, 4-hexenyl, 3,3-dimethyl-1-propenyl, 2-ethyl-1-propenyl, 1,3,5-hexatrienyl, 1,3-hexadienyl, 1,4-hexadienyl group and the like.

[0081]

As the cycloalkyl group, cyclo C3-C20 alkyl group having 3 - 20 carbon atoms can be mentioned. More specific examples thereof include monocycloalkyl such as cyclopropyl group, cyclobutyl group, cyclopentyl group, cyclohexyl group, cycloheptyl group, cyclooctyl group, cyclodecyl group, cyclododecyl group and the like, bicycloalkyl, tricycloalkyl, polycycloalkyl and the like. As the bicycloalkyl, norbornyl, pinanyl, bicyclo[2,2,2]octyl group and the like can be mentioned, and as the tricycloalkyl and polycycloalkyl, adamantyl group and the like can be mentioned.

[0082]

As the cycloalkyloxy group, a cyclo C3-C20 alkyl having 3 - 20 carbon atoms - oxy group can be mentioned. More specific examples thereof include monocycloalkyloxy such as cyclopropyloxy group, cyclobutyloxy group, cyclopentyloxy group, cyclohexyloxy group, cycloheptyloxy group, cyclooctyloxy group, cyclodecyloxy group, cyclododecyloxy

group and the like, bicycloalkyloxy, tricycloalkyloxy, polycycloalkyloxy and the like. As the cycloalkyloxy, norbornyloxy, pinanyloxy, bicyclo[2,2,2]octyloxy group and the like can be mentioned, and as the tricycloalkyloxy and
5 polycycloalkyloxy, adamantyloxy group and the like can be mentioned.

[0083]

As the lower alkoxy group, a straight chain or branched chain alkoxy group having a carbon number of 1 - 6 can be
10 mentioned. More specific examples thereof include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, tert-butoxy, sec-butoxy, n-pentyloxy, isopentyloxy, neopentyloxy, n-hexyloxy, isoheptyloxy, 3-methylpentyloxy group and the like.

[0084]

15 As the halogen-substituted lower alkyl group, the aforementioned lower alkyl group, which is substituted by 1 - 7, more preferably 1 - 3, halogen atoms can be mentioned. More specific examples thereof include fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl,
20 bromomethyl, dibromomethyl, dichlorofluoromethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, pentafluoroethyl, 2-fluoroethyl, 2-chloroethyl, 3,3,3-trifluoropropyl, heptafluoropropyl, 2,2,3,3,3-pentafluoropropyl, heptafluoroisopropyl, 3-chloropropyl, 2-chloropropyl, 3-
25 bromopropyl, 4,4,4-trifluorobutyl, 4,4,4,3,3-pentafluorobutyl, 4-chlorobutyl, 4-bromobutyl, 2-chlorobutyl, 5,5,5-trifluoropentyl, 5-chloropentyl, 6,6,6-trifluorohexyl, 6-chlorohexyl, perfluorohexyl group and the like.

[0085]

30 As the hydroxy-substituted lower alkyl group, the aforementioned lower alkyl group, which is substituted by 1 - 7, more preferably 1 - 3, hydroxy groups can be mentioned. More specific examples thereof include hydroxymethyl, 2-hydroxyethyl, 1,1-dimethyl-2-hydroxyethyl, 3-hydroxypropyl, 4-
35 hydroxybutyl, 2-hydroxybutyl, 5-hydroxypentyl, 1-hydroxypentyl,

6-hydroxyhexyl and the like.

[0086]

As the cycloalkyl lower alkyl group, the aforementioned lower alkyl group (preferably a straight chain or branched chain alkyl group having a carbon number of 1 - 6), which has 1 - 3, preferably 1, cycloalkyl group mentioned above can be mentioned. It may be substituted with a lower alkyl group on the cycloalkyl group. Specific examples of the cycloalkyl lower alkyl group include cyclopropylmethyl, cyclohexylmethyl, 2-cyclopropylethyl, 1-cyclobutylethyl, cyclopentylmethyl, 3-cyclopentylpropyl, 4-cyclohexylbutyl, 5-cycloheptylpentyl, 6-cyclooctylhexyl, 1,1-dimethyl-2-cyclohexylethyl, 2-methyl-3-cyclopropylpropyl group and the like.

[0087]

As the amino lower alkyl group, the aforementioned lower alkyl group (preferably a straight chain or branched chain alkyl group having a carbon number of 1 - 6), which has 1 - 5, preferably 1 - 3, amino group can be mentioned. Specific examples of the amino lower alkyl group include aminomethyl, diaminomethyl, triaminomethyl, 1-aminoethyl, 2-aminoethyl, 1-aminopropyl, 2-aminopropyl, 3-aminopropyl, 4-aminobutyl, 5-aminopentyl, 6-aminoethyl, 1-amino-2-methylethyl, 1-aminobutyl, 1-amino-2-methylpropyl, 1-amino-2,2-dimethylethyl, 1-amino-2-methylbutyl, 1-amino-3-methylbutyl, 1-aminoethyl, 1-amino-2-methylpentyl group and the like.

[0088]

As the phenyl lower alkyl group, the aforementioned lower alkyl group, which has 1 - 3, preferably 1, phenyl group can be mentioned. It may be substituted with a lower alkyl group on the phenyl group. Specific examples of the phenyl lower alkyl group include benzyl, 2-phenylethyl, 1-phenylethyl, 3-phenylpropyl, 4-phenylbutyl, 1,1-dimethyl-2-phenylethyl, 5-phenylpentyl, 6-phenylhexyl, 2-methyl-3-phenylpropyl, diphenylmethyl, 2,2-diphenylethyl group and the like.

[0089]

As the furyl lower alkyl group, the aforementioned lower alkyl group, which has 1 - 3, preferably 1, furyl group can be mentioned. It may be substituted with a lower alkyl group on the furyl group. Specific examples of the furyl lower alkyl group include (2-furyl)methyl, 2-(3-furyl)ethyl, 1-(2-furyl)ethyl, 3-(3-furyl)propyl, 4-(2-furyl)butyl, 5-(3-furyl)pentyl, 6-(2-furyl)hexyl, 1,1-dimethyl-2-(3-furyl)ethyl, 2-methyl-3-(2-furyl)propyl group and the like.

10 [0090]

As the pyridyl lower alkyl group, the aforementioned lower alkyl group, which has 1 - 3, preferably 1, pyridyl group can be mentioned. It may be substituted with a lower alkyl group on the pyridyl group. Specific examples of the pyridyl lower alkyl group include (4-pyridyl)methyl, 1-(3-pyridyl)ethyl, 2-(2-pyridyl)ethyl, 3-(2-pyridyl)propyl, 4-(3-pyridyl)butyl, 5-(4-pyridyl)pentyl, 6-(2-pyridyl)hexyl, 1,1-dimethyl-2-(3-pyridyl)ethyl, 2-methyl-3-(4-pyridyl)propyl group and the like.

20 [0091]

As the lower alkoxy lower alkyl group, the aforementioned lower alkyl group (preferably a straight chain or branched chain alkyl group having a carbon number of 1 - 6), which has 1 - 3, preferably 1, lower alkoxy group (preferably a straight chain or branched chain alkoxy group having a carbon number of 1 - 6) mentioned above can be mentioned. Specific examples of the lower alkoxy lower alkyl group include methoxymethyl, ethoxymethyl, propoxymethyl, hexyloxymethyl, methoxyethyl, ethoxyethyl, propoxyethyl, isopropoxymethyl, butoxy methyl, tert-butoxy methyl, pentyloxymethyl, hexyloxymethyl group and the like.

[0092]

As the lower alkoxycarbonyl group, a straight chain or branched chain alkoxycarbonyl group having a carbon number of 1 - 6, wherein the lower alkoxy moiety is the aforementioned

lower alkoxy group can be mentioned. More specific examples thereof include methoxycarbonyl, ethoxycarbonyl, n-propoxycarbonyl, isopropoxycarbonyl, n-butoxycarbonyl, isobutoxycarbonyl, tert-butoxycarbonyl, sec-butoxycarbonyl, n-pentyloxycarbonyl, neopentyloxy, n-hexyloxycarbonyl, isohexyloxycarbonyl, 3-methylpentyloxycarbonyl group and the like.

[0093]

As the lower alkylcarbonyl group, a straight chain or branched chain alkylcarbonyl group having a carbon number of 1 - 6, wherein the lower alkyl moiety is the aforementioned lower alkyl group can be mentioned. More specific examples thereof include acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, pivaloyl and the like.

[0094]

As the amino lower alkylcarbonyl group, the aforementioned lower alkylcarbonyl group having 1 - 5, preferably 1 or 2, amino groups, can be mentioned. More specific examples thereof include aminomethylcarbonyl, 2-aminoethylcarbonyl, 1-aminoethylcarbonyl, 3-aminopropylcarbonyl, 4-aminobutylcarbonyl, 5-aminopentylcarbonyl, 6-aminoethylcarbonyl, 1,1-dimethyl-2-aminoethylcarbonyl, 2-methyl-3-aminopropylcarbonyl group and the like.

[0095]

As the lower alkoxycarbonyl lower alkyl group, the aforementioned lower alkyl group (preferably straight chain or branched chain alkyl group having a carbon number of 1 - 6), which has 1 - 3, preferably 1, lower alkoxycarbonyl group (e.g., methoxycarbonyl, ethoxycarbonyl, n-propoxycarbonyl, isopropoxycarbonyl, n-butoxycarbonyl, isobutoxycarbonyl, tert-butoxycarbonyl, sec-butoxycarbonyl, n-pentyloxycarbonyl, neopentyloxy, n-hexyloxycarbonyl, isohexyloxycarbonyl, 3-methylpentyloxycarbonyl group etc.) can be mentioned. Specific examples of the lower alkoxycarbonyl lower alkyl group include

methoxycarbonylmethyl group, ethoxycarbonylmethyl group, propoxycarbonylmethyl group, isopropoxycarbonylmethyl group, butoxycarbonylmethyl group, isobutoxycarbonylmethyl group, sec-butoxycarbonylmethyl group, tert-butoxycarbonylmethyl group, 2-methoxycarbonylethyl group, 2-ethoxycarbonylethyl group, 2-propoxycarbonylethyl group, 3-methoxycarbonylpropyl group, 3-ethoxycarbonylpropyl group, 4-methoxycarbonylbutyl group, 4-ethoxycarbonylbutyl group and the like.

[0096]

As the lower alkoxy lower alkoxy group, the aforementioned lower alkoxy group (preferably straight chain or branched chain alkoxy group having a carbon number of 1 - 6), which has 1 - 3, preferably 1, lower alkoxy group (preferably straight chain or branched chain alkoxy group having a carbon number of 1 - 6) mentioned above can be mentioned. Specific examples of the lower alkoxy lower alkoxy group include methoxymethoxy, ethoxymethoxy, propoxymethoxy, hexyloxymethoxy, methoxyethoxy, ethoxyethoxy, propoxyethoxy, isopropoxymethoxy, butoxymethoxy, tert-butoxymethoxy, pentyloxymethoxy, hexyloxymethoxy group and the like.

[0097]

As the phenyl lower alkoxy lower alkoxy group, the aforementioned lower alkoxy lower alkoxy group having 1 - 3, preferably 1, phenyl group can be mentioned. Specific examples of the phenyl lower alkoxy lower alkoxy group include benzyloxymethoxy, 2-phenylethoxymethoxy, 1-phenylethoxymethoxymethoxy, 3-phenylpropoxymethoxy, 4-phenylbutoxymethoxy, 1,1-dimethyl-2-phenylethoxymethoxy, 5-phenylpentyloxymethoxy, 6-phenylhexyloxymethoxy, 2-benzyloxyethoxy, 3-benzyloxypropoxy, 4-benzyloxybutoxy, 1,1-dimethyl-2-benzyloxyethoxy, 5-benzyloxypropoxy, 6-benzyloxyhexyloxy, 2-methyl-3-benzyloxypropoxy group and the like.

[0098]

As the lower alkoxy lower alkoxy lower alkyl group, the

aforementioned lower alkyl group (preferably straight chain or branched chain alkyl group having a carbon number of 1 - 6), which has 1 - 3, preferably 1, lower alkoxy lower alkoxy group mentioned above can be mentioned. Specific examples of the

5 lower alkoxy lower alkoxy lower alkyl group include methoxymethoxymethyl, 3-(3-methoxypropoxy)propyl, ethoxymethoxymethyl, 3-(3-ethoxypropoxy)propyl, 4-(4-ethoxybutoxy)butyl, 5-(5-isopropoxypentyloxy)pentyl, 6-(6-propoxyhexyloxy)hexyl, 1,1-dimethyl-2-(2-butoxyethoxy)ethyl,
10 2-methyl-3-(3-tert-butoxypropoxy)propyl, 2-(2-pentyloxyethoxy)ethyl, hexyloxymethoxymethyl group and the like.

[0099]

As the lower alkoxy lower alkoxy lower alkoxy lower alkyl
15 group, the aforementioned lower alkoxy lower alkyl group having 1 - 3, preferably 1, lower alkoxy lower alkoxy group mentioned above can be mentioned. Specific examples of the lower alkoxy lower alkoxy lower alkoxy lower alkyl group include methoxyethoxyethoxyethyl, ethoxyethoxyethoxyethyl
20 group and the like.

[0100]

As the phenyl lower alkoxy group, the aforementioned lower alkoxy group having 1 - 3, preferably 1, phenyl group can be mentioned. Specific examples of the phenyl lower alkoxy
25 group include benzyloxy, 2-phenylethoxy, 1-phenylethoxy, 3-phenylpropoxy, 4-phenylbutoxy, 1,1-dimethyl-2-phenylethoxy, 5-phenylpentyloxy, 6-phenylhexyloxy, 2-benzyloxy, 3-benzyloxy, 4-benzyloxy, 1,1-dimethyl-2-benzyloxy, 5-benzyloxy, 6-benzyloxy, 2-methyl-3-benzyloxy group and the like.

30 [0101]

As the phosphono lower alkoxy group, the aforementioned lower alkoxy group (preferably straight chain or branched chain alkoxy group having a carbon number of 1 - 6), which has 1 - 3, preferably 1, phosphono group can be mentioned.
35 Specific examples of the phosphono lower alkoxy group include

phosphonomethoxy, phosphonoethoxy, phosphonopropoxy, phosphonobutoxy, phosphonopentyloxy, phosphonohexyloxy group and the like.

[0102]

5 As the piperidyl group optionally having a lower alkyl group, a piperidyl group optionally having 1 - 3, preferably 1, lower alkyl group mentioned above can be mentioned. Specific examples of the piperidyl group optionally having a lower alkyl group include piperidyl, 2-methylpiperidyl, 3-methylpiperidyl, 2-ethylpiperidyl, 3-ethylpiperidyl group and
10 the like.

[0103]

As the halogen-substituted piperidyl group, a piperidyl group substituted by 1 - 7, more preferably 1 - 3, halogen
15 atoms can be mentioned. More specific examples thereof include fluoropiperidyl, difluoropiperidyl, chloropiperidyl, dichloropiperidyl, bromopiperidyl, dibromopiperidyl group and the like.

[0104]

20 The tri-lower alkylsilyl group is a silyl group substituted by 3 lower alkyl groups mentioned above. Specific examples thereof include trimethylsilyl, ethyldimethylsilyl, n-propyldimethylsilyl, tert-butyldimethylsilyl, triethylsilyl, methyldiethylsilyl, dimethylethylsilyl, triisopropylsilyl
25 group and the like.

[0105]

As the lower alkylene group, a straight chain or branched chain alkylene group having a carbon number of 1 - 6 can be mentioned. More specific examples thereof include methylene,
30 ethylene, trimethylene, 2-methyltrimethylene, 3-methyltetramethylene, 2,2-dimethyltrimethylene, 1-methyltrimethylene, methylmethylene, ethylmethylene, tetramethylene, pentamethylene, hexamethylene group and the like.

35 [0106]

As the alkylene group, a straight chain or branched chain alkylene group having a carbon number of 1 - 30 can be mentioned. More specific examples thereof include methylene, ethylene, trimethylene, tetramethylene, hexamethylene, 5 heptamethylene, octamethylene, decamethylene, undecamethylene, dodecamethylene, tridecamethylene, tetradecamethylene, hexadecamethylene, octadecamethylene, tricosamethylene, hexacosamethylene, triacontamethylene, 1-methylethylene, 2-ethyltrimethylene, 1-methylheptamethylene, 2-methylheptamethylene, 1-butylhexamethylene, 2-methyl-5-ethylheptamethylene, 2,3,6-trimethylheptamethylene, 6-ethyldecamethylene, 7-methyltetradecamethylene, 7-ethylhexadecamethylene, 7,12-dimethyloctadecamethylene, 8,11-dimethyloctadecamethylene, 7,10-dimethyl-7-ethylhexadecamethylene, 1-octadecylethylene, 9,10-dioctyloctadecamethylene, 8,9-dinonylhexadecamethylene, ethenylene, 1-octadecenylethylene, 7,11-octadecadienylene, 7-ethenyl-9-hexadecamethylene, 7,12-dimethyl-7,11-octadecadienylene, 8,11-dimethyl-7,11-octadecadienylene, 9,10-dioctyl-7,11-octadecadienylene, 8,9-dinonyl-6,10-hexadecadienylene group and the like.

[0107]

When the heterocyclic compound represented by the formula (I) is a cation, it is preferably present as a salt together with anion. The anion includes a halogen ion (e.g., Cl⁻, I⁻) and the like.

[0108]

In the formula (I),


[0109]

30 —W—Z—

[0110]

is


[0111]



[0112]

R¹ is preferably the following group

[0113]




[0114]

wherein

R^{8a} is

- (1) an alkyl group,
- 10 (2) a cycloalkyl group,
- (3) a lower alkoxy group,
- (4) a cycloalkyloxy group,
- (5) a lower alkoxy lower alkoxy group,
- (6) an amino group optionally having 1 or 2 substituents
- 15 selected from the group consisting of an alkyl group and a hydroxy-substituted lower alkyl group, or
- (7) the following group

[0115]




20 [0116]

wherein Aa' is an alkylene group and A is a lower alkylene group, or

the following group

[0117]




[0118]

wherein

 R^{9a} is

- (1) an alkyl group,
- 5 (2) a hydroxy-substituted lower alkyl group,
- (3) a cycloalkyl group,
- (4) a lower alkoxy group,
- (5) a cycloalkyloxy group,
- (6) a lower alkoxy lower alkoxy group,
- 10 (7) a phenyloxy group,
- (8) an amino group optionally having 1 or 2 substituents selected from the group consisting of an alkyl group,
- (9) a piperidyl group optionally having a piperidyl group,
- (10) a piperazinyl group optionally having a lower alkyl group,
- 15 or
- (11) the following group

[0119]




20 [0120]

wherein Ab' is an alkylene group and A is a lower alkylene group,

more preferably,

the following group

25 [0121]




[0122]

wherein

 $R^{8a'}$ is

- (1) an alkyl group,
- (2) a cycloalkyl group,
- (3) a lower alkoxy group,
- (4) a cycloalkyloxy group,
- 5 (5) a lower alkoxy lower alkoxy group, or
- (6) an amino group optionally having 1 or 2 substituents selected from the group consisting of an alkyl group and a hydroxy-substituted lower alkyl group, or the following group

10 [0123]



[0124]

wherein


R^{9a'} is


- 15 (1) an alkyl group,
- (2) a hydroxy-substituted lower alkyl group,
- (3) a cycloalkyl group,
- (4) a lower alkoxy group,
- (5) a cycloalkyloxy group,
- 20 (6) a lower alkoxy lower alkoxy group,
- (7) a phenyloxy group,
- (8) an amino group optionally having 1 or 2 substituents selected from the group consisting of an alkyl group,
- (9) a piperidyl group optionally having a piperidyl group, or
- 25 (10) a piperazinyl group optionally having a lower alkyl group.

As R²,

the following group

[0125]





[0126]

wherein

 Y^{1a} is a lower alkylene group,5 Y^{2a} is a lower alkylene group, R^{3a} is

(1) an alkyl group,

(2) a cycloalkyl group,

(3) a piperidyl group optionally having 1 or 2 substituents

10 selected from the group consisting of a lower alkyl group,

(4) a tetrahydropyranyl group,

(5) a lower alkoxy carbonyl lower alkyl group,


(6) a lower alkoxy lower alkoxy lower alkyl group,

(7) an amino lower alkyl group optionally having a lower

15 alkyl carbonyl group, or

(8) the following group

[0127]



[0128]

20 wherein Ac' is an alkylene group, Y^{1a} is a lower alkylene group
and A is a lower alkylene group,



 R^{4a} is

(1) an alkyl group, or

(2) a cycloalkyl group is preferable, more preferably, R^2 is

25 the following group

[0129]



[0130]

wherein

5 Y^{1a} is a lower alkylene group,

Y^{2a} is a lower alkylene group,

$R^{3a'}$ is

(1) an alkyl group,

(2) a cycloalkyl group,

10 (3) a piperidyl group optionally having 1 or 2 substituents selected from the group consisting of a lower alkyl group,

(4) a tetrahydropyranyl group,

(5) a lower alkoxycarbonyl lower alkyl group,

(6) a lower alkoxy lower alkoxy lower alkyl group, or

15 (7) an amino lower alkyl group optionally having a lower alkylcarbonyl group,

R^{4a} is


(1) an alkyl group, or

(2) a cycloalkyl group.

20 [0131]

The heterocyclic compound represented by the formula (I) is preferably a heterocyclic compound represented by the following formula (II)

[0132]



25


[0133]

wherein each symbol is as defined in the present specification.

More preferably, it is a heterocyclic compound

represented by the following formula (III)

[0134]



[0135]

5 wherein each symbol is as defined in the present specification.

That is, in the formula (I),


[0136]

=====J

[0137]

10 shown at the 3-position and the 4-position of the bicyclic heterocycle skeleton containing Z and W is preferably -CH=CH-, and


[0138]



15 [0139]

in the monocyclic heterocycle containing Q is preferably

[0140]




[0141]

20 A heterocyclic compound represented by the above-mentioned formula (I) (hereinafter sometimes to be referred to as compound (I)) can be produced by various methods. For example, it can be produced by a method shown by the following reaction scheme.

[Reaction scheme - 1]

[0142]



[0143]

5 wherein each symbol is as defined above.

In the formula (I-a), the halogen atom for X_1 is as defined above.

[0144]

Examples of the group that causes a substitution reaction
 10 similar to that by a halogen atom include a lower
 alkanesulfonyloxy group, an arylsulfonyloxy group, an
 aralkylsulfonyloxy group and the like.

[0145]

Specific examples of the lower alkanesulfonyloxy group
 15 for X_1 include a straight chain or branched chain
 alkanesulfonyloxy group having a carbon number of 1 - 6 such
 as methanesulfonyloxy, ethanesulfonyloxy, n-propanesulfonyloxy,
 isopropanesulfonyloxy, n-butanessulfonyloxy, tert-
 butanesulfonyloxy, n-pentanesulfonyloxy, n-hexanesulfonyloxy
 20 group and the like.

[0146]

Examples of the arylsulfonyloxy group for X_1 include
 phenylsulfonyloxy, naphthylsulfonyloxy group and the like,
 which optionally have, as a substituent on the phenyl ring, 1
 25 - 3 groups selected from the group consisting of a straight
 chain or branched chain alkyl group having a carbon number of
 1 - 6, a straight chain or branched chain alkoxy group having
 a carbon number of 1 - 6, a nitro group and a halogen atom.
 Specific examples of the above-mentioned phenylsulfonyloxy
 30 group optionally having substituent(s) include
 phenylsulfonyloxy, 4-methylphenylsulfonyloxy, 2-

methylphenylsulfonyloxy, 4-nitrophenylsulfonyloxy, 4-methoxyphenylsulfonyloxy, 2-nitrophenylsulfonyloxy, 3-chlorophenylsulfonyloxy group and the like. Specific examples of the naphthylsulfonyloxy group include α -naphthylsulfonyloxy, β -naphthylsulfonyloxy group and the like.

[0147]

Examples of the aralkylsulfonyloxy group for X_1 include a straight chain or branched chain alkanesulfonyloxy group having a carbon number of 1 - 6 and substituted by a phenyl group, which optionally have, as a substituent on the phenyl ring, 1 - 3 groups selected from the group consisting of a straight chain or branched chain alkyl group having a carbon number of 1 - 6, a straight chain or branched chain alkoxy group having a carbon number of 1 - 6, a nitro group and a halogen atom, a straight chain or branched chain alkanesulfonyloxy group having a carbon number of 1 - 6 and substituted by a naphthyl group and the like. Specific examples of the above-mentioned alkanesulfonyloxy group substituted by a phenyl group include benzylsulfonyloxy, 2-phenylethylsulfonyloxy, 4-phenylbutylsulfonyloxy, 4-methylbenzylsulfonyloxy, 2-methylbenzylsulfonyloxy, 4-nitrobenzylsulfonyloxy, 4-methoxybenzylsulfonyloxy, 3-chlorobenzylsulfonyloxy group and the like. Specific examples of the above-mentioned alkanesulfonyloxy group substituted by a naphthyl group include α -naphthylmethylsulfonyloxy, β -naphthylmethylsulfonyloxy group and the like.

[0148]

The reaction of a compound represented by the formula (I-a) and a compound represented by the formula (I-b) is performed without solvent or in an inert solvent, in the presence or absence of a basic compound.

[0149]

Examples of the inert solvent include water; ethers such as dioxane, tetrahydrofuran, diethyl ether, diethylene glycol dimethylether, ethylene glycol dimethylether and the like;

aromatic hydrocarbons such as benzene, toluene, xylene and the like; lower alcohols such as methanol, ethanol, isopropanol and the like; ketones such as acetone, methylethyl ketone and the like; polar solvents such as N,N-dimethylformamide (DMF),
5 dimethyl sulfoxide (DMSO), hexamethylphosphoric acid triamide, acetonitrile and the like.

[0150]

As the basic compound, known ones can be widely used and, for example, alkali metal hydroxide such as sodium hydroxide,
10 potassium hydroxide, cesium hydroxide, lithium hydroxide and the like; alkali metal carbonate such as sodium carbonate, potassium carbonate, cesium carbonate, lithium carbonate and the like; alkali metal hydrogen carbonate such as lithium hydrogen carbonate, sodium hydrogen carbonate, potassium
15 hydrogen carbonate and the like; alkali metal such as sodium, potassium and the like; inorganic base such as sodium amide, sodium hydride, potassium hydride and the like, and alkali metal alcoholates such as sodium methoxide, sodium ethoxide, potassium methoxide, potassium ethoxide and the like; organic
20 base such as triethylamine, tripropylamine, pyridine, quinoline, piperidine, imidazole, N-ethyldiisopropylamine, dimethylaminopyridine, trimethylamine, dimethylaniline, N-methylmorpholine, 1,5-diazabicyclo[4.3.0]nonene-5(DBN), 1,8-diazabicyclo[5.4.0]undecene-7(DBU), 1,4-
25 diazabicyclo[2.2.2]octane(DABCO) and the like.

[0151]

One kind alone from these basic compounds is used, or two or more kinds thereof are mixed and used.

[0152]

30 The amount of the basic compound to be used is generally 0.5 - 10-fold mol, preferably 0.5 - 6-fold mol, relative to the compound of the formula (I-a).

[0153]

The above-mentioned reaction can be performed by adding,
35 as necessary, an alkali metal iodide such as potassium iodide,

sodium iodide and the like as a reaction promoter.

[0154]


The proportion of the compound of the formula (I-a) and the compound of the formula (I-b) to be used in the above-mentioned reaction scheme - 1 is generally at least 0.5-fold mol, preferably about 0.5- to 5-fold mol, of the latter relative to the former.

[0155]

The above-mentioned reaction is performed generally at room temperature - 200°C, preferably room temperature - 150°C, and completes in about 1 - 30 hr.

[Reaction scheme - 2]

[0156]



[0157]

wherein X_2 is a hydroxyl group, a halogen atom or a group that causes a substitution reaction similar to that by a halogen atom, and other symbols are as defined above.

The halogen atom or group that causes a substitution reaction similar to that by a halogen atom for X_2 is as defined above.

[0158]

The reaction of a compound represented by the formula (I-c) and a compound represented by the formula (I-d) is performed under the reaction conditions similar to those of the reaction of a compound represented by the formula (I-a) and a compound represented by the formula (I-b) in the aforementioned reaction scheme - 1.

[0159]

When compound (I-d) wherein X_2 is a hydroxyl group is used, the reaction of compound (I-c) and compound (I-d) can

also be performed in a suitable solvent, in the presence of a condensing agent.

[0160]

Specific examples of the solvent to be used here include
5 water; halogenated hydrocarbons such as chloroform,
dichloromethane, dichloroethane, carbon tetrachloride and the
like; aromatic hydrocarbons such as benzene, toluene, xylene
and the like; ethers such as diethyl ether, diisopropyl ether,
tetrahydrofuran, dimethoxyethane and the like; esters such as
10 methyl acetate, ethyl acetate, isopropyl acetate and the like;
alcohols such as methanol, ethanol, isopropanol, propanol,
butanol, 3-methoxy-1-butanol, ethylcellosolve,
methylcellosolve and the like; aprotic polar solvent such as
acetonitrile, pyridine, acetone, DMF, DMSO,
15 hexamethylphosphoric acid triamide and the like, and a mixed
solvent thereof and the like.

[0161]

As the condensing agent, a mixture of azocarboxylate such
as diethylazodicarboxylate and the like and phosphorus
20 compound such as triphenylphosphine and the like, and the like
can be mentioned.

[0162]

The amount of the condensing agent to be used is
generally at least an equimolar amount, preferably equimole to
25 2-fold molar amount, relative to compound (I-c).

[0163]

The amount of compound (I-d) to be used is generally at
least an equimolar amount, preferably equimole to 2-fold molar
amount, relative to compound (I-c).

30 [0164]

This reaction preferably proceeds generally at 0 - 200°C,
preferably about 0 - 150°C, and generally completes in about 1
- 10 hr.


[0165]

35 The compound of the formula (I-a) to be used as a

starting material is produced, for example, by of the method shown in the following reaction scheme - 3, and the compound represented by the formula (I-d) is produced, for example, by of the method shown in the following reaction scheme - 4.

5 [Reaction scheme - 3]

[0166]



[0167]

wherein X_3 is a hydroxyl group, a halogen atom or a group that causes a substitution reaction similar to that by a halogen atom, and other symbols are as defined above.


The halogen atom or group that causes a substitution reaction similar to that by a halogen atom for X_3 is as defined above.

15 [0168]

The reaction of a compound represented by the formula (I-c) and a compound represented by $X_3\text{-A-X}_1$ is performed under the reaction conditions similar to those of the reaction of a compound represented by the formula (I-c) and a compound represented by the formula (I-d) in the aforementioned reaction scheme - 2.

[Reaction scheme - 4]

[0169]



25 [0170]

wherein X_4 is a hydroxyl group, a halogen atom or a group that causes a substitution reaction similar to that by a halogen atom, and other symbols are as defined above.



The halogen atom or group that causes a substitution reaction similar to that by a halogen atom for X_4 is as defined above.

[0171]

5 The reaction of a compound represented by the formula (I-b) and a compound represented by X_2-A-X_4 is performed under the reaction conditions similar to those of the reaction of a compound represented by the formula (I-a) and a compound represented by the formula (I-b) in the aforementioned
 10 reaction scheme - 1. Both the compound of the formula (I-b) and a compound represented by X_2-A-X_4 are easily-available known compounds.

[Reaction scheme - 5]

[0172]



[0173]

wherein X_5 is a halogen atom or a group that causes a substitution reaction similar to that by a halogen atom, and other symbols are as defined above.

20 The halogen atom or group that causes a substitution reaction similar to that by a halogen atom for X_5 is as defined above.

[0174]

The reaction of a compound represented by the formula (I-e) and a compound represented by R^2-X_5 is performed under the reaction conditions similar to those of the reaction of a compound represented by the formula (I-a) and a compound
 5 represented by the formula (I-b) in the aforementioned reaction scheme - 1.

[0175]

When


[0176]



[0177]

in the monocyclic heterocycle containing Q is

[0178]




15 [0179]

wherein $R^{2'}$ is as defined above,

the compound can be synthesized in the same manner as in the below-mentioned Example 383.

A compound wherein R^8 is

20 [0180]




[0181]

wherein each symbol is as defined above,

a compound wherein R^9 is


25 [0182]



[0183]

wherein each symbol is as defined above, and
a compound wherein R³ is

5 [0184]



[0185]

wherein each symbol is as defined above,
can be synthesized by a combination of the methods described
10 in the below-mentioned Example 14 and Example 22.

[0186]

A compound (I) having a hydroxyl group on the bicyclic
heterocycle skeleton containing Z and W is produced by
treating a compound (I) having a methoxy group on the skeleton
15 in a suitable solvent or without solvent, in the presence of
an acid.

[0187]

Examples of the solvent used here include aromatic
hydrocarbons such as benzene, toluene, xylene and the like;
20 ethers such as diethyl ether, tetrahydrofuran, dioxane,
monoglyme, diglyme and the like; halogenated hydrocarbons such
as dichloromethane, dichloroethane, chloroform, carbon
tetrachloride and the like; fatty acid such as acetic acid and
the like; esters such as ethyl acetate, methyl acetate and the
25 like; ketones such as acetone, methyl ethyl ketone and the
like; acetonitrile, pyridine, DMF, DMSO, hexamethylphosphoric
acid triamide and a mixed solvent thereof and the like.

[0188]

Examples of the acid include mineral acid such as hydrobromic acid, hydrochloric acid, conc. sulfuric acid and the like, fatty acid such as formic acid, acetic acid and the like, organic acid such as p-toluenesulfonic acid and the like, Lewis acid such as aluminum chloride, zinc chloride, iron chloride, tin chloride, boron trifluoride, boron tribromide and the like, iodide such as sodium iodide, potassium iodide and the like, a mixture of the above-mentioned Lewis acid and iodide and the like.

[0189]

Such acid is preferably used in an amount of generally 0.1- to 15-fold molar amount, preferably 0.5- to 10-fold molar amount, relative to compound (I). When the reaction is performed without solvent, an acid is generally used in an excess amount.

[0190]

This reaction is performed generally at 0 - 150°C, preferably about 0 - 100°C, and generally completes in about 0.5 - 75 hr.

[0191]

The starting compound used for each of the above-mentioned reaction schemes may be a preferable salt, and the object compound obtained in each reaction may form a preferable salt. The preferable salt thereof may be similar to the preferable salts of compound (I) shown below.

[0192]

The preferable salt of compound (I) is a pharmaceutically acceptable salt and, for example, metal salts such as alkali metal salt (e.g., sodium salt, potassium salt etc.), alkaline earth metal salt (e.g., calcium salt, magnesium salt etc.) and the like; salts with inorganic bases such as ammonium salt, alkali metal carbonate (e.g., lithium carbonate, potassium carbonate, sodium carbonate, cesium carbonate etc.), alkali metal hydrogen carbonate (e.g., lithium hydrogen carbonate,

sodium hydrogen carbonate, potassium hydrogen carbonate etc.), alkali metal hydroxide (e.g., lithium hydroxide, sodium hydroxide, potassium hydroxide, cesium hydroxide etc.) and the like; salts with organic bases such as tri(lower)alkylamine (e.g., trimethylamine, triethylamine, N-ethyldiisopropylamine etc.), pyridine, quinoline, piperidine, imidazole, picoline, dimethylaminopyridine, dimethylaniline, N-(lower)alkyl-morpholine (e.g., N-methylmorpholine etc.), 1,5-diazabicyclo[4.3.0]nonene-5 (DBN), 1,8-diazabicyclo[5.4.0]undecene-7 (DBU), 1,4-diazabicyclo[2.2.2]octane (DABCO) and the like; salts with inorganic acids such as hydrochloride, hydrobromide, hydroiodide, sulfate, nitrate, phosphate and the like; salts with organic acids such as formate, acetate, propionate, oxalate, malonate, succinate, fumarate, maleate, lactate, malate, citrate, tartrate, carbonate, picrate, methanesulfonate, ethanesulfonate, p-toluenesulfonate, glutamate, pamoate and the like; and the like can be mentioned.

In the following, compound (I) and a salt thereof are sometimes to be generically referred to as the compound of the present invention.

[0193]

In addition, a compound wherein a solvate (e.g., hydrate, ethanolate etc.) is added to a starting material or object compound shown in each reaction scheme is also encompassed in each formula. As a preferable solvate, hydrate can be mentioned.

[0194]

Each object compound obtained in each of the above-mentioned reaction schemes can be isolated and purified from the reaction mixture by for example, cooling the reaction mixture, applying an isolation operation of filtration, concentration, extraction and the like to separate a crude reaction product, and applying a general purification operation such as column chromatography, recrystallization and

the like.

[0195]

Compound (I) naturally encompasses isomers such as a geometric isomer, a stereoisomer, an optical isomer and the
5 like.

[0196]

Compound (I) usable in the present invention is also encompasses same compounds labeled with the isotope, wherein one or plural atoms is(are) replaced by one or plural atoms
10 having a particular atomic mass or mass number. Examples of the isotope that can be incorporated into compound (I) include hydrogen, carbon, nitrogen, oxygen, sulfur, fluorine and chlorine isotopes such as ^2H , ^3H , ^{13}C , ^{14}C , ^{15}N , ^{18}O , ^{17}O , ^{18}F , ^{36}Cl and the like. Compound (I) labeled with particular isotope,
15 which contains the above-mentioned isotope and/or other isotope of other atom, for example, compound (I) incorporating a radioactive isotope such as ^3H , ^{14}C and the like, is useful for drug tissue distribution assay and/or substrate tissue distribution assay. Tritiated (i.e., ^3H) or carbon-14 (i.e.,
20 ^{14}C) isotope are particularly preferred because of easiness of preparation and detectability. Furthermore, substitution with a heavier isotope such as deuterium (i.e., ^2H) and the like is expected to provide improved metabolic stability and particular therapeutic advantage attributable to increased in
25 vivo half-time or decreased amount of necessary administration. An isotope-labeled compound of compound (I) can be generally prepared according to the method disclosed in WO2006/112464, by substituting a non-isotope-labeled reagent with an easily available isotope-labeled reagent.

30 [0197]

Compound (I) may be a pharmaceutically acceptable cocrystal or a cocrystal salt. Here, the cocrystal or cocrystal salt means a crystalline substance, which is constituted from two or more kinds of specific solids each
35 having different physical properties (e.g., structure, melting

point, heat of fusion and the like) at room temperature. The cocrystal and cocrystal salt can be produced by applying a cocrystallization method known per se.

[0198]

5 Compound (I) and a salt thereof are used in the form of a general pharmaceutical preparation. Such preparation is prepared using a diluent or excipient generally used such as filler, extender, binder, humidifying agent, disintegrant, surface activating agent, lubricant and the like. The
10 pharmaceutical preparation can have various forms depending on the treatment object, and representative examples include tablet, pill, powder, liquid, suspension, emulsion, granule, capsule, suppository, injection (liquid, suspension etc.) and the like.

15 [0199]

For formulation of a tablet, various ones conventionally known as a carrier in this field can be widely used. Examples thereof include excipients such as lactose, sucrose, sodium chloride, glucose, urea, starch, calcium carbonate, kaolin,
20 crystalline cellulose, silicic acid and the like, binders such as water, ethanol, propanol, simple syrup, glucose solution, starch solution, gelatin solution, carboxymethylcellulose, shellac, methylcellulose, potassium phosphate, polyvinylpyrrolidone and the like, disintegrants such as dry
25 starch, sodium alginate, agar powder, laminaran powder, sodium hydrogen carbonate, calcium carbonate, polyoxyethylene sorbitan fatty acid esters, sodium lauryl sulfate, stearic acid monoglyceride, starch, lactose and the like, disintegration inhibitors such as sucrose, stearin, cacao
30 butter, hydrogenation oil and the like, absorption promoters such as quaternary ammonium base, sodium lauryl sulfate and the like, moisturizers such as glycerol, starch and the like, adsorbent such as starch, lactose, kaolin, bentonite, colloidal silicic acid and the like, lubricants such as
35 purified talc, stearate, boric acid powder, polyethylene

glycol and the like; and the like. Where necessary, the tablet can take the form of a tablet having a general coating, for example, sugar-coated tablet, gelatin-coated tablet, enteric tablet, film-coated tablet or double-compressed tablet, or
5 multi-layer tablet.

[0200]

For formulation of a pill, various ones conventionally known as a carrier in this field can be widely used. Examples thereof include excipients such as glucose, lactose, starch,
10 cacao butter, hydrogenated vegetable oil, kaolin, talc and the like, binders such as gum arabic powder, tragacanth powder, gelatin, ethanol and the like, disintegrants such as laminaran, agar and the like; and the like.

[0201]

15 For formulation of a suppository, various ones conventionally known as a carrier in this field can be widely used. Examples thereof include polyethylene glycol, cacao butter, higher alcohol, higher alcohol esters, gelatin, semisynthetic glyceride and the like.

20 [0202]

A capsule is prepared by a conventional method by generally mixing an active ingredient compound with various carriers mentioned above and filling the mixture in a hard gelatin capsule, a soft capsule and the like.

25 [0203]

For formulation of an injection, a liquid, an emulsion and a suspension are preferably sterilized and isotonic with blood. For formulation into such form, various ones conventionally known as a diluent in this field can be widely
30 used. Examples thereof include water, ethyl alcohol, macrogol, propylene glycol, ethoxylated isostearyl alcohol, polyoxylated isostearyl alcohol, polyoxyethylene sorbitan fatty acid esters and the like.

[0204]

35 In this case, sodium chloride, glucose or glycerol in an

amount sufficient for the preparation of an isotonic solution may be contained in a pharmaceutical preparation, or general solubilizing agent, buffering agent, soothing agent and the like may be further added. Where necessary, colorant, preservative, fragrant material, flavor, sweetening agent and the like and other pharmaceutical products may be further contained in the pharmaceutical preparation.

[0205]

The amount of compound (I) or a salt thereof to be contained in the pharmaceutical preparation of the present invention is not particularly limited and is appropriately selected from a wide range. It is generally about 1 - 70 wt%, preferably about 1 - 30 wt%, of the preparation composition.

[0206]

The administration method of the pharmaceutical preparation of the present invention is not particularly limited, and a method suitable for various dosage forms, age, sex and other conditions of patients, level of disease and the like is employed for administration. For example, tablet, pill, liquid, suspension, emulsion, granule and capsule are orally administered. An injection is intravenously administered singly or as a mixture with a general fluid replacement such as glucose, amino acid and the like. Where necessary, it is administered singly by intramuscular, intradermal, subcutaneous or intraperitoneal administration. A suppository is intrarectally administered.

[0207]

While the dose of the pharmaceutical preparation of the present invention is appropriately selected according to use, age, sex and other conditions of patients, level of disease and the like, the amount of the active ingredient compound is generally about 0.1 - 10 mg per day and per 1 kg body weight. The active ingredient compound in the range of about 1 - 200 mg is desirably contained in a unit administration form of preparation.

Effect of the Invention

[0208]

The compound of the present invention has a D₂ receptor partial agonist effect, a 5-HT_{2A} receptor antagonist effect and
5 a serotonin uptake inhibitory effect (or serotonin reuptake inhibitory effect).

[0209]

The D₂ receptor partial agonist effect suppresses dopaminergic (DA) neurotransmission when it is enhanced, and
10 accelerates the DAergic neurotransmission when it is lowered and thus has a function to stabilize the DA neurotransmission to a normal state (dopamine system stabilizer). According to this function, excellent clinically improving effect on the abnormal DA neurotransmission (enhancement and lowering), for
15 example, improving effect on positive and negative symptoms, improving effect on cognitive impairment, improving effect on depressive symptom etc. are developed without causing side effects (see Michio Toru: Clinical Psychiatry, vol. 46, pages 855 - 864 (2004), Tetsuro Kikuchi and Tsuyoshi Hirose: Brain
20 Science, vol. 25, pages 579 - 583 (2004), and Harrison, T. S. and Perry, C. M.: Drugs 64: 1715-1736, 2004).

[0210]

5-HT_{2A} receptor antagonist effect reduces extrapyramidal side effects, develops superior clinical effects, and is
25 effective, for example, for improvement of negative symptoms, improvement of cognitive impairment, improvement of depressive symptom, improvement of insomnia and the like (see Jun Ishigooka and Ken Inada: Japanese Journal of Clinical Psychopharmacology, vol. 4, pages 1653 - 1664 (2001),
30 Mitsukuni Murasaki: Japanese Journal of Clinical Psychopharmacology, vol. 1, pages 5 - 22 (1998), Pullar, I.A. et al.: Eur. J. Pharmacol., 407: 39-46, 2000, and Meltzer, H. Y. et al.: Prog. Neuro-psychopharmacol. Biol. Psychiatry 27: 1159-1172, 2003).

35 [0211]

Serotonin uptake inhibitory effect (or serotonin reuptake inhibitory effect) is effective, for example, for improvement of depressive symptom (see Mitsukuni Murasaki: Japanese Journal of Clinical Psychopharmacology, vol. 1, pages 5 - 22 (1998)).

[0212]

The compound of the present invention is excellent in all of these three effects, or remarkably excellent in one or two of these effects.

[0213]

In addition, some of the compounds of the present invention have α_1 receptor antagonist effect in addition to the above-mentioned effects. The α_1 receptor antagonist effect is effective for improving positive symptoms of schizophrenia (see Svensson, T. H.: Prog. Neuro-psychopharmacol. Biol. Psychiatry 27: 1145-1158, 2003).

[0214]

Therefore, the compound of the present invention has a wide treatment spectrum for and excellent clinical effect on schizophrenia and other central nervous system diseases.

[0215]

Accordingly, the compound, the medicament, and pharmaceutical composition of the present invention are extremely effective for the improvement of various central nervous system disorders including schizophrenia, treatment-resistant, refractory or chronic schizophrenia, emotional disturbance, psychotic disorder, mood disorder, bipolar disorder (e.g., bipolar disorder type I and bipolar disorder type II), mania, depression, endogenous depression, major depression, melancholic and treatment-resistant depression, dysthymic disorder, cyclothymic disorder, anxiety disorder (e.g., panic attack, panic disorder, agoraphobia, social phobia, obsessive-compulsive disorder, post-traumatic stress disorder, generalized anxiety disorder, acute stress disorder, etc.), somatoform disorder (e.g., hysteria, somatization

disorder, conversion disorder, pain disorder, hypochondriasis, etc.), factitious disorder, dissociative disorder, sexual disorder (e.g., sexual dysfunction, sexual desire disorder, sexual arousal disorder, erectile dysfunction, etc.), eating
5 disorder (e.g., anorexia nervosa, bulimia nervosa, etc.), sleep disorder, adjustment disorder, substance-related disorder (e.g., alcohol abuse, alcohol intoxication and drug addiction, stimulant intoxication, narcotism, etc.), anhedonia (e.g., anhedonia, anhedonia, iatrogenic anhedonia, anhedonia
10 of a psychic or mental cause, anhedonia associated with depression, anhedonia associated with schizophrenia, etc.), delirium, cognitive impairment, cognitive impairment associated with Alzheimer's disease, Parkinson's disease, and other neurodegenerative diseases, cognitive impairment caused
15 by Alzheimer's disease, Parkinson's disease and associated neurodegenerative diseases, cognitive impairment in schizophrenia, cognitive impairment caused by treatment-resistant, refractory or chronic schizophrenia, vomiting, motion sickness, obesity, migraine, pain, mental retardation,
20 autistic disorder (autism), Tourette's disorder, tic disorder, attention deficit hyperactivity disorder, conduct disorder, Down's syndrome and the like.

[0216]

Moreover, the compound of the present invention scarcely
25 shows side effects and is superior in the tolerability and safety.

[0217]

Furthermore, the compound of the present invention is markedly superior in the solubility in oil such as sesame oil
30 and benzyl benzoate, and can be applied to an oil injection. An oil preparation of the compound of the present invention shows superior blood concentration sustainability. Since the compound of the present invention changes, in blood, to a compound (compound (1)) disclosed in patent document 1, the
35 compound of the present invention is also superior in the

long-term maintenance of the blood concentration of compound (1) having desired efficacy.

[0218]

In addition, the compound of the present invention is easily crystallized, superior in the operability, and also superior in the chemical stability.

[0219]

In addition, the compound (I) of the present invention can exert effects such as decreasing the amount of administration, improving side effects, enhancing therapeutic efficacy or the like which could not be attained by conventional treatment by administering with at least one clinically used drug(s) selected from the group consisting of (1) mood stabilizers, (2) serotonin reuptake inhibitors, (3) norepinephrine reuptake inhibitors, (4) serotonin and norepinephrine reuptake inhibitors and (5) antidepressants.


[0220]

The present invention is explained in more detail in the following by referring to Reference Example, Example and Experimental Example, which are not to be construed as

Reference Example 1

Synthesis of 7-(tert-butyl dimethylsilanyloxy)-1-hydroxymethyl-3,4-dihydro-1H-quinolin-2-one

[0221]



[0222]

7-(tert-Butyl-dimethylsilanyloxy)-3,4-dihydro-1H-quinolin-2-one (830 mg) was suspended in DMF (13 ml), formaldehyde (4.3 ml) and triethylamine (0.083 ml) were added, and the mixture was stirred at 80°C overnight. After cooling

to room temperature, water was added, and the mixture was extracted with ethyl acetate, dried over sodium sulfate, and purified by moderate-pressure silica gel column chromatography (hexane:ethyl acetate=2:1) to give the title compound (36 mg)


5 as white crystals.

[0223]

Reference Example 2

Synthesis of acetic acid 7-(tert-butyldimethylsilanyloxy)-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester

10 [0224]



[0225]

To a solution of 7-(tert-butyldimethylsilanyloxy)-1-hydroxymethyl-3,4-dihydro-1H-quinolin-2-one (37 mg) obtained in Reference Example 1 in dichloromethane were added pyridine (0.049 ml) and acetyl chloride (0.022 ml) and the mixture was stirred at room temperature overnight, and concentrated under reduced pressure. The residue was purified by moderate-pressure silica gel column chromatography (hexane:ethyl acetate=2:1) to give the title compound (26 mg) as a colorless oil.


¹H-NMR (CDCl₃) δ: 0.20 (s, 6H), 0.99 (s, 9H), 2.10 (s, 3H), 2.65-2.72 (m, 2H), 2.83-2.89 (m, 2H), 5.89 (brs, 2H), 6.51-6.56 (m, 2H), 6.99-7.04 (m, 1H)

25 [0226]

Reference Example 3

Synthesis of 7-(4-chlorobutoxy)-1-hydroxymethyl-3,4-dihydro-1H-quinolin-2-one

[0227]



[0228]


The compound was synthesized in the same manner as in Reference Example 1.

5 [0229]

Reference Example 4

Synthesis of acetic acid 7-(4-chlorobutoxy)-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester

[0230]



10

[0231]

The compound was synthesized in the same manner as in Reference Example 2.


$^1\text{H-NMR}$ (CDCl_3) δ : 1.90-2.03 (m, 4H), 2.12 (s, 3H), 2.64-2.72 (m, 2H), 2.84-2.90 (m, 2H), 3.63 (t, $J = 6.2$ Hz, 2H), 3.99 (t, $J = 5.7$ Hz, 2H), 5.91 (brs, 2H), 6.58 (dd, $J = 2.3, 8.2$ Hz, 1H), 6.62 (d, $J = 2.3$ Hz, 1H), 7.08 (d, $J = 8.2$ Hz, 1H)

[0232]

Reference Example 5

20 Synthesis of 7-benzyloxy-1-hydroxymethyl-3,4-dihydro-1H-quinolin-2-one

[0233]



[0234]


The compound was synthesized in the same manner as in Reference Example 1.

[0235]

Reference Example 6

- 5 Synthesis of tetradecanoic acid 7-benzyloxy-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester

[0236]



[0237]


- 10 The compound was synthesized in the same manner as in Reference Example 2.

[0238]

Reference Example 7

- Synthesis of tetradecanoic acid 7-hydroxy-2-oxo-3,4-dihydro-
15 2H-quinolin-1-ylmethyl ester

[0239]



[0240]

- To a solution of tetradecanoic acid 7-benzyloxy-2-oxo-
20 3,4-dihydro-2H-quinolin-1-ylmethyl ester (528 mg) obtained in Reference Example 6 in ethanol (10 ml) was added 10% palladium carbon (53 mg), and the mixture was substituted with hydrogen and stirred at room temperature for 2.5 hr. The catalyst was filtered off, and the residue was concentrated under reduced
25 pressure and purified by moderate-pressure silica gel column

chromatography (ethyl acetate). After concentration under reduced pressure, the residue was recrystallized from hexane-ethyl acetate to give the title compound (209 mg) as a white powder.


5 $^1\text{H-NMR}$ (CDCl_3) δ : 0.88 (t, $J = 6.8$ Hz, 3H), 1.20-1.35 (m, 20H), 1.58-1.68 (m, 2H), 2.35 (t, $J = 7.6$ Hz, 2H), 2.65-2.71 (m, 2H), 2.82-2.88 (m, 2H), 5.05 (brs, 1H), 5.90 (brs, 2H), 6.53 (dd, $J = 2.4, 8.1$ Hz, 1H), 6.56 (d, $J = 2.4$ Hz, 1H), 7.03 (d, $J = 8.1$ Hz, 1H)

10 [0241]

Reference Example 8

Synthesis of acetic acid 7-(4-chlorobutoxy)-2-oxo-2H-quinolin-1-ylmethyl ester

[0242]



15

[0243]

Acetic acid 7-(4-chlorobutoxy)-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester (339 mg) obtained in Reference Example 4 was dissolved in tetrahydrofuran (10 ml), 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) (709 mg) was added, and the mixture was stirred at room temperature for 2 days. To the reaction mixture was added aqueous sodium hydrogen carbonate solution and the mixture was stirred, filtered, and the filtrate was extracted with methylene chloride, dried over sodium sulfate, and concentrated under reduced pressure, and the residue was purified by moderate-pressure silica gel column chromatography (ethyl acetate) and concentrated under reduced pressure to give the title compound (299 mg) as a colorless oil.

30 $^1\text{H-NMR}$ (CDCl_3) δ : 1.94-2.04 (m, 4H), 2.13 (s, 3H), 3.60-3.68 (m, 2H), 4.05-4.12 (m, 2H), 6.32 (brs, 2H), 6.53 (d, $J = 9.5$ Hz,


1H), 6.83 (dd, J = 2.2, 8.6 Hz, 1H), 6.89 (d, J = 2.2 Hz, 1H),
7.46 (d, J = 8.6 Hz, 1H), 7.63 (d, J = 9.5 Hz, 1H)

[0244]

Reference Example 9

5 Synthesis of tetradecanoic acid 7-hydroxy-2-oxo-2H-quinolin-1-ylmethyl ester

[0245]



[0246]

10 The compound was synthesized in the same manner as in Reference Example 8.


¹H-NMR (CDCl₃) δ: 0.88 (t, J = 6.8 Hz, 3H), 1.17-1.32 (m, 20H),
1.55-1.70 (m, 2H), 2.35 (t, J = 7.6 Hz, 2H), 6.31 (brs, 2H),
6.52 (d, J = 9.5 Hz, 1H), 6.55-6.68 (m, 1H), 6.78-6.82 (m, 1H),
15 6.84-6.87 (m, 1H), 7.43 (d, J = 8.5 Hz, 1H), 7.63 (d, J = 9.5
Hz, 1H)

[0247]

Reference Example 10

Synthesis of (2-butoxy ethoxy)-acetic acid 7-benzyloxy-2-oxo-
20 3,4-dihydro-2H-quinolin-1-ylmethyl ester

[0248]



[0249]

To a solution (20 ml) of 7-benzyloxy-1-hydroxymethyl-3,4-
25 dihydro-1H-quinolin-2-one (760 mg) obtained in Reference
Example 5, (2-butoxy ethoxy)acetic acid (473 mg), 1-(3-

dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (771 mg) in methylene chloride was added 4-dimethylaminopyridine (65.5 mg), and the mixture was stirred at room temperature overnight. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. This was purified by moderate-pressure silica gel column chromatography (hexane:ethyl acetate=1:0 to 0:1), and concentrated under reduced pressure to give the title compound (765 mg) as a colorless oil.


¹H-NMR (CDCl₃) δ: 0.90 (t, J = 7.4 Hz, 3H), 1.29-1.40 (m, 2H), 1.50-1.59 (m, 2H), 2.64-2.71 (m, 2H), 2.82-2.90 (m, 2H), 3.44 (t, J = 6.7 Hz, 2H), 3.57-3.63 (m, 2H), 3.70-3.75 (m, 2H), 4.18 (s, 2H), 5.06 (s, 2H), 5.95 (brs, 2H), 6.64-6.70 (m, 2H), 7.07 (d, J = 8.0 Hz, 1H), 7.30-7.45 (m, 5H)

[0250]

Reference Example 11

Synthesis of (2-butoxy ethoxy)-acetic acid 7-hydroxy-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester

[0251]



[0252]

The compound was synthesized in the same manner as in Reference Example 7.


¹H-NMR (CDCl₃) δ: 0.90 (t, J = 7.4 Hz, 3H), 1.29-1.40 (m, 2H), 1.52-1.61 (m, 2H), 2.64-2.72 (m, 2H), 2.81-2.88 (m, 2H), 3.49 (t, J = 6.8 Hz, 2H), 3.62-3.67 (m, 2H), 3.71-3.76 (m, 2H), 4.19 (s, 2H), 5.98 (brs, 2H), 6.42-6.53 (m, 1H), 6.57 (dd, J = 2.3, 8.1 Hz, 1H), 6.65 (d, J = 2.3 Hz, 1H), 7.02 (d, J = 8.1 Hz, 1H)

[0253]

Reference Example 12

Synthesis of undec-10-enoic acid 7-(4-chlorobutoxy)-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester

[0254]



5 [0255]

The compound was synthesized in the same manner as in Reference Example 10.


$^1\text{H-NMR}$ (CDCl_3) δ : 1.23-1.40 (m, 10H), 1.57-1.68 (m, 2H), 1.90-2.07 (m, 6H), 2.35 (t, $J = 7.5$ Hz, 2H), 2.65-2.71 (m, 2H),
 10 2.83-2.89 (m, 2H), 3.62 (t, $J = 6.2$ Hz, 2H), 3.98 (t, $J = 6.8$ Hz, 2H), 4.90-4.95 (m, 1H), 4.95-5.02 (m, 1H), 5.74-5.86 (m, 1H), 5.91 (brs, 2H), 6.58 (dd, $J = 2.3, 8.1$ Hz, 1H), 6.61 (d, $J = 2.3$ Hz, 1H), 7.07 (d, $J = 8.1$ Hz, 1H)

[0256]

15 Reference Example 13

Synthesis of tetradecanoic acid 7-(4-chlorobutoxy)-2-oxo-2H-quinolin-1-ylmethyl ester

[0257]



20 [0258]

To a solution (5 ml) of tetradecanoic acid 7-hydroxy-2-oxo-2H-quinolin-1-ylmethyl ester (208 mg) obtained in Reference Example 9 in dimethylformamide were added 1-bromo-4-chlorobutane (0.358 ml) and potassium carbonate (107 mg) and
 25 the mixture was stirred at room temperature for 2 days. To the

reaction mixture was added aqueous ammonium chloride solution, and the mixture was extracted with ethyl acetate. This was dried over sodium sulfate, and concentrated to give a crude product. The crude product was purified by silica gel column chromatography (hexane:ethyl acetate=1:0 to 2:1) to give the title compound (216 mg) as a white powder.


¹H-NMR (CDCl₃) δ: 0.88 (t, J = 6.9 Hz, 3H), 1.18-1.33 (m, 20H), 1.56-1.67 (m, 2H), 1.94-2.04 (m, 4H), 2.36 (t, J = 8.5 Hz, 2H), 3.61-3.66 (m, 2H), 4.04-4.10 (m, 2H), 6.33 (brs, 2H), 6.53 (d, J = 9.4 Hz, 1H), 6.82 (dd, J = 2.2, 8.6 Hz, 1H), 6.88 (d, J = 2.2 Hz, 1H), 7.45 (d, J = 8.6 Hz, 1H), 7.63 (d, J = 9.4 Hz, 1H)

[0259]

Reference Example 14

Synthesis of (2-butoxy-ethoxy)-acetic acid 7-hydroxy-2-oxo-2H-quinolin-1-ylmethyl ester

[0260]



[0261]

The compound was synthesized in the same manner as in Reference Example 8.


¹H-NMR (CDCl₃) δ: 0.88 (t, J = 7.3 Hz, 3H), 1.22-1.38 (m, 2H), 1.48-1.59 (m, 2H), 3.40-3.50 (m, 2H), 3.58-3.64 (m, 2H), 3.67-3.73 (m, 2H), 4.18 (s, 2H), 6.39 (brs, 2H), 6.50 (d, J = 9.4 Hz, 1H), 6.81-6.87 (m, 1H), 6.90-6.94 (m, 1H), 7.42 (d, J = 8.5 Hz, 1H), 7.64 (d, J = 9.5 Hz, 1H)

[0262]

Reference Example 15

Synthesis of docosanoic acid 7-(4-chlorobutoxy)-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester

[0263]



[0264]

The compound was synthesized in the same manner as in

5 Reference Example 12.


$^1\text{H-NMR}$ (CDCl_3) δ : 0.88 (t, $J = 6.8$ Hz, 3H), 1.19-1.35 (m, 36H),
 1.58-1.68 (m, 2H), 1.89-2.03 (m, 4H), 2.35 (t, $J = 7.6$ Hz, 2H),
 2.64-2.72 (m, 2H), 2.82-2.90 (m, 2H), 3.62 (t, $J = 6.2$ Hz, 2H),
 3.98 (t, $J = 5.6$ Hz, 2H), 5.91 (brs, 2H), 6.58 (dd, $J = 2.3$,
 10 8.2 Hz, 1H), 6.60 (d, $J = 2.3$ Hz, 1H), 7.07 (d, $J = 8.2$ Hz,
 1H)

[0265]

Reference Example 16

Synthesis of undec-10-enoic acid 7-(4-chlorobutoxy)-2-oxo-2H-
 15 quinolin-1-ylmethyl ester

[0266]



[0267]

The compound was synthesized in the same manner as in

20 Reference Example 8.


$^1\text{H-NMR}$ (CDCl_3) δ : 1.20-1.39 (m, 10H), 1.57-1.67 (m, 2H), 1.95-
 2.05 (m, 6H), 2.36 (t, $J = 7.5$ Hz, 2H), 3.61-3.66 (m, 2H),
 4.04-4.10 (m, 2H), 4.90-4.95 (m, 1H), 4.95-5.01 (m, 1H), 5.74-
 5.85 (m, 1H), 6.33 (brs, 2H), 6.52 (d, $J = 9.5$ Hz, 1H), 6.83
 25 (dd, $J = 2.2$, 8.6 Hz, 1H), 6.88 (d, $J = 2.2$ Hz, 1H), 7.45 (d,
 $J = 8.6$ Hz, 1H), 7.62 (d, $J = 9.5$ Hz, 1H)

[0268]

Reference Example 17

Synthesis of 7-(4-bromobutoxy)-4,4-dimethyl-3,4-dihydro-1H-quinolin-2-one

5 [0269]



[0270]

To a solution (20 ml) of 7-hydroxy-4,4-dimethyl-3,4-dihydro-1H-quinolin-2-one (0.4 g) in DMF were added 1,4-dibromobutane (0.75 ml) and potassium carbonate (0.35 g) and the mixture was stirred at 60°C for 6 hr. After cooling to room temperature, water was added to the reaction mixture and the mixture was extracted with ethyl acetate. The organic layer was washed with water, dried over magnesium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography.

(dichloromethane:methanol=100:1→50:1) to give the title compound (0.6 g) as a colorless solid.


¹H-NMR (CDCl₃) δ: 1.30 (6H, s), 1.88-1.98 (2H, m), 2.02-2.10 (2H, m), 2.47 (2H, s), 3.48 (2H, t, J=6.6Hz), 3.97 (2H, t, J=6.0Hz), 6.32 (1H, d, J=2.5Hz), 6.57 (1H, dd, J=8.5, 2.5Hz), 7.18 (1H, d, J=8.5Hz), 8.11 (1H, brs)

[0271]

Reference Example 18

25 Synthesis of 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-4,4-dimethyl-3,4-dihydro-1H-quinolin-2-one

[0272]



[0273]

To a solution (20 ml) of 7-(4-bromobutoxy)-4,4-dimethyl-3,4-dihydro-1H-quinolin-2-one (0.6 g) obtained in Reference Example 17 in DMF were added 1-benzo[b]thiophen-4-ylpiperazine hydrochloride (0.52 g) and potassium carbonate (0.64 g) and the mixture was stirred at 60°C for 6 hr. After cooling to room temperature, water was added to the reaction mixture and the mixture was extracted with ethyl acetate. The organic layer was washed with water, dried over magnesium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography

(dichloromethane:methanol=100:1→50:1) and crystallized from ethanol to give the title compound (0.33 g) as a white powder.


¹H-NMR (CDCl₃) δ: 1.30 (6H, s), 1.68-1.78 (2H, m), 1.80-1.90 (2H, m), 2.46 (2H, s), 2.52 (2H, t, J=7.4Hz), 2.72 (4H, m), 3.19 (4H, m), 3.98 (2H, t, J=6.2Hz), 6.30 (1H, d, J=2.5Hz), 6.59 (1H, dd, J=8.5, 2.5Hz), 6.90 (1H, d, J=7.2Hz), 7.18 (1H, d, J=8.5Hz), 7.27 (1H, t, J=7.8Hz), 7.36-7.44 (2H, m), 7.55 (1H, d, J=8.1Hz), 7.69 (1H, brs)

[0274]

Reference Example 19

Synthesis of iodomethyldodecanoate

[0275]



25

[0276]

To a solution of chloromethyl dodecanoate [61413-67-0] (800 mg) in dichloromethane (10 ml) and acetonitrile (10 ml) was added sodium iodide (1.45 g), and the mixture was stirred at room temperature for 3 days. The solvent was evaporated under reduced pressure, water was added, and the mixture was extracted with dichloromethane, and dried over Na₂SO₄. The

solvent was evaporated under reduced pressure to give
iodomethyldodecanoate (1.05 g).

oil: brown


¹H-NMR (CDCl₃) δ ppm : 0.88 (3H, t, J=7.0 Hz), 1.20-1.40 (16H,
5 m), 1.50-1.70 (2H, m), 2.30-2.40 (2H, m), 5.91 (2H, s)

[0277]

Example 1

Synthesis of 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-
yl)butoxy]-1-hydroxymethyl-3,4-dihydro-1H-quinolin-2-one

10 [0278]



[0279]

To a solution of 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-
1-yl)butoxy]-3,4-dihydro-1H-quinolin-2-one (1 g) synthesized
15 in the same manner as in WO2006/112464 (Example 11) in DMF (10
ml) were added 37% aqueous formalin solution (3.7 ml) and
triethylamine (0.05 ml), and the mixture was heated at 80°C for
20 hr. Water was added to the reaction mixture, and the
mixture was extracted with ethyl acetate, and dried over
20 magnesium sulfate. The solvent was evaporated under reduced
pressure and the residue was purified by silica gel column
chromatography (dichloromethane:methanol=30:1) to give a
mixture (1 g, 3:2) of 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-
1-yl)butoxy]-1-hydroxymethyl-3,4-dihydro-1H-quinolin-2-one and
25 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-3,4-
dihydro-1H-quinolin-2-one.

¹H-NMR (CDCl₃) δ: 1.68-1.80 (2H, m), 1.80-1.90 (2H, m), 2.48-
2.55 (2H, m), 2.58-2.66 (2H, m), 2.66-2.78 (4H, m), 2.78-2.85
(1.2H, m), 2.86-2.92 (0.8H, m), 3.14-3.25 (4H, m), 3.94-4.40
30 (2H, m), 5.36 (1.2H, s), 6.31 (0.4H, d, J=2.3Hz), 6.53 (0.4H,
dd, J=2.4, 8.3Hz), 6.58 (0.6H, dd, J=2.4, 8.2Hz), 6.86 (0.6H,


d, J=2.4Hz), 6.89 (1H, d, J=7.2Hz), 7.20-7.80 (1H, m), 7.27 (1H, t, J=8.4Hz), 7.36-7.44 (2H, m), 7.55 (1H, d, J=8.0Hz), 7.74-7.80 (0.4H, br)

[0280]

5 Example 2

Synthesis of 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-1-benzyloxymethyl-1H-quinolin-2-one

[0281]




10 [0282]

Example 3

Synthesis of 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-benzyloxymethoxy-quinoline

[0283]



15

[0284]

7-[4-(4-Benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-1H-quinolin-2-one (1.0 g, 2.31 mmol) synthesized in the same manner as in WO2006/112464 (Example 1) was suspended in
20 tetrahydrofuran (THF) (20 ml) and, under a nitrogen atmosphere, sodium hydride (55% oil) (0.15 g, 3.44 mmol) was added and the mixture was stirred with heating under reflux for 30 min. The mixture was ice-cooled, benzylchloromethylether (0.48 ml, 3.46 mmol) was added, and the mixture was stirred at room
25 temperature for 3 hr. To the reaction mixture was added ice water to discontinue the reaction, and the mixture was

extracted with ethyl acetate. The organic layer was dried over sodium sulfate, and concentrated under reduced pressure. The residue was purified by moderate-pressure silica gel column chromatography (hexane:ethyl acetate=100:0 to 0:100). The first fraction was concentrated under reduced pressure to give 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-benzyloxymethoxy-quinoline (0.15 g) as a colorless oil.

$^1\text{H-NMR}$ (CDCl_3) δ : 1.73-1.83 (2H, m), 1.88-1.97 (2H, m), 2.54 (2H, t, $J=7.5\text{Hz}$), 2.66-2.79 (4H, m), 3.15-3.25 (4H, m), 4.14 (2H, t, $J=6.5\text{Hz}$), 4.83 (2H, s), 5.78 (2H, s), 6.80 (1H, d, $J=8.5\text{Hz}$), 6.89 (1H, dd, $J=0.5\text{Hz}$, $J=7.5\text{Hz}$), 7.04 (1H, dd, $J=2.5\text{Hz}$, $J=9.0\text{Hz}$), 7.21 (1H, d, $J=2.5\text{Hz}$), 7.24-7.43 (8H, m), 7.54 (1H, d, $J=8.0\text{Hz}$), 7.60 (1H, d, $J=8.0\text{Hz}$), 7.94 (1H, d, $J=8.5\text{Hz}$)


The second fraction was concentrated to dryness under reduced pressure to give 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-1-benzyloxymethyl-1H-quinolin-2-one (0.86 g) as a white amorphous solid.

$^1\text{H-NMR}$ (CDCl_3) δ : 1.71-1.81 (2H, m), 1.85-1.94 (2H, m), 2.52 (2H, t, $J=7.5\text{Hz}$), 2.64-2.78 (4H, m), 3.13-3.25 (4H, m), 4.09 (2H, t, $J=6.0\text{Hz}$), 4.67 (2H, s), 5.84 (2H, s), 6.50 (1H, d, $J=9.5\text{Hz}$), 6.83 (1H, dd, $J=2.5\text{Hz}$, $J=8.5\text{Hz}$), 6.89 (1H, dd, $J=0.5\text{Hz}$, $J=7.5\text{Hz}$), 7.10 (1H, d, $J=2.0\text{Hz}$), 7.22-7.46 (9H, m), 7.55 (1H, d, $J=8.0\text{Hz}$), 7.60 (1H, d, $J=9.5\text{Hz}$)

[0285]

Example 4

Synthesis of 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-1-benzyloxymethyl-3,4-dihydro-1H-quinolin-2-one [0286]



[0287]

7-[4-(4-Benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy]-3,4-dihydro-1H-quinolin-2-one (1.0 g, 2.30 mmol) synthesized in the same manner as in WO2006/112464 (Example 11) was suspended in tetrahydrofuran (THF) (20 ml) and, under a nitrogen
5 atmosphere, sodium hydride (55% oil) (0.15 g, 3.44 mmol) was added, and the mixture was stirred with heating under reflux for 30 min. The mixture was ice-cooled, benzylchloromethylether (0.48 ml, 3.46 mmol) was added, and the mixture was stirred at room temperature for 3 hr. To the
10 reaction mixture was added ice water to discontinue the reaction, and the mixture was extracted with ethyl acetate. The organic layer was dried over sodium sulfate, and concentrated under reduced pressure. The residue was purified by moderate-pressure silica gel column chromatography
15 (hexane:ethyl acetate=100:0 to 0:100) and concentrated under reduced pressure to give the title compound (yield 0.95 g, 74%) as a pale-yellow oil.


¹H-NMR (CDCl₃) δ: 1.68-1.90 (4H, m), 2.51 (2H, t, J=7.5Hz), 2.59-2.76 (6H, m), 2.78-2.85 (2H, m), 3.13-3.24 (4H, m), 3.98
20 (2H, t, J=6.0Hz), 4.66 (2H, s), 5.44 (2H, s), 6.08 (1H, dd, J=2.5Hz, J=8.0Hz), 6.89 (1H, dd, J=0.5Hz, J=7.5Hz), 7.00 (1H, d, J=2.5Hz), 7.03 (1H, d, J=8.0Hz), 7.23-7.43 (8H, m), 7.55 (1H, d, J=8.0Hz)

[0288]

25 Example 5

Synthesis of carbonic acid 7-[4-(4-benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester phenyl ester

[0289]



30

[0290]

7-[4-(4-Benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-3,4-dihydro-1H-quinolin-2-one (1.0 g, 2.30 mmol) synthesized in the same manner as in WO2006/112464 (Example 11) was suspended in tetrahydrofuran (THF) (20 ml) and, under a nitrogen atmosphere, sodium hydride (55% oil) (0.11 g, 2.52 mmol) was added, and the mixture was stirred with heating under reflux for 30 min. The mixture was cooled to -70°C, chloromethylphenylcarbonate (0.64 g, 3.43 mmol) was added, and the mixture was stirred at -70°C for 3 hr. Water was added to the reaction mixture to discontinue the reaction, and the mixture was extracted with ethyl acetate. The organic layer was dried over sodium sulfate, and concentrated under reduced pressure. The residue was purified by moderate-pressure silica gel column chromatography (hexane:ethyl acetate=100:0 to 0:100) and concentrated under reduced pressure to give the title compound (yield 0.95 g, 74%) as a colorless oil.


¹H-NMR (CDCl₃) δ: 1.69-1.91 (4H, m), 2.52 (2H, t, J=7.5Hz), 2.64-2.77 (6H, m), 2.85-2.92 (2H, m), 3.14-3.24 (4H, m), 4.01 (2H, t, J=6.5Hz), 6.06 (2H, s), 6.62 (1H, dd, J=2.5Hz, J=8.5Hz), 6.75 (1H, d, J=2.5Hz), 6.86-6.91 (1H, m), 7.09 (1H, d, J=8.5Hz), 7.19-7.29 (5H, m), 7.34-7.44 (3H, m), 7.55 (1H, d, J=8.0Hz)

[0291]

25 Example 6

Synthesis of 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-1-(tert-butyldimethylsilanyloxymethyl)-3,4-dihydro-1H-quinolin-2-one

[0292]



[0293]

To a solution (15 ml) of 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-3,4-dihydro-1H-quinolin-2-one (1.5 g) synthesized in the same manner as in WO2006/112464 (Example 5 11) in dimethylformamide (DMF) were added 37% aqueous formalin solution (5.5 ml) and a catalytic amount of triethylamine (0.08 ml) and the mixture was stirred at 80°C for 20 hr. After cooling to room temperature, and water was added to the reaction mixture. The obtained insoluble material was 10 collected by filtration, dried, and dissolved in dichloromethane (15 ml). Imidazole (0.313 g) and tert-butylchlorodimethylsilane (0.519 g) were added, and the mixture was stirred at room temperature for 1.5 hr. Methanol was added, and the mixture was concentrated. This was purified 15 by moderate-pressure silica gel column chromatography (hexane:ethyl acetate=1:0 to 2:1) to give the title compound (yield 550 mg, 41.3%) as a colorless amorphous solid.


¹H-NMR (CDCl₃) δ: 0.14 (6H, s), 0.90 (9H, s), 1.70-1.80 (2H, m), 1.80-1.92 (2H, m), 2.42 (2H, t, J=7.5Hz), 2.58-2.64 (2H, m), 20 2.68-2.76 (4H, m), 2.78-2.84 (2H, m), 3.14-3.24 (4H, m), 4.00 (2H, t, J=6.3Hz), 5.45 (2H, s), 6.58 (1H, dd, J=8.2Hz, 2.5Hz), 6.76 (1H, dd, J=7.6Hz, 0.6Hz), 7.00-7.04 (2H, m), 7.27 (1H, t, J=7.8Hz), 7.36-7.42 (2H, m), 7.54 (1H, d, J=8.1Hz)

[0294]

25 Example 7

Synthesis of carbonic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester phenyl ester

[0295]



30

[0296]

Using 7-[4-(4-benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy]-1H-quinolin-2-one synthesized in the same manner as in WO2006/112464 (Example 1) and in the same manner as in Example 5, the title compound was obtained.


5 $^1\text{H-NMR}$ (CDCl_3) δ : 1.71-1.80 (2H, m), 1.85-1.95 (2H, m), 2.53 (2H, t, $J=7.5\text{Hz}$), 2.65-2.76 (4H, m), 3.14-3.23 (4H, m), 4.08-4.14 (2H, m), 6.46 (2H, brs), 6.53 (1H, d, $J=9.5\text{Hz}$), 6.84-6.91 (2H, m), 6.97 (1H, d, $J=2.0\text{Hz}$), 7.18-7.30 (4H, m), 7.35-7.43 (4H, m), 7.47 (1H, d, $J=8.5\text{Hz}$), 7.55 (1H, d, $J=8.0\text{Hz}$), 7.64
10 (1H, d, $J=9.5\text{Hz}$)

[0297]

Example 8

Synthesis of 7-[4-(4-benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy]-1-(tetrahydropyran-2-yloxymethyl)-3,4-dihydro-1H-quinolin-2-one
15

[0298]



[0299]

A solution of 7-[4-(4-benzo[b]thiophen-4-yl)piperazin-1-yl)-butoxy]-1-hydroxymethyl-3,4-dihydro-1H-quinolin-2-one
20 (0.26 g), which is a mixture with 7-[4-(4-benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy]-3,4-dihydro-1H-quinolin-2-one, was suspended in dichloromethane (10 ml), 3,4-dihydro-2H-pyran (0.08 ml) was added, p-toluenesulfonic acid hydrate (0.11 g)
25 was added with stirring under ice-cooling, and the mixture was stirred at room temperature overnight. With stirring under ice-cooling, aqueous sodium hydrogen carbonate solution was added to the reaction mixture, and the mixture was extracted with dichloromethane, and dried over magnesium sulfate. The
30 solvent was evaporated under reduced pressure and the residue

was purified by silica gel column chromatography (dichloromethane:methanol=60:1) to give 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-1-(tetrahydro-2H-pyran-2-yloxy)methyl-3,4-dihydro-1H-quinolin-2-one (180 mg).


5 $^1\text{H-NMR}$ (CDCl_3) δ : 1.50-1.80 (10H, m), 2.40-2.90 (6H, m), 2.72 (4H, brs), 3.20 (4H, brs), 3.40-4.00 (2H, m), 4.01 (2H, t, $J=6.2\text{Hz}$), 4.90-5.30 (3H, m), 6.58 (1H, dd, $J=8.2\text{Hz}$, 2.4Hz), 6.90 (1H, d, $J=7.6\text{Hz}$), 6.95 (1H, d, $J=2.4\text{Hz}$), 7.04 (1H, d, $J=8.2\text{Hz}$), 7.27 (1H, t, $J=7.9\text{Hz}$), 7.36-7.44 (2H, m), 7.55 (1H, 10 d, $J=8.1\text{Hz}$)

[0300]

Example 9

Synthesis of piperidine-1-carboxylic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-15 2H-quinolin-1-ylmethyl ester

[0301]



[0302]

To a solution (3 ml) of carboxylic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester phenyl ester (0.29 g) synthesized in the same manner as in Example 5 in THF were added piperidine (0.5 ml) and 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) (0.05 ml), and the mixture was stirred at room 25 temperature for 16 hr. Water was added and the reaction mixture was extracted with ethyl acetate, dried over sodium sulfate, and concentrated under reduced pressure. The residue was purified by moderate-pressure basic silica gel column chromatography (hexane:ethyl acetate=1:0 to 1:1) to remove 30 phenol, and concentrated under reduced pressure. The residue

was purified by moderate-pressure silica gel column chromatography (hexane:ethyl acetate=1:0 to 0:1) to give the title compound (yield 0.21 g, 74%) as a colorless oil.


¹H-NMR (CDCl₃) δ: 1.40-1.62 (6H, m), 1.69-1.90 (4H, m), 2.52
5 (2H, t, J=7.5Hz), 2.62-2.79 (6H, m), 2.81-2.90 (2H, m), 3.13-
3.26 (4H, m), 3.31-3.51 (4H, m), 3.99 (2H, t, J=6.0Hz), 5.93
(2H, s), 6.59 (1H, dd, J=2.5Hz, 8.0Hz), 6.78 (1H, d, J=2.5Hz),
6.86-6.92 (1H, m), 7.05 (1H, d, J=8.5Hz), 7.23-7.30 (1H, m),
7.38 (1H, d, J=5.5Hz), 7.41 (1H, dd, J=0.5Hz, 5.5Hz), 7.54 (1H,
10 d, J=8.0Hz)

[0303]

Example 10

Synthesis of piperidine-1-carboxylic acid 7-[4-(4-
benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-
15 1-ylmethyl ester

[0304]



[0305]

To a solution (5 ml) of carbonic acid 7-[4-(4-
20 benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-
1-ylmethyl ester phenyl ester (0.44 g) synthesized in the same
manner as in Example 7 in THF was added piperidine (0.76 ml),
and the mixture was stirred at room temperature for 3.5 days.
Water was added to the reaction mixture and the mixture was
25 extracted with ethyl acetate, dried over sodium sulfate, and
concentrated under reduced pressure. The residue was purified
by moderate-pressure basic silica gel column chromatography
(hexane:ethyl acetate=1:0 to 1:1) to give the title compound
(0.44 g, yield quantitative) as a colorless amorphous solid.

30 ¹H-NMR (CDCl₃) δ: 1.38-1.61 (6H, m), 1.72-1.82 (2H, m), 1.85-


1.96 (2H, m), 2.54 (2H, t, J=7.5Hz), 2.66-2.80 (4H, m), 3.14-3.25 (4H, m), 3.29-3.52 (4H, m), 4.10 (2H, t, J=6.0Hz), 6.36 (2H, s), 6.52 (1H, d, J=9.5Hz), 6.83 (1H, dd, J=2.0Hz, 8.5Hz), 6.89 (1H, d, J=7.5Hz), 7.12 (1H, t, J=2.0Hz), 7.23-7.31 (1H, m), 7.37-7.46 (3H, m), 7.55 (1H, d, J=8.0Hz), 7.62 (1H, d, J=9.5Hz)

[0306]

Example 11

Synthesis of benzoic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester

[0307]



[0308]

Sodium hydride (55% oil) (0.15 g, 2.52 mmol) was suspended in tetrahydrofuran (THF) (20 ml) and, under a nitrogen atmosphere, 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-3,4-dihydro-1H-quinolin-2-one (1.0 g, 2.30 mmol) synthesized in the same manner as in WO2006/112464 (Example 11) was added, and the mixture was stirred with heating under reflux for 25 min. The mixture was cooled to 0°C, chloromethyl benzoate (0.627 g, 3.67 mmol) was added, and the mixture was stirred at room temperature for 2.5 hr. Under ice-cooling, aqueous ammonium chloride was added to the reaction mixture to discontinue the reaction, and the mixture was extracted with ethyl acetate. The organic layer was dried over sodium sulfate, and concentrated under reduced pressure. The residue was purified by moderate-pressure silica gel column chromatography (hexane:ethyl acetate=1:0 to 2:3) and concentrated under reduced pressure to give the title compound (yield 1.132 g, 86.55%) as a colorless amorphous solid.

¹H-NMR (CDCl₃) δ: 1.64-1.75 (m, 2H), 1.77-1.86 (m, 2H), 2.44-2.51 (m, 2H), 2.61-2.77 (m, 6H), 2.87-2.93 (m, 2H), 3.11-3.22 (m, 4H), 3.97 (t, J = 6.3 Hz, 2H), 6.17 (brs, 2H), 6.61 (dd, J = 2.4, 8.3 Hz, 1H), 6.74 (d, J = 2.4 Hz, 1H), 6.84-6.91 (m, 1H), 7.09 (d, J = 8.3 Hz, 1H), 7.27 (dd, = 7.7, 7.7 Hz, 1H), 7.37-7.46 (m, 4H), 7.51-7.58 (m, 2H), 8.00-8.07 (m, 2H)


[0309]

Example 12

Synthesis of benzoic acid 7-[4-(4-benzo[b]thiophen-4-

ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester

[0310]



[0311]

Using 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-

yl)butoxy]-1H-quinolin-2-one synthesized in the same manner as in WO2006/112464 (Example 1) and in the same manner as in Example 11, the title compound was obtained.

¹H-NMR (CDCl₃) δ: 1.67-1.78 (m, 2H), 1.81-1.91 (m, 2H), 2.45-2.53 (m, 2H), 2.63-2.75 (m, 4H), 3.11-3.22 (m, 4H), 4.07 (t, J = 6.3 Hz, 2H), 6.56 (d, J = 9.5Hz, 1H), 6.59 (brs, 2H), 6.84 (dd, J = 2.2, 8.6 Hz, 1H), 6.86-6.90 (m, 1H), 6.98 (d, J = 2.2 Hz, 1H), 7.27 (dd, J = 7.8, 7.8 Hz, 1H), 7.37-7.44 (m, 4H), 7.46 (d, J = 8.6 Hz, 1H), 7.51-7.59 (m, 2H), 7.65 (d, J = 9.5Hz, 1H), 8.02-8.07 (m, 2H)


[0312]

Example 13

Synthesis of cyclopentanecarboxylic acid 7-[4-(4-

benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester

[0313]



[0314]

To a solution (20 ml) of 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-1-hydroxymethyl-3,4-dihydro-1H-quinolin-2-one (962 mg, 2.066 mmol) synthesized in the same manner as in Example 1, cyclopentanecarboxylic acid (0.448 ml, 4.13 mmol), 2-chloro-1,3-dimethylimidazolium chloride (768 mg, 4.55 mmol) in methylene chloride was added triethylamine (1.267 ml, 9.09 mmol), and the mixture was stirred at room temperature for 1 hr. 2-Chloro-1,3-dimethylimidazolium chloride (768 mg, 4.55 mmol) was added, and the mixture was heated under reflux for 1 hr. After cooling to room temperature, water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. This was purified by moderate-pressure basic silica gel column (hexane:ethyl acetate=1:3) and concentrated under reduced pressure to give the title compound (yield 261 mg, 22.49%) as a colorless oil.


¹H-NMR (CDCl₃) δ: 1.50-1.63 (m, 2H), 1.63-1.79 (m, 4H), 1.79-1.95 (m, 6H), 2.52 (t, J = 7.4 Hz, 2H), 2.64-2.83 (m, 7H), 2.83-2.89 (m, 2H), 3.13-3.25 (m, 4H), 3.98 (d, J = 6.2 Hz, 2H), 5.91 (brs, 2H), 6.57-6.61 (m, 2H), 6.89 (d, J = 7.6 Hz, 1H), 7.04-7.09 (m, 1H), 7.27 (dd, J = 7.8, 7.8Hz, 1H), 7.36-7.43 (m, 2H), 7.54 (d, J = 8.0 Hz, 1H)

[0315]

Example 14

Synthesis of cyclohexanecarboxylic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester

[0316]



[0317]

To a solution (15 ml) of 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-1-hydroxymethyl-3,4-dihydro-1H-quinolin-2-one (550 mg) synthesized in the same manner as in
 5 Example 1 in dichloromethane was added pyridine (0.287 ml), cyclohexanecarbonyl chloride (0.158 ml) with stirring under ice-cooling and the mixture was stirred at room temperature overnight. Water was added to the reaction mixture and the
 10 mixture was extracted with ethyl acetate. The organic layer was dried over sodium sulfate, and concentrated under reduced pressure. The residue was purified by moderate-pressure silica gel column chromatography (hexane:ethyl acetate=1:0 to 1:3), and concentrated under reduced pressure. The residue was
 15 purified by basic silica gel column chromatography, and concentrated to dryness under reduced pressure to give the title compound (yield 172 mg, 25.3%) as a colorless amorphous solid.


¹H-NMR (CDCl₃) δ: 1.15-1.32 (m, 3H), 1.40-1.53 (m, 2H), 1.57-
 20 1.65 (m, 1H), 1.68-1.79 (m, 4H), 1.81-1.96 (m, 4H), 2.36 (tt, J = 3.6, 11.2 Hz, 1H), 2.52 (t, J = 7.5 Hz, 2H), 2.65-2.76 (m, 6H), 2.83-2.90 (m, 2H), 3.15-3.24 (m, 4H), 3.98 (t, J = 6.2 Hz, 2H), 5.91 (brs, 2H), 6.56-6.63 (m, 2H), 6.87-6.92 (m, 1H),
 7.05-7.09 (m, 1H), 7.27 (dd, J = 7.7, 7.7 Hz, 1H), 7.37-7.43
 25 (m, 2H), 7.55 (d, J = 8.0 Hz, 1H)

[0318]

Example 15

Synthesis of 2,2-dimethylpropionic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-
 30 2H-quinolin-1-ylmethyl ester

[0319]



[0320]

In the same manner as in Example 11, the title compound was obtained.


¹H-NMR (CDCl₃) δ: 1.22 (s, 9H), 1.68-1.90 (m, 4H), 2.48-2.55 (m, 2H), 2.65-2.76 (m, 6H), 2.82-2.89 (m, 2H), 3.13-3.24 (m, 4H), 3.97 (t, J = 6.2 Hz, 2H), 5.90 (s, 2H), 6.57-6.62 (m, 2H), 6.87-6.92 (m, 1H), 7.07 (d, J = 8.1Hz, 1H), 7.27 (dd, J = 7.7. 7.7 Hz, 1H), 7.37-7.43 (m, 2H), 7.55 (d, J = 8.1 Hz, 1H)

[0321]

Example 16

Synthesis of N-butyl-N-methylcarbamic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester

[0322]



[0323]

Using carbonic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester phenyl ester synthesized in the same manner as in Example 5 and in the same manner as in Example 10, the title compound was obtained.

¹H-NMR (CDCl₃) δ: {0.82 (t, J=7.0Hz), 0.94 (t, J=7.0Hz) total 3H (1 : 1)}, 1.14-1.58 (4H, m), 1.64-1.91 (4H, m), 2.52 (2H, t, J=7.5Hz), 2.63-2.78 (6H, m), 2.81-2.96 (5H, m), 3.13-3.33 (6H,


m), 3.99 (2H, t, J=6.0Hz), 5.92 (2H, s), 6.59 (1H, dd, J=2.0Hz, 8.0Hz), 6.77 (1H, d, J=6.0Hz), 6.89 (1H, d, J=7.5Hz), 7.06 (1H, d, J=8.0Hz), 7.27 (1H, dd, J=8.0Hz, 8.0Hz), 7.38 (1H, d, J=5.5Hz), 7.41 (1H, d, J=7.5Hz), 7.55 (1H, d, J=8.0Hz)

5 [0324]

Example 17

Synthesis of N-decylcarbamic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester

10 [0325]



[0326]

Using carbonic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester phenyl ester synthesized in the same manner as in Example 5 and in the same manner as in Example 10, the title compound was obtained.


¹H-NMR (CDCl₃) δ: 0.87 (3H, t, J=7.0Hz), 1.16-1.34 (14H, m), 1.42-1.53 (2H, m), 1.69-1.89 (4H, m), 2.52 (2H, t, J=7.5Hz), 2.62-2.77 (6H, m), 2.80-2.88 (2H, m), 3.12-3.25 (6H, m), 4.00 (2H, t, J=6.0Hz), 4.85 (1H, t, J=5.5Hz), 5.91 (2H, s), 6.59 (1H, dd, J=2.0Hz, 8.0Hz), 6.79 (1H, d, J=2.0Hz), 6.86-6.91 (1H, m), 7.05 (1H, d, J=8.0Hz), 7.27 (1H, dd, J=8.0Hz, 8.0Hz), 7.36-7.44 (2H, m), 7.54 (1H, d, J=8.0Hz)

25 [0327]

Example 18

Synthesis of 2,2-dimethylpropionic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester

30 [0328]



[0329]

Using 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-1H-quinolin-2-one synthesized in the same manner as
 5 in WO2006/112464 (Example 1) and in the same manner as in Example 11, the title compound was obtained.


¹H-NMR (CDCl₃) δ: 1.20 (s, 9H), 1.71-1.81 (m, 2H), 1.85-1.95 (m, 2H), 2.54 (t, J = 7.5 Hz, 2H), 2.67-2.78 (m, 4H), 3.15-3.24 (m, 4H), 4.06 (t, J = 6.2 Hz, 2H), 6.33 (brs, 2H), 6.52 (d, J =
 10 9.5 Hz, 1H), 6.80 (d, J = 2.2 Hz, 1H), 6.84 (dd, J = 2.2, 8.6 Hz, 1H), 6.88-6.91 (m, 1H), 7.27 (dd, J = 7.8, 7.8 Hz, 1H), 7.37-7.43 (m, 2H), 7.45 (d, J = 8.6 Hz, 1H), 7.55 (d, J = 8.1 Hz, 1H), 7.63 (d, J = 9.5 Hz, 1H)

[0330]

15 Example 19

Synthesis of butyric acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester

[0331]



20

[0332]


In the same manner as in Example 11, the title compound was obtained.

¹H-NMR (CDCl₃) δ: 0.96 (t, J = 7.4 Hz, 3H), 1.63-1.79 (m, 4H),
 25 1.80-1.90 (m, 2H), 2.35 (t, J = 7.4 Hz, 2H), 2.52 (t, J = 7.4 Hz, 2H), 2.64-2.77 (m, 6H), 2.82-2.90 (m, 2H), 3.14-3.25 (m,

4H), 3.99 (t, $J = 6.2$ Hz, 2H), 5.92 (brs, 2H), 6.57-6.63 (m, 2H), 6.87-6.92 (m, 1H), 7.07 (d, $J = 8.1$ Hz, 1H), 7.27 (dd, $J = 7.8, 7.8$ Hz, 1H), 7.37-7.44 (m, 2H), 7.55 (d, $J = 8.0$ Hz, 1H)
[0333]

5 Example 20

Synthesis of butyric acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester
[0334]




10 [0335]

Using 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-1H-quinolin-2-one synthesized in the same manner as in WO2006/112464 (Example 1) and in the same manner as in Example 11, the title compound was obtained.

15 $^1\text{H-NMR}$ (CDCl_3) δ : 0.94 (t, $J = 7.4$ Hz, 3H), 1.62-1.72 (m, 2H), 1.72-1.82 (m, 2H), 1.86-1.96 (m, 2H), 2.35 (t, $J = 7.4$ Hz, 2H), 2.54 (t, $J = 7.4$ Hz, 2H), 2.65-2.78 (m, 4H), 3.13-3.25 (m, 4H), 4.08 (t, $J = 6.2$ Hz, 2H), 6.34 (brs, 2H), 6.52 (d, $J = 9.5$ Hz, 1H), 6.84 (dd, $J = 2.2, 8.6$ Hz, 1H), 6.86-6.91 (m, 2H), 7.27
20 (dd, $J = 7.8, 7.8$ Hz, 1H), 7.37-7.43 (m, 2H), 7.45 (d, $J = 8.6$ Hz, 1H), 7.55 (d, $J = 8.0$ Hz, 1H), 7.63 (d, $J = 9.5$ Hz, 1H)
[0336]

Example 21

Synthesis of dodecanoic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester
25 [0337]



[0338]


In the same manner as in Example 14, the title compound was obtained.

5 $^1\text{H-NMR}$ (CDCl_3) δ : 0.87 (3H, t, $J=6.8$ Hz), 1.20-1.36 (16H, m), 1.58-1.69 (2H, m), 1.69-1.80 (2H, m), 1.80-1.90 (2H, m), 2.36 (2H, t, $J=7.6$ Hz), 2.52 (2H, t, $J=7.4$ Hz), 2.64-2.76 (6H, m), 2.82-2.90 (2H, m), 3.14-3.26 (4H, br), 3.98 (2H, t, $J=6.2$ Hz), 5.92 (2H, brs), 6.56-6.64 (2H, m), 6.89 (1H, d, $J=7.6$ Hz),
 10 7.07 (1H, d, $J=8.1$ Hz), 7.27 (1H, t, $J=7.8$ Hz), 7.40 (2H, dd, $J=5.6, 12.6$ Hz), 7.55 (1H, d, $J=8.0$ Hz)

[0339]

Example 22

Synthesis of dodecanoic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester
 15 [0340]



[0341]


To a solution (5 ml) of dodecanoic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester (150 mg) synthesized in the same manner as in Example 21 in THF was added trifluoroacetic acid (TFA) (0.11 ml), then to a solution (3 ml) of 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) (0.27 g) in THF was added,
 25 and the mixture was stirred at room temperature for 3 days. To the reaction mixture were added water and sodium carbonate, and the mixture was extracted with dichloromethane, dried over

sodium sulfate, and concentrated under reduced pressure. The residue was purified by preparative thin layer chromatography (ethyl acetate) to give the title compound (yield 50 mg, 33.4%) as a brown oil.

5 $^1\text{H-NMR}$ (CDCl_3) δ : 0.87 (3H, t, $J=6.9$ Hz), 1.20-1.34 (16H, m), 1.55-1.68 (2H, m), 1.72-1.82 (2H, m), 1.85-1.94 (2H, m), 2.36 (2H, t, $J=7.5$ Hz), 2.50-2.60 (2H, m), 2.73 (4H, m), 3.20 (4H, m), 4.08 (2H, t, $J=5.3$ Hz), 6.34 (2H, brs), 6.52 (1H, d, $J=9.5$ Hz), 6.84 (1H, dd, $J=2.2, 8.5$ Hz), 6.86-6.92 (2H, m), 7.24-
10 7.30 (1H, m), 7.40 (2H, dd, $J=5.6, 10.9$ Hz), 7.45 (1H, d, $J=8.6$ Hz), 7.55 (1H, d, $J=8.0$ Hz), 7.62 (1H, d, $J=9.5$ Hz)
[0342]

Example 23

Synthesis of hexadecanoic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester
15
[0343]



[0344]


20 In the same manner as in Example 14, the title compound was obtained.

$^1\text{H-NMR}$ (CDCl_3) δ : 0.88 (t, $J = 6.8$, 3H), 1.18-1.34 (m, 26H), 1.57-1.80 (m, 4H), 1.80-1.90 (m, 2H), 2.36 (t, $J = 7.5$ Hz, 2H), 2.53 (t, $J = 7.5$ Hz, 2H), 2.63-2.77 (m, 6H), 2.83-2.89 (m, 2H),
25 3.15-3.25 (m, 2H), 3.98 (t, $J = 6.2$ Hz, 2H), 5.92 (brs, 2H), 6.59 (dd, $J = 2.3, 8.1$ Hz, 1H), 6.62 (d, $J = 2.3$ Hz, 1H), 6.87-6.92 (m, 1H), 7.07 (d, $J = 8.1$ Hz, 1H), 7.27 (dd, $J = 7.8, 7.8$ Hz, 1H), 7.37-7.43 (m, 2H), 7.55 (d, $J = 8.0$ Hz, 1H)
[0345]

30 Example 24

Synthesis of octanoic acid 7-[4-(4-benzo[b]thiophen-4-

ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester
[0346]



5 [0347]


In the same manner as in Example 14, the title compound was obtained.

¹H-NMR (CDCl₃) δ: 0.86 (t, J = 6.9Hz, 3H), 1.19-1.35 (m, 8H), 1.59-1.68 (m, 2H), 1.69-1.80 (m, 2H), 1.80-1.90 (m, 2H), 2.36
10 (t, J = 7.5 Hz, 2H), 2.53 (t, J = 7.5 Hz, 2H), 2.65-2.78 (m, 6H), 2.83-2.89 (m, 2H), 3.14-3.24 (m, 4H), 3.98 (t, J = 6.2 Hz, 2H), 5.92 (brs, 2H), 6.60 (dd, J = 2.2, 8.1 Hz, 1H), 6.62 (d, J = 2.2, 1H), 6.88-6.92 (m, 1H), 7.07 (d, J = 8.1 Hz, 1H), 7.27 (dd, J = 7.8, 7.8 Hz, 1H), 7.37-7.43 (m, 2H), 7.55 (d, J
15 = 8.1 Hz, 1H)

[0348]

Example 25

Synthesis of phenylacetic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester
20 [0349]



[0350]

In the same manner as in Example 14, the title compound was obtained.


¹H-NMR (CDCl₃) δ: 1.62-1.86 (m, 4H), 2.52 (t, J = 7.4 Hz, 2H), 2.65-2.77 (m, 6H), 2.82-2.88 (m, 2H), 3.14-3.25 (m, 4H), 3.68

(s, 2H), 3.85 (t, J = 6.2 Hz, 2H), 5.94 (brs, 2H), 6.51 (d, J = 2.3 Hz, 1H), 6.58 (dd, J = 2.3, 8.2 Hz, 1H), 6.88-6.92 (m, 1H), 7.06 (d, J = 8.2 Hz, 1H), 7.23-7.34 (m, 6H), 7.37-7.43 (m, 2H), 7.55 (d, J = 8.1 Hz, 1H)

5 [0351]

Example 26

Synthesis of phenylacetic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester
[0352]



10

[0353]

Using 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-1H-quinolin-2-one synthesized in the same manner as in WO2006/112464 (Example 1) and in the same manner as in

15 Example 11, the title compound was obtained.

¹H-NMR (CDCl₃) δ: 1.65-1.88 (m, 4H), 2.52 (t, J = 7.4 Hz, 2H), 2.64-2.78 (m, 4H), 3.14-3.25 (m, 4H), 3.67 (s, 2H), 3.87 (t, J = 6.2 Hz, 2H), 6.35 (brs, 2H), 6.52 (d, J = 9.5 Hz, 1H), 6.72 (d, J = 2.1 Hz, 1H), 6.82 (dd, J = 2.1, 8.6 Hz, 1H), 6.84-6.92 (m, 1H), 7.22-7.31 (m, 6H), 7.37-7.46 (m, 3H), 7.55 (d, J = 8.0 Hz, 1H), 7.63 (d, J = 9.5 Hz, 1H)

20


[0354]

Example 27

Synthesis of N-butylcarbamic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester

25

[0355]



[0356]

Using carbonic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester phenyl ester synthesized in the same manner as in Example 5 and in the same manner as in Example 10, the title compound was obtained.


$^1\text{H-NMR}$ (CDCl_3) δ : 0.92 (3H, t, $J=7.5\text{Hz}$), 1.24-1.40 (2H, m), 1.43-1.53 (2H, m), 1.69-1.80 (2H, m), 1.81-1.91 (2H, m), 2.53 (2H, t, $J=7.5\text{Hz}$), 2.64-2.77 (6H, m), 2.82-2.89 (2H, m), 3.13-3.27 (6H, m), 4.00 (2H, t, $J=6.0\text{Hz}$), 4.74-4.82 (1H, m), 5.92 (2H, s), 6.59 (1H, dd, $J=2.0\text{Hz}$, 8.0Hz), 6.79 (1H, d, $J=6.0\text{Hz}$), 6.89 (1H, d, $J=7.5\text{Hz}$), 7.05 (1H, d, $J=8.0\text{Hz}$), 7.24-7.30 (1H, m), 7.38 (1H, d, $J=5.5\text{Hz}$), 7.41 (1H, d, $J=5.5\text{Hz}$), 7.55 (1H, d, $J=8.0\text{Hz}$)

[0357]

Example 28

Synthesis of N,N-dibutylcarbamic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester

[0358]



[0359]

Using carbonic acid 7-[4-(4-benzo[b]thiophen-4-

ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester phenyl ester synthesized in the same manner as in Example 5 and in the same manner as in Example 10, the title compound was obtained.


5 $^1\text{H-NMR}$ (CDCl_3) δ : 0.80 (3H, t, $J=7.0\text{Hz}$), 0.93 (3H, t, $J=7.0\text{Hz}$); 1.13-1.58 (8H, m), 1.68-1.90 (4H, m), 2.52 (2H, t, $J=7.5\text{Hz}$), 2.62-2.78 (6H, m), 2.80-2.89 (2H, m), 3.09-3.30 (8H, m), 3.98 (2H, t, $J=6.0\text{Hz}$), 5.93 (2H, s), 6.59 (1H, dd, $J=2.5\text{Hz}$, 8.5Hz), 6.76 (1H, d, $J=2.5\text{Hz}$), 6.90 (1H, d, $J=7.5\text{Hz}$), 7.06 (1H, d, $J=8.5\text{Hz}$), 7.24-7.30 (1H, m), 7.38 (1H, d, $J=5.5\text{Hz}$), 7.41 (1H, d, $J=5.5\text{Hz}$), 7.55 (1H, d, $J=8.0\text{Hz}$)

[0360]

Example 29

Synthesis of N-cyclohexylmethylcarbamic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester

[0361]



[0362]

20 Using carbonic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester phenyl ester synthesized in the same manner as in Example 5 and in the same manner as in Example 10, the title compound was obtained.

25 $^1\text{H-NMR}$ (CDCl_3) δ : 0.81-0.98 (2H, m), 1.07-1.30 (3H, m), 1.36-1.50 (1H, m), 1.59-1.80 (7H, m), 1.81-1.91 (2H, m), 2.53 (2H, t, $J=7.5\text{Hz}$), 2.63-2.78 (6H, m), 2.81-2.89 (2H, m), 3.05 (2H, $J=6.5\text{Hz}$), 3.14-3.24 (4H, m), 4.00 (2H, t, $J=6.0\text{Hz}$), 4.84 (1H, t, $J=5.5\text{Hz}$), 5.92 (2H, s), 6.59 (1H, dd, $J=2.5\text{Hz}$, 8.5Hz), 6.80 (1H, d, $J=2.0\text{Hz}$), 6.87-6.92 (1H, m), 7.05 (1H, d, $J=8.5\text{Hz}$),


7.24-7.30 (1H, m), 7.37-7.44 (2H, m), 7.55 (1H, d, J=8.0Hz)

[0363]

Example 30

Synthesis of octanoic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester

[0364]



[0365]

In the same manner as in Example 22, the title compound was obtained.


¹H-NMR (CDCl₃) δ: 0.85 (t, J = 6.9 Hz, 3H), 1.16-1.33 (m, 8H), 1.57-1.68 (m, 2H), 1.74-1.96 (m, 4H), 2.36 (t, J = 7.5 Hz, 2H), 2.52-2.63 (m, 2H), 2.69-2.85 (m, 4H), 3.15-3.29 (m, 4H), 4.08 (t, J = 6.2 Hz, 2H), 6.34 (brs, 2H), 6.52 (d, J = 9.5 Hz, 1H), 6.84 (dd, J = 2.1, 8.6 Hz, 1H), 6.86-6.92 (m, 2H), 7.27 (dd, J = 7.8, 7.8 Hz, 1H), 7.37-7.42 (m, 2H), 7.45 (d, J = 8.6Hz, 1H), 7.55 (d, J = 8.0 Hz, 1H), 7.62 (d, J = 9.5 Hz, 1H)

[0366]

Example 31

Synthesis of icosanoic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester

[0367]



[0368]

To a solution (6 ml) of arachidic acid (1048 mg, 3.35 mmol) in 1,2-dichloroethane was added thionyl chloride (1.217 ml, 16.77 mmol), and the mixture was heated under reflux, and concentrated under reduced pressure to give acid chloride. To a solution (15 ml) of 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-1-hydroxymethyl-3,4-dihydro-1H-quinolin-2-one (781 mg, 1.677 mmol) synthesized in the same manner as in Example 1 in dichloromethane were added pyridine (1.357 ml, 16.77 mmol) and the above-mentioned acid chloride, and the mixture was stirred at room temperature for 3 hr. The organic layer was dried over sodium sulfate, and concentrated under reduced pressure. The residue was purified by moderate-pressure silica gel column chromatography (hexane:ethyl acetate=1:0 to 1:1), and concentrated under reduced pressure. The residue was purified by basic silica gel column chromatography (hexane:ethyl acetate=1:0 to 1:1), and concentrated to dryness under reduced pressure to give the title compound (yield 856 mg, 67%) as a colorless oil.


¹H-NMR (CDCl₃) δ: 0.88 (t, J = 6.8 Hz, 3H), 1.19-1.35 (m, 32H), 1.57-1.68 (m, 2H), 1.69-1.79 (m, 2H), 1.80-1.90 (m, 2H), 2.36 (t, J = 7.6 Hz, 2H), 2.52 (t, J = 7.5 Hz, 2H), 2.64-2.77 (m, 6H), 2.83-2.89 (m, 2H), 3.14-3.25 (m, 4H), 3.98 (t, J = 6.2 Hz, 2H), 5.92 (brs, 2H), 6.60 (dd, J = 2.3, 8.1 Hz, 1H), 6.62 (d, J = 2.3 Hz, 1H), 6.87-6.92 (m, 1H), 7.07 (d, J = 8.1 Hz, 1H), 7.27 (dd, J = 7.8, 7.8 Hz, 1H), 7.37-7.43 (m, 2H), 7.55 (d, J = 8.1 Hz, 1H)

[0369]

Example 32

Synthesis of cyclohexanecarboxylic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester

[0370]



[0371]

Using 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-1H-quinolin-2-one synthesized in the same manner as in WO2006/112464 (Example 1) and in the same manner as in Example 11, the title compound was obtained.


$^1\text{H-NMR}$ (CDCl_3) δ : 1.14-1.31 (m, 3H), 1.39-1.52 (m, 2H), 1.54-1.65 (m, 1H), 1.67-1.82 (m, 4H), 1.84-1.95 (m, 4H), 2.31-2.41 (m, 1H), 2.54 (t, $J = 7.6$ Hz, 2H), 2.65-2.79 (m, 4H), 3.13-3.25 (m, 4H), 4.07 (t, $J = 6.2$ Hz, 2H), 6.33 (brs, 2H), 6.52 (d, $J = 9.5$ Hz, 1H), 6.81-6.86 (m, 2H), 6.89 (d, $J = 7.6$ Hz, 1H), 7.27 (dd, $J = 7.8, 7.8$ Hz, 1H), 7.37-7.47 (m, 3H), 7.55 (d, $J = 8.0$ Hz, 1H), 7.62 (d, $J = 9.5$ Hz, 1H)

[0372]

Example 33

Synthesis of (Z)-octadec-9-enoic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester

[0373]



[0374]

In the same manner as in Example 14, the title compound was obtained.


$^1\text{H-NMR}$ (CDCl_3) δ : 0.87 (t, $J = 6.8$ Hz, 3H), 1.20-1.36 (m, 20H), 1.58-1.68 (m, 2H), 1.69-1.79 (m, 2H), 1.80-1.90 (m, 2H), 1.93-

2.07 (m, 4H), 2.36 (t, J = 7.5 Hz, 2H), 2.52 (t, J = 7.5 Hz, 2H), 2.64-2.79 (m, 6H), 2.83-2.90 (m, 2H), 3.14-3.25 (m, 4H), 3.99 (t, J = 6.3 Hz, 2H), 5.28-5.40 (m, 2H), 5.92 (brs, 2H), 6.60 (dd, J = 2.3, 8.1 Hz, 1H), 6.62 (d, J = 2.3 Hz, 1H),
 5 6.87-6.92 (m, 1H), 7.07 (d, J = 8.1 Hz, 1H), 7.27 (t, J = 7.8 Hz, 1H), 7.37-7.43 (m, 2H), 7.55 (d, J = 8.0 Hz, 1H)

[0375]

Example 34

Synthesis of N-decylcarbamic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester
 10 [0376]



[0377]


Using carbonic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester
 15 phenyl ester synthesized in the same manner as in Example 7 and in the same manner as in Example 9, the title compound was obtained.

¹H-NMR (CDCl₃) δ: 0.87 (3H, t, J=7.0Hz), 1.16-1.35 (12H, m),
 20 1.42-1.53 (4H, m), 1.72-1.83 (2H, m), 1.86-1.95 (2H, m), 2.54 (2H, t, J=7.5Hz), 2.67-2.80 (4H, m), 3.13-3.28 (6H, m), 4.11 (2H, t, J=6.0Hz), 4.87 (1H, t, J=5.5Hz), 6.33 (2H, s), 6.51 (1H, d, J=9.5Hz), 6.83 (1H, dd, J=2.0Hz, J=8.5Hz), 6.87-6.92 (1H, m), 7.16 (1H, d, J=1.5Hz), 7.24-7.30 (1H, m), 7.36-7.45
 25 (3H, m), 7.55 (1H, d, J=8.0Hz), 7.62 (1H, d, J=9.5Hz)

[0378]

Example 35

Synthesis of N-butylcarbamic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester
 30 [0379]



[0380]

Using carbonic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester
 5 phenyl ester synthesized in the same manner as in Example 7
 and in the same manner as in Example 9, the title compound was
 obtained.


¹H-NMR (CDCl₃) δ: 0.91 (3H, t, J=7.5Hz), 1.28-1.39 (2H, m),
 1.43-1.53 (2H, m), 1.73-1.82 (2H, m), 1.87-1.95 (2H, m), 2.54
 10 (2H, t, J=7.5Hz), 2.67-2.78 (4H, m), 3.15-3.24 (6H, m), 4.11
 (2H, t, J=6.0Hz), 4.88 (1H, t, J=5.5Hz), 6.32 (2H, s), 6.51
 (1H, d, J=9.5Hz), 6.83 (1H, dd, J=2.0Hz, J=8.5Hz), 6.89 (1H, d,
 J=7.5Hz), 7.15 (1H, d, J=1.5Hz), 7.24-7.30 (1H, m), 7.37-7.45
 (3H, m), 7.55 (1H, d, J=8.0Hz), 7.61 (1H, d, J=9.5Hz)

15 [0381]

Example 36

Synthesis of N-butyl-N-methylcarbamic acid 7-[4-(4-
 benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-
 1-ylmethyl ester

20 [0382]



[0383]

Using carbonic acid 7-[4-(4-benzo[b]thiophen-4-
 ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester
 25 phenyl ester synthesized in the same manner as in Example 7

and in the same manner as in Example 9, the title compound was obtained.


¹H-NMR (CDCl₃) δ: {0.87 (t, J=7.5Hz), 0.94 (t, J=7.5Hz) total 3H (1 : 1)}, 1.08-1.19 (1H, m), 1.26-1.43 (2H, m), 1.47-1.57 (1H, m), 1.72-1.83 (2H, m), 1.85-1.95 (2H, m), 2.54 (2H, t, J=7.5Hz), 2.66-2.79 (4H, m), {2.82 (s), 2.92 (s) total 3H (1 : 1)}, 3.12-3.25 (5H, m), 3.30 (1H, t, J=7.5Hz), 4.10 (2H, t, J=6.0Hz), 6.35 (2H, s), 6.52 (1H, dd, J=1.5Hz, J=9.5Hz), 6.83 (1H, dd, J=1.5Hz, J=8.5Hz), 6.89 (1H, d, J=7.5Hz), 7.10 (1H, d, J=16.5Hz), 7.25-7.30 (1H, m), 7.37-7.45 (3H, m), 7.55 (1H, d, J=8.0Hz), 7.62 (1H, d, J=9.5Hz)

[0384]

Example 37

Synthesis of cyclopentanecarboxylic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester

[0385]



[0386]

To a solution (10 ml) of cyclopentanecarboxylic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester (252 mg) synthesized in the same manner as in Example 13 in THF was added 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) (509 mg), and the mixture was stirred at room temperature stirred for 2 days. To the reaction mixture were added water and sodium carbonate, and the mixture was extracted with dichloromethane, dried over sodium sulfate, and concentrated under reduced pressure. The residue was purified by moderate-pressure silica gel column chromatography (hexane:ethyl acetate=1:0 to 0:1) and further by NH silica gel column chromatography (hexane:ethyl

acetate=1:0 to 0:1) to give the title compound (yield 38 mg, 15%) as a colorless amorphous solid.


¹H-NMR (CDCl₃) δ: 1.50-1.62 (m, 2H), 1.62-1.95 (m, 10H), 2.54 (t, J = 7.5Hz, 2H), 2.67-2.83 (m, 5H), 3.14-3.25 (m, 4H), 4.07 (t, J = 6.2 Hz, 2H), 6.33 (brs, 2H), 6.52 (d, J = 9.5 Hz, 1H), 6.81-6.86 (m, 2H), 6.89 (d, J = 7.4 Hz, 1H), 7.27 (t, J = 7.9, 7.9 Hz, 1H), 7.37-7.47 (m, 3H), 7.55 (d, J = 7.9 Hz, 1H), 7.62 (d, J = 9.5 Hz, 1H)

[0387]

10 Example 38

Synthesis of N-octadecylcarbamic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester

[0388]



15

[0389]

Using carbonic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester phenyl ester synthesized in the same manner as in Example 7 and in the same manner as in Example 9, the title compound was obtained.

¹H-NMR (CDCl₃) δ: 0.88 (3H, t, J=7.0Hz), 1.13-1.34 (30H, m), 1.43-1.53 (2H, m), 1.73-1.83 (2H, m), 1.85-1.965 (2H, m), 2.54 (2H, t, J=7.5Hz), 2.66-2.79 (4H, m), 3.13-3.25 (6H, m), 4.12 (2H, t, J=6.0Hz), 4.85 (1H, t, J=5.5Hz), 6.33 (2H, s), 6.52 (1H, d, J=9.5Hz), 6.83 (1H, dd, J=2.0Hz, J=8.5Hz), 6.89 (1H, d, J=7.5Hz), 7.16 (1H, d, J=1.5Hz), 7.24-7.30 (1H, m), 7.36-7.45 (3H, m), 7.55 (1H, d, J=8.0Hz), 7.62 (1H, d, J=9.5Hz)


[0390]

30 Example 39

Synthesis of (Z)-octadec-9-enoic acid 7-[4-(4-

benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester

[0391]



5 [0392]

Using 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-1H-quinolin-2-one synthesized in the same manner as in WO2006/112464 (Example 1) and in the same manner as in Example 11, the title compound was obtained.


10 ¹H-NMR (CDCl₃) δ: 0.87 (t, J = 6.8 Hz, 3H), 1.18-1.35 (m, 20H), 1.57-1.68 (m, 2H), 1.72-1.82 (m, 2H), 1.86-2.04 (m, 6H), 2.36 (t, J = 7.4 Hz, 2H), 2.52 (t, J = 7.4 Hz, 2H), 2.67-2.79 (m, 4H), 3.14-3.24 (m, 4H), 4.08 (t, J = 6.2 Hz, 2H), 5.26-5.39 (m, 2H), 6.34 (brs, 2H), 6.52 (d, J = 9.5 Hz, 1H), 6.84 (dd, J =
15 2.2, 8.6 Hz, 1H), 6.86-6.91 (m, 2H), 7.27 (t, J = 7.9 Hz, 1H), 7.37-7.43 (m, 2H), 7.45 (d, J = 8.6 Hz, 1H), 7.55 (d, J = 8.0 Hz, 1H), 7.62 (d, J = 9.5 Hz, 1H)

[0393]

Example 40

20 Synthesis of 2-pentylheptanoic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester

[0394]



25 [0395]


In the same manner as in Example 31, the title compound was obtained.

¹H-NMR (CDCl₃) δ: 0.85 (t, 6H), 1.17-1.31 (m, 12H), 1.37-1.49 (m, 2H), 1.55-1.78 (m, 4H), 1.79-1.89 (m, 2H), 2.32-2.41 (m, 1H), 2.52 (t, J = 7.4 Hz, 2H), 2.64-2.77 (m, 6H), 2.82-2.89 (m, 2H), 3.13-3.24 (m, 4H), 3.97 (t, J = 6.2 Hz, 2H), 5.94 (brs, 2H), 6.59 (dd, J = 2.3, 8.2 Hz, 1H), 6.63 (d, J = 2.3 Hz, 1H), 6.87-6.92 (m, 1H), 7.06 (d, J = 8.2 Hz, 1H), 7.27 (dd, J = 7.8, 7.8 Hz, 1H), 7.37-7.43 (m, 2H), 7.55 (d, J = 8.0 Hz, 1H),

10 [0396]

Example 41

Synthesis of icosanoic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester [0397]



15

[0398]

In the same manner as in Example 22, the title compound was obtained.

¹H-NMR (CDCl₃) δ: 0.88 (t, J = 6.8 Hz, 3H), 1.18-1.33 (m, 32H), 1.58-1.67 (m, 2H), 1.72-1.82 (m, 2H), 1.86-1.96 (m, 2H), 2.36 (t, J = 7.5 Hz, 2H), 2.54 (t, J = 7.5 Hz, 2H), 2.67-2.77 (m, 4H), 3.14-3.24 (m, 4H), 4.08 (t, J = 6.2 Hz, 2H), 6.34 (brs, 2H), 6.52 (d, J = 9.5 Hz, 1H), 6.84 (dd, J = 2.1, 8.6 Hz, 1H), 6.86-6.91 (m, 2H), 7.27 (dd, J = 7.9, 7.9 Hz, 1H), 7.36-7.43 (m, 2H), 7.44 (d, J = 8.6 Hz, 1H), 7.55 (d, J = 8.0 Hz, 1H), 7.62 (d, J = 9.5 Hz, 1H)

25


[0399]

Example 42

Synthesis of hexadecanoic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester

30

[0400]



[0401]

In the same manner as in Example 22, the title compound
5 was obtained.


$^1\text{H-NMR}$ (CDCl_3) δ : 0.87 (t, $J = 6.8$ Hz, 3H), 1.18-1.32 (m, 24H),
1.58-1.67 (m, 2H), 1.72-1.95 (m, 4H), 2.36 (t, $J = 7.5$ Hz, 2H),
2.54 (t, $J = 7.5$ Hz, 2H), 2.66-2.78 (m, 4H), 3.14-3.24 (m, 4H),
4.08 (t, $J = 6.2$ Hz, 2H), 6.34 (brs, 2H), 6.52 (d, $J = 9.5$ Hz,
10 1H), 6.84 (dd, $J = 2.2, 8.6$ Hz, 1H), 6.86-6.91 (m, 2H), 7.27
(dd, $J = 7.8, 7.8$ Hz, 1H), 7.36-7.43 (m, 2H), 7.44 (d, $J = 9.5$
Hz, 1H), 7.55 (d, $J = 8.6$ Hz, 1H), 7.62 (d, $J = 9.5$ Hz, 1H)

[0402]

Example 43

15 Synthesis of N-pentadecylcarbamic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester

[0403]



20 [0404]


Using carbonic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester
phenyl ester synthesized in the same manner as in Example 7
and in the same manner as in Example 9, the title compound was
25 obtained.

$^1\text{H-NMR}$ (CDCl_3) δ : 0.88 (3H, t, $J=7.0\text{Hz}$), 1.16-1.33 (24H, m),

1.42-1.53 (2H, m), 1.72-1.83 (2H, m), 1.86-1.95 (2H, m), 2.54
 (2H, t, J=7.5Hz), 2.67-2.78 (4H, m), 3.14-3.24 (6H, m), 4.11
 (2H, t, J=6.0Hz), 4.86 (1H, t, J=5.5Hz), 6.33 (2H, s), 6.51
 (1H, d, J=9.5Hz), 6.83 (1H, dd, J=2.0Hz, J= 8.5Hz), 6.89 (1H,
 5 d, J=7.5Hz), 7.39 (1H, d, J=1.5Hz), 7.24-7.29 (1H, m), 7.37-
 7.44 (3H, m), 7.55 (1H, d, J=8.0Hz), 7.61 (1H, d, J=9.5Hz)
 [0405]

Example 44

Synthesis of N-methyl-N-octadecylcarbamic acid 7-[4-(4-
 10 benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-
 1-ylmethyl ester
 [0406]



[0407]

15 Using carbonic acid 7-[4-(4-benzo[b]thiophen-4-
 ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester
 phenyl ester synthesized in the same manner as in Example 7
 and in the same manner as in Example 9, the title compound was
 obtained.


20 ¹H-NMR (CDCl₃) δ: 0.88 (3H, t, J=7.0Hz), 1.01-1.32 (30H, m),
 1.33-1.43 (1H, m), 1.47-1.58 (1H, m), 1.72-1.83 (2H, m), 1.85-
 1.95 (2H, m), 2.54 (2H, t, J=7.5Hz), 2.66-2.78 (4H, m), {2.82
 (s), 2.93 (s) total 3H (1 : 1)}, 3.12-3.24 (5H, m), 3.25-3.32
 (1H, m), 4.09 (2H, t, J=5.5Hz), 6.36 (2H, s), 6.52 (1H, dd,
 25 J=2.0Hz, J=9.5Hz), 6.83 (1H, d, J=8.5Hz), 6.89 (1H, d,
 J=7.5Hz), 7.10 (1H, d, J=17.5Hz), 7.24-7.30 (1H, m), 7.36-7.46
 (3H, m), 7.55 (1H, d, J=8.0Hz), 7.66 (1H, dd, J=4.0Hz,
 J=9.5Hz)

[0408]

30 Example 45

Synthesis of N,N-dibutylcarbamic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester

[0409]



5

[0410]

Using carbonic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester phenyl ester synthesized in the same manner as in Example 7

10 and in the same manner as in Example 9, the title compound was obtained.


¹H-NMR (CDCl₃) δ: 0.72 (3H, t, J=7.5Hz), 0.93 (3H, t, J=7.5Hz), 1.06-1.19 (2H, m), 1.24-1.42 (4H, m), 1.48-1.59 (2H, m), 1.72-1.83 (2H, m), 1.85-1.95 (2H, m), 2.54 (2H, t, J=7.5Hz), 2.65-2.83 (4H, m), 3.12 (2H, t, J=7.5Hz), 3.15-3.23 (4H, m), 3.26 (2H, J=7.5Hz), 4.09 (2H, t, J=6.0Hz), 6.36 (2H, s), 6.51 (1H, d, J=9.5Hz), 6.83 (1H, dd, J=2.0Hz, J=8.5Hz), 6.90 (1H, d, J=7.5Hz), 7.07 (1H, d, J=2.0Hz), 7.25-7.31 (1H, m), 7.37-7.45 (3H, m), 7.55 (1H, d, J=8.0Hz), 7.61 (1H, d, J=9.5Hz)

20 [0411]

Example 46

Synthesis of N-methylcarbamic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester

25 [0412]



[0413]

Using carbonic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester phenyl ester synthesized in the same manner as in Example 5 and in the same manner as in Example 10, the title compound was obtained.


¹H-NMR (CDCl₃) δ: 1.70-1.80 (2H, m), 1.81-1.91 (2H, m), 2.53 (2H, t, J=7.5Hz), 2.63-2.77 (6H, m), 2.79-2.89 (5H, m), 3.14-3.24 (4H, m), 4.00 (2H, t, J=6.0Hz), 4.75 (1H, d, J=4.0Hz), 5.92 (2H, s), 6.59 (1H, dd, J=2.5Hz, 8.5Hz), 6.78 (1H, d, J=2.5Hz), 6.90 (1H, d, J=7.5Hz), 7.06 (1H, d, J=8.5Hz), 7.24-7.30 (1H, m), 7.38 (1H, d, J=5.5Hz), 7.41 (1H, d, J=5.5Hz), 7.55 (1H, d, J=8.0Hz)

[0414]

Example 47

Synthesis of N,N-dimethylcarbamic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester

[0415]



[0416]

Using carbonic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester phenyl ester synthesized in the same manner as

in Example 5 and in the same manner as in Example 10, the title compound was obtained.


¹H-NMR (CDCl₃) δ: 1.69-1.79 (2H, m), 1.81-1.90 (2H, m), 2.52 (2H, t, J=7.5Hz), 2.64-2.77 (6H, m), 2.83-2.91 (2H, m), 2.88 (3H, s), 2.95 (3H, s), 3.14-3.24 (4H, m), 4.00 (2H, t, J=6.5Hz), 5.92 (2H, s), 6.59 (1H, dd, J=2.5Hz, 8.5Hz), 6.78 (1H, d, J=2.5Hz), 6.90 (1H, d, J=7.5Hz), 7.06 (1H, d, J=8.5Hz), 7.24-7.30 (1H, m), 7.38 (1H, d, J=5.5Hz), 7.42 (1H, d, J=5.5Hz), 7.55 (1H, d, J=8.0Hz)

10 [0417]

Example 48

Synthesis of octadecanoic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester

15 [0418]



[0419]

To a solution (20 ml) of 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-1-hydroxymethyl-3,4-dihydro-1H-quinolin-2-one (640 mg, 2.066 mmol) synthesized in the same manner as in Example 1, stearic acid (587 mg, 2.062 mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (395 mg, 2.062 mmol) in methylene chloride was added 4-dimethylaminopyridine (33.6 mg, 0.275 mmol), and the mixture was stirred at room temperature overnight. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate. This was purified by moderate-pressure silica gel column chromatography (hexane:ethyl acetate=1:0 to 0:1) and further by basic silica gel column chromatography (hexane:ethyl acetate=1:0 to 0:1) and concentrated under reduced pressure to give the title compound (yield 649 mg,

64.5%) as a colorless oil.


¹H-NMR (CDCl₃) δ: 0.88 (t, J = 6.9 Hz, 3H), 1.18-1.35 (m, 28H), 1.59-1.68 (m, 2H), 1.69-1.79 (m, 2H), 1.80-1.90 (m, 2H), 2.36 (t, J = 7.5 Hz, 2H), 2.52 (t, J = 7.4 Hz, 2H), 2.65-2.76 (m, 6H), 2.83-2.90 (m, 2H), 3.14-3.24 (m, 4H), 3.98 (t, J = 6.2 Hz, 2H), 5.92 (brs, 2H), 6.60 (dd, J = 2.2, 8.1 Hz, 1H), 6.62 (d, J = 2.2 Hz, 1H), 6.87-6.92 (m, 1H), 7.07 (d, J = 8.1 Hz, 1H), 7.27 (dd, J = 7.8, 7.8 Hz, 1H), 7.37-7.43 (m, 2H), 7.55 (d, J = 8.0 Hz, 1H)

10 [0420]

Example 49

Synthesis of carbonic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester ethyl ester

15 [0421]



[0422]

In the same manner as in Example 14, the title compound was obtained.

20 ¹H-NMR (CDCl₃) δ: 1.32 (3H, t, J=7.2 Hz), 1.70-1.80 (2H, m), 1.80-1.90 (2H, m), 2.52 (2H, t, J=7.4 Hz), 2.65-2.73 (2H, m), 2.72 (4H, m), 2.86 (2H, t, J=7.2 Hz), 3.14-3.24 (4H, br), 4.00 (2H, t, J=6.2 Hz), 4.25 (2H, q, J=7.2 Hz), 5.94 (2H, brs), 6.59 (1H, dd, J=2.3, 8.3 Hz), 6.69 (1H, d, J=2.3 Hz), 6.90 (1H, d, J=7.6 Hz), 7.06 (1H, d, J=8.1 Hz), 7.27 (1H, t, J=7.8 Hz), 7.37-7.43 (2H, m), 7.55 (1H, d, J=8.1 Hz)


[0423]

Example 50

30 Synthesis of carbonic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester

ethyl ester

[0424]



[0425]

5 In the same manner as in Example 22, the title compound was obtained.


¹H-NMR (CDCl₃) δ: 1.31 (3H, t, J=7.1 Hz), 1.72-1.84 (2H, m), 1.84-1.96 (2H, m), 2.56 (2H, t, J=7.4 Hz), 2.70-2.80 (4H, m), 3.16-3.26 (4H, m), 4.10 (2H, t, J=6.2 Hz), 4.26 (2H, q, J=7.1 Hz), 6.35 (2H, brs), 6.50 (1H, d, J=9.5 Hz), 6.84 (1H, dd, J=2.2, 8.6 Hz), 6.88-6.95 (2H, m), 7.27 (1H, t, J=7.8 Hz), 7.37-7.41 (2H, m), 7.44 (1H, d, J=8.6 Hz), 7.55 (1H, d, J=8.0 Hz), 7.61 (1H, d, J=9.5 Hz)

[0426]

15 Example 51

Synthesis of N-ethylcarbamic acid 7-[4-(4-benzo[b]thiophen-4-yl)piperazin-1-yl]butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester

[0427]



[0428]

Using carbonic acid 7-[4-(4-benzo[b]thiophen-4-yl)piperazin-1-yl]butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester phenyl ester synthesized in the same manner as in Example 5 and in the same manner as in Example 10, the

title compound was obtained.


¹H-NMR (CDCl₃) δ: 1.14 (3H, t, J=7.0Hz), 1.69-1.80 (2H, m),
1.81-1.90 (2H, m), 2.52 (2H, t, J=7.5Hz), 2.61-2.79 (6H, m),
2.81-2.90 (2H, m), 3.09-3.31 (6H, m), 4.00 (2H, t, J=6.0Hz),
5 4.73-4.84 (1H, m), 5.92 (2H, s), 6.59 (1H, dd, J=2.5Hz, 8.5Hz),
6.79 (1H, d, J=2.0Hz), 6.90 (1H, d, J=7.5Hz), 7.06 (1H, d,
J=8.5Hz), 7.24-7.30 (1H, m), 7.37-7.44 (2H, m), 7.55 (1H, d,
J=8.0Hz)

[0429]

10 Example 52

Synthesis of N,N-diethylcarbamic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester

[0430]



15

[0431]


Using carbonic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester phenyl ester synthesized in the same manner as
20 in Example 5 and in the same manner as in Example 10, the
title compound was obtained.

¹H-NMR (CDCl₃) δ: 1.00-1.19 (6H, m), 1.66-1.79 (2H, m), 1.80-
1.91 (2H, m), 2.52 (2H, t, J=7.5Hz), 2.63-2.78 (6H, m), 2.82-
2.90 (2H, m), 3.14-3.38 (8H, m), 3.99 (2H, t, J=6.0Hz), 5.93
25 (2H, s), 6.59 (1H, dd, J=2.5Hz, 8.5Hz), 6.77 (1H, d, J=2.5Hz),
6.90 (1H, d, J=7.5Hz), 7.06 (1H, d, J=8.5Hz), 7.24-7.30 (1H,
m), 7.38 (1H, d, J=5.5Hz), 7.41 (1H, d, J=5.5Hz), 7.55 (1H, d,
J=8.0Hz)

[0432]

Example 53

Synthesis of N-methylcarbamic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester
[0433]



[0434]


Using carbonic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester phenyl ester synthesized in the same manner as in Example 7 and in the same manner as in Example 9, the title compound was obtained.

$^1\text{H-NMR}$ (CDCl_3) δ : 1.73-1.84 (2H, m), 1.85-1.96 (2H, m), 2.55 (2H, t, $J=7.5\text{Hz}$), 2.66-2.78 (4H, m), {2.82 (s), 2.84 (s) total 3H (1 : 1)}, 3.13-3.26 (4H, m), 4.12 (2H, t, $J=6.0\text{Hz}$), 4.76-4.86 (1H, m), 6.33 (2H, s), 6.51 (1H, d, $J=9.5\text{Hz}$), 6.83 (1H, dd, $J=2.0\text{Hz}$, $J=8.5\text{Hz}$), 6.89 (1H, d, $J=7.5\text{Hz}$), 7.15 (1H, d, $J=2.0\text{Hz}$), 7.24-7.31 (1H, m), 7.37-7.46 (3H, m), 7.55 (1H, d, $J=8.0\text{Hz}$), 7.62 (1H, d, $J=9.5\text{Hz}$)

[0435]

Example 54

Synthesis of 2-pentylheptanoic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester
[0436]



[0437]

In the same manner as in Example 22, the title compound was obtained.

[0438]


¹H-NMR (CDCl₃) δ: 0.80 (t, J = 6.5 Hz, 6H), 1.13-1.24 (m, 12H),
 5 1.37-1.48 (m, 2H), 1.54-1.66 (m, 2H), 1.71-1.81 (m, 2H), 1.85-
 1.95 (m, 2H), 2.33-2.43 (m, 1H), 2.54 (t, J = 7.4 Hz, 2H),
 2.64-2.79 (m, 4H), 3.13-3.26 (m, 4H), 4.07 (t, J = 6.2 Hz, 2H),
 6.36 (brs, 2H), 6.52 (d, J = 9.5 Hz, 1H), 6.83 (dd, J = 2.1,
 8.6 Hz, 1H), 6.87-6.93 (m, 2H), 7.27 (dd, J = 7.8, 7.8 Hz, 1H),
 10 7.37-7.43 (m, 2H), 7.44 (d, J = 8.6 Hz, 1H), 7.55 (d, J = 8.0
 Hz, 1H), 7.62 (d, J = 9.5Hz, 1H)

[0439]

Example 55

Synthesis of N-ethylcarbamic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester

[0440]



[0441]

Using carbonic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester
 20 phenyl ester synthesized in the same manner as in Example 7
 and in the same manner as in Example 9, the title compound was
 obtained.


¹H-NMR (CDCl₃) δ: 1.14 (3H, t, J=7.0Hz), 1.72-1.82 (2H, m),
 25 1.85-1.95 (2H, m), 2.54 (2H, t, J=7.5Hz), 2.66-2.78 (4H, m),
 3.13-3.30 (6H, m), 4.12 (2H, t, J=6.0Hz), 4.80-4.89 (1H, m),
 6.33 (2H, s), 6.51 (1H, d, J=9.5Hz), 6.83 (1H, dd, J=2.0Hz,
 J=8.5Hz), 6.87-6.92 (1H, m), 7.13-7.17 (1H, m), 7.24-7.30 (1H,
 m), 7.37-7.45 (3H, m), 7.55 (1H, d, J=8.0Hz), 7.62 (1H, d,
 30 J=9.5Hz)

[0442]

Example 56

Synthesis of N,N-dimethylcarbamic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester

5 [0443]



[0444]

Using carbonic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester
10 phenyl ester synthesized in the same manner as in Example 7 and in the same manner as in Example 9, the title compound was obtained.


¹H-NMR (CDCl₃) δ: 1.72-1.82 (2H, m), 1.86-1.95 (2H, m), 2.54 (2H, t, J=7.5Hz), 2.67-2.78 (4H, m), 2.86 (3H, s), 2.96 (3H, s), 3.15-3.24 (4H, m), 4.10 (2H, t, J=6.0Hz), 6.35 (2H, s),
15 6.52 (1H, d, J=9.5Hz), 6.83 (1H, dd, J=2.0Hz, J=8.5Hz), 6.89 (1H, d, J=7.5Hz), 7.12 (1H, d, J=2.0Hz), 7.24-7.31 (1H, m), 7.37-7.45 (3H, m), 7.55 (1H, d, J=8.0Hz), 7.62 (1H, d, J=9.5Hz)

20 [0445]

Example 57

Synthesis of N,N-diethylcarbamic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester

25 [0446]



[0447]

Using carbonic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester
 5 phenyl ester synthesized in the same manner as in Example 7
 and in the same manner as in Example 9, the title compound was
 obtained.


¹H-NMR (CDCl₃) δ: 1.01 (3H, t, J=7.0Hz), 1.15 (3H, t, J=7.0Hz),
 1.72-1.82 (2H, m), 1.84-1.95 (2H, m), 2.54 (2H, t, J=7.5Hz),
 10 2.64-2.808 (4H, m), 3.11-3.26 (6H, m), 3.34 (2H, q, J=7.0Hz),
 4.09 (2H, t, J=6.0Hz), 6.36 (2H, s), 6.52 (1H, d, J=9.5Hz),
 6.83 (1H, dd, J=2.0Hz, J=8.5Hz), 6.87-6.92 (1H, m), 7.09 (1H,
 d, J=2.0Hz), 7.24-7.31 (1H, m), 7.37-7.46 (3H, m), 7.55 (1H, d,
 J=8.0Hz), 7.62 (1H, d, J=9.5Hz)

15 [0448]

Example 58

Synthesis of hexanoic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester

[0449]



20

[0450]

Using 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-1H-quinolin-2-one synthesized in the same manner as
 in WO2006/112464 (Example 1) and in the same manner as in
 25 Example 11, the title compound was obtained.


¹H-NMR (CDCl₃) δ: 0.85 (t, J = 6.8 Hz, 3H), 1.25-1.33 (m, 4H),

1.58-1.69 (m, 2H), 1.70-1.85 (m, 2H), 1.85-1.95 (m, 2H), 2.36 (t, J = 7.5 Hz, 2H), 2.54 (t, J = 7.4 Hz, 2H), 2.67-2.78 (m, 4H), 3.15-3.25 (m, 4H), 4.08 (t, J = 6.2 Hz, 2H), 6.34 (brs, 2H), 6.52 (d, J = 9.5 Hz, 1H), 6.84 (dd, J = 2.2, 8.6 Hz, 1H),
 5 6.84-6.92 (m, 2H), 7.27 (dd, J = 7.8, 7.8 Hz, 1H), 7.37-7.43 (m, 2H), 7.45 (d, J = 8.6 Hz, 1H), 7.55 (d, J = 8.1 Hz, 1H), 7.62 (d, J = 9.5 Hz, 1H)

[0451]

Example 59

10 Synthesis of decanoic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester
 [0452]



[0453]


15 Using 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-1H-quinolin-2-one synthesized in the same manner as in WO2006/112464 (Example 1) and in the same manner as in Example 11, the title compound was obtained.

¹H-NMR (CDCl₃) δ: 0.86 (t, J = 6.8 Hz, 3H), 1.17-1.32 (m, 12H),
 20 1.57-1.68 (m, 2H), 1.72-1.82 (m, 2H), 1.85-1.95 (m, 2H), 2.36 (t, J = 7.5 Hz, 2H), 2.54 (t, J = 7.5 Hz, 2H), 2.65-2.78 (m, 4H), 3.13-3.25 (m, 4H), 4.08 (t, J = 6.2 Hz, 2H), 6.34 (brs, 2H), 6.52 (d, J = 9.5 Hz, 1H), 6.84 (d, J = 2.2, 8.6 Hz, 1H),
 25 6.86-6.92 (m, 2H), 7.27 (dd, J = 7.8, 7.8 Hz, 1H), 7.37-7.43 (m, 2H), 7.45 (d, J = 8.6 Hz, 1H), 7.55 (d, J = 8.0 Hz, 1H), 7.62 (d, J = 9.5 Hz, 1H)

[0454]

Example 60

Synthesis of octadecanoic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester
 30 [0455]



[0456]


In the same manner as in Example 22, the title compound was obtained.

5 $^1\text{H-NMR}$ (CDCl_3) δ : 0.88 (t, $J = 6.8$ Hz, 3H), 1.18-1.33 (m, 28H), 1.58-1.67 (m, 2H), 1.72-1.82 (m, 2H), 1.85-1.95 (m, 2H), 2.36 (t, $J = 7.5$ Hz, 2H), 2.54 (t, $J = 7.5$ Hz, 2H), 2.66-2.79 (m, 4H), 3.14-3.25 (m, 4H), 4.08 (t, $J = 6.2$ Hz, 2H), 6.34 (brs, 2H), 6.52 (d, $J = 9.5$ Hz, 1H), 6.84 (dd, $J = 2.2, 8.6$ Hz, 1H),
 10 6.87-6.91 (m, 2H), 7.27 (dd, $J = 7.8, 7.8$ Hz, 1H), 7.37-7.43 (m, 2H), 7.45 (d, $J = 8.6$ Hz, 1H), 7.55 (d, $J = 8.0$ Hz, 1H), 7.62 (d, $J = 9.5$ Hz, 1H)

[0457]

Example 61

15 Synthesis of acetic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester
 [0458]



[0459]

20 Acetic acid 7-(4-chlorobutoxy)-2-oxo-2H-quinolin-1-ylmethyl ester (299 mg), 1-benzo[b]thiophen-4-ylpiperazine hydrochloride (235 mg), potassium carbonate (319 mg) and sodium iodide (152 mg) were suspended in DMF (5 ml), and this was stirred at 70°C for 3 hr and further at 80°C for 4 hr.
 25 After cooling to room temperature, to the reaction mixture was added aqueous ammonium chloride solution, and the mixture was extracted with ethyl acetate, dried over sodium sulfate, and concentrated under reduced pressure. The residue was purified


by moderate-pressure silica gel column chromatography (hexane:ethyl acetate=1:0 to 1:9) and further by basic silica gel column chromatography, and concentrated under reduced pressure to give the title compound (132 mg) as a colorless
5 amorphous solid.

$^1\text{H-NMR}$ (CDCl_3) δ : 1.73-1.83 (m, 2H), 1.84-1.95 (m, 2H), 2.13 (s, 3H), 2.54 (t, $J = 7.4$ Hz, 2H), 2.68 -2.77 (m, 4H), 3.15-3.24 (m, 4H), 4.09 (t, $J = 6.3$ Hz, 2H), 6.33 (brs, 2H), 6.52 (d, $J = 9.5$ Hz, 1H), 6.85 (dd, $J = 2.2, 8.6$ Hz, 1H), 6.87-6.92 (m,
10 2H), 7.27 (dd, $J = 7.8, 7.8$ Hz, 1H), 7.37-7.43 (m, 2H), 7.45 (d, $J = 8.6$ Hz, 1H), 7.55 (d, $J = 8.1$ Hz, 1H), 7.63 (d, $J = 9.5$ Hz, 1H)

[0460]

Example 62

15 Synthesis of N-benzylcarbamic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester
[0461]



[0462]

20 Using carbonic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester phenyl ester synthesized in the same manner as in Example 7 and in the same manner as in Example 9, the title compound was obtained.

25 $^1\text{H-NMR}$ (CDCl_3) δ : 1.69-1.80 (2H, m), 1.82-1.92 (2H, m), 2.52 (2H, t, $J=7.5\text{Hz}$), 2.64-2.77 (4H, m), 3.11-3.24 (4H, m), 4.07 (2H, t, $J=6.0\text{Hz}$), 4.41 (2H, t, $J=6.0\text{Hz}$), 5.26 (1H, t, $J=6.0\text{Hz}$), 6.37 (2H, s), 6.51 (1H, d, $J=9.5\text{Hz}$), 6.83 (1H, dd, $J=2.0\text{Hz}$, $J=8.5\text{Hz}$), 6.88 (1H, d, $J=7.0\text{Hz}$), 7.15 (1H, d, $J=1.5\text{Hz}$), 7.23-
30 7.34 (6H, m), 7.38 (1H, d, $J=5.5\text{Hz}$), 7.41 (1H, d, $J=5.5\text{Hz}$),


7.43 (1H, J=8.5Hz), 7.55 (1H, d, J=8.0Hz), 7.61 (1H, d, J=9.5Hz)

[0463]

Example 63

5 Synthesis of N-cyclohexylmethylcarbamic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester

[0464]



10 [0465]

Using carbonic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester phenyl ester synthesized in the same manner as in Example 7 and in the same manner as in Example 9, the title compound was
15 obtained.


¹H-NMR (CDCl₃) δ: 0.83-0.97 (2H, m), 1.02-1.28 (3H, m), 1.36-1.50 (1H, m), 1.54-1.84 (7H, m), 1.86-1.96 (2H, m), 2.54 (2H, t, J=7.5Hz), 2.65-2.81 (4H, m), 3.05 (2H, t, J=6.5Hz), 3.13-3.27 (4H, m), 4.11 (2H, t, J=6.0Hz), 4.90 (1H, t, J=6.0Hz),
20 6.33 (2H, s), 6.51 (1H, d, J=9.5Hz), 6.83 (1H, dd, J=2.0Hz, J=8.5Hz), 6.89 (1H, d, J=7.5Hz), 7.16 (1H, d, J=2.0Hz), 7.24-7.30 (1H, m), 7.37-7.45 (3H, m), 7.55 (1H, d, J=8.0Hz), 7.62 (1H, d, J=9.5Hz)

[0466]

25 Example 64

Synthesis of {7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethoxycarbonylamino}acetic acid methyl ester

[0467]



[0468]

Using carbonic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester
 5 phenyl ester synthesized in the same manner as in Example 7
 and in the same manner as in Example 9, the title compound was
 obtained.


$^1\text{H-NMR}$ (CDCl_3) δ : 1.73-1.84 (2H, m), 1.86-1.94 (2H, m), 2.54
 (2H, t, $J=7.5\text{Hz}$), 2.66-2.81 (4H, m), 3.12-3.27 (4H, m), 3.74
 10 (3H, s), 4.00 (2H, d, $J=5.5\text{Hz}$), 4.11 (2H, t, $J=6.0\text{Hz}$), 5.34-
 5.44 (1H, m), 6.36 (2H, s), 6.51 (1H, d, $J=9.5\text{Hz}$), 6.84 (1H,
 dd, $J=2.0\text{Hz}$, $J=8.5\text{Hz}$), 6.87-6.92 (1H, m), 7.09 (1H, d,
 $J=2.0\text{Hz}$), 7.25-7.30 (1H, m), 7.37-7.46 (3H, m), 7.55 (1H, d,
 $J=8.0\text{Hz}$), 7.62 (1H, d, $J=9.5\text{Hz}$)

15 [0469]

Example 65

Synthesis of tetradecanoic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester

[0470]



20

[0471]

In the same manner as in Example 61, the title compound
 was obtained.

$^1\text{H-NMR}$ (CDCl_3) δ : 0.87 (t, $J = 6.8\text{ Hz}$, 3H), 1.18-1.33 (m, 20H),
 25 1.58-1.68 (m, 2H), 1.72-1.82 (m, 2H), 1.84-1.95 (m, 2H), 2.36


(t, J = 7.5 Hz, 2H), 2.54 (t, J = 7.5 Hz, 2H), 2.66-2.79 (m, 4H), 3.13-3.25 (m, 4H), 4.08 (t, J = 6.2 Hz, 2H), 6.34 (brs, 2H), 6.52 (d, J = 9.5 Hz, 1H), 6.84 (dd, J = 2.2, 8.6 Hz, 1H), 6.87-6.91 (m, 2H), 7.27 (dd, J = 7.8, 7.8 Hz, 1H), 7.37-7.43 (m, 2H), 7.45 (d, J = 8.6 Hz, 1H), 7.55 (d, J = 8.1 Hz, 1H), 7.62 (d, J = 9.5 Hz, 1H)

[0472]

Example 66

Synthesis of 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-1-(2,2,2-trifluoroethoxymethyl)-3,4-dihydro-1H-quinolin-2-one

[0473]



[0474]


2,2,2-Trifluoroethanol (0.10 ml) was dissolved in anhydrous THF (3 ml) under a nitrogen atmosphere and sodium hydride (about 55% oil) (60 mg) was added under ice-cooling. The reaction mixture was stirred at room temperature for 30 min under a nitrogen atmosphere. The obtained solution was ice-cooled again and, under a nitrogen atmosphere, a solution (3 ml) of carbonic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester phenyl ester (0.25 g) obtained in Example 5 in anhydrous THF was added using a cannula. The reaction mixture was stirred at room temperature for 18 hr under a nitrogen atmosphere. To the reaction mixture was added ice water to discontinue the reaction, and the mixture was extracted with ethyl acetate. The organic layer was dried over sodium sulfate, and concentrated by filtration. The obtained residue was

purified by silica gel column chromatography (ethyl acetate) to give the title compound (90 mg) as a colorless oil.

¹H-NMR (CDCl₃) δ: 1.69-1.93 (4H, m), 2.47-2.56 (2H, m), 2.64-2.76 (6H, m), 2.80-2.87 (2H, m), 3.13-3.25 (4H, m), 3.93-4.14
5 (4H, m), 5.42 (2H, s), 6.61 (1H, dd, J=2.5Hz, J=8.5Hz), 6.86-6.91 (2H, m), 7.05 (1H, d, J=8.5Hz), 7.24-7.28 (1H, m), 7.37 (1H, d, J=5.5Hz), 7.41 (1H, d, J=5.5Hz), 7.54 (1H, d, J=8.0Hz)
[0475]

Example 67

10 Synthesis of morpholine-4-carboxylic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester
[0476]



15 [0477]

Using carbonic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester phenyl ester synthesized in the same manner as in Example 7 and in the same manner as in Example 9, the title compound was
20 obtained.


¹H-NMR (CDCl₃) δ: 1.72-1.82 (2H, m), 1.87-1.96 (2H, m), 2.54 (2H, t, J=7.5Hz), 2.66-2.80 (4H, m), 3.16-3.34 (4H, m), 3.37-3.73 (8H, m), 4.10 (2H, d, J=6.0Hz), 6.37 (2H, s), 6.52 (1H, d, J=9.5Hz), 6.84 (1H, dd, J=2.0Hz, J=8.5Hz), 6.89 (1H, d, J=7.5Hz), 7.09 (1H, d, J=2.5Hz), 7.24-7.30 (1H, m), 7.37-7.43 (2H, m), 7.45 (1H, d, J=8.5Hz), 7.55 (1H, d, J=8.0Hz), 7.63 (1H, d, J=9.5Hz)
25 [0478]

Example 68

30 Synthesis of decanoic acid 7-[4-(4-benzo[b]thiophen-4-

ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester

[0479]



5 [0480]

In the same manner as in Example 11, the title compound was obtained.


¹H-NMR (CDCl₃) δ: 0.87 (t, J = 6.8 Hz, 3H), 1.20-1.34 (m, 12H), 1.58-1.68 (m, 2H), 1.69-1.80 (m, 2H), 1.80-1.90 (m, 2H), 2.36
 10 (t, J = 7.6 Hz, 2H), 2.52 (t, J = 7.5 Hz, 2H), 2.64-2.77 (m, 6H), 2.83-2.89 (m, 2H), 3.13-3.24 (m, 4H), 3.98 (t, J = 6.2 Hz, 2H), 5.92 (brs, 2H), 6.60 (dd, J = 2.2, 8.1 Hz, 1H), 6.62 (d, J = 2.2 Hz, 1H), 6.87-6.92 (m, 1H), 7.07 (d, J = 8.1 Hz, 1H), 7.27 (dd, J = 7.9, 7.9 Hz, 1H), 7.37-7.43 (m, 2H), 7.55 (d, J
 15 = 8.0 Hz, 1H)

[0481]

Example 69

Synthesis of 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl benzyloxycarbamate

20 [0482]



[0483]


Using carbonic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester
 25 phenyl ester synthesized in the same manner as in Example 7 and in the same manner as in Example 9, the title compound was

obtained.

¹H-NMR (CDCl₃) δ: 1.67-1.79 (2H, m), 1.81-1.92 (2H, m), 2.49 (2H, t, J=7.5Hz), 2.60-2.74 (4H, m), 3.07-3.21 (4H, m), 4.05 (2H, d, J=6.0Hz), 4.85 (2H, s), 6.37 (2H, s), 6.46 (1H, d, J=9.5Hz), 6.80-6.88 (2H, m), 7.03 (1H, d, J=2.0Hz), 7.23-7.45 (9H, m), 7.54 (1H, d, J=8.0Hz), 7.58 (1H, d, J=9.5Hz), 8.11 (1H, s)
[0484]

Example 70

Synthesis of hexanoic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester
[0485]




[0486]

In the same manner as in Example 11, the title compound was obtained.

¹H-NMR (CDCl₃) δ: 0.88 (t, J = 6.9 Hz, 3H), 1.26-1.34 (m, 4H), 1.59-1.69 (m, 2H), 1.69-1.80 (m, 2H), 1.80-1.90 (m, 2H), 2.36 (t, J = 7.5 Hz, 2H), 2.53 (t, J = 7.4 Hz, 2H), 2.64-2.77 (m, 6H), 2.83-2.89 (m, 2H), 3.14-3.24 (m, 4H), 3.98 (t, J = 6.2 Hz, 2H), 5.92 (brs, 2H), 6.60 (dd, J = 2.2, 8.1 Hz, 1H), 6.62 (d, J = 2.2 Hz, 1H), 6.88-6.92 (m, 1H), 7.07 (d, J = 8.1 Hz, 1H), 7.27 (dd, J = 7.8, 7.8Hz, 1H), 7.37-7.43 (m, 2H), 7.55 (d, J = 8.0 Hz, 1H)
[0487]

Example 71

Synthesis of N-cyclohexylcarbamic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester
[0488]



[0489]

Using carbonic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester
 5 phenyl ester synthesized in the same manner as in Example 7
 and in the same manner as in Example 9, the title compound was
 obtained.


$^1\text{H-NMR}$ (CDCl_3) δ : 1.02-1.22 (3H, m), 1.24-1.41 (2H, m), 1.52-
 1.97 (9H, m), 2.54 (2H, t, $J=7.5\text{Hz}$), 2.64-2.82 (4H, m), 3.11-
 10 3.28 (4H, m), 3.45-3.59 (1H, m), 4.11 (2H, t, $J=6.0\text{Hz}$), 4.83
 (1H, d, $J=8.0\text{Hz}$), 6.31 (2H, s), 6.50 (1H, d, $J=9.5\text{Hz}$), 6.83
 (1H, dd, $J=2.0\text{Hz}$, $J=8.5\text{Hz}$), 6.89 (1H, d, $J=7.5\text{Hz}$), 7.14 (1H,
 brs), 7.24-7.30 (1H, m), 7.36-7.45 (3H, m), 7.55 (1H, d,
 $J=8.0\text{Hz}$), 7.60 (1H, d, $J=9.5\text{Hz}$)

15 [0490]

Example 72

Synthesis of carbonic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester methyl ester

20 [0491]



[0492]

In the same manner as in Example 14, the title compound
 was obtained.


25 $^1\text{H-NMR}$ (CDCl_3) δ : 1.68-1.80 (2H, m), 1.80-1.90 (2H, m), 2.52

(2H, t, J=7.4 Hz), 2.64-2.78 (6H, m), 2.86 (2H, t, J=7.0 Hz),
 3.14-3.24 (4H, br), 3.83 (3H, s), 4.00 (2H, t, J=6.2 Hz), 5.95
 (2H, brs), 6.59 (1H, dd, J=2.4, 8.2 Hz), 6.69 (1H, d, J=2.2
 Hz), 6.90 (1H, d, J=7.4 Hz), 7.06 (1H, d, J=8.2 Hz), 7.27 (1H,
 5 t, J=7.8 Hz), 7.36-7.44 (2H, m), 7.55 (1H, d, J=8.0 Hz)

[0493]

Example 73

Synthesis of ({7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-
 yl)butoxy]-2-oxo-2H-quinolin-1-
 10 ylmethoxycarbonyl}methylamino)acetic acid methyl ester
 [0494]



[0495]


Using carbonic acid 7-[4-(4-benzo[b]thiophen-4-
 15 ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester
 phenyl ester synthesized in the same manner as in Example 7
 and in the same manner as in Example 9, the title compound was
 obtained.

¹H-NMR (CDCl₃) δ: 1.72-1.83 (2H, m), 1.85-1.97 (2H, m), 2.50-
 20 2.60 (2H, m), 2.66-2.81 (4H, m), {2.92 (s), 3.02(s) total 3H
 (1:1)}, 3.14-3.27 (4H, m), {3.53 (s), 3.74 (s) total 3H (1:1)},
 3.91 (1H, s), 4.06 (1H, s), 4.07-4.17 (2H, m), 6.33 (1H, s),
 6.38 (1H, s), {6.50 (d, J=9.5Hz), 6.52 (d, J=9.5Hz total 1H
 (1:1)}, 6.80-6.86 (1H, m), {6.88 (brs), 6.90 (brs) total 1H
 25 (1:1)}, {6.98 (d, J=2.0Hz), 7.06 (d, J=2.0Hz) total 1H (1:1)},
 7.24-7.30 (1H, m), 7.37-7.46 (3H, m), 7.55 (1H, d, J=8.0Hz),
 {7.61 (d, J=9.5Hz), 7.63 (d, J=9.0Hz) total 1H (1:1)}

[0496]

Example 74

Synthesis of undec-10-enoic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester [0497]



5 [0498]


In the same manner as in Example 61, the title compound was obtained.

¹H-NMR (CDCl₃) δ: 1.19-1.38 (m, 10H), 1.58-1.67 (m, 2H), 1.72-1.82 (m, 2H), 1.86-1.95 (m, 2H), 1.97-2.06 (m, 2H), 2.36 (t, J = 7.5 Hz, 2H), 2.54 (t, J = 7.5 Hz, 2H), 2.66-2.79 (m, 4H), 3.15-3.24 (m, 4H), 4.08 (t, J = 6.2 Hz, 2H), 4.88-4.94 (m, 1H), 4.94-5.02 (m, 1H), 5.73-5.85 (m, 1H), 6.34 (brs, 2H), 6.52 (d, J = 9.5 Hz, 1H), 6.84 (dd, J = 2.2, 8.6 Hz, 1H), 6.87-6.91 (m, 2H), 7.27 (dd, J = 7.8, 7.8 Hz, 1H), 7.37-7.43 (m, 2H), 7.45 (d, J = 8.6 Hz, 1H), 7.55 (d, J = 8.1 Hz, 1H), 7.62 (d, J = 9.5 Hz, 1H)

[0499]

Example 75

Synthesis of N-octadecylcarbamic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester [0500]



[0501]

In the same manner as in Example 9, the title compound was obtained.


¹H-NMR (CDCl₃) δ: 0.88 (3H, t, J=7.0Hz), 1.16-1.35 (30H, m),
 1.42-1.54 (2H, m), 1.70-1.80 (2H, m), 1.81-1.90 (2H, m), 2.52
 (2H, t, J=7.5Hz), 2.62-2.78 (6H, m), 2.81-2.90 (2H, m), 3.12-
 3.27 (6H, m), 4.00 (2H, t, J=6.0Hz), 4.79 (1H, t, J=5.5Hz),
 5 5.92 (2H, s), 6.59 (1H, dd, J=2.5Hz, 8.0Hz), 6.80 (1H, d,
 J=2.0Hz), 6.89 (1H, d, J=7.5Hz), 7.05 (1H, d, J=8.0Hz), 7.24-
 7.30 (1H, m), 7.38 (1H, d, J=5.5Hz), 7.41 (1H, d, J=5.5Hz),
 7.55 (1H, d, J=8.0Hz)

[0502]

10 Example 76

Synthesis of N-pentadecylcarbamic acid 7-[4-(4-
 benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-
 2H-quinolin-1-ylmethyl ester

[0503]



15

[0504]

In the same manner as in Example 9, the title compound
 was obtained.

¹H-NMR (CDCl₃) δ: 0.88 (3H, t, J=7.0Hz), 1.16-1.35 (24H, m),
 20 1.43-1.53 (2H, m), 1.69-1.80 (2H, m), 1.81-1.90 (2H, m), 2.53
 (2H, t, J=7.5Hz), 2.63-2.77 (6H, m), 2.81-2.90 (2H, m), 3.14-
 3.25 (6H, m), 4.00 (2H, t, J=6.0Hz), 4.80 (1H, t, J=5.5Hz),
 5.92 (2H, s), 6.59 (1H, dd, J=2.5Hz, 8.0Hz), 6.80 (1H, d,
 J=2.0Hz), 6.89 (1H, d, J=7.5Hz), 7.05 (1H, d, J=8.0Hz), 7.24-
 25 7.30 (1H, m), 7.38 (1H, d, J=5.5Hz), 7.41 (1H, dd, J=0.5Hz,
 J=5.5Hz), 7.55 (1H, d, J=8.0Hz)


[0505]

Example 77

Synthesis of 2-methylbutyric acid 7-[4-(4-benzo[b]thiophen-4-
 30 ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-

ylmethyl ester

[0506]



[0507]

5 In the same manner as in Example 48, the title compound was obtained.


¹H-NMR (CDCl₃) δ: 0.91 (t, J = 7.4 Hz, 3H), 1.17 (d, J = 7.0 Hz, 3H), 1.42-1.55 (m, 1H), 1.64-1.92 (m, 5H), 2.43 (m, 1H), 2.52 (t, J = 7.5 Hz, 2H), 2.64-2.79 (m, 6H), 2.83-2.90 (m, 2H),
 10 3.14-3.25 (m, 4H), 3.98 (t, J = 6.2 Hz, 2H), 5.92 (brs, 2H), 6.57-6.63 (m, 2H), 6.90 (d, J = 7.4 Hz, 1H), 7.07 (d, J = 8.3 Hz, 1H), 7.27 (dd, J = 7.8 Hz, 7.8 Hz, 1H), 7.37-7.43 (m, 2H), 7.55 (d, J = 8.0 Hz, 1H)

[0508]

15 Example 78

Synthesis of 2-methylhexanoic acid 7-[4-(4-benzo[b]thiophen-4-yl)piperazin-1-yl]butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester

[0509]



[0510]

In the same manner as in Example 48, the title compound was obtained.

¹H-NMR (CDCl₃) δ: 0.86 (t, J = 6.9 Hz, 3H), 1.16 (d, J = 7.0 Hz, 3H), 1.23-1.32 (m, 4H), 1.36-1.48 (m, 1H), 1.58-1.79 (m, 3H),
 25 1.79-1.89 (m, 2H), 2.43-2.56 (m, 3H), 2.64-2.77 (m, 6H), 2.83-


2.90 (m, 2H), 3.14-3.25 (m, 4H), 3.98 (t, J = 6.2 Hz, 2H),
5.92 (brs, 2H), 6.57-6.62 (m, 2H), 6.90 (d, J = 7.5 Hz, 1H),
7.07 (d, J = 8.0 Hz, 1H), 7.27 (dd, J = 7.8, 7.8 Hz, 1H), 7.38
(d, J = 5.6 Hz, 1H), 7.41 (d, J = 5.6 Hz, 1H), 7.55 (d, J =
5 8.0 Hz, 1H)

[0511]

Example 79

Synthesis of N-methyl-N-octadecylcarbamic acid 7-[4-(4-
benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-
10 2H-quinolin-1-ylmethyl ester

[0512]



[0513]

In the same manner as in Example 9, the title compound
15 was obtained.


¹H-NMR (CDCl₃) δ: 0.88 (3H, t, J=7.0Hz), 1.10-1.34 (30H, m),
1.38-1.57 (2H, m), 1.68-1.90 (4H, m), 2.52 (2H, t, J=7.5Hz),
2.63-2.79 (6H, m), 2.81-2.95 (5H, m), 3.13-3.31 (6H, m), 3.99
(2H, t, J=5.5Hz), 5.93 (2H, s), 6.59 (1H, d, J=8.0Hz), 6.77
20 (1H, d, J=8.0Hz), 6.89 (1H, d, J=7.5Hz), 7.06 (1H, d, J=8.0Hz),
7.24-7.31 (1H, m), 7.36-7.43 (2H, m), 7.55 (1H, d, J=8.0Hz)

[0514]

Example 80

Synthesis of N-benzylcarbamic acid 7-[4-(4-benzo[b]thiophen-4-
25 ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-
ylmethyl ester

[0515]



[0516]

Using carbonic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester phenyl ester synthesized in the same manner as in Example 5 and in the same manner as in Example 10, the title compound was obtained.


¹H-NMR (CDCl₃) δ: 1.69-1.89 (4H, m), 2.51 (2H, t, J=7.5Hz), 2.63-2.77 (6H, m), 2.86 (2H, t, J=7.5Hz), 3.13-3.25 (4H, m), 3.98 (2H, t, J=6.0Hz), 4.40 (2H, t, J=6.0Hz), 5.10-5.18 (1H, m), 5.97 (2H, s), 6.59 (1H, dd, J=2.5Hz, J=8.5Hz), 6.80 (1H, d, J=2.0Hz), 6.89 (1H, d, J=7.5Hz), 7.06 (1H, d, J=8.5Hz), 7.23-7.35 (6H, m), 7.37-7.43 (2H, m), 7.55 (1H, d, J=8.0Hz)

[0517]

Example 81

Synthesis of 2-methylpentanoic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester

[0518]



[0519]

In the same manner as in Example 48, the title compound was obtained.

¹H-NMR (CDCl₃) δ: 0.88 (t, J = 7.2 Hz, 3H), 1.16 (d, J = 7.0 Hz, 3H), 1.28-1.46 (m, 3H), 1.61-1.68 (m, 1H), 1.68-1.79 (m, 2H),


1.79-1.90 (m, 2H), 2.45-2.56 (m, 3H), 2.64-2.78 (m, 6H), 2.82-2.90 (m, 2H), 3.12-3.25 (m, 4H), 3.98 (t, J = 6.2 Hz, 2H), 5.92 (brs, 2H), 6.56-6.62 (m, 2H), 6.90 (d, J = 7.6 Hz, 1H), 7.04-7.10 (m, 1H), 7.27 (dd, J = 7.8, 7.8 Hz, 1H), 7.38 (d, J = 5.5 Hz, 1H), 7.41 (d, J = 5.5 Hz, 1H), 7.55 (d, J = 8.0 Hz, 1H)

[0520]

Example 82

Synthesis of tetradecanoic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester

[0521]



[0522]

In the same manner as in Example 14, the title compound was obtained.


¹H-NMR (CDCl₃) δ: 0.87 (t, J = 6.8 Hz, 3H), 1.20-1.33 (m, 20H), 1.57-1.68 (m, 2H), 1.69-1.79 (m, 2H), 1.80-1.90 (m, 2H), 2.36 (t, J = 7.6 Hz, 2H), 2.52 (t, J = 7.5 Hz, 2H), 2.65-2.77 (m, 6H), 2.83-2.90 (m, 2H), 3.14-3.24 (m, 4H), 3.98 (t, J = 6.2 Hz, 2H), 5.92 (brs, 2H), 6.60 (dd, J = 2.2, 8.1 Hz, 1H), 6.62 (d, J = 2.2 Hz, 1H), 6.90 (d, J = 9.0 Hz, 1H), 7.07 (d, J = 8.1 Hz, 1H), 7.24-7.30 (m, 1H), 7.38 (d, J = 5.6 Hz, 1H), 7.41 (d, J = 5.6 Hz, 1H), 7.55 (d, J = 8.0 Hz, 1H)

[0523]

Example 83

Synthesis of N-cyclohexylcarbamic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester

[0524]



[0525]

In the same manner as in Example 9, the title compound was obtained.


¹H-NMR (CDCl₃) δ: 1.05-1.21 (4H, m), 1.25-1.43 (2H, m), 1.63-1.93 (8H, m), 2.52 (2H, t, J=7.5Hz), 2.63-2.78 (6H, m), 2.81-2.90 (2H, m), 3.14-3.26 (4H, m), 3.46-3.58 (1H, m), 4.00 (2H, t, J=6.0Hz), 4.71 (1H, d, J=8.0Hz), 5.91 (2H, s), 6.59 (1H, dd, J=2.0Hz, J=8.0Hz), 6.79 (1H, d, J=2.0Hz), 6.90 (1H, dd, J=0.5Hz, J=7.5Hz), 7.05 (1H, d, J=8.0Hz), 7.24-7.31 (1H, m), 7.38 (1H, d, J=5.5Hz), 7.41 (1H, dd, J=0.5Hz, J=5.5Hz), 7.55 (1H, d, J=8.0Hz)

[0526]

Example 84

Synthesis of 2,2-dimethylhexanoic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester

[0527]



[0528]

In the same manner as in Example 48, the title compound was obtained.

¹H-NMR (CDCl₃) δ: 0.84 (t, J = 6.9 Hz, 3H), 1.14-1.29 (m, 4H), 1.17 (s, 6H), 1.47-1.54 (m, 2H), 1.68-1.78 (m, 2H), 1.79-1.89 (m, 2H), 2.52 (t, J = 7.5 Hz, 2H), 2.65-2.76 (m, 6H), 2.83-2.89 (m, 2H), 3.15-3.23 (m, 4H), 3.97 (d, J = 6.3 Hz, 2H),


5.91 (brs, 2H), 6.57-6.62 (m, 2H), 6.88-6.92 (m, 1H), 7.07 (d, $J = 8.2$ Hz, 1H), 7.27 (dd, $J = 7.8$ Hz, 7.8 Hz, 1H), 7.37-7.43 (m, 2H), 7.55 (d, $J = 8.0$ Hz, 1H)

[0529]

5 Example 85

Synthesis of acetic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester

[0530]



10

[0531]

In the same manner as in Example 48, the title compound was obtained.

$^1\text{H-NMR}$ (CDCl_3) δ : 1.64-1.80 (m, 2H), 1.80-1.90 (m, 2H), 2.12 (s, 3H), 2.53 (t, $J = 7.3$ Hz, 2H), 2.65-2.77 (m, 6H), 2.83-2.90 (m, 2H), 3.13-3.24 (m, 4H), 3.99 (t, $J = 6.2$ Hz, 2H), 5.91 (brs, 2H), 6.60 (dd, $J = 2.3, 8.2$ Hz, 1H), 6.63 (d, $J = 2.3$ Hz, 1H), 6.90 (d, $J = 7.5$ Hz, 1H), 7.07 (d, $J = 8.2$ Hz, 1H), 7.24-7.30 (m, 1H), 7.38 (d, $J = 5.6$ Hz, 1H), 7.41 (d, $J = 5.6$ Hz, 1H), 7.55 (d, $J = 8.0$ Hz, 1H)

20


[0532]

Example 86

Synthesis of morpholine-4-carboxylic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester

25

[0533]



[0534]

Using carbonic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester phenyl ester synthesized in the same manner as in Example 5 and in the same manner as in Example 10, the title compound was obtained.


$^1\text{H-NMR}$ (CDCl_3) δ : 1.69-1.79 (2H, m), 1.81-1.90 (2H, m), 2.53 (2H, t, $J=7.5\text{Hz}$), 2.64-2.78 (6H, m), 2.83-2.90 (2H, m), 3.13-3.25 (4H, m), 3.38-3.55 (4H, m), 3.56-3.74 (4H, m), 4.00 (2H, t, $J=6.5\text{Hz}$), 5.94 (2H, s), 6.60 (1H, dd, $J=2.5\text{Hz}$, $J=8.5\text{Hz}$), 6.74 (1H, d, $J=2.5\text{Hz}$), 6.90 (1H, d, $J=7.5\text{Hz}$), 7.07 (1H, d, $J=8.5\text{Hz}$), 7.24-7.30 (1H, m), 7.39 (1H, d, $J=5.5\text{Hz}$), 7.41 (1H, dd, $J=0.5\text{Hz}$, $J=5.5\text{Hz}$), 7.55 (1H, d, $J=8.0\text{Hz}$)

[0535]

Example 87

Synthesis of 2-methylbutyric acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester

[0536]



[0537]

In the same manner as in Example 22, the title compound was obtained.

$^1\text{H-NMR}$ (CDCl_3) δ : 0.89 (t, $J = 7.5 \text{ Hz}$, 3H), 1.16 (d, $J = 7.0 \text{ Hz}$, 3H), 1.42-1.54 (m, 1H), 1.60-1.81 (m, 3H), 1.85-1.95 (m, 2H), 2.44 (dt, $J = 7.0, 7.0 \text{ Hz}$, 1H), 2.54 (t, $J = 7.5 \text{ Hz}$, 2H),


2.64-2.79 (m, 4H), 3.15-3.25 (m, 4H), 4.07 (t, J = 6.2 Hz, 2H),
 6.34 (brs, 2H), 6.52 (d, J = 9.5 Hz, 1H), 6.81-6.87 (m, 2H),
 6.87-6.92 (m, 1H), 7.27 (dd, J = 7.8, 7.8 Hz, 1H), 7.37-7.43
 (m, 2H), 7.45 (d, J = 8.3 Hz, 1H), 7.55 (d, J = 8.0 Hz, 1H),
 5 7.63 (d, J = 9.5 Hz, 1H)

[0538]

Example 88

Synthesis of 2-methylhexanoic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester

10 [0539]



[0540]

In the same manner as in Example 22, the title compound was obtained.


15 ¹H-NMR (CDCl₃) δ: 0.81 (t, J = 7.0 Hz, 3H), 1.15 (d, J = 7.0 Hz, 3H), 1.18-1.29 (m, 4H), 1.35-1.47 (m, 1H), 1.59-1.81 (m, 3H), 1.85-1.94 (m, 2H), 2.44-2.58 (m, 3H), 2.65-2.80 (m, 4H), 3.13-3.25 (m, 4H), 4.07 (t, J = 6.2 Hz, 2H), 6.34 (brs, 2H), 6.52 (d, J = 9.5 Hz, 1H), 6.81-6.87 (m, 2H), 6.87-6.92 (m, 1H),
 20 7.27 (dd, J = 7.9, 7.9 Hz, 1H), 7.37-7.43 (m, 2H), 7.45 (d, J = 8.4 Hz, 1H), 7.55 (d, J = 8.0 Hz, 1H), 7.62 (d, J = 9.5 Hz, 1H)

[0541]

Example 89

25 Synthesis of {7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethoxycarbonylamino}acetic acid methyl ester

[0542]



[0543]

In the same manner as in Example 9, the title compound was obtained.


¹H-NMR (CDCl₃) δ: 1.70-1.79 (2H, m), 1.81-1.90 (2H, m), 2.53 (2H, t, J=7.5Hz), 2.64-2.77 (6H, m), 2.82-2.89 (2H, m), 3.14-3.24 (4H, m), 3.75 (3H, s), 3.97-4.05 (4H, m), 4.34 (1H, t, J=5.0Hz), 5.95 (2H, s), 6.60 (1H, dd, J=2.0Hz, J=8.5Hz), 6.77 (1H, d, J=2.0Hz), 6.89 (1H, d, J=7.5Hz), 7.06 (1H, d, J=8.5Hz), 7.24-7.31 (1H, m), 7.38 (1H, d, J=5.5Hz), 7.41 (1H, d, J=5.5Hz), 7.55 (1H, d, J=8.0Hz)

[0544]

Example 90

Synthesis of ((7-[4-(4-benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethoxycarbonyl)methylamino)acetic acid methyl ester

[0545]



[0546]

In the same manner as in Example 9, the title compound was obtained.

¹H-NMR (CDCl₃) δ: 1.70-1.79 (2H, m), 1.81-1.91 (2H, m), 2.49-2.57 (2H, m), 2.63-2.78 (6H, m), 2.81-2.90 (2H, m), {3.64 (s), 3.75 (s) total 3H (1:1)}, 3.14-3.25 (4H, m), {3.64 (s), 3.75 (s) total 3H (1:1)}, 3.93 (s, 1H), 3.97-4.04 (2H, m), 4.06 (1H,


s), 5.91 (1H, s), 5.96 (1H, s), 6.56-6.63 (1H, m), {6.68 (d, J=2.0Hz), 6.77 (d, J=2.0Hz) total 1H (1:1)}, 6.90 (1H, d, J=7.5Hz), 7.06 (1H, dd, J=8.0Hz, J=8.0Hz), 7.24-7.31 (1H, m), 7.38 (1H, d, J=5.5Hz), 7.41 (1H, d, J=5.5Hz), 7.55 (1H, d, J=8.0Hz)

[0547]

Example 91

Synthesis of pentadecanoic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester

[0548]



[0549]

In the same manner as in Example 48, the title compound was obtained.


¹H-NMR (CDCl₃) δ: 0.87 (t, J = 6.8 Hz, 3H), 1.17-1.35 (m, 22H), 1.55-1.68 (m, 2H), 1.69-1.80 (m, 2H), 1.80-1.90 (m, 2H), 2.36 (t, J = 7.6 Hz, 2H), 2.52 (t, J = 7.5 Hz, 2H), 2.64-2.76 (m, 6H), 2.83-2.89 (m, 2H), 3.13-3.24 (m, 4H), 3.98 (t, J = 6.2 Hz, 2H), 5.92 (brs, 2H), 6.59 (dd, J = 2.3, 8.2 Hz, 1H), 6.62 (d, J = 2.3 Hz, 1H), 6.87-6.92 (m, 1H), 7.07 (d, J = 8.2 Hz, 1H), 7.27 (dd, J = 7.8, 7.8 Hz, 1H), 7.37-7.43 (m, 2H), 7.55 (d, J = 8.0 Hz, 1H)

[0550]

Example 92

Synthesis of 2-methylheptanoic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester

[0551]



[0552]

In the same manner as in Example 48, the title compound was obtained.


¹H-NMR (CDCl₃) δ: 0.85 (t, J = 6.8 Hz, 3H), 1.16 (d, J = 7.0 Hz, 3H), 1.19-1.34 (m, 6H), 1.34-1.47 (m, 1H), 1.60-1.79 (m, 3H), 1.79-1.90 (m, 2H), 2.42-2.56 (m, 3H), 2.64-2.78 (m, 6H), 2.82-2.90 (m, 2H), 3.12-3.26 (m, 4H), 3.97 (t, J = 6.2 Hz, 2H), 5.92 (brs, 2H), 6.57-6.62 (m, 2H), 6.87-6.92 (m, 1H), 7.07 (d, J = 8.1 Hz, 1H), 7.27 (dd, J = 7.8, 7.8 Hz, 1H), 7.37-7.43 (m, 2H), 7.55 (d, J = 8.0 Hz, 1H)

[0553]

Example 93

Synthesis of N-(3,3,3-trifluoropropyl)carbamic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester

[0554]



[0555]

In the same manner as in Example 9, the title compound was obtained.


¹H-NMR (CDCl₃) δ: 1.69-1.79 (2H, m), 1.80-1.90 (2H, m), 2.29-2.43 (2H, m), 2.52 (2H, t, J=7.5Hz), 2.61-2.77 (6H, m), 2.79-2.89 (2H, m), 3.13-3.26 (4H, m), 3.46 (2H, dt, J=6.5Hz, J=6.5Hz), 3.99 (2H, t, J=6.0Hz), 5.20 (1H, t, J=6.0Hz), 5.92 (2H, s), 6.59 (1H, dd, J=2.0Hz, J=8.5Hz), 6.74 (1H, d, J=2.0Hz), 6.89 (1H, d, J=7.5Hz), 7.05 (1H, d, J=8.5Hz), 7.23-

7.30 (1H, m), 7.38 (1H, d, J=5.5Hz), 7.41 (1H, d, J=5.5Hz),
7.54 (1H, d, J=8.0Hz)

[0556]

Example 94

5 Synthesis of 2-methylpentanoic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester
[0557]



[0558]

10 In the same manner as in Example 22, the title compound was obtained.


¹H-NMR (CDCl₃) δ: 0.86 (t, J = 7.2 Hz, 3H), 1.15 (d, J = 7.0 Hz, 3H), 1.23-1.45 (m, 3H), 1.59-1.82 (m, 3H), 1.85-1.95 (m, 2H), 2.46-2.58 (m, 3H), 2.65-2.79 (m, 4H), 3.14-3.25 (m, 4H),
15 4.07 (t, J = 6.2 Hz, 2H), 6.34 (brs, 2H), 6.52 (d, J = 9.4 Hz, 1H), 6.82-6.87 (m, 2H), 6.90 (d, J = 7.6 Hz, 1H), 7.25-7.30 (m, 1H), 7.39 (d, J = 5.5 Hz, 1H), 7.42 (d, J = 5.5 Hz, 1H), 7.43-7.47 (m, 1H), 7.55 (d, J = 8.1 Hz, 1H), 7.63 (d, J = 9.5 Hz, 1H)

20 [0559]

Example 95

Synthesis of heptadecanoic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester

25 [0560]



[0561]

In the same manner as in Example 48, the title compound was obtained.


¹H-NMR (CDCl₃) δ: 0.88 (t, J = 6.9 Hz, 3H), 1.16-1.35 (m, 26H), 1.57-1.68 (m, 2H), 1.68-1.79 (m, 2H), 1.79-1.90 (m, 2H), 2.36 (t, J = 7.5 Hz, 2H), 2.52 (d, J = 7.4 Hz, 2H), 2.64-2.77 (m, 6H), 2.83-2.90 (m, 2H), 3.14-3.24 (m, 4H), 3.98 (t, J = 6.2 Hz, 2H), 5.92 (brs, 2H), 6.57-6.63 (m, 2H), 6.87-6.92 (m, 1H), 7.07 (d, J = 8.1 Hz, 1H), 7.27 (dd, J = 7.8, 7.8 Hz, 1H), 7.37-7.43 (m, 2H), 7.55 (d, J = 8.0 Hz, 1H)

[0562]

Example 96

Synthesis of furan-3-carboxylic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester

[0563]



[0564]

In the same manner as in Example 48, the title compound was obtained.

¹H-NMR (CDCl₃) δ: 1.64-1.77 (m, 2H), 1.78-1.88 (m, 2H), 2.50 (t, J = 7.5 Hz, 2H), 2.63-2.75 (m, 6H), 2.85-2.92 (m, 2H), 3.12-3.23 (m, 4H), 3.98 (t, J = 6.2 Hz, 2H), 6.09 (brs, 2H), 6.60 (dd, J = 2.3, 8.3 Hz, 1H), 6.71 (d, J = 2.3 Hz, 1H), 6.74-6.77


(m, 1H), 6.87-6.91 (m, 1H), 7.09 (d, $J = 8.3$ Hz, 1H), 7.27 (dd, $J = 7.9, 7.9$ Hz, 1H), 7.37-7.43 (m, 3H), 7.55 (d, $J = 7.9$ Hz, 1H), 8.01-8.05 (m, 1H)

[0565]

5 Example 97

Synthesis of N-(2-methoxyethyl)carbamic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester

[0566]



10

[0567]

Using carbonic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester phenyl ester synthesized in the same manner as
 15 in Example 5 and in the same manner as in Example 10, the title compound was obtained.


$^1\text{H-NMR}$ (CDCl_3) δ : 1.69-1.91 (4H, m), 2.53 (2H, t, $J=7.5\text{Hz}$), 2.62-2.78 (6H, m), 2.81-2.91 (2H, m), 3.13-3.26 (4H, m), 3.33 (3H, s), 3.35-3.48 (4H, m), 4.00 (2H, t, $J=6.0\text{Hz}$), 5.12-5.21
 20 (1H, m), 5.92 (2H, s), 6.59 (1H, dd, $J=2.0\text{Hz}$, $J=8.0\text{Hz}$), 6.78 (1H, d, $J=2.0\text{Hz}$), 6.90 (1H, d, $J=7.5\text{Hz}$), 7.06 (1H, d, $J=8.0\text{Hz}$), 7.24-7.30 (1H, m), 7.38 (1H, d, $J=5.5\text{Hz}$), 7.42 (1H, d, $J=5.5\text{Hz}$), 7.55 (1H, d, $J=8.0\text{Hz}$)

[0568]

25 Example 98

Synthesis of N-furan-2-yl-N-methylcarbamic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester

[0569]



[0570]

Using carbonic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester phenyl ester synthesized in the same manner as in Example 5 and in the same manner as in Example 10, the title compound was obtained.


¹H-NMR (CDCl₃) δ: 1.69-1.90 (4H, m), 2.52 (2H, t, J=7.5Hz), 2.62-2.77 (6H, m), 2.81-2.90 (2H, m), 3.12-3.27 (4H, m), 3.99 (2H, t, J=6.0Hz), 4.39 (2H, d, J=6.0Hz), 5.11-5.19 (1H, m), 5.95 (2H, s), 6.23 (1H, brs), 6.30 (1H, brs), 6.59 (1H, dd, J=2.5Hz, J=8.0Hz), 6.77 (1H, d, J=2.5Hz), 6.89 (1H, d, J=7.5Hz), 7.06 (1H, d, J=8.0Hz), 7.24-7.30 (1H, m), 7.34 (1H, brs), 7.38 (1H, d, J=5.5Hz), 7.41 (1H, d, J=5.5Hz), 7.55 (1H, d, J=8.0Hz)

[0571]

Example 99

Synthesis of 3-{7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethoxycarbonylamino}-propionic acid ethyl ester

[0572]



[0573]

Using carbonic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester

phenyl ester synthesized in the same manner as in Example 7 and in the same manner as in Example 9, the title compound was obtained.


¹H-NMR (CDCl₃) δ: 1.23 (3H, t, J=7.0Hz), 1.73-1.83 (2H, m),
 5 1.86-1.96 (2H, m), 2.49-2.59 (4H, m), 2.66-2.80 (4H, m), 3.15-
 3.27 (4H, m), 3.45-3.53 (2H, m), 4.07-4.15 (4H, m), 5.36-5.43
 (1H, m), 6.32 (2H, s), 6.51 (1H, d, J=9.5Hz), 6.83 (1H, dd,
 J=2.0Hz, J=8.5Hz), 6.89 (1H, d, J=7.5Hz), 7.11 (1H, d,
 J=2.0Hz), 7.24-7.30 (1H, m), 7.37-7.46 (3H, m), 7.55 (1H, d,
 10 J=8.0Hz), 7.61 (1H, d, J=9.5Hz)

[0574]

Example 100

Synthesis of (2-butoxyethoxy)acetic acid 7-[4-(4-
 benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-
 15 2H-quinolin-1-ylmethyl ester

[0575]



[0576]

In the same manner as in Example 48, the title compound
 20 was obtained.


¹H-NMR (CDCl₃) δ: 0.90 (t, J = 7.4 Hz, 3H), 1.29-1.40 (m, 2H),
 1.50-1.59 (m, 2H), 1.69-1.80 (m, 2H), 1.80-1.90 (m, 2H), 2.53
 (t, J = 7.4 Hz, 2H), 2.64-2.77 (m, 6H), 2.83-2.90 (m, 2H),
 3.13-3.24 (m, 4H), 3.45 (t, J = 7.7 Hz, 2H), 3.58-3.63 (m, 2H),
 25 3.71-3.76 (m, 2H), 3.98 (t, J = 6.2 Hz, 2H), 4.22 (s, 2H),
 5.99 (brs, 2H), 6.57-6.62 (m, 2H), 6.87-6.92 (m, 1H), 7.07 (d,
 J = 7.8 Hz, 1H), 7.27 (dd, J = 7.8, 7.8 Hz, 1H), 7.36-7.44 (m,
 2H), 7.55 (d, J = 8.0 Hz, 1H)

[0577]

30 Example 101

Synthesis of 4-{7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-

yl)butoxy]-2-oxo-2H-quinolin-1-ylmethoxycarbonylamino}butyric acid methyl ester
[0578]



5 [0579]

Using carbonic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester phenyl ester synthesized in the same manner as in Example 7 and in the same manner as in Example 9, the title compound was
10 obtained.


¹H-NMR (CDCl₃) δ: 1.73-1.95 (6H, m), 2.36 (2H, t, J=7.0Hz), 2.54 (2H, t, J=7.5Hz), 2.66-2.80 (4H, m), 3.116-3.31 (6H, m), 3.64 (3H, s), 4.11 (2H, t, J=6.0Hz) 5.06 (1H, t, J=6.0Hz), 6.32 (2H, s), 6.51 (1H, d, J=9.5Hz), 6.83 (1H, dd, J=2.0Hz, J=8.5Hz), 6.89 (1H, d, J=7.5Hz), 7.12 (1H, d, J=1.5Hz), 7.24-7.30 (1H, m), 7.36-7.46 (3H, m), 7.55 (1H, d, J=8.0Hz), 7.61 (1H, d, J=9.5Hz)
15

[0580]

Example 102

20 Synthesis of 1-methylpiperidine-4-carboxylic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester

[0581]



25 [0582]

In the same manner as in Example 48, the title compound

was obtained.


¹H-NMR (CDCl₃) δ: 1.58-2.06 (m, 10H), 2.04 (s, 3H), 2.28-2.40 (m, 1H), 2.52 (t, J = 7.4 Hz, 2H), 2.63-2.82 (m, 8H), 2.82-2.90 (m, 2H), 3.14-3.25 (m, 4H), 3.97 (t, J = 6.3 Hz, 2H),
 5 5.93 (brs, 2H), 6.56-6.62 (m, 2H), 6.88-6.92 (m, 1H), 7.07 (d, J = 8.1 Hz, 1H), 7.27 (dd, J = 7.8, 7.8 Hz, 1H), 7.37-7.43 (m, 2H), 7.55 (d, J = 8.0 Hz, 1H)

[0583]

Example 103

10 Synthesis of 2,2-dimethylhexanoic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester

[0584]



15 [0585]

In the same manner as in Example 22, the title compound was obtained.


¹H-NMR (CDCl₃) δ: 0.77 (t, J = 6.8 Hz, 3H), 1.09-1.20 (m, 10H), 1.42-1.52 (m, 2H), 1.68-1.95 (m, 4H), 2.54 (t, J = 7.5 Hz, 2H),
 20 2.66-2.78 (m, 4H), 3.14-3.25 (m, 4H), 4.07 (t, J = 6.2 Hz, 2H), 6.33 (brs, 2H), 6.52 (d, J = 9.5 Hz, 1H), 6.81-6.86 (m, 2H), 6.87-6.92 (m, 1H), 7.27 (dd, J = 7.8, 7.8 Hz, 1H), 7.36-7.37 (m, 3H), 7.55 (d, J = 8.0 Hz, 1H), 7.62 (d, J = 9.5 Hz, 1H)

[0586]

25 Example 104

Synthesis of pentadecanoic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester

[0587]



[0588]

In the same manner as in Example 22, the title compound was obtained.


¹H-NMR (CDCl₃) δ: 0.87 (t, J = 6.8 Hz, 3H), 1.16-1.34 (m, 22H), 1.57-1.67 (m, 2H), 1.67-1.82 (m, 2H), 1.85-1.95 (m, 2H), 2.36 (t, J = 7.5 Hz, 2H), 2.54 (t, J = 7.5 Hz, 2H), 2.65-2.79 (m, 4H), 3.13-3.25 (m, 4H), 4.08 (t, J = 6.2 Hz, 2H), 6.34 (brs, 2H), 6.52 (d, J = 9.5 Hz, 1H), 6.84 (dd, J = 2.2, 8.6 Hz, 1H), 6.86-6.92 (m, 2H), 7.27 (dd, J = 7.8, 7.8 Hz, 1H), 7.37-7.43 (m, 2H), 7.45 (d, J = 8.6 Hz, 1H), 7.55 (d, J = 8.1 Hz, 1H), 7.62 (d, J = 9.5 Hz, 1H)

[0589]

Example 105

Synthesis of 4-methylpentanoic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester

[0590]



[0591]

In the same manner as in Example 48, the title compound was obtained.

¹H-NMR (CDCl₃) δ: 0.89 (d, J = 6.3 Hz, 6H), 1.51-1.63 (m, 3H), 1.69-1.80 (m, 2H), 1.80-1.90 (m, 2H), 2.33-2.40 (m, 2H), 2.52 (t, J = 7.4 Hz, 2H), 2.65-2.77 (m, 6H), 2.83-2.90 (m, 2H), 3.14-3.24 (m, 4H), 3.99 (t, J = 6.2 Hz, 2H), 5.91 (brs, 2H),


6.57-6.63 (m, 2H), 6.87-6.92 (m, 1H), 7.07 (d, J = 8.0 Hz, 1H),
7.27 (dd, J = 7.8, 7.8 Hz, 1H), 7.37-7.43 (m, 2H), 7.55 (d, J
= 8.1 Hz, 1H)

[0592]

5 Example 106

Synthesis of cycloheptanecarboxylic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester

[0593]



10

[0594]

In the same manner as in Example 48, the title compound was obtained.


¹H-NMR (CDCl₃) δ: 1.40-1.59 (m, 6H), 1.64-1.79 (m, 6H), 1.80-
15 1.90 (m, 2H), 1.90-1.99 (m, 2H), 2.48-2.59 (m, 3H), 2.64-2.78
(m, 6H), 2.82-2.90 (m, 2H), 3.14-3.23 (m, 4H), 3.98 (t, J =
6.2 Hz, 2H), 5.91 (brs, 2H), 6.57-6.63 (m, 2H), 6.90 (d, J =
7.3 Hz, 1H), 7.05-7.09 (m, 1H), 7.27 (dd, J = 7.8, 7.8 Hz, 1H),
7.37-7.43 (m, 2H), 7.55 (d, J = 8.0 Hz, 1H)

20 [0595]

Example 107

Synthesis of benzyloxycarbamic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester

25 [0596]



[0597]


In the same manner as in Example 9, the title compound was obtained.

¹H-NMR (CDCl₃) δ: 1.67-1.89 (4H, m), 2.51 (2H, t, J=7.5Hz),
 2.61-2.76 (6H, m), 2.81-2.90 (2H, m), 3.10-3.23 (4H, m), 4.00
 (2H, t, J=6.0Hz), 4.87 (2H, s), 6.00 (2H, s), 6.60 (1H, dd,
 J=2.5Hz, J=8.5Hz), 6.73 (1H, d, J=2.5Hz), 6.86-6.91 (1H, m),
 7.07 (1H, d, J=8.5Hz), 7.24-7.42 (8H, m), 7.55 (1H, d,
 J=8.0Hz), 7.59 (1H, brs)

[0598]

Example 108

Synthesis of heptadecanoic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester
 [0599]



[0600]

In the same manner as in Example 22, the title compound was obtained.

¹H-NMR (CDCl₃) δ: 0.87 (t, J = 6.9 Hz, 3H), 1.17-1.33 (m, 26H),
 1.57-1.67 (m, 2H), 1.69-1.82 (m, 2H), 1.85-1.95 (m, 2H), 2.36
 (t, J = 7.5 Hz, 2H), 2.54 (t, J = 7.5 Hz, 2H), 2.67-2.77 (m,
 4H), 3.14-3.24 (m, 4H), 4.08 (t, J = 6.2 Hz, 2H), 6.34 (brs,
 2H), 6.52 (d, J = 9.5 Hz, 1H), 6.84 (dd, J = 2.2, 8.6 Hz, 1H),
 6.86-6.91 (m, 2H), 7.27 (dd, J = 7.8, 7.8 Hz, 1H), 7.36-7.43
 (m, 2H), 7.44 (d, J = 8.6 Hz, 1H), 7.55 (d, J = 8.0 Hz, 1H),
 7.62 (d, J = 9.5 Hz, 1H)


[0601]

Example 109

Synthesis of N-(2-methoxyethyl)carbamic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester

1-ylmethyl ester

[0602]



[0603]

5 In the same manner as in Example 10, the title compound was obtained.


¹H-NMR (CDCl₃) δ: 1.73-1.83 (2H, m), 1.86-1.96 (2H, m), 2.55 (2H, t, J=7.5Hz), 2.67-2.80 (4H, m), 3.16-3.25 (4H, m), 3.32 (3H, s), 3.36-3.47 (4H, m), 4.11 (2H, d, J=6.0Hz), 5.17-5.24
10 (1H, m), 6.33 (2H, s), 6.51 (1H, d, J=9.5Hz), 6.83 (1H, dd, J=2.0Hz, J=8.5Hz), 6.89 (1H, d, J=7.5Hz), 7.13 (1H, d, J=2.0Hz), 7.24-7.30 (1H, m), 7.37-7.47 (3H, m), 7.55 (1H, d, J=8.0Hz), 7.62 (1H, d, J=9.5Hz)

[0604]

15 Example 110

Synthesis of N-furan-2-yl-N-methylcarbamic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester

[0605]



20

[0606]

In the same manner as in Example 10, the title compound was obtained.

¹H-NMR (CDCl₃) δ: 1.71-1.82 (2H, m), 1.83-1.96 (2H, m), 2.54
25 (2H, t, J=7.5Hz), 2.65-2.80 (4H, m), 3.13-3.28 (4H, m), 4.10


(2H, t, J=6.0Hz), 4.39 (2H, d, J=6.0Hz), 5.19-5.29 (1H, m),
6.21 (1H, d, J=3.0Hz), 6.30 (1H, d, J=3.0Hz), 6.36 (2H, s),
6.50 (1H, d, J=9.5Hz), 6.83 (1H, dd, J=2.0Hz, J=8.5Hz), 6.87-
6.91 (1H, m), 7.12 (1H, d, J=1.5Hz), 7.24-7.30 (1H, m), 7.33
5 (1H, brs), 7.37-7.46 (3H, m), 7.55 (1H, d, J=8.0Hz), 7.61 (1H,
d, J=9.5Hz)

[0607]

Example 111

Synthesis of N-benzyl-N-methylcarbamic acid 7-[4-(4-
10 benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-
1-ylmethyl ester

[0608]



[0609]

15 In the same manner as in Example 10, the title compound
was obtained.


¹H-NMR (CDCl₃) δ: 1.69-1.79 (2H, m), 1.82-1.92 (2H, m), 2.53
(2H, t, J=7.0Hz), 2.64-2.76 (4H, m), {2.80 (s), 2.93 (s) total
3H (1:1)}, 3.13-3.25 (4H, m), 4.02 (1H, t, J=6.0Hz), 4.08 (1H,
20 t, J=6.0Hz), 4.37 (1H, s), 4.52 (1H, s), 6.41 (1H, s), 6.43
(1H, s), 6.52 (1H, dd, J=8.5Hz, J=8.5Hz), 6.80-6.91 (2H, m),
{6.99-7.09 (m), 7.14-7.19 (m) total 3H (1:1)}, 7.21-7.35 (4H,
m), 7.37-7.46 (3H, m), 7.55 (1H, d, J=8.0Hz), 7.62 (1H, dd,
J=9.0Hz, J=9.0Hz)

25 [0610]

Example 112

Synthesis of N-allylcarbamic acid 7-[4-(4-benzo[b]thiophen-4-
ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester

[0611]



[0612]

In the same manner as in Example 10, the title compound was obtained.


5 $^1\text{H-NMR}$ (CDCl_3) δ : 1.73-1.83 (2H, m), 1.85-1.96 (2H, m), 2.54 (2H, t, $J=7.5\text{Hz}$), 2.64-2.80 (4H, m), 3.13-3.26 (4H, m), 3.84 (2H, t, $J=5.5\text{Hz}$), 4.11 (2H, t, $J=6.0\text{Hz}$), 4.91-5.01 (1H, m), 5.08-5.24 (2H, m), 5.77-5.90 (1H, m), 6.35 (2H, s), 6.51 (1H, d, $J=9.5\text{Hz}$), 6.84 (1H, dd, $J=2.0\text{Hz}$, $J=8.5\text{Hz}$), 6.89 (1H, d, $J=7.5\text{Hz}$), 7.14 (1H, brs), 7.24-7.30 (1H, m), 7.37-7.47 (3H, m), 7.55 (1H, d, $J=8.0\text{Hz}$), 7.62 (1H, d, $J=9.5\text{Hz}$)

[0613]

Example 113

Synthesis of N-pyridin-2-yl-N-methylcarbamic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester

[0614]



[0615]

20 In the same manner as in Example 10, the title compound was obtained.

$^1\text{H-NMR}$ (CDCl_3) δ : 1.64-1.81 (2H, m), 1.83-1.93 (2H, m), 2.53 (2H, t, $J=7.5\text{Hz}$), 2.66-2.80 (4H, m), 3.12-3.25 (4H, m), 4.08 (2H, t, $J=6.0\text{Hz}$), 4.53 (2H, d, $J=5.0\text{Hz}$), 6.01 (1H, t, $J=5.0\text{Hz}$), 25 6.38 (2H, s), 6.52 (1H, d, $J=9.5\text{Hz}$), 6.83 (1H, dd, $J=2.0\text{Hz}$,


J=8.5Hz), 6.88 (1H, d, J=7.5Hz), 7.03-7.19 (2H, m), 7.21-7.30 (2H, m), 7.36-7.46 (3H, m), 7.55 (1H, d, J=8.0Hz), 7.59-7.67 (2H, m), 8.40-8.57 (1H, m)

[0616]

5 Example 114

Synthesis of undec-10-enoic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester

[0617]



10

[0618]

In the same manner as in Example 48, the title compound was obtained.

¹H-NMR (CDCl₃) δ: 1.21-1.40 (m, 10H), 1.54-1.68 (m, 2H), 1.68-1.79 (m, 2H), 1.79-1.90 (m, 2H), 1.97-2.06 (m, 2H), 2.36 (t, J = 9.5 Hz, 2H), 2.52 (t, J = 7.4 Hz, 2H), 2.64-2.76 (m, 6H), 2.83-2.96 (m, 2H), 3.14-3.23 (m, 4H), 3.99 (t, J = 6.3 Hz, 2H), 4.89-4.94 (m, 1H), 4.94-5.02 (m, 1H), 5.73-5.86 (m, 1H), 5.92 (brs, 2H), 6.57-6.63 (m, 2H), 6.87-6.92 (m, 1H), 7.07 (d, J = 8.1 Hz, 1H), 7.27 (dd, J = 7.9, 7.9 Hz, 1H), 7.36-7.43 (m, 2H), 7.55 (d, J = 7.9 Hz, 1H)

20


[0619]

Example 115

Synthesis of furan-3-carboxylic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester

25

[0620]



[0621]

In the same manner as in Example 22, the title compound was obtained.


¹H-NMR (CDCl₃) δ: 1.67-1.81 (m, 2H), 1.81-1.97 (m, 2H), 2.52
5 (dd, J = 7.5 Hz, 2H), 2.62-2.78 (m, 4H), 3.11-3.24 (m, 4H),
4.08 (t, J = 6.2 Hz, 2H), 6.51 (brs, 2H), 6.54 (d, J = 9.5 Hz,
1H), 6.74-6.77 (m, 1H), 6.84 (dd, J = 2.2, 8.6 Hz, 1H), 6.89
(d, J = 7.6 Hz, 1H), 6.96 (d, J = 2.2 Hz, 1H), 7.27 (dd, J =
7.8, 7.8 Hz, 1H), 7.37-7.43 (m, 3H), 7.46 (d, J = 8.6 Hz, 1H),
10 7.55 (d, J = 8.0 Hz, 1H), 7.64 (d, J = 9.5 Hz, 1H), 8.01-8.04
(m, 1H)

[0622]

Example 116

Synthesis of N-phenethylcarbamic acid 7-[4-(4-
15 benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-
1-ylmethyl ester

[0623]



[0624]

20 In the same manner as in Example 10, the title compound was obtained.

¹H-NMR (CDCl₃) δ: 1.71-1.82 (2H, m), 1.85-1.96 (2H, m), 2.53
(2H, t, J=7.5Hz), 2.63-2.77 (4H, m), 2.81 (2H, t, J=7.0Hz),
3.13-3.26 (4H, m), 3.44-3.52 (2H, m), 4.11 (2H, t, J=6.0Hz),
25 4.90 (1H, t, J=5.5Hz), 6.32 (2H, s), 6.50 (1H, d, J=9.5Hz),
6.84 (1H, dd, J=2.0Hz, J=8.5Hz), 6.88 (1H, d, J=7.5Hz), 7.12-
7.34 (7H, m), 7.37-7.47 (3H, m), 7.55 (1H, d, J=8.0Hz), 7.61
(1H, d, J=9.5Hz)


[0625]

30 Example 117

Synthesis of N-isopropyl-carbamic acid 7-[4-(4-

benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester

[0626]



5 [0627]


In the same manner as in Example 10, the title compound was obtained.

¹H-NMR (CDCl₃) δ: 1.15 (6H, d, J=6.5Hz), 1.72-1.82 (2H, m), 1.85-1.94 (2H, m), 2.54 (2H, t, J=7.5Hz), 2.66-2.78 (4H, m),
 10 3.12-3.26 (4H, m), 3.78-3.90 (1H, m), 4.10 (2H, d, J=6.0Hz), 4.93 (1H, d, J=7.5Hz), 6.29 (2H, s), 6.48 (1H, d, J=9.5Hz), 6.82 (1H, dd, J=2.0Hz, J=8.5Hz), 6.88 (1H, d, J=7.5Hz), 7.13 (1H, brs), 7.26 (1H, dd, J=8.0Hz, J=8.0Hz), 7.35-7.44 (3H, m), 7.54 (1H, d, J=8.0Hz), 7.57 (1H, d, J=9.5Hz)

15 [0628]

Example 118

Synthesis of 2-methylheptanoic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester
 [0629]



20

[0630]

In the same manner as in Example 22, the title compound was obtained.

¹H-NMR (CDCl₃) δ: 0.81 (d, J = 6.8 Hz, 3H), 1.15 (d, J = 7.0 Hz, 3H),
 25 3H), 1.17-1.30 (m, 6H), 1.35-1.46 (m, 1H), 1.58-1.71 (m, 1H), 1.71-1.82 (m, 2H), 1.82-1.98 (m, 2H), 2.43-2.58 (m, 3H), 2.66-


2.79 (m, 4H), 3.14-3.25 (m, 4H), 4.07 (d, J = 6.2 Hz, 2H),
 6.35 (brs, 2H), 6.52 (d, J = 9.5 Hz, 1H), 6.84 (dd, J = 2.2,
 8.5 Hz, 1H), 6.85-6.92 (m, 2H), 7.27 (dd, J = 7.9, 7.9 Hz, 1H),
 7.37-7.43 (m, 2H), 7.44 (d, J = 8.5 Hz, 1H), 7.55 (d, J = 8.0
 5 Hz, 1H), 7.62 (d, J = 9.5 Hz, 1H)

[0631]

Example 119

Synthesis of cycloheptanecarboxylic acid 7-[4-(4-
 benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-
 10 1-ylmethyl ester

[0632]



[0633]

In the same manner as in Example 22, the title compound
 15 was obtained.


¹H-NMR (CDCl₃) δ: 1.37-1.58 (m, 6H), 1.62-1.81 (m, 6H), 1.84-
 1.97 (m, 4H), 2.50-2.58 (m, 3H), 2.67-2.79 (m, 4H), 3.15-3.25
 (m, 4H), 4.07 (t, J = 6.2 Hz, 2H), 6.33 (brs, 2H), 6.52 (d, J
 = 9.5 Hz, 1H), 6.82-6.86 (m, 2H), 6.87-6.92 (m, 1H), 7.27 (dd,
 20 J = 8.0, 8.0 Hz, 1H), 7.37-7.43 (m, 2H), 7.43-7.47 (m, 1H),
 7.55 (d, J = 8.0 Hz, 1H), 7.62 (d, J = 9.5 Hz, 1H)

[0634]

Example 120

Synthesis of tetrahydropyran-4-carboxylic acid 7-[4-(4-
 25 benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-
 2H-quinolin-1-ylmethyl ester

[0635]



[0636]

In the same manner as in Example 48, the title compound was obtained.


¹H-NMR (CDCl₃) δ: 1.69-1.90 (m, 8H), 2.52 (t, J = 7.4 Hz, 2H), 2.56-2.65 (m, 1H), 2.65-2.77 (m, 6H), 2.83-2.90 (m, 2H), 3.14-3.25 (m, 4H), 3.37-3.45 (m, 2H), 3.90-4.01 (m, 4H), 5.94 (brs, 2H), 6.57 (d, J = 2.2 Hz, 1H), 6.60 (d, J = 2.2, 8.2 Hz, 1H), 6.90 (d, J = 7.6 Hz, 1H), 7.07 (d, J = 8.2 Hz, 1H), 7.24-7.30 (m, 1H), 7.38 (d, J = 5.6 Hz, 1H), 7.42 d, J = 5.6 Hz, 1H), 7.55 (d, J = 8.0 Hz, 1H)

[0637]

Example 121

Synthesis of malonic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester tert-butyl ester

[0638]



[0639]

In the same manner as in Example 48, the title compound was obtained.

¹H-NMR (CDCl₃) δ: 1.44 (s, 9H), 1.69-1.80 (m, 2H), 1.80-1.89 (m, 2H), 2.52 (d, J = 7.4 Hz, 2H), 2.64-2.79 (m, 6H), 2.83-2.90 (m, 2H), 3.14-3.25 (m, 4H), 3.35 (s, 2H), 4.01 (t, J = 6.2 Hz, 2H), 5.96 (brs, 2H), 6.00 (dd, J = 2.3, 8.2 Hz, 1H), 6.67 (d, J = 2.3 Hz, 1H), 6.90 (d, J = 7.4 Hz, 1H), 7.07 (d, J = 8.2 Hz,


1H), 7.25-7.30 (m, 1H), 7.37-7.43 (m, 2H), 7.55 (d, J = 8.0 Hz, 1H).

[0640]

Example 122

5 Synthesis of N-isobutylcarbamic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester

[0641]



[0642]

10 In the same manner as in Example 10, the title compound was obtained.


¹H-NMR (CDCl₃) δ: 0.86-0.93 (6H, m), 1.69-1.82 (3H, m), 1.84-1.94 (2H, m), 2.54 (2H, t, J=7.5Hz), 2.65-2.78 (4H, m), 3.03 (2H, t, J=6.5Hz), 3.13-3.25 (4H, m), 4.10 (2H, d, J=6.0Hz),
15 5.09 (1H, t, J=6.0Hz), 6.32 (2H, s), 6.49 (1H, d, J=9.5Hz), 6.82 (1H, dd, J=2.0Hz, J=8.5Hz), 6.86-6.91 (1H, m), 7.13 (1H, d, J=2.0Hz), 7.24-7.30 (1H, m), 7.36-7.44 (3H, m), 7.54 (1H, d, J=8.0Hz), 7.58 (1H, d, J=9.5Hz)

[0643]

20 Example 123

Synthesis of 4,4-difluoropiperidine-1-carboxylic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester

[0644]



[0645]

In the same manner as in Example 48, the title compound was obtained.


¹H-NMR (CDCl₃) δ: 1.72-2.07 (8H, m), 2.54 (2H, t, J=7.5Hz), 2.64-2.78 (4H, m), 3.13-3.25 (4H, m), 3.48-3.71 (4H, m), 4.10 (2H, d, J=6.0Hz), 6.36 (2H, s), 6.52 (1H, d, J=9.5Hz), 6.85 (1H, dd, J=2.0Hz, J=8.5Hz), 6.89 (1H, d, J=7.5Hz), 7.06 (1H, d, J=2.0Hz), 7.27 (1H, dd, J=8.0Hz, J=8.0Hz), 7.39 (1H, d, J=5.5Hz), 7.41 (1H, d, J=5.5Hz), 7.45 (1H, d, J=8.5Hz), 7.55 (1H, d, J=8.0Hz), 7.63 (1H, d, J=9.5Hz)

[0646]

Example 124

Synthesis of 4,4,4-trifluorobutyric acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester

[0647]



[0648]

In the same manner as in Example 48, the title compound was obtained.

¹H-NMR (CDCl₃) δ: 1.69-1.80 (m, 2H), 1.80-1.90 (m, 2H), 2.43-2.57 (m, 4H), 2.62-2.77 (m, 8H), 2.83-2.90 (m, 2H), 3.13-3.24 (m, 4H), 3.99 (t, J = 6.2 Hz, 2H), 5.95 (brs, 2H), 6.57-6.63 (m, 2H), 6.87-6.92 (m, 1H), 7.08 (d, J = 8.1 Hz, 1H), 7.27 (dd,


J = 7.8, 7.8 Hz, 1H), 7.37-7.42 (m, 2H), 7.55 (d, J= 8.1 Hz, 1H)

[0649]

Example 125

5 Synthesis of N-furan-2-ylmethyl-N-methylcarbamic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester

[0650]



10 [0651]

In the same manner as in Example 10, the title compound was obtained.


¹H-NMR (CDCl₃) δ: 1.69-1.82 (2H, m), 1.84-1.94 (2H, m), 2.53 (2H, t, J=7.5Hz), 2.65-2.78 (4H, m), {2.84 (s), 2.97 (s) total 3H (1:1)}, 3.13-3.26 (4H, m), 4.05 (1H, d, J=6.0Hz), 4.10 (1H, t, J=6.0Hz), 4.31 (1H, s), 4.49 (1H, s), {6.02 (d, J=2.5Hz), 6.24 (d, J=2.5Hz) total 1H (1:1)}, {6.17 (brs), 6.32 (brs) total 1H (1:1)}, 6.39 (2H, s), 6.52 (1H, d, J=9.5Hz), 6.83 (1H, dd, J=2.0Hz, J=8.5Hz), 6.89 (1H, d, J=7.5Hz), {7.02 (brs), 7.12 (brs) total 1H (1:1)}, {7.19 (brs), 7.36 (brs) total 1H (1:1)}, 7.24-7.31 (1H, m), 7.36-7.46 (3H, m), 7.55 (1H, d, J=8.0Hz), 7.62 (1H, d, J=9.5Hz)

[0652]

Example 126

25 Synthesis of 4-methylpentanoic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester

[0653]



[0654]

In the same manner as in Example 22, the title compound was obtained.


5 $^1\text{H-NMR}$ (CDCl_3) δ : 0.87 (d, $J = 6.3$ Hz, 6H), 1.50-1.62 (m, 3H), 1.70-1.82 (m, 2H), 1.86-1.95 (m, 2H), 2.33-2.40 (m, 2H), 2.54 (t, $J = 7.5$ Hz, 2H), 2.66-2.79 (m, 4H), 3.14-3.24 (m, 4H), 4.08 (t, $J = 6.2$ Hz, 2H), 6.33 (brs, 2H), 6.52 (d, $J = 9.5$ Hz, 1H), 6.84 (dd, $J = 2.2, 8.6$ Hz, 1H), 6.86-6.91 (m, 2H), 7.27
10 (dd, $J = 7.8, 7.8$ Hz, 1H), 7.37-7.43 (m, 2H), 7.45 (d, $J = 8.6$ Hz, 1H), 7.55 (d, $J = 8.0$ Hz, 1H), 7.63 (d, $J = 9.5$ Hz, 1H)

[0655]

Example 127

Synthesis of cyclobutanecarboxylic acid 7-[4-(4-
15 benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester

[0656]



[0657]

20 In the same manner as in Example 48, the title compound was obtained.

$^1\text{H-NMR}$ (CDCl_3) δ : 1.68-1.79 (m, 2H), 1.80-2.03 (m, 4H), 2.15-2.25 (m, 2H), 2.25-2.37 (m, 2H), 2.52 (t, $J = 7.5$ Hz, 2H), 2.64-2.77 (m, 6H), 2.83-2.89 (m, 2H), 3.13-3.24 (m, 5H), 3.98
25 (t, $J = 6.2$ Hz, 2H), 5.92 (brs, 2H), 6.57-6.62 (m, 2H), 6.90 (d, $J = 7.5$ Hz, 1H), 7.07 (d, $J = 8.4$ Hz, 1H), 7.24-7.30 (m, 1H), 7.38 (d, $J = 5.6$ Hz, 1H), 7.41 (d, $J = 5.6$ Hz, 1H), 7.55


(d, J = 8.1 Hz, 1H)

[0658]

Example 128

Synthesis of benzofuran-5-carboxylic acid 7-[4-(4-
5 benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-
2H-quinolin-1-ylmethyl ester

[0659]



[0660]

10 In the same manner as in Example 48, the title compound
was obtained.


¹H-NMR (CDCl₃) δ: 1.62-1.74 (m, 2H), 1.75-1.86 (m, 2H), 2.46 (t,
J = 7.5 Hz, 2H), 2.58-2.71 (m, 4H), 2.71-2.79 (m, 2H), 2.82-
2.93 (m, 2H), 3.07-3.20 (m, 4H), 3.96 (t, J = 6.3 Hz, 2H),
15 6.19 (brs, 2H), 6.61 (dd, J = 2.3, 8.3 Hz, 1H), 6.77 (d, J =
2.3 Hz, 1H), 6.79-6.83 (m, 1H), 6.85-6.90 (m, 1H), 7.10 (d, J
= 8.3 Hz, 1H), 7.27 (dd, J = 7.9, 7.9 Hz, 1H), 7.36-7.41 (m,
2H), 7.52 (d, J = 8.7 Hz, 1H), 7.55 (d, J = 7.9 Hz, 1H), 7.65
(d, J = 2.2 Hz, 1H), 8.03 (dd, J = 1.7, 8.7 Hz, 1H). 8.36 (d,
20 J = 1.7 Hz, 1H)

[0661]

Example 129

Synthesis of N-methoxycarbamic acid (7-{4-[4-
(benzo[b]thiophen-4-yl)piperazin-1-yl]butoxy}-2-oxo-2H-
25 quinolin-1-yl)methyl

[0662]



[0663]

In the same manner as in Example 10, the title compound was obtained.


5 $^1\text{H-NMR}$ (CDCl_3) δ : 1.72-1.82 (2H, m), 1.84-1.95 (2H, m), 2.54 (2H, t, $J=7.5\text{Hz}$), 2.65-2.79 (4H, m), 3.13-3.26 (4H, m), {3.51(s), 3.73 (s) total 3H (1:3)}, 4.07-4.17 (2H, m), {6.33 (s), 6.39 (s) total 2H (1:3)}, 6.48-6.53 (1H, m), 6.80-6.88 (2H, m), {7.05 (d, $J=2.0\text{Hz}$), 7.13 (d, $J=2.0\text{Hz}$) total 1H (3:1)},
 10 7.24-7.30 (1H, m), 7.37-7.47 (3H, m), 7.55 (1H, d, $J=8.0\text{Hz}$), {7.58 (brs), 7.83 (brs) total 1H (1:3)}, 7.62 (1H, d, $J=9.5\text{Hz}$)

[0664]

Example 130

Synthesis of tetrahydropyran-4-carboxylic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester
 15

[0665]



[0666]

20 In the same manner as in Example 22, the title compound was obtained.

$^1\text{H-NMR}$ (CDCl_3) δ : 1.71-1.95 (m, 8H), 2.54 (t, $J = 7.5 \text{ Hz}$, 2H), 2.57-2.66 (m, 1H), 2.67-2.79 (m, 4H), 3.14-3.25 (m, 4H), 3.34-3.43 (m, 2H), 3.93 (dt, $J = 3.6, 7.6 \text{ Hz}$, 2H), 4.08 (t, $J = 6.3 \text{ Hz}$, 2H), 6.35 (brs, 2H), 6.52 (d, $J = 9.5 \text{ Hz}$, 1H), 6.81-6.87 (m, 2H), 6.87-6.92 (m, 1H), 7.27 (dd, $J = 7.9, 7.9 \text{ Hz}$, 1H),

25


7.39 (d, $J = 5.5$ Hz, 1H), 7.42 (d, $J = 5.5$ Hz, 1H), 7.46 (d, $J = 8.4$ Hz, 1H), 7.55 (d, $J = 7.9$ Hz, 1H), 7.63 (d, $J = 9.5$ Hz, 1H)

[0667]

5 Example 131

Synthesis of thiophene-2-carboxylic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester

[0668]



10

[0669]

In the same manner as in Example 48, the title compound was obtained.

$^1\text{H-NMR}$ (CDCl_3) δ : 1.66-1.76 (m, 2H), 1.77-1.89 (m, 2H), 2.50 (t, $J = 7.5$ Hz, 2H), 2.62-2.76 (m, 6H), 2.85-2.92 (m, 2H), 3.10-3.23 (m, 4H), 3.98 (t, $J = 6.2$ Hz, 2H), 6.14 (brs, 2H), 6.61 (dd, $J = 2.3, 8.2$ Hz, 1H), 6.75 (d, $J = 2.3$ Hz, 1H), 6.86-6.91 (m, 1H), 7.05-7.11 (m, 2H), 7.27 (dd, $J = 7.8, 7.8$ Hz, 1H), 7.37-7.43 (m, 2H), 7.53-7.58 (m, 2H), 7.82 (dd, $J = 1.2, 3.8$ Hz, 1H)

20


[0670]

Example 132

Synthesis of nicotinic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester

25

[0671]



[0672]

In the same manner as in Example 48, the title compound was obtained.


¹H-NMR (CDCl₃) δ: 1.64-1.76 (m, 2H), 1.77-1.88 (m, 2H), 2.49 (t, J = 7.5 Hz, 2H), 2.61-2.78 (m, 6H), 2.87-2.94 (m, 2H), 3.10-3.24 (m, 4H), 3.98 (t, J = 6.3 Hz, 2H), 6.19 (brs, 2H), 6.62 (dd, J = 2.3, 8.3 Hz, 1H), 6.72 (d, J = 2.3 Hz, 1H), 6.88 (d, J = 7.5 Hz, 1H), 7.10 (d, J = 8.3 Hz, 1H), 7.27 (dd, J = 7.8, 7.8 Hz, 1H), 7.35-7.42 (m, 3H), 7.55 (d, J = 8.0 Hz, 1H), 8.30 (ddd, J = 2.0, 2.0, 8.0 Hz, 1H), 8.77 (dd, J = 1.7 Hz, 4.9 Hz, 1H), 9.21-9.25 (m, 1H)

[0673]

Example 133

Synthesis of carbonic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester 4-nitrophenyl ester

[0674]



[0675]

20

7-[4-(4-Benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-1H-quinolin-2-one (2.0 g) was suspended in anhydrous THF (40 ml) under a nitrogen atmosphere, and sodium hydride (about 55% oil) (0.22 g) was added. The mixture was refluxed for 30 min under a nitrogen atmosphere. The obtained solution was cooled to was cooled to -70°C, and a solution (20 ml) of chloromethyl-4-nitrophenyl carbonate (1.50 g) in anhydrous THF with cannula. The reaction mixture was stirred at room temperature for 3 hr. Water was added to the reaction mixture to discontinue the reaction, and the mixture was extracted with ethyl acetate. The organic layer was dried over sodium sulfate, and

30


concentrated by filtration. The obtained residue was purified by silica gel column chromatography (ethyl acetate) to give the component (R_f value: 0.62, ethyl acetate, 0.67 g) as a pale-yellow amorphous compound. The obtained compound was used

[0676]

Example 134

Synthesis of carbonic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester dodecyl ester

[0677]



[0678]

1-Dodecanol (0.10 g) was dissolved in anhydrous THF (5 ml) under a nitrogen atmosphere and sodium hydride (about 55% oil) (25 mg) was added under ice-cooling with stirring. The reaction mixture was stirred at room temperature for 30 min under a nitrogen atmosphere, and then the mixture was ice-cooled. To the mixture was added a solution (5ml) of carbonic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester 4-nitrophenyl ester obtained in Example 133 (0.33 g) in anhydrous THF using a cannula. Under a nitrogen atmosphere, the reaction mixture was stirred with ice-cooling for 2 hr, and at room temperature for 1 hr.

Water was added to the reaction mixture to discontinue the reaction, and the mixture was extracted with ethyl acetate. The organic layer was dried over sodium sulfate, and concentrated by filtration. The obtained residue was purified by silica gel column chromatography (ethyl acetate:hexane =1:1) to give the title compound (0.14 g) as a colorless oil.


¹H-NMR (CDCl₃) δ: 0.87 (3H, t, J=7.0Hz), 1.17-1.38 (18H, m), 1.59-1.70 (2H, m), 1.73-1.82 (2H, m), 1.86-1.95 (2H, m), 2.54 (2H, t, J=7.5Hz), 2.69-2.78 (4H, m), 3.16-3.24 (4H, m), 4.10 (2H, t, J=6.0Hz), 4.18 (2H, t, J=6.5Hz), 6.35 (2H, brs), 6.50 (1H, d, J=9.5Hz), 6.84 (1H, dd, J=2.0Hz, J=8.5Hz), 6.89 (1H, d, J=7.5Hz), 6.93 (1H, d, J=2.0Hz), 7.24-7.30 (1H, m), 7.38 (1H, d, J=5.5Hz), 7.42 (1H, d, J=5.5Hz), 7.44 (1H, d, J=8.5Hz), 7.55 (1H, d, J=8.0Hz), 7.61 (1H, d, J=9.5Hz)

[0679]

10 Example 135

Synthesis of carbonic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester decyl ester

[0680]



15

[0681]

Using 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-1H-quinolin-2-one synthesized in the same manner as in WO2006/112464 (Example 1), and in the same manner as in

20 Example 5, the title compound was obtained.


¹H-NMR (CDCl₃) δ: 0.87 (3H, t, J=7.0Hz), 1.17-1.38 (14H, m), 1.62-1.70 (2H, m), 1.72-1.83 (2H, m), 1.86-1.96 (2H, m), 2.54 (2H, t, J=7.5Hz), 2.64-2.81 (4H, m), 3.12-3.26 (4H, m), 4.07-4.13 (2H, m), 4.18 (2H, t, J=6.5Hz), 6.35 (2H, brs), 6.50 (1H, d, J=9.5Hz), 6.84 (1H, dd, J=2.0Hz, J=8.5Hz), 6.89 (1H, d, J=7.5Hz), 6.93 (1H, d, J=2.0Hz), 7.24-7.30 (1H, m), 7.38 (1H, d, J=5.5Hz), 7.42 (1H, d, J=5.5Hz), 7.44 (1H, d, J=8.5Hz), 7.55 (1H, d, J=8.0Hz), 7.61 (1H, d, J=9.5Hz)

[0682]

30 Example 136

Synthesis of cyclobutanecarboxylic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester

[0683]



5

[0684]

In the same manner as in Example 22, the title compound was obtained.

¹H-NMR (CDCl₃) δ: 1.66-1.84 (m, 2H), 1.84-2.05 (m, 4H), 2.14-2.24 (m, 2H), 2.24-2.36 (m, 2H), 2.55 (t, J = 7.5 Hz, 2H), 2.65-2.80 (m, 4H), 3.12-3.26 (m, 5H), 4.08 (t, J = 6.2 Hz, 2H), 6.34 (brs, 2H), 6.52 (d, J = 9.5 Hz, 1H), 6.84 (dd, J = 2.2, 8.5 Hz, 1H), 6.87 (d, J = 2.2 Hz, 1H), 6.89 (d, J = 7.6 Hz, 1H), 7.24-7.30 (m, 1H), 7.39 (d, J = 5.6 Hz, 1H), 7.41 (d, J = 5.6 Hz, 1H), 7.44 (d, J = 8.5 Hz, 1H), 7.55 (d, J = 8.0 Hz, 1H), 7.62 (d, J = 9.5 Hz, 1H)

15


[0685]

Example 137

Synthesis of benzofuran-5-carboxylic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester

20

[0686]



[0687]

25

In the same manner as in Example 22, the title compound

was obtained.


¹H-NMR (CDCl₃) δ: 1.66-1.78 (m, 2H), 1.78-1.92 (m, 2H), 2.48 (t, J = 7.4 Hz, 2H), 2.59-2.74 (m, 4H), 3.10-3.20 (m, 4H), 4.07 (t, J = 6.2 Hz, 2H), 6.57 (d, J = 9.5 Hz, 1H), 6.61 (brs, 2H),
 5 6.76-6.81 (m, 1H), 6.84 (dd, J = 2.1, 8.6 Hz, 1H), 6.87 (d, J = 7.6 Hz, 1H), 7.00-7.04 (m, 1H), 7.27 (dd, J = 7.9, 7.9 Hz, 1H), 7.37-7.42 (m, 2H), 7.47 (d, J = 8.6 Hz, 1H), 7.50 (d, J = 8.7 Hz, 1H), 7.55 (d, J = 7.9 Hz, 1H), 7.62-7.69 (m, 2H), 8.03 (dd, J = 1.7, 8.7 Hz, 1H), 8.35 (d, J = 1.7 Hz, 1H)

10 [0688]

Example 138

Synthesis of 4,4,4-trifluorobutyric acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester

15 [0689]



[0690]

In the same manner as in Example 22, the title compound was obtained.


20 ¹H-NMR (CDCl₃) δ: 1.68-1.82 (m, 2H), 1.86-1.96 (m, 2H), 2.43-2.58 (m, 4H), 2.62-2.69 (m, 2H), 2.69-2.79 (m, 4H), 3.14-3.26 (m, 4H), 4.08 (t, J = 6.2 Hz, 2H), 6.36 (brs, 2H), 6.52 (d, J = 9.5 Hz, 1H), 6.83-6.88 (m, 2H), 6.88-6.92 (m, 1H), 7.27 (dd, J = 7.9, 7.9 Hz, 1H), 7.37-7.43 (m, 2H), 7.46 (d, J = 8.3 Hz, 1H), 7.55 (d, J = 7.9 Hz, 1H), 7.64 (d, J = 9.5 Hz, 1H)
 25

[0691]

Example 139

Synthesis of N-(3,3,3-trifluoropropyl)carbamic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester
 30

[0692]



[0693]

In the same manner as in Example 134, the title compound
5 was obtained.


$^1\text{H-NMR}$ (CDCl_3) δ : 1.72-1.95 (4H, m), 2.30-2.44 (2H, m), 2.54
(2H, t, $J=7.5\text{Hz}$), 2.65-2.82 (4H, m), 3.13-3.26 (4H, m), 3.48
(2H, dt, $J=6.5\text{Hz}$, $J=6.5\text{Hz}$), 4.04-4.14 (2H, m), 5.32-5.39 (1H,
m), 6.31 (2H, s), 6.48 (1H, d, $J=9.5\text{Hz}$), 6.83 (1H, dd, $J=2.0\text{Hz}$,
10 $J=8.5\text{Hz}$), 6.86-6.91 (1H, m), 7.07 (1H, d, $J=2.0\text{Hz}$), 7.24-7.30
(1H, m), 7.37-7.44 (3H, m), 7.54 (1H, d, $J=8.0\text{Hz}$), 7.58 (1H, d,
 $J=9.5\text{Hz}$)

[0694]

Example 140

15 Synthesis of carbonic acid 7-[4-(4-benzo[b]thiophen-4-
ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester
(E)-3-phenyl-allyl ester

[0695]



20 [0696]

In the same manner as in Example 134, the title compound
was obtained.

$^1\text{H-NMR}$ (CDCl_3) δ : 1.69-1.80 (2H, m), 1.82-1.94 (2H, m), 2.51
(2H, t, $J=7.5\text{Hz}$), 2.63-2.77 (4H, m), 3.12-3.24 (4H, m), 4.05-
25 4.11 (2H, m), 4.34 (1H, dd, $J=1.0\text{Hz}$, $J=6.5\text{Hz}$), 4.83 (1H, dd,


J=1.0Hz, J=6.5Hz), 6.16-6.30 (1H, m), 6.38 (2H, brs), 6.50 (1H, dd, J=2.0Hz, J=9.5Hz), 6.57-6.70 (1H, m), 6.80-6.85 (1H, m), 6.87(1H, brd, J=7.5Hz), 6.93 (1H, brs), 7.20-7.46 (9H, m), 7.54 (1H, d, J=8.0Hz), 7.59 (1H, dd, J=3.5Hz, J=9.5Hz)

5 [0697]

Example 141

Synthesis of thiophene-2-carboxylic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester

10 [0698]



[0699]

In the same manner as in Example 22, the title compound was obtained.


15 ¹H-NMR (CDCl₃) δ: 1.66-1.82 (m, 2H), 1.84-1.93 (m, 2H), 2.52 (t, J = 7.5 Hz, 2H), 2.64-2.77 (m, 4H), 3.12-3.24 (m, 4H), 4.08 (t, J = 6.2 Hz, 2H), 6.52-6.60 (m, 3H), 6.84 (dd, J = 2.1, 8.6 Hz, 1H), 6.89 (d, J = 7.8 Hz, 1H), 7.00 (d, J = 2.1 Hz, 1H), 7.07 (dd, J = 3.8, 4.9 Hz, 1H), 7.27 (dd, J = 7.8, 7.8 Hz, 1H),
 20 7.38 (d, J = 5.6 Hz, 1H), 7.41 (d, J = 5.6 Hz, 1H), 7.45 (d, J = 8.6 Hz, 1H), 7.53-7.59 (m, 2H), 7.64 (d, J = 9.5 Hz, 1H), 7.82 (dd, J = 1.2, 3.8 Hz, 1H)

[0700]

Example 142

25 Synthesis of carbonic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester decyl ester

[0701]



[0702]

In the same manner as in Example 5, the title compound was obtained.


¹H-NMR (CDCl₃) δ: 0.87 (3H, t, J=7.0Hz), 1.19-1.41 (14H, m), 1.62-1.80 (4H, m), 1.82-1.91 (2H, m), 2.52 (2H, t, J=7.5Hz), 2.64-2.77 (6H, m), 2.82-2.90 (2H, m), 3.14-3.24 (4H, m), 4.00 (2H, t, J=6.0Hz), 4.17 (2H, t, J=6.5Hz), 5.94 (2H, s), 6.59 (1H, dd, J=2.5Hz, J=8.5Hz), 6.69 (1H, dd, J=2.5Hz), 6.90 (1H, d, J=7.5Hz), 7.06 (1H, d, J=8.5Hz), 7.25-7.30 (1H, m), 7.38 (1H, d, J=5.5Hz), 7.40-7.43 (1H, m), 7.55 (1H, d, J=8.0Hz)

[0703]

Example 143

Synthesis of carbonic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester hexyl ester

[0704]



[0705]

In the same manner as in Example 14, the title compound was obtained.


¹H-NMR (CDCl₃) δ: 0.88 (3H, t, J=6.9 Hz), 1.20-1.90 (12H, m), 2.52 (2H, t, J=7.4 Hz), 2.60-2.80 (6H, m), 2.83-2.88 (2H, m), 3.20 (4H, br), 4.00 (2H, t, J=6.2 Hz), 4.18 (2H, t, J=6.7 Hz), 5.94 (2H, brs), 6.59 (1H, dd, J=2.4, 8.2 Hz), 6.69 (1H, d, J=2.3 Hz), 6.90 (1H, d, J=7.6 Hz), 7.06 (1H, d, J=8.3 Hz),

7.20-7.30 (1H, m), 7.35-7.45 (2H, m), 7.55 (1H, d, J=8.0 Hz)
[0706]

Example 144

Synthesis of carbonic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester hexadecyl ester

[0707]



[0708]

10 In the same manner as in Example 14, the title compound was obtained.


¹H-NMR (CDCl₃) δ: 0.88 (3H, t, J=6.8 Hz), 1.20-1.90 (32H, m), 2.53 (2H, t, J=7.4 Hz), 2.64-2.78 (6H, m), 2.80-2.90 (2H, m), 3.20 (4H, br), 4.00 (2H, t, J=6.2 Hz), 4.17 (2H, t, J=6.8 Hz),
15 5.94 (2H, brs), 6.59 (1H, dd, J=2.3, 8.3 Hz), 6.69 (1H, d, J=2.3 Hz), 6.89 (1H, d, J=7.6 Hz), 7.06 (1H, d, J=8.3 Hz), 7.27 (1H, t, J=7.8 Hz), 7.35-7.45 (2H, m), 7.54 (1H, d, J=8.0 Hz)

[0709]

20 Example 145

Synthesis of carbonic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester heptyl ester

[0710]



25

[0711]

In the same manner as in Example 14, the title compound was obtained.


¹H-NMR (CDCl₃) δ: 0.87 (3H, t, J=7.0 Hz), 1.22-1.40 (6H, m),
5 1.52-1.90 (8H, m), 2.53 (2H, t, J=7.4 Hz), 2.64-2.78 (6H, m),
2.86 (2H, t, J=7.2 Hz), 3.20 (4H, br), 4.00 (2H, t, J=6.2 Hz),
4.17 (2H, t, J=6.8 Hz), 5.94 (2H, brs), 6.59 (1H, dd, J=2.4,
8.3 Hz), 6.69 (1H, d, J=2.3 Hz), 6.90 (1H, d, J=7.6 Hz), 7.06
(1H, d, J=8.2 Hz), 7.27 (1H, t, J=7.8 Hz), 7.35-7.45 (2H, m),
10 7.55 (1H, d, J=8.1 Hz)

[0712]

Example 146

Synthesis of carbonic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester
15 cyclohexyl ester

[0713]



[0714]

Using 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-1H-quinolin-2-one synthesized in the same manner as
20 in WO2006/112464 (Example 1), and in the same manner as in Example 5, the title compound was obtained.


¹H-NMR (CDCl₃) δ: 1.17-1.28 (1H, m), 1.29-1.41 (2H, m), 1.42-1.57 (3H, m), 1.68-1.82 (4H, m), 1.84-1.98 (4H, m), 2.53 (2H,
25 t, J=7.5Hz), 2.64-2.80 (4H, m), 3.12-3.26 (4H, m), 4.09 (2H, t, J=6.0Hz), 4.64-4.72 (1H, m), 6.34 (2H, s), 6.49 (1H, d, J=9.5Hz), 6.83 (1H, dd, J=2.0Hz, 8.5Hz), 6.89 (1H, d, J=7.5Hz), 6.92 (1H, d, J=2.0Hz), 7.23-7.30 (1H, m), 7.36-7.44 (3H, m), 7.54 (1H, d, J=8.0Hz), 7.59 (1H, d, J=9.5Hz)

30 [0715]

Example 147

Synthesis of carbonic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester 2,2,2-trifluoro-ethyl ester

5 [0716]



[0717]

In the same manner as in Example 5, the title compound was obtained.


10 ¹H-NMR (CDCl₃) δ: 1.69-1.79 (2H, m), 1.81-1.90 (2H, m), 2.51 (2H, t, J=7.5Hz), 2.63-2.76 (6H, m), 2.81-2.90 (2H, m), 3.13-3.26 (4H, m), 3.99 (2H, t, J=6.0Hz), 4.55 (2H, q, J=8.0Hz), 6.00 (2H, s), 6.61 (1H, dd, J=2.5Hz, 8.0Hz), 6.65 (1H, d, J=2.5Hz), 6.86-6.91 (1H, m), 7.07 (1H, d, J=8.5Hz), 7.23-7.29 (1H, m), 7.37 (1H, d, J=5.5Hz), 7.39-7.43 (1H, m), 7.54 (1H, d, J=8.0Hz)

[0718]

Example 148

20 Synthesis of malonic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester tert-butyl ester

[0719]



[0720]

25 In the same manner as in Example 22, the title compound was obtained.


¹H-NMR (CDCl₃) δ: 1.38 (s, 9H), 1.69-1.83 (m, 2H), 1.85-1.95 (m, 2H), 2.55 (t, J = 7.4 Hz, 2H), 2.67-2.79 (m, 4H), 3.14-3.25 (m, 4H), 3.35 (s, 2H), 4.13 (t, J = 6.1 Hz, 2H), 6.37 (brs, 2H), 6.51 (d, J = 9.5 Hz, 1H), 6.84 (dd, J = 2.2, 8.6 Hz, 1H),
 5 6.87-6.92 (m, 2H), 7.27 (dd, J = 7.8, 7.8 Hz, 1H), 7.37-7.43 (m, 2H), 7.44 (d, J = 8.6 Hz, 1H), 7.55 (d, J = 8.0 Hz, 1H), 7.63 (d, J = 9.5 Hz, 1H)

[0721]

Example 149

10 Synthesis of carbonic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester octyl ester

[0722]



15 [0723]

In the same manner as in Example 14, the title compound was obtained.


¹H-NMR (CDCl₃) δ: 0.87 (3H, t, J=6.8 Hz), 1.20-1.40 (8H, m), 1.60-1.90 (8H, m), 2.53 (2H, t, J=7.4 Hz), 2.64-2.78 (6H, m),
 20 2.86 (2H, t, J=6.8 Hz), 3.20 (4H, br), 4.00 (2H, t, J=6.2 Hz), 4.17 (2H, t, J=6.8 Hz), 5.94 (2H, brs), 6.59 (1H, dd, J=2.3, 8.2 Hz), 6.69 (1H, d, J=2.3 Hz), 6.90 (1H, d, J=7.6 Hz), 7.06 (1H, d, J=8.1 Hz), 7.27 (1H, t, J=7.8 Hz), 7.36-7.44 (2H, m), 7.54 (1H, d, J=8.0 Hz)

25 [0724]

Example 150

Synthesis of carbonic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester cyclohexyl ester

30 [0725]



[0726]

In the same manner as in Example 5, the title compound was obtained.


¹H-NMR (CDCl₃) δ: 1.17-1.28 (1H, m), 1.29-1.41 (2H, m), 1.43-1.58 (3H, m), 1.68-1.79 (4H, m), 1.80-1.89 (2H, m), 1.90-1.99 (2H, m), 2.52 (2H, t, J=7.5Hz), 2.64-2.77 (6H, m), 2.82-2.89 (2H, m), 3.14-3.25 (4H, m), 4.00 (2H, t, J=6.0Hz), 4.62-4.71 (1H, m), 5.94 (2H, s), 6.59 (1H, dd, J=2.5Hz, 8.5Hz), 6.69 (1H, d, J=2.5Hz), 6.90 (1H, d, J=7.5Hz), 7.06 (1H, d, J=8.5Hz), 7.24-7.30 (1H, m), 7.38 (1H, d, J=5.5Hz), 7.40-7.44 (1H, m), 7.55 (1H, d, J=8.0Hz)

[0727]

Example 151

Synthesis of carbonic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester butyl ester

[0728]



[0729]

In the same manner as in Example 5, the title compound was obtained.

¹H-NMR (CDCl₃) δ: 0.93 (3H, t, J=7.4 Hz), 1.34-1.46 (2H, m), 1.60-1.90 (6H, m), 2.52 (2H, t, J=7.4 Hz), 2.64-2.76 (6H, m), 2.82-2.88 (2H, m), 3.16-3.26 (4H, br), 4.00 (2H, t, J=6.2 Hz), 4.19 (2H, t, J=6.7Hz), 5.94 (2H, brs), 6.59 (1H, dd, J=2.3, 8.2


Hz), 6.69 (1H, d, J=2.3 Hz), 6.89 (1H, d, J=7.6 Hz), 7.06 (1H, d, J=8.0 Hz), 7.27 (1H, t, J=7.8 Hz), 7.36-7.44 (2H, m), 7.55 (1H, d, J=8.1 Hz)

[0730]

5 Example 152

Synthesis of N-methyl-N-pyridin-2-ylmethylcarbamic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester

[0731]



10

[0732]

In the same manner as in Example 14, the title compound was obtained.

¹H-NMR (CDCl₃) δ: 1.68-1.81 (2H, m), 1.82-1.94 (2H, m), 2.47-2.58 (2H, m), 2.64-2.78 (4H, m), {2.91 (s), 3.06 (s) total 3H (1:1)}, 3.13-3.25 (4H, m), 4.00-4.10 (2H, m), 4.47 (1H, s), 4.65 (1H, s), 6.37 (1H, brs), 6.43 (1H, brs), {6.48 (d, J=9.5Hz), 6.53 (d, J=9.5Hz) total 1H (1:1)}, 6.78-6.97 (2H, m), 6.99-7.05 (1H, m), 7.13-7.21 (1H, m), 7.23-7.31 (2H, m), 7.36-7.47 (3H, m), 7.52-7.68 (3H, m), {8.38 (d, J=4.5Hz), 8.54 (d, J=4.5Hz) total 1H (1:1)}

20


[0733]

Example 153

Synthesis of thiomorpholine-4-carboxylic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester

25

[0734]



[0735]

In the same manner as in Example 14, the title compound was obtained.


¹H-NMR (CDCl₃) δ: 1.72-1.82 (2H, m), 1.86-1.95 (2H, m), 2.45-2.52 (2H, m), 2.54 (2H, t, J=7.5Hz), 2.58-2.64 (2H, m), 2.68-2.79 (4H, m), 3.15-3.26 (4H, m), 3.63-3.72 (2H, m), 3.73-3.83 (2H, m), 4.10 (2H, d, J=6.5Hz), 6.36 (2H, s), 6.52 (1H, d, J=9.5Hz), 6.84 (1H, dd, J=2.0Hz, J=8.5Hz), 6.87-6.92 (1H, m), 7.06 (1H, d, J=2.0Hz), 7.24-7.30 (1H, m), 7.37-7.47 (3H, m), 7.55 (1H, d, J=8.0Hz), 7.63 (1H, d, J=9.5Hz)

[0736]

Example 154

Synthesis of dodecanoic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-4,4-dimethyl-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester

[0737]



[0738]

Using 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-4,4-dimethyl-3,4-dihydro-1H-quinolin-2-one obtained in Reference Example 18, the title compound was synthesized in the same manner as in Example 5.

¹H-NMR (CDCl₃) δ: 0.87 (3H, t, J=6.9 Hz), 1.20-1.32 (22H, m),


1.56-1.68 (2H, m), 1.68-1.80 (2H, m), 1.80-1.90 (2H, m), 2.35
(2H, t, J=7.5 Hz), 2.50-2.56 (4H, m), 2.68-2.76 (4H, m), 3.14-
3.24 (4H, m), 3.99 (2H, t, J=6.2 Hz), 5.97 (2H, brs), 6.62-6.68
(2H, m), 6.89 (1H, d, J=7.6 Hz), 7.20 (1H, d, J=8.3 Hz), 7.27
5 (1H, t, J=7.8 Hz), 7.40 (2H, dd, J=5.6, 12.5 Hz), 7.54 (1H, d,
J=8.0 Hz)

[0739]

Example 155

Synthesis of 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-1-hydroxymethyl-4,4-dimethyl-3,4-dihydro-1H-quinolin-2-one

[0740]



[0741]

15 To a solution of 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-4,4-dimethyl-3,4-dihydro-1H-quinolin-2-one (0.4 g) obtained in Reference Example 18 in DMF (10 ml) were added 37% aqueous formalin solution (1.5 ml) and triethylamine (0.02 ml), and the mixture was heated at 80°C for 10 hr. Water was
20 added to the reaction mixture, and the mixture was extracted with ethyl acetate, and dried over magnesium sulfate. The solvent was evaporated under reduced pressure to give a mixture (0.46 g, 1:3) of 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-1-hydroxymethyl-4,4-dimethyl-3,4-dihydro-1H-quinolin-2-one and 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-4,4-dimethyl-3,4-dihydro-1H-quinolin-2-one.
25

amorphous: colorless

¹H-NMR (CDCl₃) δ: 1.26 (3H, t, J=7.2Hz), 1.27 (1.5H, s), 1.29
30 (4.5H, s), 1.68-1.78 (2H, m), 1.78-1.90 (2H, m), 2.46 (1.5H, s), 2.48 (0.5H, s), 2.52 (2H, t, J=7.4Hz), 2.72 (4H, m), 3.19


(4H, m), 3.95-4.05 (2H, m), 5.41 (0.5H, s), 6.36 (0.75H, d, J=2.5Hz), 6.58 (0.75H, dd, J=2.5, 8.5Hz), 6.64 (0.25H, dd, J=2.4, 8.5Hz), 6.87-6.92 (1.25H, m), 7.17 (0.75H, d, J=8.5Hz), 7.18 (0.25H, d, J=8.5Hz), 7.27 (1H, t, J=7.8Hz), 7.36-7.44 (2H, m), 7.54 (1H, d, J=8.0Hz), 8.32 (0.75H, brs)

[0742]

Example 156

Synthesis of carbonic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)-butoxy]-4,4-dimethyl-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester decyl ester

[0743]



[0744]

7-[4-(4-Benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-1-hydroxymethyl-4,4-dimethyl-3,4-dihydro-1H-quinolin-2-one (460 mg), which is a mixture with 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-4,4-dimethyl-3,4-dihydro-1H-quinolin-2-one obtained in Example 155, was suspended in methylene chloride (10 ml), pyridine (0.06 ml) and decyl chloroformate (103 mg) were added, and the mixture was stirred under ice-cooling for 4 hr. Water was added to the reaction mixture, and the mixture was extracted with methylene chloride, and dried over magnesium sulfate. The solvent was evaporated under reduced pressure and the residue was purified by silica gel column chromatography (ethyl acetate:n-hexane=2:1) to give carbonic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)-butoxy]-4,4-dimethyl-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester decyl ester (108 mg).

colorless oil

¹H-NMR (CDCl₃) δ: 0.87 (3H, t, J=6.8 Hz), 1.20-1.40 (20H, m),


1.62-1.70 (2H, m), 1.70-1.80 (2H, m), 1.80-1.90 (2H, m), 2.50-2.56 (4H, m), 2.73 (4H, m), 3.20 (4H, m), 4.00 (2H, t, J=6.2 Hz), 4.17 (2H, t, J=6.8 Hz), 5.99 (2H, s), 6.65 (1H, dd, J=2.4, 8.5 Hz), 6.71 (1H, d, J=2.3 Hz), 6.89 (1H, d, J=7.6 Hz), 7.20
5 (1H, d, J=8.4 Hz), 7.27 (1H, t, J=7.8 Hz), 7.36-7.44 (2H, m), 7.54 (1H, d, J=8.1 Hz)

[0745]

Example 157

Synthesis of carbonic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-4,4-dimethyl-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester phenyl ester

[0746]



[0747]

15 To a solution of 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-4,4-dimethyl-3,4-dihydro-1H-quinolin-2-one (0.38 g) obtained in Reference Example 18 in THF (10 ml) was added 60% sodium hydride (40 mg) with stirring under ice-cooling, and the mixture was heated under reflux for 0.5 hr. Thereafter,
20 with stirring under ice-cooling, a solution of chloromethyl phenylcarbonate (0.23 g) in THF (1 ml) was added dropwise, and the mixture was stirred at room temperature overnight. With stirring under ice-cooling, water was added to the reaction mixture, and the mixture was extracted with ethyl acetate,
25 washed with water, and dried over magnesium sulfate. The solvent was evaporated under reduced pressure and the residue was purified by silica gel column chromatography (ethyl acetate:n-hexane=1:1) to give carbonic acid 7-[4-(4-

benzo[b]thiophen-4-ylpiperazin-1-yl)-butoxy]-4,4-dimethyl-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester phenyl ester (130 mg).

colorless oil


¹H-NMR (CDCl₃) δ: 1.30 (6H, s), 1.68-1.90 (4H, m), 2.46-2.56 (2H, m), 2.57 (2H, s), 2.68-2.78 (4H, br), 3.14-3.24 (4H, br), 4.02 (2H, t, J=6.2 Hz), 6.11 (2H, s), 6.68 (1H, dd, J=2.4, 8.5 Hz), 6.75 (1H, d, J=2.4 Hz), 6.89 (1H, d, J=7.6 Hz), 7.16-7.46 (9H, m), 7.55 (1H, d, J=8.0 Hz).

[0748]

Example 158

Synthesis of N-decylcarbamic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)-butoxy]-4,4-dimethyl-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester

[0749]



[0750]

To a solution of 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-4,4-dimethyl-3,4-dihydro-1H-quinolin-2-one (0.21 g) obtained in Reference Example 18 in THF (10 ml) was added with stirring under ice-cooling 60% sodium hydride (27 mg), and the mixture was heated under reflux for 0.5 hr. Thereafter, with stirring under ice-cooling, a solution of chloromethyl phenylcarbonate (0.17 g) in THF (1 ml) was added dropwise, and the mixture was stirred at room temperature overnight. With stirring under ice-cooling, water was added to the reaction mixture, and the mixture was extracted with ethyl acetate, washed with water, and dried over magnesium sulfate. The solvent was evaporated under reduced pressure. To a solution of the obtained residue in THF (10 ml) was added decylamine

(0.5 ml), and the mixture was stirred at room temperature overnight. With stirring under ice-cooling, water was added to the reaction mixture, and the mixture was extracted with ethyl acetate, washed with water, and dried over magnesium sulfate.

5 The solvent was evaporated under reduced pressure and the residue was purified by silica gel column chromatography (ethyl acetate:n-hexane=2:1) to give N-decylcarbamic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)-butoxy]-4,4-dimethyl-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester (126 mg).

yellow oil


¹H-NMR (CDCl₃) δ: 0.87 (3H, t, J=6.8 Hz), 1.18-1.34 (20H, m), 1.42-1.52 (2H, m), 1.70-1.80 (2H, m), 1.80-1.90 (2H, m), 2.48-2.56 (4H, m), 2.66-2.78 (4H, br), 3.12-3.24 (6H, m), 4.01 (2H, t, J=6.1 Hz), 4.76-4.84 (1H, m), 5.96 (2H, s), 6.64 (1H, dd, J=2.3, 8.5 Hz), 6.81 (1H, d, J=2.0 Hz), 6.89 (1H, d, J=7.6 Hz), 7.19 (1H, d, J=8.5 Hz), 7.24-7.30 (1H, m), 7.36-7.44 (2H, m), 7.55 (1H, d, J=8.0 Hz)

[0751]

20 Example 163

Synthesis of carbonic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester methyl ester

[0752]



[0753]

To a solution of n-hexylalcohol (50.5 mg) in tetrahydrofuran (5 ml) was added with stirring under ice-cooling 60% sodium hydride (18 mg) by small portions, and the mixture was stirred at the same temperature for 0.5 hr, to a solution of carbonic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester

phenyl ester (240 mg) in tetrahydrofuran (1 ml) was added with stirring under ice-cooling sodium methoxide (30 mg), and the mixture was stirred for 3 hr. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate, and
 5 dried over sodium sulfate. The solvent was evaporated under reduced pressure and the residue was purified by silica gel column chromatography (ethyl acetate) to give carbonic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester methyl ester (42 mg).

10 oil: colorless


$^1\text{H-NMR}$ (CDCl_3) δ ppm : 1.72-1.84 (2H, m), 1.85-1.96 (2H, m), 2.55 (2H, t, $J=7.4$ Hz), 2.68-2.80 (4H, br), 3.14-3.26 (4H, br), 3.83 (3H, s), 4.10 (2H, t, $J=6.2$ Hz), 6.35 (2H, s), 6.50 (1H, d, $J=9.5$ Hz), 6.84 (1H, dd, $J=2.2, 8.6$ Hz), 6.89 (1H, d, $J=7.6$
 15 Hz), 6.92 (1H, d, $J=2.0$ Hz), 7.27 (1H, t, $J=7.8$ Hz), 7.36-7.46 (3H, m), 7.50 (1H, d, $J=8.0$ Hz), 7.60 (1H, d, $J=9.5$ Hz)

[0754]

Example 165

Synthesis of carbonic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester
 20 propyl ester

[0755]



[0756]

25 In the same manner as in Example 175, the compound was obtained (yield 78 mg, 27.5%) as a colorless oil.

$^1\text{H-NMR}$ (CDCl_3) δ ppm : 0.94 (3H, t, $J=7.4$ Hz), 1.58-1.84 (4H, m), 1.84-1.96 (2H, m), 2.54 (2H, t, $J=7.5$ Hz), 2.66-2.80 (4H, br), 3.14-3.28 (4H, br), 4.09 (2H, t, $J=6.0$ Hz), 4.15 (2H, t, $J=6.7$ Hz), 6.34 (2H, s), 6.49 (1H, d, $J=9.5$ Hz), 6.83 (1H, dd,
 30


J=2.1, 8.6 Hz), 6.89 (1H, d, J=7.6 Hz), 6.93 (1H, d, J=2.0 Hz), 7.26 (1H, t, J=7.8 Hz), 7.36-7.44 (3H, m), 7.54 (1H, d, J=8.0 Hz), 7.62 (1H, d, J=9.5 Hz)

[0757]

5 Example 168

Synthesis of carbonic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester butyl ester

[0758]



[0759]

In the same manner as in Example 175, the compound was obtained (yield 47 mg, 14.3%) as a colorless oil.

¹H-NMR (CDCl₃) δ ppm : 0.92 (3H, t, J=7.4 Hz), 1.32-1.44 (2H, m), 1.60-1.70 (2H, m), 1.72-1.84 (2H, m), 1.86-1.96 (2H, m), 2.55 (2H, t, J=7.5 Hz), 2.68-2.80 (4H, br), 3.16-3.26 (4H, br), 4.06-4.15 (2H, m), 4.20 (2H, t, J=6.7 Hz), 6.35 (2H, s), 6.50 (1H, d, J=9.5 Hz), 6.84 (1H, dd, J=2.2, 8.6 Hz), 6.89 (1H, d, J=7.7 Hz), 6.93 (1H, d, J=2.1 Hz), 7.27 (1H, t, J=7.8 Hz), 7.36-7.46 (3H, m), 7.55 (1H, d, J=8.0 Hz), 7.61 (1H, d, J=9.5 Hz)

15

20


[0760]

Example 170

Synthesis of carbonic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester isobutyl ester

25

[0761]



[0762]

In the same manner as in Example 175, the compound was obtained (yield 48 mg, 14.6%) as a colorless oil.


$^1\text{H-NMR}$ (CDCl_3) δ ppm : 0.94 (6H, d, $J=6.7$ Hz), 1.70–2.04 (5H, m), 2.55 (2H, t, $J=7.4$ Hz), 2.66–2.80 (4H, br), 3.14–3.24 (4H, br), 3.98 (2H, d, $J=6.6$ Hz), 4.10 (2H, t, $J=6.2$ Hz), 6.35 (2H, s), 6.51 (1H, d, $J=9.5$ Hz), 6.84 (1H, dd, $J=2.2, 8.6$ Hz), 6.89 (1H, d, $J=7.6$ Hz), 6.93 (1H, d, $J=2.0$ Hz), 7.27 (1H, t, $J=7.8$ Hz), 7.37–7.46 (3H, m), 7.55 (1H, d, $J=8.1$ Hz), 7.61 (1H, d, $J=9.5$ Hz)

[0763]

Example 175

Synthesis of carbonic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester hexyl ester

[0764]



[0765]

To a solution of n-hexylalcohol (50.5 mg) in tetrahydrofuran (5 ml) was added with stirring under ice-cooling 60% sodium hydride (18 mg) by small portions, and the mixture was stirred at the same temperature for 0.5 hr, a solution of carbonic acid 7-[4-(4-benzo[b]thiophen-4-

ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester
phenyl ester (240 mg) in tetrahydrofuran (1 ml) was added
dropwise, and the mixture was stirred under ice-cooling for 3
hr. Water was added to the reaction mixture, and the mixture
5 was extracted with ethyl acetate, and dried over sodium
sulfate. The solvent was evaporated under reduced pressure and
the residue was purified by silica gel column chromatography
(ethyl acetate) to give carbonic acid 7-[4-(4-
benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-
10 1-ylmethyl ester hexyl ester (30 mg).

oil: colorless


$^1\text{H-NMR}$ (CDCl_3) δ ppm : 0.87 (3H, t, $J=6.9$ Hz), 1.20-1.40 (6H,
m), 1.60-1.72 (2H, m), 1.72-1.84 (2H, m), 1.84-2.00 (2H, m),
2.55 (2H, t, $J=7.4$ Hz), 2.65-2.82 (4H, br), 3.10-3.28 (4H, br),
15 4.10 (2H, t, $J=6.2$ Hz), 4.19 (2H, t, $J=6.7$ Hz), 6.35 (2H, s),
6.50 (1H, d, $J=9.5$ Hz), 6.84 (1H, dd, $J=2.2, 8.6$ Hz), 6.89 (1H,
d, $J=7.6$ Hz), 6.93 (1H, d, $J=2.1$ Hz), 7.27 (1H, t, $J=7.8$ Hz),
7.36-7.46 (3H, m), 7.55 (1H, d, $J=8.0$ Hz), 7.61 (1H, d, $J=9.6$
Hz)

20 [0766]

Example 177

Synthesis of carbonic acid 7-[4-(4-benzo[b]thiophen-4-
ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester
nonyl ester

25 [0767]



[0768]


In the same manner as in Example 175, the compound was
obtained (yield 40 mg, 10.8%) as a colorless oil.

30 $^1\text{H-NMR}$ (CDCl_3) δ ppm : 0.86 (3H, t, $J=6.9$ Hz), 1.20-1.40 (12H,

m), 1.60-1.70 (2H, m), 1.72-1.82 (2H, m), 1.85-1.95 (2H, m),
 2.55 (2H, t, J=7.4 Hz), 2.68-2.78 (4H, br), 3.14-3.28 (4H, br),
 4.06-4.14 (2H, m), 4.18 (2H, t, J=6.7 Hz), 6.35 (2H, s), 6.50
 (1H, d, J=9.5 Hz), 6.84 (1H, dd, J=2.1, 8.6 Hz), 6.89 (1H, d,
 5 J=7.6 Hz), 6.93 (1H, d, J=2.0 Hz), 7.27 (1H, t, J=7.8 Hz),
 7.36-7.46 (3H, m), 7.55 (1H, d, J=8.0 Hz), 7.61 (1H, d, J=9.5
 Hz)
 [0769]

Example 179

10 Synthesis of carbonic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester
 tetradecyl ester
 [0770]



15 [0771]

In the same manner as in Example 175, the colorless amorphous compound was obtained (yield 33 mg, 9.3%).


¹H-NMR (CDCl₃) δ ppm : 0.87 (3H, t, J=6.9 Hz), 1.20-1.40 (22H, m), 1.55-1.95 (6H, m), 2.56 (2H, t, J=7.4 Hz), 2.68-2.80 (4H, br), 3.15-3.25 (4H, br), 4.10 (2H, t, J=6.2 Hz), 4.18 (2H, t, J=6.7 Hz), 6.35 (2H, s), 6.50 (1H, d, J=9.5 Hz), 6.84 (1H, dd, J=2.2, 8.6 Hz), 6.89 (1H, d, J=7.6 Hz), 6.93 (1H, d, J=2.0 Hz), 7.27 (1H, t, J=7.8 Hz), 7.36-7.46 (3H, m), 7.55 (1H, d, J=8.0 Hz), 7.61 (1H, d, J=9.5 Hz)

25 [0772]

Example 180

Synthesis of carbonic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester
 hexadecyl ester

30 [0773]



[0774]

In the same manner as in Example 175, the colorless amorphous compound was obtained (yield 48 mg, 15%).







5 ^1H -NMR (CDCl_3) δ ppm : 0.87 (3H, t, $J=6.8$ Hz), 1.20–1.38 (26H, m), 1.60–1.96 (6H, m), 2.55 (2H, t, $J=7.4$ Hz), 2.70–2.80 (4H, br), 3.16–3.24 (4H, br), 4.10 (2H, t, $J=6.2$ Hz), 4.18 (2H, t, $J=6.7$ Hz), 6.35 (2H, s), 6.50 (1H, d, $J=9.5$ Hz), 6.84 (1H, dd, $J=2.2, 8.6$ Hz), 6.89 (1H, d, $J=7.6$ Hz), 6.93 (1H, d, $J=2.0$ Hz),
 10 7.27 (1H, t, $J=7.8$ Hz), 7.36–7.46 (3H, m), 7.55 (1H, d, $J=8.1$ Hz), 7.61 (1H, d, $J=9.5$ Hz)







[0775]







In the same manner as in the above-mentioned Examples, the compounds described in the following Table 1 can be
 15 synthesized.







[0776]








Table 1

Example	Structure Formula	
159		N-Benzyl-N-methylcarbamic acid 7-[4-(4-benzo[b]thiophen-4-yl)piperazin-1-yl]butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester
160		N-Phenethylcarbamic acid 7-[4-(4-benzo[b]thiophen-4-yl)piperazin-1-yl]butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester
161		(7-{4-[4-(Benzo[b]thiophen-4-yl)piperazin-1-yl]butoxy}-2-oxo-3,4-dihydro-2H-quinolin-1-yl)methyl N-methoxycarbamate
162		N-Allylcarbamic acid 7-[4-(4-benzo[b]thiophen-4-yl)piperazin-1-yl]butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester
163		Carbonic acid 7-[4-(4-benzo[b]thiophen-4-yl)piperazin-1-yl]butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester methyl ester
164		Carbonic acid 7-[4-(4-benzo[b]thiophen-4-yl)piperazin-1-yl]butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester propyl ester






165		Carbonic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester propyl ester
166		Carbonic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester isopropyl ester
167		Carbonic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester isopropyl ester
168		Carbonic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester butyl ester
169		Carbonic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester isobutyl ester
170		Carbonic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester isobutyl ester

171		Carbonic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester pentyl ester
172		Carbonic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester pentyl ester
173		Carbonic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester 3-methylbutyl ester
174		Carbonic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester 3-methylbutyl ester
175		Carbonic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester hexyl ester
176		Carbonic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester nonyl ester







177		Carbonic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester nonyl ester
178		Carbonic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester tetradecyl ester
179		Carbonic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester tetradecyl ester
180		Carbonic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester hexadecyl ester
181		Carbonic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester benzyl ester
182		Carbonic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester benzyl ester







183		7-[4-(4-Benzo[b]thiophen-4-yl)piperazin-1-yl]butoxy]-1-methoxymethyl-3,4-dihydro-1H-quinolin-2-one
184		7-[4-(4-Benzo[b]thiophen-4-yl)piperazin-1-yl]butoxy]-1-methoxymethyl-1H-quinolin-2-one
185		7-[4-(4-Benzo[b]thiophen-4-yl)piperazin-1-yl]butoxy]-2-methoxymethoxyquinoline
186		7-[4-(4-Benzo[b]thiophen-4-yl)piperazin-1-yl]butoxy]-1-ethoxymethyl-3,4-dihydro-1H-quinolin-2-one
187		7-[4-(4-Benzo[b]thiophen-4-yl)piperazin-1-yl]butoxy]-1-ethoxymethyl-1H-quinolin-2-one
188		7-[4-(4-Benzo[b]thiophen-4-yl)piperazin-1-yl]butoxy]-1-isopropoxymethyl-3,4-dihydro-1H-quinolin-2-one
189		7-[4-(4-Benzo[b]thiophen-4-yl)piperazin-1-yl]butoxy]-1-isopropoxymethyl-1H-quinolin-2-one

190		Aminoacetic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester
191		Aminoacetic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester
192		2-Aminopropionic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester
193		2-Aminopropionic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester
194		2-Amino-3-methylbutyric acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester
195		2-Amino-3-methylbutyric acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester

196		2-Amino-4-methylpentanoic acid 7-[4-(4-benzo[b]thiophen-4-yl)piperazin-1-yl]butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester
197		2-Amino-4-methylpentanoic acid 7-[4-(4-benzo[b]thiophen-4-yl)piperazin-1-yl]butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester
198		Pyrrolidine-2-carboxylic acid 7-[4-(4-benzo[b]thiophen-4-yl)piperazin-1-yl]butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester
199		Pyrrolidine-2-carboxylic acid 7-[4-(4-benzo[b]thiophen-4-yl)piperazin-1-yl]butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester
200		Calcium {7-[4-(4-benzo[b]thiophen-4-yl)piperazin-1-yl]butoxy}-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl phosphate







201		Calcium {7-[4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl]butoxy}-2-oxo-2H-quinolin-1-yl)methyl phosphate
202		Calcium (7-{4-[4-(benzo[b]thiophen-4-yl)piperazin-1-yl]butoxy}quinolin-2-yl)methyl phosphate
203		Propionic acid 7-[4-(4-benzo[b]thiophen-4-yl)piperazin-1-yl]butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester
204		Pentanoic acid 7-[4-(4-benzo[b]thiophen-4-yl)piperazin-1-yl]butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester
205		Heptanoic acid 7-[4-(4-benzo[b]thiophen-4-yl)piperazin-1-yl]butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester
206		Nonanoic acid 7-[4-(4-benzo[b]thiophen-4-yl)piperazin-1-yl]butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester







207		Undecanoic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester
208		Tridecanoic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester
209		Nonadecanoic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester
210		Henicosanoic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester
211		Docosanoic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester
212		Tricosanoic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester







213		Tetracosanoic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester
214		2,2-Dimethylbutyric acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester
215		2,2-Dimethylpentanoic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester
216		2,2-Dimethyldodecanoic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester
217		Isobutyric acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester
218		3-Methylbutyric acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester







219		Decanoic acid 1-{7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-yl}ethyl ester
220		Dodecanoic acid 1-{7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-yl}ethyl ester
221		Tetradecanoic acid 1-{7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-yl}ethyl ester
222		Hexadecanoic acid 1-{7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-yl}ethyl ester
223		(2-Methoxyethoxy)acetic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester
224		[2-(2-Methoxyethoxy)ethoxy]acetic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester







225		(9Z,12Z)-Octadeca-9,12-dienoic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester
226		(9Z,12Z,15Z)-Octadeca-9,12,15-trienoic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester
227		(4Z,7Z,10Z,13Z,16Z,19Z)-Docosa-4,7,10,13,16,19-hexaenoic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester
228		(6Z,9Z,12Z,15Z)-Octadeca-6,9,12,15-tetraenoic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester
229		Isonicotinic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester







230		Pyrimidine-5-carboxylic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester
231		Pyridazine-4-carboxylic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester
232		Propionic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester
233		Pentanoic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester
234		Heptanoic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester
235		Nonanoic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester







236		Undecanoic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester
237		Tridecanoic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester
238		Nonadecanoic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester
239		Henicosanoic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester
240		Docosanoic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester
241		Tricosanoic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester

242		Tetracosanoic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester
243		2,2-Dimethylbutyric acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester
244		2,2-Dimethylpentanoic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester
245		2,2-Dimethyldodecanoic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester
246		Isobutyric acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester
247		3-Methylbutyric acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester







248		Decanoic acid 1-{7-[4-(4-benzo[b]thiophen-4-yl)piperazin-1-yl]butoxy}-2-oxo-2H-quinolin-1-yl}ethyl ester
249		Dodecanoic acid 1-{7-[4-(4-benzo[b]thiophen-4-yl)piperazin-1-yl]butoxy}-2-oxo-2H-quinolin-1-yl}ethyl ester
250		Tetradecanoic acid 1-{7-[4-(4-benzo[b]thiophen-4-yl)piperazin-1-yl]butoxy}-2-oxo-2H-quinolin-1-yl}ethyl ester
251		Hexadecanoic acid 1-{7-[4-(4-benzo[b]thiophen-4-yl)piperazin-1-yl]butoxy}-2-oxo-2H-quinolin-1-yl}ethyl ester
252		1-Methylpiperidine-4-carboxylic acid 7-[4-(4-benzo[b]thiophen-4-yl)piperazin-1-yl]butoxy}-2-oxo-2H-quinolin-1-ylmethyl ester
253		(2-Methoxyethoxy)acetic acid 7-[4-(4-benzo[b]thiophen-4-yl)piperazin-1-yl]butoxy}-2-oxo-2H-quinolin-1-ylmethyl ester

254		[2-(2-Methoxyethoxy)ethoxy]acetic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester
255		(2-Butoxyethoxy)acetic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester
256		(9Z,12Z)-Octadeca-9,12-dienoic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester
257		(9Z,12Z,15Z)-Octadeca-9,12,15-trienoic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester
258		(4Z,7Z,10Z,13Z,16Z,19Z)-Docosa-4,7,10,13,16,19-hexaenoic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester
259		(6Z,9Z,12Z,15Z)-Octadeca-6,9,12,15-tetraenoic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester







260		Isonicotinic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester
261		Nicotinic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester
262		Pyrimidine-5-carboxylic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester
263		Pyridazine-4-carboxylic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester
264		Pyridine-2-carboxylic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester
265		Pyridine-2-carboxylic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester

266		Furan-2-carboxylic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester
267		Furan-2-carboxylic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester
268		Thiophene-3-carboxylic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester
269		Thiophene-3-carboxylic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester
270		Quinoline-6-carboxylic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester
271		Quinoline-6-carboxylic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester

272		Benzoic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-4,4-dimethyl-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester
273		2,2-Dimethylpropionic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-4,4-dimethyl-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester
274		Butyric acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-4,4-dimethyl-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester
275		Phenylacetic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-4,4-dimethyl-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester
276		Octanoic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-4,4-dimethyl-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester
277		Cyclohexanecarboxylic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-4,4-dimethyl-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester







278		Cyclopentanecarboxylic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-4,4-dimethyl-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester
279		(Z)-Octadec-9-enoic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-4,4-dimethyl-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester
280		Hexadecanoic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-4,4-dimethyl-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester
281		Icosanoic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-4,4-dimethyl-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester
282		2-Pentyl-heptanoic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-4,4-dimethyl-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester
283		Decanoic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-4,4-dimethyl-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester

284		Hexanoic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-4,4-dimethyl-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester
285		Octadecanoic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-4,4-dimethyl-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester
286		Acetic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-4,4-dimethyl-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester
287		Propionic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-4,4-dimethyl-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester
288		Pentanoic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-4,4-dimethyl-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester
289		Heptanoic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-4,4-dimethyl-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester







290		Nonanoic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-4,4-dimethyl-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester
291		Undecanoic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-4,4-dimethyl-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester
292		Tridecanoic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-4,4-dimethyl-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester
293		Tetradecanoic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-4,4-dimethyl-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester
294		Pentadecanoic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-4,4-dimethyl-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester
295		Heptadecanoic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-4,4-dimethyl-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester








296		Nonadecanoic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-4,4-dimethyl-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester
297		Henicosanoic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-4,4-dimethyl-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester
298		Docosanoic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-4,4-dimethyl-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester
299		Tricosanoic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-4,4-dimethyl-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester
300		Tetracosanoic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-4,4-dimethyl-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester
301		Malonic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-4,4-dimethyl-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester tert-butyl ester







302		2-Methyl-butyrac acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-4,4-dimethyl-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester
303		2-Methyl-pentanoic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-4,4-dimethyl-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester
304		2-Methyl-hexanoic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-4,4-dimethyl-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester
305		2,2-Dimethyl-hexanoic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-4,4-dimethyl-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester
306		Isobutyric acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-4,4-dimethyl-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester
307		3-Methyl-butyrac acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-4,4-dimethyl-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester
308		4-Methyl-pentanoic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-4,4-dimethyl-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester







309		Cyclobutanecarboxylic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-4,4-dimethyl-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester
310		Decanoic acid 1-{7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-4,4-dimethyl-2-oxo-3,4-dihydro-2H-quinolin-1-yl}-ethyl ester
311		Dodecanoic acid 1-{7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-4,4-dimethyl-2-oxo-3,4-dihydro-2H-quinolin-1-yl}-ethyl ester
312		Tetradecanoic acid 1-{7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-4,4-dimethyl-2-oxo-3,4-dihydro-2H-quinolin-1-yl}-ethyl ester
313		Hexadecanoic acid 1-{7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-4,4-dimethyl-2-oxo-3,4-dihydro-2H-quinolin-1-yl}-ethyl ester
314		Tetrahydro-pyran-4-carboxylic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-4,4-dimethyl-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester






315		(2-Methoxy-ethoxy)-acetic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-4,4-dimethyl-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester
316		[2-(2-Methoxy-ethoxy)-ethoxy]-acetic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-4,4-dimethyl-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester
317		(2-Butoxy-ethoxy)-acetic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-4,4-dimethyl-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester
318		Cycloheptanecarboxylic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-4,4-dimethyl-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester
319		4,4,4-Trifluoro-butyric acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-4,4-dimethyl-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester
320		Piperidine-1-carboxylic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-4,4-dimethyl-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester






321		N-Butyl-N-methylcarbamic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-4,4-dimethyl-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester
322		N,N-Dibutylcarbamic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-4,4-dimethyl-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester
323		N-Cyclohexylmethylcarbamic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-4,4-dimethyl-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester
324		N-Butylcarbamic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-4,4-dimethyl-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester
325		N-Methylcarbamic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-4,4-dimethyl-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester
326		N,N-Dimethylcarbamic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-4,4-dimethyl-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester







327		N-Ethylcarbamic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-4,4-dimethyl-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester
328		N,N-Diethylcarbamic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-4,4-dimethyl-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester
329		N-Pentadecylcarbamic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-4,4-dimethyl-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester
330		N-Octadecylcarbamic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-4,4-dimethyl-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester
331		N-Methyl-N-octadecylcarbamic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-4,4-dimethyl-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester
332		N-Cyclohexylcarbamic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-4,4-dimethyl-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester
333		N-Benzylcarbamic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-4,4-dimethyl-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester

334		N-Benzyl-N-methylcarbamic acid 7-[4-(4-benzo[b]thiophen-4-yl)piperazin-1-yl]butoxy]-4,4-dimethyl-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester
335		N-Phenethylcarbamic acid 7-[4-(4-benzo[b]thiophen-4-yl)piperazin-1-yl]butoxy]-4,4-dimethyl-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester
336		Morpholine-4-carboxylic acid 7-[4-(4-benzo[b]thiophen-4-yl)piperazin-1-yl]butoxy]-4,4-dimethyl-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester
337		N-(2-Methoxyethyl)carbamic acid 7-[4-(4-benzo[b]thiophen-4-yl)piperazin-1-yl]butoxy]-4,4-dimethyl-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester
338		{7-[4-(4-Benzo[b]thiophen-4-yl)piperazin-1-yl]butoxy]-4,4-dimethyl-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethoxycarbonylamino}acetic acid methyl ester
339		({7-[4-(4-Benzo[b]thiophen-4-yl)piperazin-1-yl]butoxy]-4,4-dimethyl-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethoxycarbonyl}-methyl-amino)acetic acid methyl ester



340		(7-[4-[4-(Benzo[b]thiophen-4-yl)piperazin-1-yl]butoxy]-4,4-dimethyl-2-oxo-3,4-dihydro-2H-quinolin-1-yl)methyl N-methoxycarbamate
341		7-[4-(4-benzo[b]thiophen-4-yl)piperazin-1-yl]butoxy]-4,4-dimethyl-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl N-benzyloxycarbamate
342		N-(3,3,3-Trifluoropropyl)carbamic acid 7-[4-(4-benzo[b]thiophen-4-yl)piperazin-1-yl]butoxy]-4,4-dimethyl-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester
343		N-Furan-2-ylmethylcarbamic acid 7-[4-(4-benzo[b]thiophen-4-yl)piperazin-1-yl]butoxy]-4,4-dimethyl-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester
344		Carbonic acid 7-[4-(4-benzo[b]thiophen-4-yl)piperazin-1-yl]butoxy]-4,4-dimethyl-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester methyl ester
345		Carbonic acid 7-[4-(4-benzo[b]thiophen-4-yl)piperazin-1-yl]butoxy]-4,4-dimethyl-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester ethyl ester

346		Carbonic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-4,4-dimethyl-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester propyl ester
347		Carbonic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-4,4-dimethyl-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester isopropyl ester
348		Carbonic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-4,4-dimethyl-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester butyl ester
349		Carbonic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-4,4-dimethyl-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester isobutyl ester
350		Carbonic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-4,4-dimethyl-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester pentyl ester

351		Carbonic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-4,4-dimethyl-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester 3-methyl-butyl ester
352		Carbonic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-4,4-dimethyl-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester hexyl ester
353		Carbonic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-4,4-dimethyl-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester nonyl ester
354		Carbonic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-4,4-dimethyl-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester tetradecyl ester
355		Carbonic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-4,4-dimethyl-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester hexadecyl ester

356		Carbonic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-4,4-dimethyl-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester benzyl ester
357		Carbonic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-4,4-dimethyl-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester heptyl ester
358		Carbonic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-4,4-dimethyl-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester octyl ester
359		Carbonic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-4,4-dimethyl-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester 2,2,2-trifluoro-ethyl ester
360		Carbonic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-4,4-dimethyl-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester cyclohexyl ester
361		7-[4-(4-Benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-1-methoxymethyl-4,4-dimethyl-3,4-dihydro-1H-quinolin-2-one

362		7-[4-(4-Benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-1-ethoxymethyl-4,4-dimethyl-3,4-dihydro-1H-quinolin-2-one
363		7-[4-(4-Benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-1-isopropoxymethyl-4,4-dimethyl-3,4-dihydro-1H-quinolin-2-one
364		7-[4-(4-Benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-1-benzyloxymethyl-4,4-dimethyl-3,4-dihydro-1H-quinolin-2-one
365		7-[4-(4-Benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-4,4-dimethyl-1-(2,2,2-trifluoroethoxymethyl)-3,4-dihydro-1H-quinolin-2-one
366		Amino-acetic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-4,4-dimethyl-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester
367		2-Amino-propionic acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-4,4-dimethyl-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester
368		2-Amino-3-methyl-butyric acid 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-4,4-dimethyl-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester


369		2-Amino-4-methyl-pentanoic acid 7-[4-(4-benzo[b]thiophen-4-yl)piperazin-1-yl]butoxy]-4,4-dimethyl-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester
370		Pyrrolidine-2-carboxylic acid 7-[4-(4-benzo[b]thiophen-4-yl)piperazin-1-yl]butoxy]-4,4-dimethyl-2-oxo-3,4-dihydro-2H-quinolin-1-ylmethyl ester

[0777]

Example 371

Synthesis of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)-butoxy]-quinolin-2-yloxymethyl dodecanoate

5 [0778]



[0779]

To a solution of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)-butoxy]-1H-quinolin-2-one (800 mg) synthesized in the same manner as in WO2006/112464 (Example 1) in dimethylformamide (30 ml) was added silver carbonate (I) (0.76 g), chloromethyldodecanoate[61413-67-0] (1.15 g) was added, and the mixture was stirred at 60°C for 6 hr. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate and dried over Na₂SO₄. The solvent was evaporated under reduced pressure and the residue was purified by silica gel column chromatography (ethyl acetate:n-hexane=2:1) to give 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)-butoxy]-quinolin-2-yloxymethyl dodecanoate (22 mg).

oil: colorless


¹H-NMR (CDCl₃) δ ppm : 0.87 (3H, t, J=7.1 Hz), 1.16-2.10 (18H, m), 2.36 (2H, t, J=7.5 Hz), 2.58 (2H, t, J=7.5 Hz), 2.76 (4H, br), 3.21 (4H, br), 4.15 (2H, t, J=6.3 Hz), 6.25 (2H, s), 6.80 (1H, d, J=8.7 Hz), 6.90 (1H, d, J=7.4 Hz), 7.06 (1H, dd, J=2.5, 8.8 Hz), 7.22 (1H, d, J=2.3 Hz), 7.27 (1H, t, J=7.8 Hz), 7.36-7.44 (2H, m), 7.55 (1H, d, J=8.0 Hz), 7.61 (1H, d, J=8.8 Hz), 7.96 (1H, d, J=8.7 Hz)

[0780]

Example 372

Synthesis of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)-butoxy]-quinolin-2-ylloxymethyl cyclohexyl carbonate

[0781]



[0782]

To a solution of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)-butoxy]-1H-quinolin-2-one (700 mg) synthesized in the same manner as in WO2006/112464 (Example 1) in dimethylformamide (20 ml) was added silver carbonate (I) (0.53 g), chloromethyl cyclohexyl carbonate [40510-86-9] (0.68 g) was added, and the mixture was stirred at 60°C for 6 hr. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate, and dried over Na₂SO₄. The solvent was evaporated under reduced pressure and the residue was purified by silica gel column chromatography (ethyl acetate:n-hexane=2:1) to give 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)-butoxy]-quinolin-2-ylloxymethyl cyclohexyl carbonate (60 mg).

amorphous: colorless

¹H-NMR (CDCl₃) δ ppm : 1.10-2.00 (14H, m), 2.56 (2H, t, J=7.5 Hz), 2.75 (4H, br), 3.21 (4H, br), 4.14 (2H, t, J=6.3 Hz), 4.64-4.74 (1H, m), 6.27 (2H, s), 6.82 (1H, d, J=8.7 Hz), 6.90


(1H, d, J=7.2 Hz), 7.06 (1H, dd, J=2.5, 8.8 Hz), 7.20-7.30 (2H, m), 7.35-7.45 (2H, m), 7.55 (1H, d, J=8.0 Hz), 7.61 (1H, d, J=8.9 Hz), 7.96 (1H, d, J=8.7 Hz)

[0783]

5 Example 373

Synthesis of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)-butoxy]-quinolin-2-yloxymethylhexyl carbonate

[0784]



10 [0785]

To a solution of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)-butoxy]-1H-quinolin-2-one (730 mg) synthesized in the same manner as in WO2006/112464 (Example 1) in dimethylformamide (20 ml) was added silver carbonate (I) (0.56 g), chloromethyl hexyl carbonate[663597-51-1] (0.72 g) was added, and the mixture was stirred at 60°C for 10 hr. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate, and dried over Na₂SO₄. The solvent was evaporated under reduced pressure and the residue was purified by silica gel column chromatography (ethyl acetate:n-hexane=2:1) to give 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)-butoxy]-quinolin-2-yloxymethyl hexyl carbonate (95 mg).

oil: yellow


¹H-NMR (CDCl₃) δ ppm : 0.87 (3H, t, J=6.9 Hz), 1.20-1.40 (6H, m), 1.60-1.70 (2H, m), 1.74-1.84 (2H, m), 1.88-1.98 (2H, m), 2.57 (2H, t, J=7.6 Hz), 2.76 (4H, br), 3.21 (4H, br), 4.14 (2H, t, J=6.3 Hz), 4.19 (2H, t, J=6.7 Hz), 6.27 (2H, s), 6.82 (1H, d, J=8.7 Hz), 6.90 (1H, d, J=7.6 Hz), 7.06 (1H, dd, J=2.5, 8.8 Hz), 7.23 (1H, d, J=2.4 Hz), 7.27 (1H, t, J=7.9 Hz), 7.35-7.45 (2H, m), 7.55 (1H, d, J=8.0 Hz), 7.61 (1H, d, J=8.8 Hz), 7.96 (1H, d, J=8.7 Hz)

[0786]

Example 374

Synthesis of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)-butoxy]-quinolin-2-yloxymethylphenyl carbonate

5 [0787]



[0788]

To a solution of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)-butoxy]-1H-quinolin-2-one (1.5 g) synthesized in the same manner as in WO2006/112464 (Example 1) in dimethylformamide (50 ml) was added silver carbonate (I) (1.14 g), chloromethyl phenyl carbonate[35180-03-1] (1.42 g) was added, and the mixture was stirred at 60°C for 4 hr. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate, and dried over Na₂SO₄. The solvent was evaporated under reduced pressure and the residue was purified by silica gel column chromatography (ethyl acetate:n-hexane=2:1) to give 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)-butoxy]-quinolin-2-yloxymethyl phenyl carbonate (20 mg).

20 oil: colorless

¹H-NMR (CDCl₃) δ ppm : 1.70-2.10 (4H, m), 2.59 (2H, t, J=7.4 Hz), 2.78 (4H, br), 3.22 (4H, br), 4.10-4.18 (2H, m), 6.38 (2H, s), 6.80-6.95 (4H, m), 7.08 (1H, dd, J=2.4, 8.8 Hz), 7.18-7.45 (7H, m), 7.55 (1H, d, J=8.0Hz), 7.63 (1H, d, J=8.9 Hz), 8.00 (1H, d, J=8.7 Hz)


25

[0789]

Example 375

Synthesis of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)-butoxy]-quinolin-2-yloxymethyldecyl carbamate

30 [0790]



[0791]

To a solution of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)-butoxy]-quinolin-2-yl oxymethyl phenyl carbonate (20 mg) synthesized in the same manner as in Example 374 in THF (10 ml) was added decylamine[2016-57-1] (0.1 ml), and the mixture was stirred at room temperature overnight. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate, and dried over Na₂SO₄. The solvent was evaporated under reduced pressure and the residue was purified by silica gel column chromatography (ethyl acetate:n-hexane=2:1) to give 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)-butoxy]-quinolin-2-yl oxymethyl decyl carbamate (18 mg).

oil: colorless


¹H-NMR (CDCl₃) δ ppm : 0.87 (3H, t, J=6.9 Hz), 1.10-2.40 (20H, m), 2.58 (2H, t, J=7.4 Hz), 2.76 (4H, br), 3.16-3.26 (6H, m), 4.15 (2H, t, J=6.3 Hz), 4.83 (1H, t, J=5.4 Hz), 6.23 (2H, s), 6.82 (1H, d, J=8.7 Hz), 6.90 (1H, d, J=7.6 Hz), 7.06 (1H, dd, J=2.5, 8.8 Hz), 7.23 (1H, d, J=2.4 Hz), 7.27 (1H, t, J=7.8 Hz), 7.36-7.44 (2H, m), 7.55 (1H, d, J=8.0 Hz), 7.61 (1H, d, J=8.8 Hz), 7.95 (1H, d, J=8.7 Hz)

[0792]

Example 376

Synthesis of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)-butoxy]-1-dodecanoyl-3,4-dihydroquinolin-2(1H)-one

[0793]



[0794]

To a solution of 7-[4-(4-benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy]-3,4-dihydro-1H-quinolin-2-one (0.3 g) synthesized in the same manner as in WO2006/112464 (Example 11) in methylene chloride (10 ml) was added pyridine (0.11 ml), with
 5 stirring under ice-cooling, dodecanoylchloride (0.24 ml) was added, and the mixture was stirred at room temperature overnight. Water was added to the reaction mixture and the mixture was extracted with methylene chloride, and dried over sodium sulfate. The solvent was evaporated under reduced
 10 pressure and the residue was purified by silica gel column chromatography (ethyl acetate) to give 7-[4-(4-benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy]-1-dodecanoyl-3,4-dihydro-1H-quinolin-2-one (0.4 g).

oil: colorless


15 $^1\text{H-NMR}$ (CDCl_3) δ ppm : 0.88 (3H, t, $J=6.8$ Hz), 1.20-1.40 (16H, m), 1.68-1.90 (6H, m), 2.54 (2H, t, $J=7.4$ Hz), 2.65-2.80 (6H, m), 2.80-2.88 (2H, m), 2.97 (2H, t, $J=7.6$ Hz), 3.16-3.26 (4H, m), 3.97 (2H, t, $J=6.2$ Hz), 6.67 (1H, dd, $J=2.4, 8.3$ Hz), 6.83 (1H, dd, $J=0.6, 7.7$ Hz), 7.08 (1H, d, $J=8.3$ Hz), 7.27 (1H, t,
 20 $J=7.8$ Hz), 7.37-7.43 (2H, m), 7.55 (1H, d, $J=8.0$ Hz)

[0795]

Example 377

Synthesis of 7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-1-(cyclohexanecarbonyl)-3,4-dihydroquinolin-2(1H)-
 25 one

[0796]



[0797]

To a solution of 7-[4-(4-benzo[b]thiophen-4-yl)piperazin-1-yl)-butoxy]-3,4-dihydro-1H-quinolin-2-one (1 g) synthesized
 30 in the same manner as in WO2006/112464 (Example 11) in

dichloromethane (30 ml) was added pyridine (0.37 ml), with stirring under ice-cooling, cyclohexanecarbonyl chloride (0.46 ml) was added and the mixture was stirred at room temperature overnight. Water was added to the reaction mixture and the mixture was extracted with ethyl acetate. The organic layer was dried over sodium sulfate, the solvent was evaporated under reduced pressure and the residue was purified by silica gel column chromatography (ethyl acetate:n-hexane=9:1) to give 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)-butoxy]-1-(cyclohexanecarbonyl)-3,4-dihydroquinolin-2(1H)-one (1.2 g). oil: yellow


¹H-NMR (CDCl₃) δ ppm : 1.20-2.25 (14H, m), 2.53 (2H, t, J=7.5 Hz), 2.64-2.78 (6H, m), 2.84-2.90 (2H, m), 3.12-3.24 (5H, m), 3.97 (2H, t, J=6.2 Hz), 6.59 (1H, d, J=2.3Hz), 6.63 (1H, dd, J=2.4, 8.3 Hz), 6.90 (1H, d, J=7.4 Hz), 7.08 (1H, d, J=8.3 Hz), 7.27 (1H, t, J=7.8 Hz), 7.36-7.44 (2H, m), 7.55 (1H, d, J=8.0 Hz)

[0798]

Example 378

Synthesis of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)-butoxy]quinolin-2-yl acetate

[0799]



[0800]

To a solution of 7-[4-(4-benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy]-1H-quinolin-2-one (3.14 g) synthesized in the same manner as in WO2006/112464 (Example 1) in methylene chloride (32 mL) were added with stirring under ice-cooling triethylamine (4.0 mL) and acetyl chloride (1.5 mL), and the mixture was stirred at room temperature for 39 hr. The solvent was evaporated under reduced pressure, and the residue was

purified by silica gel column chromatography (methylene chloride :ethyl acetate=7:3→1:9) to give 7-[4-(4-benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]quinolin-2-yl acetate (1.24 g).

oil: yellow


¹H-NMR (CDCl₃) δ ppm : 1.62-1.81 (2H, m), 1.81-2.00 (2H, m), 2.39 (3H, s), 2.54 (2H, t, J=7.5 Hz), 2.67-2.86 (4H, m), 3.10-3.29 (4H, m), 4.15 (2H, t, J=6.3 Hz), 6.90 (1H, d, J=7.5 Hz), 7.05 (1H, d, J=8.5 Hz), 7.10-7.29 (3H, m), 7.29-7.48 (2H, m), 7.55 (1H, d, J=7.8Hz), 7.72 (1H, d, J=9.0Hz), 8.15 (1H, d, J=8.5 Hz)

[0801]

Example 379

Synthesis of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)-butoxy]-quinolin-2-yl dodecanoate

[0802]



[0803]

To a solution of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)-butoxy]-1H-quinolin-2-one (800 mg) in dichloromethane (20 ml) synthesized in the same manner as in WO2006/112464 (Example 1) was added triethylamine (0.77 ml), with stirring under ice-cooling, dodecanoylchloride (1.1 ml) was added and the mixture was stirred at room temperature for 4 hr. Water was added to the reaction mixture and the mixture was extracted with ethyl acetate. The organic layer was dried over sodium sulfate. The solvent was evaporated under reduced pressure and the residue was purified by silica gel column chromatography (ethyl acetate) to give 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)-butoxy]-quinolin-2-yl dodecanoate (1.34 g).

oil: yellow


$^1\text{H-NMR}$ (CDCl_3) δ ppm : 0.88 (3H, t, $J=6.8$ Hz), 1.20-1.50 (16H, m), 1.72-1.86 (4H, m), 1.86-1.98 (2H, m), 2.55 (2H, t, $J=7.6$ Hz), 2.66 (2H, t, $J=7.6$ Hz), 2.75 (4H, br), 3.20 (4H, br),
 5 4.14 (2H, t, $J=6.3$ Hz), 6.90 (1H, d, $J=7.5$ Hz), 7.04 (1H, d, $J=8.6$ Hz), 7.19 (1H, dd, $J=2.4, 8.9$ Hz), 7.27 (1H, t, $J=7.8$ Hz), 7.33 (1H, d, $J=2.4$ Hz), 7.36-7.44 (2H, m), 7.55 (1H, d, $J=8.1$ Hz), 7.71 (1H, d, $J=9.0$ Hz), 8.14 (1H, d, $J=8.6$ Hz)

[0804]

10 Example 380

Synthesis of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)-butoxy]-quinolin-2-yl cyclohexanecarboxylate

[0805]



15 [0806]

To a solution of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)-butoxy]-1H-quinolin-2-one (800 mg) synthesized in the same manner as in WO2006/112464 (Example 1) in dichloromethane (20 ml) was added triethylamine (0.64 ml), with stirring under
 20 ice-cooling, cyclohexanecarbonyl chloride (0.49 ml) was added and the mixture was stirred at room temperature overnight. Water was added to the reaction mixture and the mixture was extracted with ethyl acetate. The organic layer was dried over sodium sulfate. The solvent was evaporated under reduced
 25 pressure and the residue was purified by silica gel column chromatography (ethyl acetate:n-hexane=4:1) to give 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)-butoxy]-quinolin-2-yl cyclohexanecarboxylate (1.08 g).

oil: yellow

30 $^1\text{H-NMR}$ (CDCl_3) δ ppm : 1.20-2.20 (14H, m), 2.54 (2H, t, $J=7.5$ Hz), 2.60-2.80 (5H, m), 3.20 (4H, br), 4.08-4.18 (2H, m), 6.89


(1H, d, J=7.6 Hz), 7.01 (1H, d, J=8.6 Hz), 7.18 (1H, dd, J=2.5, 8.9 Hz), 7.27 (1H, t, J=7.8 Hz), 7.34 (1H, d, J=2.4 Hz), 7.36-7.44 (2H, m), 7.54 (1H, d, J=8.0 Hz), 7.70 (1H, d, J=8.9 Hz), 8.12 (1H, d, J=8.6 Hz).

5 [0807]

Example 381

Synthesis of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)-butoxy]-quinolin-2-yl hexyl carbonate

[0808]



10

[0809]

To a solution of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)-butoxy]-1H-quinolin-2-one (800 mg) synthesized in the same manner as in WO2006/112464 (Example 1) in dichloromethane (20 ml) was added triethylamine (0.65 ml), with stirring under ice-cooling, hexylchloroformate (0.6 g) was added at room temperature overnight. Water was added to the reaction mixture and the mixture was extracted with ethyl acetate. The organic layer was dried over sodium sulfate. The solvent was

20

evaporated under reduced pressure and the residue was purified by silica gel column chromatography (ethyl acetate:n-hexane=1:2) to give 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)-butoxy]-quinolin-2-yl hexyl carbonate (1.09 g).

oil: colorless

25

¹H-NMR (CDCl₃) δ ppm : 0.91 (3H, t, J=7.0 Hz), 1.30-1.50 (6H, m), 1.70-1.84 (4H, m), 1.88-1.98 (2H, m), 2.54 (2H, t, J=7.5 Hz), 2.72 (4H, br), 3.20 (4H, br), 4.15 (2H, t, J=6.4 Hz), 4.30 (2H, t, J=6.7 Hz), 6.90 (1H, dd, J=0.4, 7.6 Hz), 7.08 (1H, d, J=8.6 Hz), 7.20 (1H, dd, J=2.4, 8.9 Hz), 7.27 (1H, t, J=7.8 Hz), 7.33 (1H, d, J=2.4 Hz), 7.36-7.44 (2H, m), 7.54 (1H, d, J=8.0 Hz), 7.72 (1H, d, J=9.0 Hz), 8.15 (1H, d, J=8.6 Hz)


30

[0810]

Example 382

Synthesis of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)-butoxy]-quinolin-2-yl diethylcarbamate

5 [0811]



[0812]

To a solution of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)-butoxy]-1H-quinolin-2-one (800 mg) synthesized in the same manner as in WO2006/112464 (Example 1) in dichloromethane (20 ml) was added triethylamine (0.65 ml), with stirring under ice-cooling, diethylcarbamoylchloride (0.5 g) was added and the mixture was stirred at room temperature overnight. Water was added to the reaction mixture and the mixture was extracted with ethyl acetate. The organic layer was dried over sodium sulfate. The solvent was evaporated under reduced pressure and the residue was purified by silica gel column chromatography (ethyl acetate:n-hexane=20:1) to give 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)-butoxy]-quinolin-2-yl diethylcarbamate (120 mg).


oil: colorless

¹H-NMR (CDCl₃) δ ppm : 1.23 (3H, t, J=7.1 Hz), 1.30 (3H, t, J=7.1 Hz), 1.72-1.84 (2H, m), 1.86-1.98 (2H, m), 2.54 (2H, t, J=7.5 Hz), 2.73 (4H, br), 3.20 (4H, br), 3.43 (2H, q, J=7.0 Hz), 3.52 (2H, q, J=7.1 Hz), 4.13 (2H, t, J=6.3 Hz), 6.89 (1H, d, J=7.2 Hz), 7.08 (1H, d, J=8.6 Hz), 7.16 (1H, dd, J=2.5, 8.9 Hz), 7.26 (1H, t, J=7.8 Hz), 7.34 (1H, d, J=2.4 Hz), 7.36-7.44 (2H, m), 7.54 (1H, d, J=7.9 Hz), 7.68 (1H, d, J=8.9 Hz), 8.09 (1H, d, J=8.6 Hz)

30 [0813]

Example 383

Synthesis of 4-(benzo[b]thiophen-4-yl)-1-(dodecanoyloxymethyl)-1-(4-(2-oxo-1,2-dihydroquinolin-7-yloxy)butyl)piperazin-1-ium iodide
[0814]



[0815]

To a solution of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)-butoxy]-1H-quinolin-2-one (0.85 g) synthesized in the same manner as in WO2006/112464 (Example 1) in dichloromethane (20 ml) was added iodomethyldodecanoate (1 g) synthesized in the same manner as in Reference Example 19, and the mixture was stirred at room temperature overnight. The solvent was evaporated under reduced pressure, ether was added and the mixture was left standing. The obtained crystals were collected by filtration to give 4-(benzo[b]thiophen-4-yl)-1-(dodecanoyloxymethyl)-1-(4-(2-oxo-1,2-dihydroquinolin-7-yloxy)butyl)piperazin-1-ium iodide (1.07 g).


powder :yellow

¹H-NMR (DMSO-d₆) δ ppm : 0.84 (3H, t, J=6.8 Hz), 1.10-2.56 (24H, m), 3.44-3.56 (4H, m), 3.60-3.90 (6H, m), 4.09 (2H, t, J=5.5 Hz), 5.57 (2H, s), 6.31 (1H, d, J=9.4 Hz), 6.80-6.86 (2H, m), 7.05 (1H, d, J=7.6 Hz), 7.35 (1H, t, J=7.9 Hz), 7.54 (1H, d, J=5.5 Hz), 7.56-7.62 (1H, m), 7.68-7.86 (3H, m), 11.63 (1H, s)

[0816]

Example 384

Synthesis of (7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-2-oxoquinolin-1(2H)-yl)methyl octyl carbonate
[0817]



[0818]

In the same manner as in Example 175, the compound was obtained (yield 25 mg, 8.7%) as a colorless oil.


¹H-NMR (CDCl₃) δ ppm : 0.86 (3H, t, J=6.9 Hz), 1.16-1.40 (10H, m), 1.58-1.72 (2H, m), 1.72-1.84 (2H, m), 1.85-1.95 (2H, m), 2.55 (2H, t, J=7.5 Hz), 2.68-2.80 (4H, br), 3.14-3.26 (4H, br), 4.10 (2H, t, J=6.2 Hz), 4.18 (2H, t, J=6.7 Hz), 6.35 (2H, s), 6.50 (1H, d, J=9.5 Hz), 6.84 (1H, dd, J=2.2, 8.6 Hz), 6.89 (1H, d, J=7.6 Hz), 6.93 (1H, d, J=2.1 Hz), 7.27 (1H, t, J=7.8 Hz), 7.36-7.46 (3H, m), 7.55 (1H, d, J=8.0 Hz), 7.61 (1H, d, J=9.5 Hz)

[0819]

Example 385

Synthesis of carbonic acid 7-[4-(4-benzo[b]thiophen-4-yl)piperazin-1-yl]butoxy]-2-oxo-2H-quinolin-1-ylmethyl ester cyclohexyl ester hydrochloride

[0820]



[0821]

Sodium hydride (55% oil) (0.962 g, 22.04 mmol) was suspended in tetrahydrofuran (THF) (200 ml), 7-[4-(4-benzo[b]thiophen-4-yl)piperazin-1-yl]butoxy]-1H-quinolin-2-one (8.31 g, 19.17 mmol) was added and the mixture was stirred at 50°C for 1 hr. The mixture was cooled to 0°C, chloromethyl cyclohexyl carbonate (4.80 g, 24.92 mmol) was added dropwise

and the mixture was stirred at room temperature overnight.

After cooling to 0°C, excess 2N hydrochloric acid was added to quench the reaction. The precipitated solid was collected by

filtration and dried. In addition, the filtrate was extracted

5 with ethyl acetate. The organic layer was concentrated and

purified by moderate-pressure silica gel column chromatography

(methylene chloride: methanol =100:0 to 20:1). Likewise, the

solid was purified by moderate-pressure silica gel column

chromatography. Concentration under reduced pressure gave the







10 title compound (yield, 5.04 g, 42%) as a white solid.

¹H-NMR (DMSO-d₆) δ ppm : 1.16 (m, 6H), 1.59-1.69 (m, 2H), 1.80 (m, 6H), 3.00-3.60 (m, 10H), 4.19 (t, J = 5.9 Hz, 2H), 4.57-4.65 (m, 1H), 6.29 (s, 2H), 6.42 (d, J = 9.5 Hz, 1H), 6.97 (dd, J = 2.3, 8.5 Hz, 1H), 6.98 (dd, J = 1.8, 7.7 Hz, 1H), 7.04 (d, J = 2.3 Hz, 1H), 7.31 (dd, J = 7.7, 7.7 Hz, 1H), 7.43 (dd, J = 1.8, 5.5 Hz, 1H), 7.63-7.71 (m, 3H), 7.86 (d, J = 9.5 Hz, 1H).

In the same manner as in the above-mentioned Examples, the compounds described in the following Table 2 can be synthesized.

[0822]









Table 2









Example	Structure Formula	
386		(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-2-oxoquinolin-1(2H)-yl)methyl dipropylcarbamate
387		(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-2-oxoquinolin-1(2H)-yl)methyl diisobutylcarbamate
388		(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-2-oxoquinolin-1(2H)-yl)methyl dihexylcarbamate
389		(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-2-oxoquinolin-1(2H)-yl)methyl nonadecylcarbonate
390		(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-2-oxoquinolin-1(2H)-yl)methyl methyl(nonyl)carbamate
391		(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-2-oxoquinolin-1(2H)-yl)methyl methyl(tetradecyl)carbamate








392		(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-2-oxoquinolin-1(2H)-yl)methyl ditetradecylcarbamate
393		(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-2-oxoquinolin-1(2H)-yl)methyl dinonylcarbamate
394		(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-2-oxoquinolin-1(2H)-yl)methyl 2,2-dimethyldecanoate
395		1-(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-2-oxoquinolin-1(2H)-yl)-2-ethoxy-2-oxoethyl decanoate
396		(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-2-oxoquinolin-1(2H)-yl)methyl 2,2-dimethyloctanoate
397		1-(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-2-oxoquinolin-1(2H)-yl)ethyl butyrate
398		1-(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-2-oxoquinolin-1(2H)-yl)ethyl 3-methylbutanoate
399		1-(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-2-oxoquinolin-1(2H)-yl)ethyl hexanoate








400		(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-2-oxoquinolin-1(2H)-yl)methyl 2-hydroxyethylcarbamate
401		(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-2-oxoquinolin-1(2H)-yl)methyl bis(2-hydroxyethyl)carbamate
402		(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-2-oxoquinolin-1(2H)-yl)methyl 4-methylpiperazine-1-carboxylate
403		(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-2-oxoquinolin-1(2H)-yl)methyl 1,4'-bipiperidine-1'-carboxylate
404		calcium 1-(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-2-oxoquinolin-1(2H)-yl)-2-methylpropyl phosphate
405		1-(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-2-oxoquinolin-1(2H)-yl)ethyl dimethylcarbamate
406		1-(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-2-oxoquinolin-1(2H)-yl)ethyl methyl(tetradecyl)carbamate

407		(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-2-oxoquinolin-1(2H)-yl)methyl 4-acetamidobutanoate
408		(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-2-oxoquinolin-1(2H)-yl)methyl 4-heptanamidobutanoate
409		1-(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-2-oxoquinolin-1(2H)-yl)ethyl dinonylcarbamate
410		1-(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-2-oxoquinolin-1(2H)-yl)ethyl ditetradecylcarbamate
411		(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-2-oxoquinolin-1(2H)-yl)methyl 4-heptanamidobutanoate
412		(5Z,8Z,11Z,14Z,17Z)-(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-2-oxoquinolin-1(2H)-yl)methyl henicososa-5,8,11,14,17-pentaenoate








413		(7Z,10Z,13Z,16Z,19Z)-(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-2-oxoquinolin-1(2H)-yl)methyl pentacos-7,10,13,16,19-pentaenoate
414		(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yloxy)methyl acetate
415		(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yloxy)methyl propionate
416		(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yloxy)methyl butyrate
417		(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yloxy)methyl pentanoate
418		(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yloxy)methyl hexanoate
419		(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yloxy)methyl heptanoate
420		(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yloxy)methyl octanoate







421		(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yloxy)methyl nonanoate
422		(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yloxy)methyl decanoate
423		(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yloxy)methyl undecanoate
424		(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yloxy)methyl tridecanoate
425		(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yloxy)methyl tetradecanoate
426		(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yloxy)methyl pentadecanoate
427		(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yloxy)methyl palmitate
428		(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yloxy)methyl heptadecanoate








429		(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yloxy)methyl stearate
430		(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yloxy)methyl icosanoate
431		(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yloxy)methyl 2,2-dimethyltetradecanoate
432		(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yloxy)methyl pivalate
433		(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yloxy)methyl 2,2-dimethylbutanoate
434		(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yloxy)methyl isobutyrate
435		(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yloxy)methyl 2-hydroxyacetate







436		(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yloxy)methyl cyclopropanecarboxylate
437		(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yloxy)methyl cyclobutanecarboxylate
438		(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yloxy)methyl cyclopentanecarboxylate
439		(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yloxy)methyl cyclohexanecarboxylate
440		(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yloxy)methyl benzoate
441		(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yloxy)methyl 2-phenylacetate
442		(9Z,12Z,15Z)-(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yloxy)methyl octadeca-9,12,15-trienoate










443		(5Z,8Z,11Z,14Z,17Z)-(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yloxy)methyl henicosa-5,8,11,14,17-pentaenoate
444		(4Z,7Z,10Z,13Z,16Z,19Z)-(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yloxy)methyl docosa-4,7,10,13,16,19-hexaenoate
445		(6Z,9Z,12Z,15Z)-(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yloxy)methyl octadeca-6,9,12,15-tetraenoate
446		(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yloxy)methyl methyl carbonate
447		(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yloxy)methyl ethyl carbonate
448		(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yloxy)methyl butyl carbonate










449		(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yloxy)methyl pentyl carbonate
450		(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yloxy)methyl 2-methoxyethyl carbonate
451		calcium (7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yloxy)methyl phosphate
452		(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yloxy)methyl methylcarbamate
453		(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yloxy)methyl ethylcarbamate
454		(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yloxy)methyl propylcarbamate
455		(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yloxy)methyl butylcarbamate










456		(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yloxy)methyl pentylcarbamate
457		(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yloxy)methyl hexylcarbamate
458		(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yloxy)methyl octylcarbamate
459		(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yloxy)methyl dodecylcarbamate
460		(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yloxy)methyl tetradecylcarbamate
461		(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yloxy)methyl hexadecylcarbamate
462		(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yloxy)methyl dimethylcarbamate









463		(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yloxy)methyl diethylcarbamate
464		(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yloxy)methyl dipropylcarbamate
465		(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yloxy)methyl diisobutylcarbamate
466		(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yloxy)methyl dibutylcarbamate
467		(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yloxy)methyl dihexylcarbamate
468		(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yloxy)methyl dioctylcarbamate
469		(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yloxy)methyl didecylcarbamate










470		(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yloxy)methyl didodecylcarbamate
471		(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yloxy)methyl ditetradecylcarbamate
472		(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yloxy)methyl dihexadecylcarbamate
473		(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yloxy)methyl bis(2-hydroxyethyl)carbamate
474		(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yloxy)methyl piperidine-1-carboxylate
475		(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yloxy)methyl 4-methylpiperazine-1-carboxylate








476		(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yl)oxy)methyl 1,4'-bipiperidine-1'-carboxylate
477		1-acetyl-7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2(1H)-one
478		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-1-propionylquinolin-2(1H)-one
479		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-1-butyrylquinolin-2(1H)-one
480		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-1-pentanoylquinolin-2(1H)-one
481		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-1-(3-methylbutanoyl)quinolin-2(1H)-one
482		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-1-hexanoylquinolin-2(1H)-one
483		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-1-hexanoyl-3,4-dihydroquinolin-2(1H)-one
484		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-1-heptanoylquinolin-2(1H)-one







485		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-1-octanoylquinolin-2(1H)-one
486		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-1-octanoyl-3,4-dihydroquinolin-2(1H)-one
487		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-1-nonanoylquinolin-2(1H)-one
488		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-1-decanoylquinolin-2(1H)-one
489		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-1-undecanoylquinolin-2(1H)-one
490		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-1-dodecanoylquinolin-2(1H)-one
491		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-1-tridecanoylquinolin-2(1H)-one
492		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-1-tetradecanoylquinolin-2(1H)-one
493		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-1-pentadecanoylquinolin-2(1H)-one

494		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-1-palmitoylquinolin-2(1H)-one
495		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-1-heptadecanoylquinolin-2(1H)-one
496		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-1-stearoylquinolin-2(1H)-one
497		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-1-nonadecanoylquinolin-2(1H)-one
498		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-1-icosanoylquinolin-2(1H)-one
499		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-1-henicosanoylquinolin-2(1H)-one
500		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-1-docosanoylquinolin-2(1H)-one
501		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-1-tricosanoylquinolin-2(1H)-one
502		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-1-tetracosanoylquinolin-2(1H)-one







503		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-1-(2-methylbutanoyl)quinolin-2(1H)-one
504		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-1-isobutyrylquinolin-2(1H)-one
505		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-1-isobutyryl-3,4-dihydroquinolin-2(1H)-one
506		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-1-(2-methylpentanoyl)quinolin-2(1H)-one
507		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-1-(2-methylhexanoyl)quinolin-2(1H)-one
508		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-1-(2,2-dimethylhexanoyl)quinolin-2(1H)-one
509		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-1-(2,2-dimethyloctanoyl)quinolin-2(1H)-one
510		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-1-(2,2-dimethyloctanoyl)-3,4-dihydroquinolin-2(1H)-one








511		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-1-(2,2-dimethyldecanoyl)quinolin-2(1H)-one
512		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-1-(2-phenylacetyl)quinolin-2(1H)-one
513		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-1-benzoylquinolin-2(1H)-one
514		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-1-benzoyl-3,4-dihydroquinolin-2(1H)-one
515		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-1-(cyclobutanecarbonyl)quinolin-2(1H)-one
516		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-1-(cyclopentanecarbonyl)quinolin-2(1H)-one
517		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-1-(cyclohexanecarbonyl)quinolin-2(1H)-one
518		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-1-(cycloheptanecarbonyl)quinolin-2(1H)-one
519		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-1-pivaloylquinolin-2(1H)-one








520		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-1-(2-hydroxyacetyl)quinolin-2(1H)-one
521		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-1-(2-hydroxyacetyl)-3,4-dihydroquinolin-2(1H)-one
522		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-1-(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoylquinolin-2(1H)-one
523		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-1-(9Z,12Z,15Z)-octadeca-9,12,15-trienoylquinolin-2(1H)-one
524		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-1-(5Z,8Z,11Z,14Z,17Z)-henicosa-5,8,11,14,17-pentaenoylquinolin-2(1H)-one
525		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-1-(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoylquinolin-2(1H)-one
526		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-1-(7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoylquinolin-2(1H)-one








527		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-1-(4Z,7Z,10Z,13Z,16Z)-docosa-4,7,10,13,16-pentaenoylquinolin-2(1H)-one
528		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-1-(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoylquinolin-2(1H)-one
529		2-amino-N-(2-(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-2-oxoquinolin-1(2H)-yl)-2-oxoethyl)acetamide
530		2-amino-N-(2-(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-2-oxoquinolin-1(2H)-yl)-2-oxoethyl)propanamide
531		2-amino-N-(2-(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-2-oxoquinolin-1(2H)-yl)-2-oxoethyl)-3-methylbutanamide
532		2-amino-N-(2-(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-2-oxoquinolin-1(2H)-yl)-2-oxoethyl)-4-methylpentanamide

533		N-(4-(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-2-oxoquinolin-1(2H)-yl)-4-oxobutyl)acetamide
534		N-(4-(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-2-oxo-3,4-dihydroquinolin-1(2H)-yl)-4-oxobutyl)acetamide
535		N-(4-(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-2-oxoquinolin-1(2H)-yl)-4-oxobutyl)heptanamide
536		1-(2-aminoacetyl)-7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2(1H)-one
537		1-(2-aminopropanoyl)-7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2(1H)-one
538		1-(2-amino-4-methylpentanoyl)-7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2(1H)-one
539		2-amino-N-(2-(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-2-oxoquinolin-1(2H)-yl)-2-oxoethyl)acetamide








540		2-amino-N-(1-(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-2-oxoquinolin-1(2H)-yl)-3-methyl-1-oxobutan-2-yl)acetamide
541		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-1-(pyrrolidine-2-carbonyl)quinolin-2(1H)-one
542		1-(1-(2-aminoacetyl)pyrrolidine-2-carbonyl)-7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2(1H)-one
543		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-1-(2-(2-methoxyethoxy)acetyl)quinolin-2(1H)-one
544		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-1-(2-(2-methoxyethoxy)acetyl)-3,4-dihydroquinolin-2(1H)-one
545		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-1-(2-(2-(2-methoxyethoxy)ethoxy)acetyl)quinolin-2(1H)-one









546		methyl 7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-2-oxoquinoline-1(2H)-carboxylate
547		methyl 7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-2-oxo-3,4-dihydroquinoline-1(2H)-carboxylate
548		ethyl 7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-2-oxoquinoline-1(2H)-carboxylate
549		propyl 7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-2-oxoquinoline-1(2H)-carboxylate
550		propyl 7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-2-oxo-3,4-dihydroquinoline-1(2H)-carboxylate
551		isobutyl 7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-2-oxoquinoline-1(2H)-carboxylate
552		butyl 7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-2-oxoquinoline-1(2H)-carboxylate









553		pentyl 7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-2-oxoquinoline-1(2H)-carboxylate
554		pentyl 7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-2-oxo-3,4-dihydroquinoline-1(2H)-carboxylate
555		hexyl 7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-2-oxoquinoline-1(2H)-carboxylate
556		isopentyl 7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-2-oxoquinoline-1(2H)-carboxylate
557		isopropyl 7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-2-oxoquinoline-1(2H)-carboxylate
558		isopropyl 7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-2-oxo-3,4-dihydroquinoline-1(2H)-carboxylate
559		cyclohexyl 7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-2-oxoquinoline-1(2H)-carboxylate

560		cyclohexyl 7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-2-oxo-3,4-dihydroquinoline-1(2H)-carboxylate
561		heptyl 7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-2-oxoquinoline-1(2H)-carboxylate
562		heptyl 7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-2-oxo-3,4-dihydroquinoline-1(2H)-carboxylate
563		octyl 7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-2-oxoquinoline-1(2H)-carboxylate
564		nonyl 7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-2-oxoquinoline-1(2H)-carboxylate
565		decyl 7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-2-oxoquinoline-1(2H)-carboxylate
566		undecyl 7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-2-oxoquinoline-1(2H)-carboxylate

567		undecyl 7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-2-oxo-3,4-dihydroquinoline-1(2H)-carboxylate
568		dodecyl 7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-2-oxoquinoline-1(2H)-carboxylate
569		tridecyl 7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-2-oxoquinoline-1(2H)-carboxylate
570		tetradecyl 7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-2-oxoquinoline-1(2H)-carboxylate
571		pentadecyl 7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-2-oxoquinoline-1(2H)-carboxylate
572		hexadecyl 7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-2-oxoquinoline-1(2H)-carboxylate
573		heptadecyl 7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-2-oxoquinoline-1(2H)-carboxylate

574		octadecyl 7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-2-oxoquinoline-1(2H)-carboxylate
575		nonadecyl 7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-2-oxoquinoline-1(2H)-carboxylate
576		icosyl 7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-2-oxoquinoline-1(2H)-carboxylate
577		henicosyl 7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-2-oxoquinoline-1(2H)-carboxylate
578		docosyl 7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-2-oxoquinoline-1(2H)-carboxylate
579		benzyl 7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-2-oxoquinoline-1(2H)-carboxylate
580		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-N-benzyl-2-oxoquinoline-1(2H)-carboxamide

581		calcium 7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-2-oxoquinolin-1(2H)-yl phosphate
582		calcium 7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-2-oxo-3,4-dihydroquinolin-1(2H)-yl phosphate
583		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-N-methyl-2-oxoquinoline-1(2H)-carboxamide
584		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-N-methyl-2-oxo-3,4-dihydroquinoline-1(2H)-carboxamide
585		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-N-ethyl-2-oxoquinoline-1(2H)-carboxamide
586		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-2-oxo-N-propylquinoline-1(2H)-carboxamide
587		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-N-butyl-2-oxoquinoline-1(2H)-carboxamide
588		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-2-oxo-N-pentylquinoline-1(2H)-carboxamide









589		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-N-hexyl-2-oxoquinoline-1(2H)-carboxamide
590		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-N-heptyl-2-oxoquinoline-1(2H)-carboxamide
591		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-N-heptyl-2-oxo-3,4-dihydroquinoline-1(2H)-carboxamide
592		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-N-octyl-2-oxoquinoline-1(2H)-carboxamide
593		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-N-nonyl-2-oxoquinoline-1(2H)-carboxamide
594		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-N-decyl-2-oxoquinoline-1(2H)-carboxamide
595		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-N-(2-hydroxyethyl)-2-oxoquinoline-1(2H)-carboxamide
596		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-N,N-dimethyl-2-oxoquinoline-1(2H)-carboxamide

597		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-N,N-dimethyl-2-oxo-3,4-dihydroquinoline-1(2H)-carboxamide
598		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-N,N-diethyl-2-oxoquinoline-1(2H)-carboxamide
599		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-2-oxo-N,N-dipropylquinoline-1(2H)-carboxamide
600		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-N,N-dibutyl-2-oxoquinoline-1(2H)-carboxamide
601		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-2-oxo-N,N-dipentylquinoline-1(2H)-carboxamide
602		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-N,N-dihexyl-2-oxoquinoline-1(2H)-carboxamide
603		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-N,N-diheptyl-2-oxoquinoline-1(2H)-carboxamide
604		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-N,N-diheptyl-2-oxo-3,4-dihydroquinoline-1(2H)-carboxamide

605		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-N,N-dinonyl-2-oxoquinoline-1(2H)-carboxamide
606		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-2-oxo-N,N-ditetradecylquinoline-1(2H)-carboxamide
607		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-N-methyl-2-oxo-N-tetradecylquinoline-1(2H)-carboxamide
608		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-N-methyl-N-nonyl-2-oxoquinoline-1(2H)-carboxamide
609		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-1-(morpholine-4-carbonyl)quinolin-2(1H)-one
610		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-1-(morpholine-4-carbonyl)-3,4-dihydroquinolin-2(1H)-one
611		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-N,N-bis(2-hydroxyethyl)-2-oxoquinoline-1(2H)-carboxamide









612		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-N,N-dibenzyl-2-oxoquinoline-1(2H)-carboxamide
613		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-1-(4-methylpiperazine-1-carbonyl)quinolin-2(1H)-one
614		1-(1,4'-bipiperidine-1'-carbonyl)-7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2(1H)-one
615		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-1-(cyclopropanecarbonyl)quinolin-2(1H)-one
616		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yl propionate
617		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yl butyrate
618		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yl pentanoate
619		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yl hexanoate

620		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yl heptanoate
621		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yl octanoate
622		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yl nonanoate
623		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yl decanoate
624		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yl undecanoate
625		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yl tridecanoate
626		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yl tetradecanoate
627		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yl pentadecanoate









628		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yl palmitate
629		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yl heptadecanoate
630		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yl stearate
631		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yl icosanoate
632		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yl 2,2-dimethyltetradecanoate
633		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yl pivalate
634		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yl 2,2-dimethylbutanoate
635		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yl isobutyrate








636		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yl 2-hydroxyacetate
637		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yl cyclopropanecarboxylate
638		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yl cyclobutanecarboxylate
639		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yl cyclopentanecarboxylate
640		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yl benzoate
641		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yl 2-phenylacetate
642		(9Z,12Z,15Z)-7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yl octadeca-9,12,15-trienoate
643		(5Z,8Z,11Z,14Z,17Z)-7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yl henicosa-5,8,11,14,17-pentaenoate








644		(4Z,7Z,10Z,13Z,16Z,19Z)-7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yl docosa-4,7,10,13,16,19-hexaenoate
645		(6Z,9Z,12Z,15Z)-7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yl octadeca-6,9,12,15-tetraenoate
646		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yl methyl carbonate
647		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yl ethyl carbonate
648		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yl butyl carbonate
649		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yl pentyl carbonate
650		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yl cyclohexyl carbonate







651		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yl 2-methoxyethyl carbonate
652		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yl diethyl phosphate
653		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yl methylcarbamate
654		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yl ethylcarbamate
655		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yl propylcarbamate
656		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yl butylcarbamate
657		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yl pentylcarbamate
658		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yl hexylcarbamate

659		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yl octylcarbamate
660		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yl decylcarbamate
661		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yl dodecylcarbamate
662		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yl tetradecylcarbamate
663		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yl hexadecylcarbamate
664		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yl dimethylcarbamate
665		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yl dipropylcarbamate
666		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yl diisobutylcarbamate






667		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yl dibutylcarbamate
668		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yl dihexylcarbamate
669		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yl dioctylcarbamate
670		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yl didecylcarbamate
671		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yl didodecylcarbamate
672		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yl ditetradecylcarbamate
673		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yl dihexadecylcarbamate
674		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yl bis(2-hydroxyethyl)carbamate

675		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yl piperidine-1-carboxylate
676		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yl 4-methylpiperazine-1-carboxylate
677		7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yl 1,4'-bipiperidine-1'-carboxylate
678		4-(benzo[b]thiophen-4-yl)-1-(4-(2-oxo-1,2-dihydroquinolin-7-yloxy)butyl)-1-(propionyloxymethyl)piperazin-1-ium chloride
679		4-(benzo[b]thiophen-4-yl)-1-(4-(2-oxo-1,2-dihydroquinolin-7-yloxy)butyl)piperazin-1-ium chloride
680		4-(benzo[b]thiophen-4-yl)-1-(4-(2-oxo-1,2-dihydroquinolin-7-yloxy)butyl)-1-(pentanoyloxymethyl)piperazin-1-ium chloride
681		4-(benzo[b]thiophen-4-yl)-1-(4-(2-oxo-1,2-dihydroquinolin-7-yloxy)butyl)piperazin-1-ium chloride








682		4-(benzo[b]thiophen-4-yl)-1-(heptanoyloxymethyl)-1-(4-(2-oxo-1,2-dihydroquinolin-7-yloxy)butyl)piperazin-1-ium chloride
683		4-(benzo[b]thiophen-4-yl)-1-(octanoyloxymethyl)-1-(4-(2-oxo-1,2-dihydroquinolin-7-yloxy)butyl)piperazin-1-ium chloride
684		4-(benzo[b]thiophen-4-yl)-1-(nonanoyloxymethyl)-1-(4-(2-oxo-1,2-dihydroquinolin-7-yloxy)butyl)piperazin-1-ium chloride
685		4-(benzo[b]thiophen-4-yl)-1-(decanoyloxymethyl)-1-(4-(2-oxo-1,2-dihydroquinolin-7-yloxy)butyl)piperazin-1-ium chloride
686		4-(benzo[b]thiophen-4-yl)-1-(undecanoyloxymethyl)-1-(4-(2-oxo-1,2-dihydroquinolin-7-yloxy)butyl)piperazin-1-ium iodide
687		4-(benzo[b]thiophen-4-yl)-1-(tetradecanoyloxymethyl)piperazin-1-ium iodide
688		4-(benzo[b]thiophen-4-yl)-1-(palmitoyloxymethyl)-1-(4-(2-oxo-1,2-dihydroquinolin-7-yloxy)butyl)piperazin-1-ium iodide







689		4-(benzo[b]thiophen-4-yl)-1-(4-(2-oxo-1,2-dihydroquinolin-7-yloxy)butyl)-1-(stearoyloxymethyl)piperazin-1-ium iodide
690		4-(benzo[b]thiophen-4-yl)-1-(icosanoyloxymethyl)-1-(4-(2-oxo-1,2-dihydroquinolin-7-yloxy)butyl)piperazin-1-ium iodide
691		4-(benzo[b]thiophen-4-yl)-1-(docosanoyloxymethyl)-1-(4-(2-oxo-1,2-dihydroquinolin-7-yloxy)butyl)piperazin-1-ium iodide
692		4-(benzo[b]thiophen-4-yl)-1-(cyclopentanecarbonyloxymethyl)-1-(4-(2-oxo-1,2-dihydroquinolin-7-yloxy)butyl)piperazin-1-ium iodide
693		4-(benzo[b]thiophen-4-yl)-1-(cyclohexanecarbonyloxymethyl)-1-(4-(2-oxo-1,2-dihydroquinolin-7-yloxy)butyl)piperazin-1-ium iodide
694		4-(benzo[b]thiophen-4-yl)-1-(isobutyryloxymethyl)-1-(4-(2-oxo-1,2-dihydroquinolin-7-yloxy)butyl)piperazin-1-ium chloride

695		4-(benzo[b]thiophen-4-yl)-1-(4-(2-oxo-1,2-dihydroquinolin-7-yloxy)butyl)-1-((2-propylpentanoyloxy)methyl)piperazin-1-ium iodide
696		4-(benzo[b]thiophen-4-yl)-1-(4-(2-oxo-1,2-dihydroquinolin-7-yloxy)butyl)-1-((2-pentylheptanoyloxy)methyl)piperazin-1-ium iodide
697		4-(benzo[b]thiophen-4-yl)-1-(4-(2-oxo-1,2-dihydroquinolin-7-yloxy)butyl)-1-(pivaloyloxymethyl)piperazin-1-ium chloride
698		4-(benzo[b]thiophen-4-yl)-1-((2,2-dimethylbutanoyloxy)methyl)-1-(4-(2-oxo-1,2-dihydroquinolin-7-yloxy)butyl)piperazin-1-ium iodide
699		4-(benzo[b]thiophen-4-yl)-1-((2,2-dimethylpentanoyloxy)methyl)-1-(4-(2-oxo-1,2-dihydroquinolin-7-yloxy)butyl)piperazin-1-ium iodide

700		4-(benzo[b]thiophen-4-yl)-1-((2,2-dimethylhexanoyloxy)methyl)-1-(4-(2-oxo-1,2-dihydroquinolin-7-yloxy)butyl)piperazin-1-ium iodide
701		4-(benzo[b]thiophen-4-yl)-1-((2,2-dimethyltetradecanoyloxy)methyl)-1-(4-(2-oxo-1,2-dihydroquinolin-7-yloxy)butyl)piperazin-1-ium iodide
702		4-(benzo[b]thiophen-4-yl)-1-((1-methylcyclohexanecarbonyloxy)methyl)-1-(4-(2-oxo-1,2-dihydroquinolin-7-yloxy)butyl)piperazin-1-ium iodide
703		4-(benzo[b]thiophen-4-yl)-1-((hexylcarbamoyloxy)methyl)-1-(4-(2-oxo-1,2-dihydroquinolin-7-yloxy)butyl)piperazin-1-ium iodide
704		4-(benzo[b]thiophen-4-yl)-1-((diethylcarbamoyloxy)methyl)-1-(4-(2-oxo-1,2-dihydroquinolin-7-yloxy)butyl)piperazin-1-ium iodide

705		4-(benzo[b]thiophen-4-yl)-1-((dibenzylcarbamoyloxy)methyl)-1-(4-(2-oxo-1,2-dihydroquinolin-7-yloxy)butyl)piperazin-1-ium iodide
706		4-(benzo[b]thiophen-4-yl)-1-(4-(2-oxo-1,2-dihydroquinolin-7-yloxy)butyl)-1-((piperidine-1-carbonyloxy)methyl)piperazin-1-ium iodide
707		4-(benzo[b]thiophen-4-yl)-1-((ethoxycarbonyloxy)methyl)-1-(4-(2-oxo-1,2-dihydroquinolin-7-yloxy)butyl)piperazin-1-ium chloride
708		4-(benzo[b]thiophen-4-yl)-1-((cyclohexyloxycarbonyloxy)methyl)-1-(4-(2-oxo-1,2-dihydroquinolin-7-yloxy)butyl)piperazin-1-ium chloride
709		4-(benzo[b]thiophen-4-yl)-1-((hexyloxycarbonyloxy)methyl)-1-(4-(2-oxo-1,2-dihydroquinolin-7-yloxy)butyl)piperazin-1-ium iodide
710		4-(benzo[b]thiophen-4-yl)-1-(4-(2-oxo-1,2-dihydroquinolin-7-yloxy)butyl)-1-(((pentan-3-yloxy)carbonyloxy)methyl)piperazin-1-ium iodide

711		4-(benzo[b]thiophen-4-yl)-1-(benzoyloxymethyl)-1-(4-(2-oxo-1,2-dihydroquinolin-7-yloxy)butyl)piperazin-1-ium chloride
712		4-(benzo[b]thiophen-4-yl)-1-(4-(2-oxo-1,2-dihydroquinolin-7-yloxy)butyl)-1-((2-phenylacetoxy)methyl)piperazin-1-ium chloride
713		bis((7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-2-oxoquinolin-1(2H)-yl)methyl)succinate
714		bis((7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-2-oxo-3,4-dihydroquinolin-1(2H)-yl)methyl)succinate
715		bis((7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-2-oxoquinolin-1(2H)-yl)methyl)glutarate
716		bis((7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-2-oxo-3,4-dihydroquinolin-1(2H)-yl)methyl)glutarate
717		bis((7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-2-oxoquinolin-1(2H)-yl)methyl)adipate







718		bis((7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-2-oxo-3,4-dihydroquinolin-1(2H)-yl)methyl) adipate
719		bis((7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-2-oxoquinolin-1(2H)-yl)methyl) heptanedioate
720		bis((7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-2-oxo-3,4-dihydroquinolin-1(2H)-yl)methyl) heptanedioate
721		bis((7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-2-oxoquinolin-1(2H)-yl)methyl) octanedioate
722		bis((7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-2-oxo-3,4-dihydroquinolin-1(2H)-yl)methyl) octanedioate
723		bis((7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-2-oxoquinolin-1(2H)-yl)methyl) decanedioate








724		bis((7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-2-oxo-3,4-dihydroquinolin-1(2H)-yl)methyl)decanedioate
725		bis((7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-2-oxoquinolin-1(2H)-yl)methyl)dodecanedioate
726		bis((7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-2-oxo-3,4-dihydroquinolin-1(2H)-yl)methyl)dodecanedioate
727		bis((7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-2-oxoquinolin-1(2H)-yl)methyl)tetradecanedioate
728		bis((7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-2-oxo-3,4-dihydroquinolin-1(2H)-yl)methyl)tetradecanedioate
729		bis((7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-2-oxoquinolin-1(2H)-yl)methyl)hexadecanedioate

730		bis((7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-2-oxo-3,4-dihydroquinolin-1(2H)-yl)methyl)hexadecanedioate
731		bis((7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-2-oxoquinolin-1(2H)-yl)methyl)octadecanedioate
732		bis((7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-2-oxo-3,4-dihydroquinolin-1(2H)-yl)methyl)octadecanedioate
733		bis((7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-2-oxoquinolin-1(2H)-yl)methyl)icosanedioate
734		bis((7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-2-oxo-3,4-dihydroquinolin-1(2H)-yl)methyl)icosanedioate
735		bis((7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-2-oxoquinolin-1(2H)-yl)methyl)docosanedioate

736		bis((7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)-2-oxo-3,4-dihydroquinolin-1(2H)-yl)methyl) docosanedioate
737		bis((7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yloxy)methyl) succinate
738		bis((7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yloxy)methyl) glutarate
739		bis((7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yloxy)methyl) adipate
740		bis((7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yloxy)methyl) heptanedioate
741		bis((7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yloxy)methyl) octanedioate

742		bis((7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yloxy)methyl) decanedioate
743		bis((7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yloxy)methyl) dodecanedioate
744		bis((7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yloxy)methyl) tetradecanedioate
745		bis((7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yloxy)methyl) hexadecanedioate
746		bis((7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yloxy)methyl) octadecanedioate
747		bis((7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yloxy)methyl) icosanedioate

748		bis((7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yl)oxy)methyl) docosanedioate
749		bis(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yl) succinate
750		bis(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yl) glutarate
751		bis(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yl) adipate
752		bis(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yl) heptanedioate
753		bis(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yl) octanedioate

754		bis(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yl)decanedioate
755		bis(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yl)dodecanedioate
756		bis(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yl)tetradecanedioate
757		bis(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yl)hexadecanedioate
758		bis(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yl)octadecanedioate
759		bis(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yl)icosanedioate
760		bis(7-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2-yl)docosanedioate


[0823]

Example A: Synthesis of deuteride of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)-butoxy]-1H-quinolin-2-one

A-1: Synthesis of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)-butoxy-1,1,2,2,3,3,4,4-d₈]-1H-quinolin-2-one
(synthesis method 1)

step 1: Synthesis of 2-benzyloxy-7-(4-bromobutoxy-1,1,2,2,3,3,4,4-d₈)quinoline

[0824]




[0825]

To a mixture of 2-benzyloxy-7-hydroxy quinoline (2.52 g) and potassium carbonate (1.67 g) in dimethylformamide (25 ml) was added 1,4-dibromobutane-d₈ (99.6 atom % D: 2.4 ml), and the mixture was stirred at room temperature overnight. To the reaction mixture was added water, ethyl acetate, the insoluble material was filtered off, and the filtrate was partitioned, washed with water, and dried over sodium sulfate. The solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (n-hexane:ethyl acetate=10:0→9:1) to give 2-benzyloxy-7-(4-bromobutoxy-1,1,2,2,3,3,4,4-d₈)quinoline (3.14 g).

2-benzyloxy-7-(4-bromobutoxy-1,1,2,2,3,3,4,4-d₈)quinoline : white powder, ¹H-NMR (CDCl₃) δ: 5.52 (2H, s), 6.81 (1H, d, J=8.7Hz), 7.02 (1H, dd, J=8.8, 2.5Hz), 7.21 (1H, d, J=2.5Hz), 7.29-7.47 (3H, m), 7.49-7.56 (2H, m), 7.60 (1H, d, J=8.8Hz), 7.91 (1H, d, J=8.7Hz)

step 2: Synthesis of 2-benzyloxy-7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)-butoxy-1,1,2,2,3,3,4,4-d₈]quinoline

[0826]




[0827]

A mixture of 2-benzyloxy-7-(4-bromobutoxy-1,1,2,2,3,3,4,4-d₈)quinoline (3.14 g), 1-benzothiophene-4-piperazine hydrochloride (2.43 g), sodium iodide (1.31 g) and potassium carbonate (2.64 g) in dimethylformamide (60 ml) was stirred at 80°C for 5 hr. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate, washed with water, and dried over sodium sulfate. The solvent was evaporated under reduced pressure and the residue was purified by silica gel column chromatography (n-hexane:ethyl acetate=7:3→5:5) to give 2-benzyloxy-7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)-butoxy-1,1,2,2,3,3,4,4-d₈]quinoline (3.73 g).

2-benzyloxy-7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)-butoxy-1,1,2,2,3,3,4,4-d₈]quinoline: pale-yellow amorphous solid, ¹H-NMR (CDCl₃) δ: 2.64-2.83 (4H, m), 3.14-3.25 (4H, m), 5.53 (2H, s), 6.81 (1H, d, J=8.8Hz), 6.89 (1H, d, J=7.6Hz), 7.03-7.08 (1H, m), 7.25-7.49 (7H, m), 7.50-7.63 (4H, m), 7.91 (1H, d, J=8.8Hz)

step 3: Synthesis of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)-butoxy-1,1,2,2,3,3,4,4-d₈]-1H-quinolin-2-one

[0828]



[0829]

A mixture of 2-benzyloxy-7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)-butoxy-1,1,2,2,3,3,4,4-d₈]quinoline (3.73 g) and 1N hydrochloric acid (35.1 ml) in tetrahydrofuran (60 ml) was stirred at 60°C for 4 hr, and ice-cooled. Ice water was

added, and the mixture was stirred. The precipitated solid was collected by filtration, washed with water and dried under reduced pressure. To a mixture of the obtained powder in ethanol (70 ml) was added under ice-cooling 1N sodium


hydroxide to basify the mixture. The solvent was evaporated under reduced pressure and the residue was washed with water, and recrystallized from a mixture of ethanol and water to give 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)-butoxy-1,1,2,2,3,3,4,4-d₈]-1H-quinolin-2-one (2.29 g).

7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)-butoxy-1,1,2,2,3,3,4,4-d₈]-1H-quinolin-2-one : white powder, ¹H-NMR (DMSO-d₆) δ: 2.54-2.67 (4H, m), 2.91-3.15 (4H, m), 6.29 (1H, d, J=9.5Hz), 6.75-6.83 (2H, m), 6.88 (1H, d, J=7.6Hz), 7.21-7.30 (1H, m), 7.39 (1H, d, J=5.5Hz), 7.50-7.66 (2H, m), 7.69 (1H, d, J=5.5Hz), 7.80 (1H, d, J=9.5Hz), 11.58 (1H, s)

[0830]

(synthesis method 2)

step 1: Synthesis of 7-(4-bromobutoxy-1,1,2,2,3,3,4,4-d₈)-1H-quinolin-2-one




[0832]

To a mixture of 7-hydroxy-1H-quinolin-2-one [70500-72-0] (0.72 g) and potassium carbonate (0.68 g) in dimethylformamide (20 ml) was added 1,4-dibromobutane-d₈ (99.6 atom % D: 3 g), and the mixture was stirred at 50°C for 5 hr. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate, washed with water, and dried over sodium sulfate. The solvent was evaporated under reduced pressure and the residue was purified by silica gel column chromatography (dichloromethane : methanol= 100 : 1) to give 7-(4-

bromobutoxy-1,1,2,2,3,3,4,4-d₈)-1H-quinolin-2-one (1.1 g).

7-(4-bromobutoxy-1,1,2,2,3,3,4,4-d₈)-1H-quinolin-2-one : white powder like, ¹H-NMR (CDCl₃) δ: 6.56 (1H, d, J=9.4Hz), 6.78-6.84 (2H, m), 7.45 (1H, d, J=8.6Hz), 7.74 (1H, d, J=9.4Hz), 12.33 (1H, brs).

step 2: Synthesis of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)-butoxy-1,1,2,2,3,3,4,4-d₈]-1H-quinolin-2-one [0833]



[0834]

A mixture of 7-(4-bromobutoxy-1,1,2,2,3,3,4,4-d₈)-1H-quinolin-2-one (0.4 g), 1-benzothiophene-4-piperazine hydrochloride (0.37 g), potassium carbonate (0.45 g) and dimethylformamide (20 ml) was stirred at 60°C for 6 hr. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate, washed with water, and dried over sodium sulfate. The solvent was evaporated under reduced pressure and the residue was purified by silica gel column chromatography (dichloromethane : methanol= 30 : 1) to give 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)-butoxy-1,1,2,2,3,3,4,4-d₈]-1H-quinolin-2-one (0.3 g).

7-[4-(4-Benzo[b]thiophen-4-yl-piperazin-1-yl)-butoxy-1,1,2,2,3,3,4,4-d₈]-1H-quinolin-2-one same as that synthesized in synthesis method 1 was obtained.

white powder m.p. 177 - 179°C (recrystallized from EtOH)


[0835]

A-2: Synthesis of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)-2,2,3,3,5,5,6,6-d₈]-butoxy-1,1,2,2,3,3,4,4-d₈]-1H-quinolin-2-one

step 1: Synthesis of tert-butyl 4-(benzo[b]thiophen-4-

yl)piperazine-2,2,3,3,5,5,6,6-d₈-1-carboxylate

[0836]



[0837]

5 A mixture of 4-bromo-benzo[b]thiophene [5118-13-8] (0.55 g), tert-butyl 1-piperazine-2,2,3,3,5,5,6,6-d₈-carboxylate (98.3 atom % D : 0.5 g), sodium t-butoxide (0.25 g), (R)-(+)-BINAP (30 mg), tris(dibenzylideneacetone)dipalladium(0) (30 mg) and toluene (20 ml) was heated under reflux under an argon
10 atmosphere for 3 hr. Water was poured into the reaction mixture, and the mixture was extracted with ethyl acetate, washed with water, and dried over magnesium sulfate. The solvent was evaporated under reduced pressure and the residue was purified by silica gel column chromatography (ethyl
15 acetate : n-hexane = 1 : 100) to give tert-butyl 4-(benzo[b]thiophen-4-yl)piperazine-2,2,3,3,5,5,6,6-d₈-1-carboxylate (0.41 g).
tert-butyl 4-(benzo[b]thiophen-4-yl)piperazine-2,2,3,3,5,5,6,6-d₈-1-carboxylate:


20 yellow powder

¹H-NMR (CDCl₃) δ: 1.50 (9H, s), 3.03-3.09 (0.06H, br), 3.59-3.65 (0.06H, br), 6.87 (1H, dd, J=0.8, 7.7Hz), 7.28 (1H, t, J=7.8Hz), 7.41 (2H, s), 7.57 (1H, d, J=8.0Hz).

Confirmed by ¹H-NMR (CDCl₃): at least 98 atom % D.

25 step 2: Synthesis of 1-benzo[b]thiophen-4-yl-piperazine-2,2,3,3,5,5,6,6-d₈

[0838]



[0839]

To a solution of tert-butyl 4-(benzo[b]thiophen-4-yl)piperazine-2,2,3,3,5,5,6,6-d₈-1-carboxylate (0.57 g) in dichloromethane (5 ml) was added trifluoroacetic acid (1 ml) and the mixture was stirred at room temperature for 3 hr. Water was poured into the reaction mixture, alkalified with aqueous sodium hydroxide solution, and the mixture was extracted with dichloromethane, washed with water, and dried over magnesium sulfate. The solvent was evaporated under reduced pressure and the residue was purified by silica gel column chromatography (basic silica gel, ethyl acetate : methanol= 20 : 1) to give 1-benzo[b]thiophen-4-yl-piperazine-2,2,3,3,5,5,6,6-d₈ (0.31 g).


1-benzo[b]thiophen-4-yl-piperazine-2,2,3,3,5,5,6,6-d₈: oil brown

¹H-NMR (CDCl₃) δ: 3.06-3.10 (0.13H, br), 6.88 (1H, dd, J=0.8, 7.6Hz), 7.27 (1H, t, J=7.8Hz), 7.38 (1H, d, J=5.4Hz), 7.42 (1H, dd, J=0.7, 5.5Hz), 7.54 (1H, d, J=8.1Hz).

Confirmed by ¹H-NMR (CDCl₃): at least 98 atom % D.

step 3: Synthesis of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl-2,2,3,3,5,5,6,6-d₈)-butoxy-1,1,2,2,3,3,4,4-d₈]-1H-quinolin-2-one

[0840]



25

[0841]

A mixture of 7-(4-bromobutoxy-1,1,2,2,3,3,4,4-d₈)-1H-

quinolin-2-one (633 mg) obtained in Example A-1, synthesis method 2, step 1, 1-benzo[b]thiophen-4-yl-piperazine-2,2,3,3,5,5,6,6-d₈ (471 mg) obtained in this Example, step 2, potassium carbonate (374 mg) and dimethylformamide (20 ml) was

5 stirred at 60°C for 6 hr. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate, washed with water, and dried over sodium sulfate. The solvent was evaporated under reduced pressure and the residue was purified by silica gel column chromatography

10 (dichloromethane : methanol= 30 : 1) to give 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl-2,2,3,3,5,5,6,6-d₈)-butoxy-1,1,2,2,3,3,4,4-d₈]-1H-quinolin-2-one (0.45 g). 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl-2,2,3,3,5,5,6,6-d₈)-butoxy-1,1,2,2,3,3,4,4-d₈]-1H-quinolin-2-one: yellow powder


15 m.p. 176 - 178°C (recrystallized from EtOH)

¹H-NMR (CDCl₃) δ: 2.64-2.72 (0.06H, m), 3.02-3.20 (0.06H, m), 6.55 (1H, d, J = 9.4Hz), 6.79-6.86 (2H, m), 6.89 (1H, dd, J = 0.7, 7.6Hz), 7.26 (1H, t, J = 7.8Hz), 7.36-7.46 (3H, m), 7.54 (1H, d, J = 8.0Hz), 7.72 (1H, d, J = 9.4Hz), 12.34 (1H, brs).

20 [0842]

A-3: Synthesis of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl-2,2,3,3,5,5,6,6-d₈)-butoxy]-1H-quinolin-2-one

[0843]



25 [0844]

A mixture of 7-(4-chlorobutoxy)-1H-quinolin-2-one (340 mg), 1-benzo[b]thiophen-4-yl-piperazine-2,2,3,3,5,5,6,6-d₈ (310 mg) obtained in Example A-2, step 2, sodium iodide (220 mg), potassium carbonate (240 mg) and dimethylformamide (10 ml) was

30 stirred at 60°C for 6 hr. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate, washed with water, and dried over sodium sulfate. The solvent

was evaporated under reduced pressure and the residue was purified by silica gel column chromatography

(dichloromethane : methanol= 30 : 1) to give 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl-2,2,3,3,5,5,6,6-d₈)-

5 butoxy]-1H-quinolin-2-one (0.31 g).

7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl-2,2,3,3,5,5,6,6-d₈)-butoxy]-1H-quinolin-2-one: yellow powder m.p. 175.5 - 177°C (recrystallized from EtOH)

¹H-NMR (CDCl₃) δ: 1.70-1.84 (2H, m), 1.84-1.96 (2H, m), 2.54


10 (2H, t, J = 7.5Hz), 2.66-2.72 (0.06H, m), 3.14-3.18 (0.06H, m), 4.12 (2H, t, J = 6.2Hz), 6.54 (1H, d, J = 9.4Hz), 6.79-6.86 (2H, m), 6.89 (1H, dd, J = 0.6, 7.6Hz), 7.26 (1H, t, J = 7.9Hz), 7.36-7.48 (3H, m), 7.54 (1H, d, J = 8.0Hz), 7.72 (1H, d, J = 9.4Hz), 12.27 (1H, brs).

15 [0845]

A-4: Synthesis of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl-2,2,3,3,5,5,6,6-d₈)-butoxy]-1H-quinolin-2-one-3,4,5,6,8-d₅

step 1: Synthesis of 7-(4-bromobutoxy)-1H-quinolin-2-one-3,4,5,6,8-d₅

20 [0846]



[0847]

To a mixture of 7-hydroxy-1H-quinolin-2-one-3,4,5,6,8-d₅ (99 atom % D: 3 g) obtained by a deuteration reaction (Org.

25 Lett. 2004, 6, 1485.; Bull. Chem. Soc. Jpn. 2008, 81, 278.) of 7-hydroxy-1H-quinolin-2-one [70500-72-0] and potassium

carbonate (3 g) in dimethylformamide (120 ml) was added 1,4-

dibromobutane (6.5 ml), and the mixture was stirred at 50°C for 4 hr. Water was added to the reaction mixture, and the mixture

30 was extracted with ethyl acetate, washed with water, and dried


over sodium sulfate. The solvent was evaporated under reduced pressure and the residue was purified by silica gel column

chromatography (dichloromethane : methanol= 100 : 1) to give
7-(4-bromobutoxy)-1H-quinolin-2-one-3,4,5,6,8-d₅ (3.45 g).

7-(4-bromobutoxy)-1H-quinolin-2-one-3,4,5,6,8-d₅ : white powder
like

5 ¹H-NMR (CDCl₃) δ ppm: 1.94-2.05 (2H, m), 2.05-2.15 (2H, m),
3.51 (2H, t, J=6.5Hz), 4.10 (2H, t, J=6.0Hz), 6.55 (0.01H, s),
6.79-6.81 (2H, m), 7.52 (0.008H, s), 7.73 (0.008H, s), 11.89
(1H, brs).

step 2: Synthesis of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-
10 1-yl-2,2,3,3,5,5,6,6-d₈)-butoxy]-1H-quinolin-2-one-3,4,5,6,8-d₅
[0848]



[0849]

A mixture of 7-(4-bromobutoxy)-1H-quinolin-2-one-
15 3,4,5,6,8-d₅ (0.6 g), 1-benzo[b]thiophen-4-yl-piperazine-
2,2,3,3,5,5,6,6-d₈ (0.5 g), potassium carbonate (360 mg) and
dimethylformamide (20 ml) was stirred at 60°C for 5 hr. Water
was added to the reaction mixture, and the mixture was
extracted with ethyl acetate, washed with water, and dried
20 over sodium sulfate. The solvent was evaporated under reduced
pressure and the residue was purified by silica gel column
chromatography (dichloromethane : methanol= 30 : 1) to give 7-
[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl-2,2,3,3,5,5,6,6-d₈)-
butoxy]-1H-quinolin-2-one-3,4,5,6,8-d₅ (0.45 g).

25 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl-2,2,3,3,5,5,6,6-
d₈)-butoxy]-1H-quinolin-2-one-3,4,5,6,8-d₅: white powder m.p.
175.5 - 177.5°C (recrystallized from EtOH)


¹H-NMR (CDCl₃) δ ppm : 1.70-1.84 (2H, m), 1.80-1.96 (2H, m),
2.54 (2H, t, J = 7.4Hz), 2.66-2.72 (<0.07H, br), 3.14-3.20
30 (<0.06H, br), 4.12 (2H, t, J = 6.2Hz), 6.54 (<0.008H, s), 6.82
(<0.025H, d, J = 5.7Hz), 6.89 (1H, dd, J = 0.6, 7.7Hz), 7.26
(1H, t, J = 7.9Hz), 7.38 (1H, d, J = 5.5Hz), 7.42 (1H, d, J =

5.9Hz), 7.54 (1H, d, J = 8.0Hz), 7.72 (<0.01H, s), 12.10 (1H, brs).

[0850]

A-5: Synthesis of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)-butoxy]-1H-quinolin-2-one-3,4,5,6,8-d₅

[0851]




[0852]

10 A mixture of 7-(4-bromobutoxy)-1H-quinolin-2-one-3,4,5,6,8-d₅ (0.6 g) obtained in Example A-4, step 1, 1-benzothiophene-4-piperazine hydrochloride (0.56 g), potassium carbonate (690 mg) and dimethylformamide (20 ml) was stirred at 60°C for 6 hr. Water was added to the reaction mixture, and
15 the mixture was extracted with ethyl acetate, washed with water, and dried over sodium sulfate. The solvent was evaporated under reduced pressure and the residue was purified by silica gel column chromatography (dichloromethane : methanol= 30 : 1) to give 7-[4-(4-benzo[b]thiophen-4-yl-
20 piperazin-1-yl)-butoxy]-1H-quinolin-2-one-3,4,5,6,8-d₅ (0.5 g).
7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)-butoxy]-1H-quinolin-2-one-3,4,5,6,8-d₅: white powder m.p. 177 - 179°C (recrystallized from EtOH)

¹H-NMR (CDCl₃) δ ppm : 1.70-1.85 (2H, m), 1.85-1.95 (2H, m),
25 2.54 (2H, t, J = 7.4Hz), 2.66-2.82 (4H, br), 3.14-3.28 (4H, br), 4.08-4.12 (2H, m), 6.54 (<0.01H, s), 6.83 (<0.02H, d, J = 10.3Hz), 6.89 (1H, d, J = 7.7Hz), 7.26 (1H, t, J = 7.8Hz), 7.36 (1H, d, J = 5.5Hz), 7.42 (1H, dd, J = 0.6, 5.5Hz), 7.54 (1H, d, J = 8.0Hz), 7.72 (<0.01H, s), 12.24 (1H, brs).

30 [0853]

A-6: Synthesis of 7-[4-(4-benzo[b]thiophen-4-yl-5,7-d₂-piperazin-1-yl)-butoxy]-1H-quinolin-2-one-3,4,5,6,8-d₅
[0854]



5 [0855]

A mixture of 7-(4-bromobutoxy)-1H-quinolin-2-one-3,4,5,6,8-d₅ (0.6 g) obtained in Example A-4, step 1, 1-benzo[b]thiophen-4-yl-5,7-d₂-piperazine hydrochloride (0.56 g) obtained by a deuteration reaction (Org. Lett. 2004, 6, 1485.;
10 Bull. Chem. Soc. Jpn. 2008, 81, 278.) of 1-benzothiophene-4-piperazine hydrochloride, potassium carbonate (690 mg) and dimethylformamide (20 ml) was stirred at 60°C for 5 hr. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate, washed with water, and dried
15 over sodium sulfate. The solvent was evaporated under reduced pressure and the residue was purified by silica gel column chromatography (dichloromethane : methanol= 30 : 1) to give 7-[4-(4-benzo[b]thiophen-4-yl-5,7-d₂-piperazin-1-yl)-butoxy]-1H-quinolin-2-one-3,4,5,6,8-d₅ (0.42 g).


20 7-[4-(4-benzo[b]thiophen-4-yl-5,7-d₂-piperazin-1-yl)-butoxy]-1H-quinolin-2-one-3,4,5,6,8-d₅: white powder m.p. 176.5 - 178.5°C (recrystallized from EtOH)

¹H-NMR (CDCl₃) δ ppm : 1.70-1.98 (4H, m), 2.54 (2H, t, J = 7.4Hz), 2.66-2.80 (4H, br), 3.14-3.26 (4H, br), 4.12 (2H, t, J = 6.1Hz), 6.54 (<0.01H, s), 6.83 (<0.02H, d, J = 10.0Hz), 6.89 (<0.01H, d, J = 7.7Hz), 7.08(<0.02H, m), 7.25-7.28 (1H, m), 7.38 (0.89H, d, J = 5.5Hz), 7.42 (1H, d, J = 5.5Hz), 7.54 (0.06H, d, J = 8.1Hz), 7.72 (<0.01H, s), 12.23 (1H, brs).

[0856]

30 A-7: Synthesis of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-

yl)-butoxy-1,1,2,2,3,3,4,4-d₈]-1H-quinolin-2-one-3,4,5,6,8-d₅
 step 1: Synthesis of 7-(4-bromobutoxy-1,1,2,2,3,3,4,4-d₈)-1H-
 quinolin-2-one-3,4,5,6,8-d₅
 [0857]




[0858]

To a mixture of 7-hydroxy-1H-quinolin-2-one-3,4,5,6,8-d₅
 (99 atom % D: 1.65 g) obtained by a deuteration reaction (Org.
 Lett. 2004, 6, 1485.; Bull. Chem. Soc. Jpn. 2008, 81, 278.) of
 10 7-hydroxy-1H-quinolin-2-one [70500-72-0] and potassium
 carbonate (1.51 g) in dimethylformamide (40 ml) was added 1,4-
 dibromobutane-d₈ (99.6 atom % D: 5.55 g), and the mixture was
 stirred at 50°C for 4 hr. Water was added to the reaction
 mixture, and the mixture was extracted with ethyl acetate,
 15 washed with water, and dried over sodium sulfate. The solvent
 was evaporated under reduced pressure and the residue was
 purified by silica gel column chromatography
 (dichloromethane : methanol= 100 : 1) to give 7-(4-
 bromobutoxy-1,1,2,2,3,3,4,4-d₈)-1H-quinolin-2-one-3,4,5,6,8-d₅
 20 (1.1 g).

7-(4-bromobutoxy-1,1,2,2,3,3,4,4-d₈)-1H-quinolin-2-one-
 3,4,5,6,8-d₅ : white powder like, ¹H-NMR (CDCl₃) δ ppm: 6.55
 (0.008H, s), 6.81 (0.021H, d, J=9.6Hz), 7.45 (0.008H, s), 7.74
 (0.008H, s), 12.28(1H, brs).

25 step 2: Synthesis of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-
 1-yl)-butoxy-1,1,2,2,3,3,4,4-d₈]-1H-quinolin-2-one-3,4,5,6,8-d₅
 [0859]



[0860]

A mixture of 7-(4-bromobutoxy-1,1,2,2,3,3,4,4-d₈)-1H-quinolin-2-one-3,4,5,6,8-d₅ (0.5 g) obtained in this Example, step 1, 1-benzothiophene-4-piperazine hydrochloride (0.45 g), potassium carbonate (0.56 g) and dimethylformamide (20 ml) was stirred at 60°C for 6 hr. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate, washed with water, and dried over sodium sulfate. The solvent was evaporated under reduced pressure and the residue was purified by silica gel column chromatography


(dichloromethane : methanol= 30 : 1) to give 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)-butoxy-1,1,2,2,3,3,4,4-d₈]-1H-quinolin-2-one-3,4,5,6,8-d₅ (0.24 g).

7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)-butoxy-1,1,2,2,3,3,4,4-d₈]-1H-quinolin-2-one-3,4,5,6,8-d₅: white powder m.p. 176 - 177.5°C (recrystallized from EtOH)
¹H-NMR (CDCl₃) δ ppm : 2.60-2.84 (4H, br), 3.10-3.28 (4H, br), 6.54 (<0.007H, s), 6.82 (<0.02H, d, J = 6.0Hz), 6.89 (1H, dd, J = 0.5, 7.6Hz), 7.27 (1H, t, J = 7.8Hz), 7.38 (1H, d, J = 5.6Hz), 7.42 (1H, dd, J = 0.5, 5.6Hz), 7.54 (1H, d, J = 8.0Hz), 7.72 (<0.009H, s), 12.13 (1H, brs).

[0861]

A-8: Synthesis of 7-[4-(4-benzo[b]thiophen-4-yl-5,7-d₂-piperazin-1-yl)-butoxy]-1H-quinolin-2-one

[0862]



[0863]

A mixture of 7-(4-chlorobutoxy)-1H-quinolin-2-one (0.5 g), 1-benzo[b]thiophen-4-yl-5,7-d₂-piperazine hydrochloride (0.56 g) obtained by a deuteration reaction (Org. Lett. 2004, 6, 1485.; Bull. Chem. Soc. Jpn. 2008, 81, 278.) of 1-benzothiophene-4-piperazine hydrochloride, sodium iodide (0.33 g), potassium carbonate (690 mg) and dimethylformamide (20 ml) was stirred at 60°C for 6 hr. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate, washed with water, and dried over sodium sulfate. The solvent was evaporated under reduced pressure and the residue was purified by silica gel column chromatography (dichloromethane : methanol= 30 : 1) to give 7-[4-(4-benzo[b]thiophen-4-yl-5,7-d₂-piperazin-1-yl)-butoxy]-1H-quinolin-2-one (0.31 g).


7-[4-(4-benzo[b]thiophen-4-yl-5,7-d₂-piperazin-1-yl)-butoxy]-1H-quinolin-2-one: white powder m.p. 179.5 - 181.5°C (recrystallized from EtOH)

¹H-NMR (CDCl₃) δ ppm : 1.68-1.84 (2H, m), 1.84-1.96 (2H, m), 2.54 (2H, t, J = 7.4Hz), 2.66-2.80 (4H, br), 3.16-3.26 (4H, br), 4.12 (2H, t, J = 6.2Hz), 6.54 (1H, d, J = 9.4Hz), 6.78-6.86 (2H, m), 6.90 (<0.02H, d, J = 7.7Hz), 7.25-7.28 (1H, m), 7.38 (0.82H, d, J = 5.6Hz), 7.40-7.48 (2H, m), 7.54 (0.05H, d, J = 8.6Hz), 7.72 (1H, d, J = 9.4Hz), 12.09 (1H, brs).

[0864]

A-9: Synthesis of 7-[4-(4-benzo[b]thiophen-4-yl-5,7-d₂-piperazin-1-yl)-butoxy-1,1,2,2,3,3,4,4-d₈]-1H-quinolin-2-one

[0865]



[0866]

A mixture of 7-(4-bromobutoxy-1,1,2,2,3,3,4,4-d₈)-1H-quinolin-2-one (0.5 g) obtained in Example A-1, synthesis
 5 method 2, step 1, 1-benzo[b]thiophen-4-yl-5,7-d₂-piperazine hydrochloride (0.46 g) obtained by a deuteration reaction (Org. Lett. 2004, 6, 1485.; Bull. Chem. Soc. Jpn. 2008, 81, 278.) of 1-benzothiophene-4-piperazine hydrochloride, potassium carbonate (0.57 g) and dimethylformamide (20 ml) was stirred
 10 at 50°C for 6 hr. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate, washed with water, and dried over sodium sulfate. The solvent was evaporated under reduced pressure and the residue was purified by silica gel column chromatography (dichloromethane :
 15 methanol= 30 : 1) to give 7-[4-(4-benzo[b]thiophen-4-yl-5,7-d₂-piperazin-1-yl)-butoxy-1,1,2,2,3,3,4,4-d₈]-1H-quinolin-2-one (0.35 g).


7-[4-(4-benzo[b]thiophen-4-yl-5,7-d₂-piperazin-1-yl)-butoxy-1,1,2,2,3,3,4,4-d₈]-1H-quinolin-2-one: white powder m.p. 176.5
 20 - 178.5°C (recrystallized from EtOH)

¹H-NMR (CDCl₃) δ ppm : 2.66-2.80 (4H, br), 3.10-3.28 (4H, br), 6.55 (1H, d, J = 9.4Hz), 6.81 (1H, dd, J = 2.4, 8.6Hz), 6.85 (1H, d, J = 2.3Hz), 6.89 (<0.04H, d, J = 7.7Hz), 7.24-7.28 (1H, m), 7.38 (0.85H, d, J = 5.6Hz), 7.40-7.46 (2H, m), 7.54 (0.06H, dd, J = 0.5, 8.0Hz), 7.72 (1H, d, J = 9.4Hz), 12.47 (1H, brs).

[0867]

A-10: Synthesis of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl-2,2,3,3,5,5,6,6-d₈)-butoxy-1,1,2,2,3,3,4,4-d₈]-1H-quinolin-2-one-3,4,5,6,8-d₅

30 [0868]



[0869]


A mixture of 7-(4-bromobutoxy-1,1,2,2,3,3,4,4-d₈)-1H-quinolin-2-one-3,4,5,6,8-d₅ (0.6 g) obtained in Example A-7, step 1, 1-benzo[b]thiophen-4-yl-piperazine-2,2,3,3,5,5,6,6-d₈ (0.57 g) obtained in Example A-2, step 2, potassium carbonate (380 mg) and dimethylformamide (20 ml) was stirred at 60°C for 5 hr. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate, washed with water, and dried over sodium sulfate. The solvent was evaporated under reduced pressure and the residue was purified by silica gel column chromatography (dichloromethane : methanol= 30 : 1) to give 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl-2,2,3,3,5,5,6,6-d₈)-butoxy-1,1,2,2,3,3,4,4-d₈]-1H-quinolin-2-one-3,4,5,6,8-d₅ (0.45 g).

7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl-2,2,3,3,5,5,6,6-d₈)-butoxy-1,1,2,2,3,3,4,4-d₈]-1H-quinolin-2-one-3,4,5,6,8-d₅: white powder m.p. 175.5 - 177.5°C (recrystallized from EtOH)
¹H-NMR (CDCl₃) δ ppm : 2.64-2.72 (<0.06H, br), 3.14-3.20 (<0.06H, br), 6.54 (<0.01H, s), 6.80-6.86 (<0.04H, m), 6.89 (1H, dd, J = 0.8, 7.6Hz), 7.26 (1H, t, J = 7.9Hz), 7.38 (1H, d, J = 5.5Hz), 7.41 (1H, dd, J = 0.7, 5.6Hz), 7.54 (1H, d, J = 8.0Hz), 7.72 (<0.01H, s), 12.35 (1H, brs).

[0870]

A-11: Synthesis of 7-[4-(4-benzo[b]thiophen-4-yl-5,7-d₂-piperazin-1-yl)-butoxy-1,1,2,2,3,3,4,4-d₈]-1H-quinolin-2-one-3,4,5,6,8-d₅

[0871]



[0872]


A mixture of 7-(4-bromobutoxy)-1,1,2,2,3,3,4,4-d₈-1H-quinolin-2-one-3,4,5,6,8-d₅ (0.5 g) obtained in Example A-7, step 1, 1-benzo[b]thiophen-4-yl-5,7-d₂-piperazine hydrochloride (0.46 g) obtained by a deuteration reaction (Org. Lett. 2004, 6, 1485.; Bull. Chem. Soc. Jpn. 2008, 81, 278.) of 1-benzothiophene-4-piperazine hydrochloride, potassium carbonate (0.56 g) and dimethylformamide (20 ml) was stirred at 50°C for 6 hr. Water was added to the reaction mixture, and the mixture was extracted with ethyl acetate, washed with water, and dried over sodium sulfate. The solvent was evaporated under reduced pressure and the residue was purified by silica gel column chromatography (dichloromethane : methanol= 30 : 1) to give 7-[4-(4-benzo [b]thiophen-4-yl-5,7-d₂-piperazin-1-yl)-butoxy-1,1,2,2,3,3,4,4-d₈]-1H-quinoline-2-one-3,4,5,6,8-d₅ (0.34 g). 7-[4-(4-benzo[b]thiophen-4-yl-5,7-d₂-piperazin-1-yl)-butoxy-1,1,2,2,3,3,4,4-d₈]-1H-quinolin-2-one-3,4,5,6,8-d₅: white powder m.p. 175.5 - 177.5°C (recrystallized from EtOH)

¹H-NMR (CDCl₃) δ ppm : 2.66-2.80 (4H, br), 3.14-3.26 (4H, br), 6.54 (<0.01H, s), 6.83 (<0.02H, d, J = 11.2Hz), 6.89 (<0.01H, d, J = 7.6Hz), 7.06-7.10 (<0.02H, m), 7.25-7.28 (1H, m), 7.38 (0.86H, d, J = 5.6Hz), 7.42 (1H, d, J = 5.6Hz), 7.54 (<0.05H, dd, J = 0.6, 8.0Hz), 7.72 (<0.01H, s), 12.28 (1H, brs).

[0873]

Example B: Synthesis of salt of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)-butoxy]-1H-quinolin-2-one

[0874]




[0875]

phosphate:

A suspension of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)-butoxy]-1H-quinolin-2-one (15 g) in dichloromethane (100 ml) and methanol (100 ml) was warmed to 60°C, dissolved, and phosphoric acid (4.39 g) was added at room temperature. The precipitated crystals were collected by filtration, and dried to give 7-[4-(4-Benzo[b]thiophen-4-yl-piperazin-1-yl)-butoxy]-1H-quinolin-2-one phosphate (17.9 g).

7-[4-(4-Benzo[b]thiophen-4-yl-piperazin-1-yl)-butoxy]-1H-quinolin-2-one phosphate (17.5 g) was recrystallized from ethanol (550 ml) and water (550 ml) to give 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)-butoxy]-1H-quinolin-2-one phosphate (14.4 g).

[0876]



[0877]

7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)-butoxy]-1H-quinolin-2-one phosphate : colorless crystals : m.p. 226 - 228°C (recrystallized from EtOH - H₂O)

¹H-NMR (DMSO-d₆) δ ppm : 1.66-1.76 (2H, m), 1.76-1.86 (2H, m), 2.63 (2H, t, J=7.0Hz), 2.76-2.86 (4H, br), 3.08-3.18 (4H, br), 4.07 (2H, t, J=6.2Hz), 6.30 (1H, d, J=9.4Hz), 6.78-6.84 (2H, m), 6.90 (1H, d, J=7.4Hz), 7.28 (1H, t, J=7.8Hz), 7.42 (1H, d, J=5.5Hz), 7.56 (1H, d, J=9.4Hz), 7.63 (1H, d, J=8.0Hz), 7.71 (1H, d, J=5.5Hz), 7.81 (1H, d, J=9.5Hz), 11.2-12.2 (1H, br).

[0878]


DL-malate:

A suspension of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-

1-yl)-butoxy]-1H-quinolin-2-one (15 g) in dichloromethane (100 ml) and methanol (100 ml) was warmed to 60°C, dissolved, and DL-malic acid (5.11 g) dissolved in water (10 ml) was added at room temperature. The precipitated crystals were collected by
 5 filtration, and dried to give 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)-butoxy]-1H-quinolin-2-one DL-malate (20 g).

7-[4-(4-Benzo[b]thiophen-4-yl-piperazin-1-yl)-butoxy]-1H-quinolin-2-one DL-malate (20 g) was recrystallized from ethanol (350 ml) and water (50 ml) to give 7-[4-(4-
 10 benzo[b]thiophen-4-yl-piperazin-1-yl)-butoxy]-1H-quinolin-2-one DL-malate (14.5 g).

[0879]



15 [0880]

7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)-butoxy]-1H-quinolin-2-one DL-malate: colorless crystal: m.p. 136 - 139°C (recrystallized from EtOH - H₂O)

¹H-NMR (DMSO-d₆) δ ppm : 1.64-1.76 (2H, m), 1.76-1.86 (2H, m),
 20 2.62 (2H, t, J=7.1Hz), 2.74-2.86 (4H, br), 3.06-3.18 (4H, br),
 4.06 (2H, t, J=6.0Hz), 4.21 (2H, s), 6.30 (1H, d, J=9.4Hz),
 6.78-6.84 (2H, m), 6.90 (1H, d, J=7.4Hz), 7.28 (1H, t,
 J=7.8Hz), 7.42 (1H, d, J=5.5Hz), 7.56 (1H, d, J=9.3Hz), 7.63
 (1H, d, J=8.0Hz), 7.71 (1H, d, J=5.5Hz), 7.81 (1H, d, J=9.5Hz),
 25 11.59 (1H, brs).

[0881]


L(+)-tartrate :

A suspension of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)-butoxy]-1H-quinolin-2-one (15 g) in dichloromethane (100
 30 ml) and methanol (100 ml) was heated to 60°C, dissolved, and L(+)-tartaric acid (5.72 g) dissolved in water (10 ml) was added at room temperature. The precipitated crystals were collected by filtration, and dried to give 7-[4-(4-

benzo[b]thiophen-4-yl-piperazin-1-yl)-butoxy]-1H-quinolin-2-one L(+)-tartrate (19.3 g).

7-[4-(4-Benzo[b]thiophen-4-yl-piperazin-1-yl)-butoxy]-1H-quinolin-2-one L(+)-tartrate (19.3 g) was recrystallized from ethanol (700 ml) and water (250 ml) to give 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)-butoxy]-1H-quinolin-2-one L(+)-tartrate (16.5 g).

[0882]



[0883]

7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)-butoxy]-1H-quinolin-2-one L(+)-tartrate: colorless crystal: m.p. 198 - 203°C (recrystallized from EtOH - H₂O)

¹H-NMR (DMSO-d₆) δ ppm : 1.64-1.76 (2H, m), 1.76-1.86 (2H, m), 2.41 (1H, dd, J=6.7, 15.6Hz), 2.59 (1H, dd, J=6.4, 15.6Hz), 2.66 (2H, t, J=7.2Hz), 2.78-2.88 (4H, br), 3.06-3.18 (4H, br), 4.07 (2H, t, J=6.2Hz), 4.16 (1H, t, J=6.5Hz), 6.30 (1H, d, J=9.4Hz), 6.78-6.84 (2H, m), 6.90 (1H, d, J=7.2Hz), 7.29 (1H, t, J=7.8Hz), 7.43 (1H, dd, J=0.6, 5.5Hz), 7.56 (1H, d, J=9.3Hz), 7.63 (1H, d, J=8.0Hz), 7.71 (1H, d, J=5.5Hz), 7.81 (1H, d, J=9.5Hz), 11.59 (1H, brs).


[0884]

oxalate:

A suspension of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)-butoxy]-1H-quinolin-2-one (3 g) in dichloromethane (20 ml) and methanol (20 ml) was warmed to 60°C, dissolved, and oxalic acid (0.69 g) dissolved in methanol (5 ml) was added at room temperature. The precipitated crystals were collected by filtration, and dried to give 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)-butoxy]-1H-quinolin-2-one oxalate (3.3 g).

7-[4-(4-Benzo[b]thiophen-4-yl-piperazin-1-yl)-butoxy]-1H-quinolin-2-one oxalate (1 g) was recrystallized from ethanol

(20 ml) and water (20 ml) to give 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)-butoxy]-1H-quinolin-2-one oxalate (0.8 g).
[0885]



5 [0886]

7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)-butoxy]-1H-quinolin-2-one oxalate : colorless crystal: m.p. 126.5 - 128°C (recrystallized from EtOH - H₂O)

¹H-NMR (DMSO-d₆) δ ppm : 1.78-1.90 (4H, br), 3.06-3.14 (2H, br),
10 3.24-3.36 (4H, br), 3.62-4.24 (6H, br), 6.31 (1H, d, J=9.4Hz),
6.78-6.86 (2H, m), 6.95 (1H, d, J=7.4Hz), 7.31 (1H, t,
J=7.9Hz), 7.48 (1H, dd, J=0.4, 5.6Hz), 7.57 (1H, d, J=9.4Hz),
7.69 (1H, d, J=8.1Hz), 7.75 (1H, d, J=5.5Hz), 7.81 (1H, d,
J=9.5Hz), 11.62 (1H, brs).


15 [0887]

succinate:

A suspension of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)-butoxy]-1H-quinolin-2-one (2 g) in dichloromethane (20 ml) and methanol (20 ml) was warmed to 60°C, dissolved, and
20 succinic acid (0.6 g) dissolved in methanol-water was added at room temperature. The precipitated crystals were collected by filtration, and dried to give 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)-butoxy]-1H-quinolin-2-one succinate (2.4 g).

7-[4-(4-Benzo[b]thiophen-4-yl-piperazin-1-yl)-butoxy]-1H-quinolin-2-one succinate (1 g) was recrystallized from ethanol
25 (20 ml) and water (8 ml) to give 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)-butoxy]-1H-quinolin-2-one succinate (0.74 g).

[0888]



30

[0889]

7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)-butoxy]-1H-

quinolin-2-one succinate: colorless crystal: m.p. 158.5 - 160°C
(recrystallized from EtOH - H₂O)

¹H-NMR (DMSO-d₆) δ ppm : 1.60-1.70 (2H, m), 1.76-1.86 (2H, m),
5 2.41 (4H, s), 2.44-2.50 (2H, m), 2.60-2.70 (4H, br), 3.04-3.10
(4H, br), 4.06 (2H, t, J=6.4Hz), 6.29 (1H, d, J=9.4Hz), 6.78-
6.84 (2H, m), 6.89 (1H, d, J=7.3Hz), 7.27 (1H, t, J=7.8Hz),
7.40 (1H, dd, J=0.4, 5.6Hz), 7.56 (1H, d, J=9.3Hz), 7.61 (1H,
d, J=8.0Hz), 7.69 (1H, d, J=5.5Hz), 7.81 (1H, d, J=9.5Hz),
10 11.58 (1H, brs).


[0890]

1/2 succinate:

A suspension of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-
1-yl)-butoxy]-1H-quinolin-2-one (2 g) in dichloromethane (20
15 ml) and methanol (20 ml) was warmed to 60°C, dissolved, and
succinic acid (0.3 g) dissolved in methanol-water was added at
room temperature. The precipitated crystals were collected by
filtration, and dried to give 7-[4-(4-benzo[b]thiophen-4-yl-
piperazin-1-yl)-butoxy]-1H-quinolin-2-one 1/2 succinate (1.84
20 g).

7-[4-(4-Benzo[b]thiophen-4-yl-piperazin-1-yl)-butoxy]-1H-
quinolin-2-one 1/2 succinate (1 g) was recrystallized from
ethanol (20 ml) and water (5 ml) to give 7-[4-(4-
benzo[b]thiophen-4-yl-piperazin-1-yl)-butoxy]-1H-quinolin-2-
25 one 1/2 succinate (0.69 g).

[0891]



[0892]

7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)-butoxy]-1H-

quinolin-2-one 1/2 succinate: colorless crystal: m.p. 158 - 160°C (recrystallized from EtOH - H₂O)

¹H-NMR (DMSO-d₆) δ ppm : 1.60-1.70 (2H, m), 1.76-1.86 (2H, m), 2.41 (2H, s), 2.47 (2H, t, J=7.2Hz), 2.60-2.70 (4H, br), 3.02-
5 3.10 (4H, br), 4.06 (2H, t, J=6.4Hz), 6.30 (1H, d, J=9.4Hz), 6.78-6.84 (2H, m), 6.88 (1H, d, J=7.3Hz), 7.28 (1H, t, J=7.8Hz), 7.40 (1H, dd, J=0.4, 5.5Hz), 7.56 (1H, d, J=9.4Hz), 7.61 (1H, d, J=7.6Hz), 7.69 (1H, d, J=5.5Hz), 7.80 (1H, d, J=9.5Hz), 11.59 (1H, brs).


10 [0893]

hydrobromide:

A suspension of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)-butoxy]-1H-quinolin-2-one (2 g) in dichloromethane (20 ml) and methanol (20 ml) was warmed to 60°C, dissolved, and a
15 solution of 47% hydrobromic acid (0.86 g) in methanol was added at room temperature. The precipitated crystals were collected by filtration, and dried to give 7-[4-(4-Benzo[b]thiophen-4-yl-piperazin-1-yl)-butoxy]-1H-quinolin-2-one hydrobromide (2.2 g).

20 7-[4-(4-Benzo[b]thiophen-4-yl-piperazin-1-yl)-butoxy]-1H-quinolin-2-one hydrobromide (1 g) was recrystallized from ethanol (20 ml) and water (5 ml) to give 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)-butoxy]-1H-quinolin-2-one hydrobromide (0.81 g).

25 [0894]



[0895]

7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)-butoxy]-1H-
30 quinolin-2-one hydrobromide: colorless crystal: m.p. 223 - 228°C (recrystallized from EtOH - H₂O)

¹H-NMR (DMSO-d₆) δ ppm : 1.80-2.00 (4H, br), 3.06-3.20 (2H, m),

3.26-3.40 (4H, br), 3.50-3.74 (4H, m), 4.09 (2H, t, J=5.4Hz),
6.31 (1H, d, J=9.4Hz), 6.80-6.86 (2H, m), 6.99 (1H, d,
J=7.6Hz), 7.33 (1H, t, J=7.9Hz), 7.51 (1H, d, J=5.5Hz), 7.59
(1H, d, J=9.2Hz), 7.72 (1H, d, J=8.0Hz), 7.78 (1H, d, J=5.5Hz),
5 7.82 (1H, d, J=9.5Hz), 9.65 (1H, brs), 11.62 (1H, s).


[0896]

malonate:

A suspension of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)-butoxy]-1H-quinolin-2-one (2 g) in dichloromethane (20
10 ml) and methanol (20 ml) was warmed to 60°C, dissolved, and
malonic acid(0.53 g) dissolved in methanol was added at room
temperature. The precipitated crystals were collected by
filtration, and dried to give 7-[4-(4-benzo[b]thiophen-4-yl-
piperazin-1-yl)-butoxy]-1H-quinolin-2-one malonate (2.4 g).

15 7-[4-(4-Benzo[b]thiophen-4-yl-piperazin-1-yl)-butoxy]-1H-
quinolin-2-one malonate (1 g) was recrystallized from ethanol
(4 ml) and water (10 ml) to give 7-[4-(4-benzo[b]thiophen-4-
yl-piperazin-1-yl)-butoxy]-1H-quinolin-2-one malonate (0.72 g).
[0897]

20



[0898]

7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)-butoxy]-1H-
quinolin-2-one malonate: colorless crystal: m.p. 134 - 136°C
25 (recrystallized from EtOH - H₂O)


¹H-NMR (DMSO-d₆) δ ppm : 1.68-1.88 (4H, m), 2.82 (2H, brs),
2.92-3.08 (6H, m), 3.12-3.22 (4H, br), 4.07 (2H, t, J=5.8Hz),
6.30 (1H, d, J=9.4Hz), 6.78-6.84 (2H, m), 6.93 (1H, d,
J=7.6Hz), 7.30 (1H, t, J=7.8Hz), 7.45 (1H, d, J=5.5Hz), 7.57
30 (1H, d, J=9.4Hz), 7.66 (1H, d, J=8.1Hz), 7.73 (1H, d, J=5.5Hz),
7.81 (1H, d, J=9.5Hz), 11.60 (1H, brs).

[0899]

1/2 pamoate:

A suspension of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)-butoxy]-1H-quinolin-2-one (1 g) in dimethylformamide (10 ml) and acetonitrile (10 ml) was warmed to give a solution,
 5 and pamoic acid (0.49 g) was added. The mixture was warmed to 60°C, dissolved, and the mixture was stood at room temperature. Water was added, the suspended substances were collected by filtration, and dried to give 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)-butoxy]-1H-quinolin-2-one 1/2 pamoate (1.5 g).

10 [0900]



[0901]

7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)-butoxy]-1H-quinolin-2-one 1/2 pamoate: yellow amorphous

15 ¹H-NMR (DMSO-d₆) δ ppm : 1.78-1.92 (4H, m), 3.4-3.8 (10H, br), 4.05-4.12 (2H, m), 4.71 (1H, s), 6.31 (1H, d, J=9.5Hz), 6.78-6.84 (2H, m), 6.96 (1H, d, J=7.6Hz), 7.04 (1H, t, J=7.4Hz), 7.13-7.19 (1H, m), 7.31 (1H, t, J=7.8Hz), 7.49 (1H, d, J=5.5Hz), 7.56 (1H, d, J=8.7Hz), 7.69 (2H, d, J=8.0Hz), 7.76
 20 (1H, d, J=5.5Hz), 7.81 (1H, d, J=9.5Hz), 8.18 (1H, d, J=8.6Hz), 8.25 (1H, s), 11.63 (1H, brs).

[0902]

Experimental Example 1

Each of the Example compounds was examined for the
 25 solubility in oil (sesame oil, benzyl benzoate).

For the specific gravity of an oil, the following values were applied.

sesame oil (specific gravity: 0.914 - 0.921)

benzyl benzoate (specific gravity: 1.123)

30 (method)

Example compound is measured in a microtube and an oil (sesame oil, or, benzyl benzoate) in an amount to make the concentration 10 mg/0.1 ml is added. After stirring, the solubility is evaluated by visual observation. When the
5 compound is not dissolved, the mixture is heated, and the solubility is evaluated after cooling.

The results are shown in Table 3 and Table 4. In the Tables, O means soluble.

[0903]

10 Table 3

Example No.	Sesame oil
Example 17	O
Example 21	O
Example 28	O
Example 44	O
Example 45	O
Example 52	O
Example 57	O
Example 60	O
Example 75	O
Example 76	O
Example 79	O
Example 134	O
Example 135	O
Example 142	O
Example 144	O
Example 149	O
Example 150	O
Example 154	O
Example 156	O
Example 158	O
Example 177	O
Example 179	O
Example 180	O
Example 373	O
Example 379	O
Example 380	O
Example 381	O
Example 384	O

[0904]

Table 4

Example No.	benzyl benzoate
Example 9	O
Example 10	O

WO 2013/035892

Example 11	○
Example 12	○
Example 13	○
Example 14	○
Example 15	○
Example 16	○
Example 17	○
Example 18	○
Example 19	○
Example 20	○
Example 21	○
Example 22	○
Example 23	○
Example 24	○
Example 25	○
Example 26	○
Example 27	○
Example 28	○
Example 29	○
Example 30	○
Example 31	○
Example 32	○
Example 33	○
Example 34	○
Example 35	○
Example 36	○
Example 37	○
Example 38	○
Example 39	○
Example 40	○
Example 41	○
Example 42	○
Example 43	○
Example 44	○
Example 45	○
Example 46	○
Example 47	○
Example 48	○
Example 49	○
Example 50	○
Example 51	○
Example 52	○
Example 53	○
Example 54	○
Example 55	○
Example 56	○
Example 57	○
Example 58	○

Example 59	○
Example 60	○
Example 61	○
Example 62	○
Example 63	○
Example 64	○
Example 65	○
Example 67	○
Example 68	○
Example 69	○
Example 70	○
Example 71	○
Example 72	○
Example 73	○
Example 74	○
Example 75	○
Example 76	○
Example 77	○
Example 78	○
Example 79	○
Example 80	○
Example 81	○
Example 82	○
Example 83	○
Example 84	○
Example 85	○
Example 86	○
Example 87	○
Example 88	○
Example 89	○
Example 90	○
Example 91	○
Example 92	○
Example 93	○
Example 94	○
Example 95	○
Example 96	○
Example 97	○
Example 98	○
Example 99	○
Example 100	○
Example 101	○
Example 102	○
Example 103	○
Example 104	○
Example 105	○
Example 106	○
Example 107	○

Example 108	O
Example 109	O
Example 110	O
Example 111	O
Example 112	O
Example 113	O
Example 114	O
Example 115	O
Example 116	O
Example 117	O
Example 118	O
Example 119	O
Example 120	O
Example 121	O
Example 122	O
Example 123	O
Example 124	O
Example 125	O
Example 126	O
Example 127	O
Example 128	O
Example 129	O
Example 130	O
Example 131	O
Example 132	O
Example 134	O
Example 135	O
Example 136	O
Example 137	O
Example 139	O
Example 140	O
Example 141	O
Example 142	O
Example 143	O
Example 144	O
Example 145	O
Example 146	O
Example 147	O
Example 148	O
Example 149	O
Example 150	O
Example 151	O
Example 152	O
Example 153	O
Example 154	O
Example 156	O
Example 158	O
Example 163	O

Example 165	○
Example 168	○
Example 170	○
Example 175	○
Example 177	○
Example 179	○
Example 180	○
Example 371	○
Example 372	○
Example 373	○
Example 379	○
Example 380	○
Example 381	○
Example 382	○
Example 384	○

[0905]

Experimental Example 2; pharmacokinetics of intramuscular preparations

A suspended fine particle preparation used as a
5 sustainable injection requires re-suspending before
administration, and the particle surface area markedly affects
the drug release profile. Thus, the particle size after re-
suspending needs to be strictly controlled, so that
coagulation and the like will not occur.

10 On the other hand, since an oil-soluble preparation
contains a drug completely dissolved therein, re-suspending
before administration is not necessary and, since the drug is
released depending on the oil-water distribution coefficient,
control of the particle size is not necessary. Furthermore,
15 since sterilization by filtration, which has been unattainable
for suspended fine particle preparations, has become possible,
a preparation can be prepared more conveniently.

Since the compound disclosed in patent document 1 shows
low solubility in an oil base material such as benzyl benzoate
20 and the like, an oil-soluble preparation cannot be produced.
When a soluble preparation is produced, an aqueous base
material using a solubilizing agent such as Captisol
(Sulfobutylether- β -cyclodextrin) and the like needs to be used.
In contrast, since the compound of the present invention shows

high solubility in an oil base material, an oil-soluble preparation can be produced.

Thus, an oil-soluble preparation of the compound of the present invention and an water soluble preparation of the compound disclosed in patent document 1 were prepared, intramuscularly administered to rats and pharmacokinetics of these preparations were evaluated.

Animal

7-week-old male rats were purchased from CHARLES RIVER LABORATORIES JAPAN, INC, preliminarily bred and rats weighing 265.2 g - 288.6 g were used for the experiment. The experiment was performed under the conditions of no fasting, free access to water and feed, and the following breeding environment. Rats per cage: 4, temperature: 23±2°C, humidity: 60±10%, light-on time: 7:00 - 19:00

Production method of preparation

As the compound disclosed in patent document 1, used was 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one (control compound) disclosed in Example 1 that expresses desired efficacy. A water-soluble preparation was obtained by dissolving the control compound in aqueous 15% Captisol and 0.78% tartaric acid solution to a concentration of 0.5%, and the pH was adjusted to 4.3 with 5N aqueous sodium hydroxide solution.

An oil-soluble preparation was obtained by dissolving the compound of the present invention disclosed in Example 146 in benzyl benzoate to a concentration of 15%, and adjusted.

Methods of administration and blood sampling

Under isoflurane anesthesia, non-fasting male rats were intramuscularly administered at left leg region (about 4 mm depth) using a syringe with 24G needle. The dose is as described below.

Test preparation 1: low dose of oil-soluble preparation of the compound of the present invention: 25 mg/kg (based on control compound)

Test preparation 2: high dose of oil-soluble preparation of the compound of the present invention: 50 mg/kg (based on control compound)

Test preparation 3: water-soluble preparation of control

5 compound: 0.1 mg/kg

The test preparation was administered to the rats. For test preparation 3, about 0.3 mL each of blood samples were collected from the jugular vein 5 min, 15 min, 30 min, 1 hr, 2 hr, 4 hr and 20 hr later. For test preparations 1 and 2, about
10 0.3 mL each of blood samples were collected from the jugular vein 6 hr, 1 day, 3 days, 7 days, 14 days, 21 days and 28 days later. For collection of blood samples, a 1 mL syringe treated with EDTA-lithium fluoride-heparin was used. The collected blood was preserved under ice-cooling, the plasma was rapidly
15 separated by centrifugation, and the concentration of the control compound was quantified by LCMS. The pharmacokinetics parameters such as C_{max}, T_{max}, AUC_{last}, AUC_{inf}, t_{1/2} and the like were determined by WinNonlin Professional Version 6.1 (model-independent method, Pharsight corporation).

20 Results

The results are shown in Fig. 1 (blood concentration profile of control compound after administration of test preparations 1, 2 and 3) and Table 5 (pharmacokinetics parameters of test preparations 1, 2 and 3).

25 [0906]

[Table 5]

	C_{max} (μg/mL)	T_{max} (day)	AUC_{last} (μg·day/mL)	AUC_{inf} (μg·day/mL)	t_{1/2} (day)
Test preparation 1	0.0258	5.00	0.270	0.473	27.99
Test preparation 2	0.0423	5.31	0.480	0.621	16.99
Test preparation 3	0.0629	0.01	0.003	0.003	0.05

Each parameter shows mean value (n=4)

[0907]

Discussion

30 In test preparation 3, the control compound disappeared


immediately after intramuscular administration. On the other hand, in test preparations 1 and 2, the control compound showed a sustained blood concentration profile. Therefrom it was shown that the improved solubility of the compound of the present invention in an oily substrate has enabled the production of a dissolution preparation that shows blood concentration sustainability of the compound of patent document 1.

[0908]

This application is based on application No. 61/532,393 filed in United States of America (filing date; September 8, 2011), the content of which is incorporated hereinto by reference.

CLAIMS

1. A heterocyclic compound represented by the formula (I)




5 wherein

A is a lower alkylene group;




in the monocyclic heterocycle containing Q is



10 wherein

R^{2'} is the following group



wherein

Y^{1'} is a lower alkylene group,

15 R^{3'} is

(1) an alkyl group,

(2) a cycloalkyl group optionally substituted by a lower alkyl group,

(3) a phenyl group,

20 (4) a phenyl lower alkyl group

(5) a lower alkoxy group,

(6) a cycloalkyloxy group,


(7) an amino group optionally having 1 or 2 substituents selected from the group consisting of an alkyl group and a

25 phenyl lower alkyl group, or


(8) a piperidyl group optionally having a piperidyl group;

-----J


at the 3-position and the 4-position of the bicyclic heterocycle skeleton containing Z and W is -CH=CH- or



- 5 wherein R⁶ and R⁷ are the same or different and each is a hydrogen or a lower alkyl group;



is



- 10 wherein

R¹ is


a lower alkoxy lower alkoxy group,

a phosphonooxy lower alkoxy group,

a phenyl lower alkoxy lower alkoxy group,

- 15 a phosphonooxy group optionally having 1 or 2 lower alkyl groups,

the following group



wherein

- 20 R⁸ is

(1) an alkyl group,

(2) a hydroxy-substituted lower alkyl group,

(3) a cycloalkyl group,

(4) a phenyl group,

- 25 (5) a phenyl lower alkyl group,

(6) an alkenyl group,

(7) a lower alkoxy group,

(8) a cycloalkyloxy group,

(9) a lower alkoxy lower alkoxy group,


- (10) an amino group optionally having 1 or 2 substituents selected from the group consisting of an alkyl group and a hydroxy-substituted lower alkyl group,

(11) a piperidyl group optionally having a piperidyl group,

- 5 (12) a piperazinyl group optionally having a lower alkyl group,

or


(13) the following group



wherein Aa is an alkylene group, and other symbols are as

10 defined above, or

the following group



wherein

 R^9 is

- 15 (1) an alkyl group,

(2) a hydroxy-substituted lower alkyl group,

(3) a cycloalkyl group,

(4) a phenyl group,

(5) a phenyl lower alkyl group,

- 20 (6) an alkenyl group,

(7) a lower alkoxy group,

(8) a cycloalkyloxy group,

(9) a lower alkoxy lower alkoxy group,

(10) a phenyloxy group,


- 25 (11) an amino group optionally having 1 or 2 substituents
selected from the group consisting of an alkyl group and a
hydroxy-substituted lower alkyl group,

(12) a piperidyl group optionally having a piperidyl group,

(13) a piperazinyl group optionally having a lower alkyl group,





or

(14) the following group



wherein Ab is an alkylene group, and other symbols are as
5 defined above;

R² is a hydrogen or
the following group



wherein

Y¹ is a lower alkylene group optionally substituted by

(1) a lower alkoxy carbonyl group or

15 (2) a lower alkyl group,

Y² is a lower alkylene group,

Y³ is a single bond or a lower alkylene group optionally
substituted by a lower alkyl group,

R³ is

20 (1) an alkyl group,

(2) a halogen-substituted lower alkyl group,


(3) an alkenyl group,

(4) an amino lower alkyl group,

(5) a cycloalkyl group,

25 (6) a phenyl group,

- (7) a phenyl lower alkyl group,
(8) a piperidyl group optionally having 1 or 2 substituents selected from the group consisting of a lower alkyl group and a piperidyl group,
5 (9) a halogen-substituted piperidyl group,
(10) a morpholinyl group,
(11) a pyrrolidinyl group,
(12) a tetrahydropyranyl group,
(13) a furyl group,
10 (14) a thienyl group,
(15) a pyridyl group,
(16) a pyrimidinyl group,
(17) a pyridazinyl group,
(18) a benzofuryl group,
15 (19) a quinolyl group,
(20) a lower alkoxy carbonyl lower alkyl group,
(21) a lower alkoxy lower alkoxy lower alkyl group,
(22) a lower alkoxy lower alkoxy lower alkoxy lower alkyl group,
20 (23) an amino group optionally having 1 or 2 substituents selected from the group consisting of an alkyl group, a cycloalkyl group, a cycloalkyl lower alkyl group, a lower alkenyl group, a halogen-substituted lower alkyl group, a lower alkoxy group, a lower alkoxy lower alkyl group, a lower alkoxy carbonyl lower alkyl group, a phenyl lower alkyl group, a phenyl lower alkoxy group, a furyl lower alkyl group, a pyridyl lower alkyl group, a hydroxy-substituted lower alkyl group,
25 (24) an amino lower alkyl group optionally having a lower alkyl carbonyl group,
30 (25) a piperazinyl group optionally having a lower alkyl group,
or
(26) the following group



wherein Ac is an alkylene group, and other symbols are as defined above,

R⁴ is

- 5 (1) an alkyl group,
- (2) a phenyl group,
- (3) a phenyl lower alkyl group,
- (4) a halogen-substituted lower alkyl group, or
- (5) a cycloalkyl group,

10 R⁵ is

- (1) a hydrogen,
- (2) a lower alkyl group,
- (3) a halogen-substituted lower alkyl group,
- (4) a phenyl lower alkyl group,
- 15 (5) a phenyl lower alkoxy lower alkyl group,
- (6) a tri-lower alkylsilyl group,
- (7) a tetrahydropyranyl group, or
- (8) a phosphono group,


R¹⁰ is

- 20 (1) an alkyl group,
- (2) an alkenyl group,
- (3) a phenyl group,
- (4) a phenyl lower alkyl group,
- (5) a hydroxy-substituted lower alkyl group,
- 25 (6) a cycloalkyl group,
- (7) an amino lower alkyl group optionally having 1 or 2 substituents selected from the group consisting of an amino lower alkylcarbonyl group and a lower alkylcarbonyl group,

- (8) a pyrrolidinyl group optionally having an amino lower alkylcarbonyl group,
 (9) an alkoxy group,
 (10) a lower alkoxy lower alkoxy lower alkyl group,
 5 (11) a lower alkoxy lower alkoxy lower alkoxy lower alkyl group,
 (12) a phenyl lower alkoxy group,
 (13) an amino group optionally having 1 or 2 substituents selected from the group consisting of an alkyl group, a
 10 hydroxy-substituted lower alkyl group and a phenyl lower alkyl group,
 (14) a morpholino group,
 (15) a piperazinyl group optionally having a lower alkyl group,
 (16) a piperidyl group optionally having a piperidyl group, or
 15 (17) a cycloalkyloxy group;
 provided when




is



, then

- 20 R^2 is not a hydrogen,
 or a salt thereof.


2. The heterocyclic compound according to claim 1, which is represented by the formula (II)




25

wherein each symbol is as defined in claim 1, or a salt thereof.


3. The heterocyclic compound according to claim 1, which is represented by the formula (III)



5 wherein




is



wherein


10 R^{1a} is the following group




wherein

R^{8a} is

- (1) an alkyl group,
- 15 (2) a cycloalkyl group,
- (3) a lower alkoxy group,
- (4) a cycloalkyloxy group,
- (5) a lower alkoxy lower alkoxy group,
- (6) an amino group optionally having 1 or 2 substituents
- 20 selected from the group consisting of an alkyl group and a hydroxy-substituted lower alkyl group, or
- (7) the following group




wherein Aa' is an alkylene group, and other symbol is as defined in claim 1, or the following group



5 wherein

R^{9a} is

- (1) an alkyl group,
- (2) a hydroxy-substituted lower alkyl group,
- (3) a cycloalkyl group,
- 10 (4) a lower alkoxy group,
- (5) a cycloalkyloxy group,
- (6) a lower alkoxy lower alkoxy group,
- (7) a phenyloxy group,
- (8) an amino group optionally having 1 or 2 substituents
- 15 selected from the group consisting of an alkyl group,
- (9) a piperidyl group optionally having a piperidyl group,
- (10) a piperazinyl group optionally having a lower alkyl group,
- or
- (11) the following group





20

wherein Ab' is an alkylene group, and other symbol is as defined in claim 1;

R^{2a} is

the following group





wherein

Y^{1a} is a lower alkylene group,

Y^{2a} is a lower alkylene group,

5 R^{3a} is

(1) an alkyl group,

(2) a cycloalkyl group,

(3) a piperidyl group optionally having 1 or 2 substituents selected from the group consisting of a lower alkyl group,


10 (4) a tetrahydropyranyl group,

(5) a lower alkoxy carbonyl lower alkyl group,

(6) a lower alkoxy lower alkoxy lower alkyl group

(7) an amino lower alkyl group optionally having a lower alkyl carbonyl group, or

15 (8) the following group



wherein Ac' is an alkylene group, Y^{1a} is a lower alkylene group and other symbols are as defined in claim 1,

R^{4a} is

20 (1) an alkyl group, or


(2) a cycloalkyl group; and

A is a lower alkylene group,

or a salt thereof.

25 4. The heterocyclic compound according to claim 2, wherein R^1 is


the following group



wherein

R^{8a'} is

- 5 (1) an alkyl group,
 - (2) a cycloalkyl group,
 - (3) a lower alkoxy group,
 - (4) a cycloalkyloxy group,
 - (5) a lower alkoxy lower alkoxy group, or
 - 10 (6) an amino group optionally having 1 or 2 substituents selected from the group consisting of an alkyl group and a hydroxy-substituted lower alkyl group, or
- the following group





15 wherein

R^{9a'} is

- (1) an alkyl group,
- (2) a hydroxy-substituted lower alkyl group,
- (3) a cycloalkyl group,
- 20 (4) a lower alkoxy group,
- (5) a cycloalkyloxy group,
- (6) a lower alkoxy lower alkoxy group,
- (7) a phenyloxy group,
- (8) an amino group optionally having 1 or 2 substituents
- 25 selected from the group consisting of an alkyl group,
- (9) a piperidyl group optionally having a piperidyl group, or
- (10) a piperazinyl group optionally having a lower alkyl group;

R² is

30 the following group



wherein

Y^{1a} is a lower alkylene group,

5 Y^{2a} is a lower alkylene group,

$R^{3a'}$ is

(1) an alkyl group,

(2) a cycloalkyl group

(3) a piperidyl group optionally having 1 or 2 substituents
10 selected from the group consisting of a lower alkyl group,

(4) a tetrahydropyranyl group,

(5) a lower alkoxycarbonyl lower alkyl group,

(6) a lower alkoxy lower alkoxy lower alkyl group

(7) an amino lower alkyl group optionally having a lower
15 alkylcarbonyl group,

R^{4a} is

(1) an alkyl group, or

(2) a cycloalkyl group;

or a salt thereof.

20

5. A pharmaceutical composition comprising the heterocyclic compound according to claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable diluent and/or a carrier.

25

6. A prophylactic and/or therapeutic agent for a central neurological disease, comprising the heterocyclic compound according to claim 1 or a pharmaceutically acceptable salt thereof as an active ingredient.

30

7. The agent according to claim 6, wherein the central

neurological disease is selected from the group consisting of schizophrenia, treatment-resistant, refractory or chronic schizophrenia, emotional disturbance, psychotic disorder, mood disorder, bipolar disorder, mania, depression, endogenous
5 depression, major depression, melancholic and treatment-resistant depression, dysthymic disorder, cyclothymic disorder, anxiety disorder, somatoform disorder, factitious disorder, dissociative disorder, sexual disorder, eating disorder, sleep disorder, adjustment disorder, substance-related disorder,
10 anhedonia, delirium, Alzheimer's disease, Parkinson disease, cognitive impairment, cognitive impairment associated with neurodegenerative diseases, cognitive impairment caused by neurodegenerative diseases, cognitive impairment in schizophrenia, cognitive impairment caused by treatment-
15 resistant, refractory or chronic schizophrenia, vomiting, motion sickness, obesity, migraine, pain, mental retardation, autistic disorder, Tourette's disorder, tic disorder, attention deficit hyperactivity disorder, conduct disorder and Down's syndrome.

20


8. Use of the heterocyclic compound according to claim 1 or a pharmaceutically acceptable salt thereof as a medicament.

9. A method of preventing and/or treating a central
25 neurological disease, comprising administering the heterocyclic compound according to claim 1 or a pharmaceutically acceptable salt thereof to a human or an animal.

30 10. The method according to claim 9, wherein the central neurological disease is selected from the group consisting of schizophrenia, treatment-resistant, refractory or chronic schizophrenia, emotional disturbance, psychotic disorder, mood disorder, bipolar disorder, mania, depression, endogenous
35 depression, major depression, melancholic and treatment-

resistant depression, dysthymic disorder, cyclothymic disorder, anxiety disorder, somatoform disorder, factitious disorder, dissociative disorder, sexual disorder, eating disorder, sleep disorder, adjustment disorder, substance-related disorder, anhedonia, delirium, Alzheimer's disease, Parkinson disease, cognitive impairment, cognitive impairment associated with neurodegenerative diseases, cognitive impairment caused by neurodegenerative diseases, cognitive impairment in schizophrenia, cognitive impairment caused by treatment-resistant, refractory or chronic schizophrenia, vomiting, motion sickness, obesity, migraine, pain, mental retardation, autistic disorder, Tourette's disorder, tic disorder, attention deficit hyperactivity disorder, conduct disorder and Down's syndrome.


11. A method of producing a heterocyclic compound represented by the formula (I)



wherein each symbol is as defined in claim 1,


or a salt thereof, comprising reacting a compound represented by

the formula



wherein X₁ is a halogen atom or a group that causes a

substitution reaction similar to that by a halogen atom, and other symbols are as defined in claim 1, or a salt thereof, with a compound represented by



wherein Q is as defined in claim 1, or a salt thereof.